<SEC-DOCUMENT>0001193125-18-105032.txt : 20180402
<SEC-HEADER>0001193125-18-105032.hdr.sgml : 20180402
<ACCEPTANCE-DATETIME>20180402172749
ACCESSION NUMBER:		0001193125-18-105032
CONFORMED SUBMISSION TYPE:	S-4
PUBLIC DOCUMENT COUNT:		25
FILED AS OF DATE:		20180402
DATE AS OF CHANGE:		20180402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL INDUSTRIES LTD
		CENTRAL INDEX KEY:			0000818686
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-224102
		FILM NUMBER:		18730391

	BUSINESS ADDRESS:	
		STREET 1:		5 BAZEL ST
		STREET 2:		P O B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
		BUSINESS PHONE:		9729267267

	MAIL ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		5 BAZEL ST PO B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Teva Pharmaceutical Finance Netherlands III B.V.
		CENTRAL INDEX KEY:			0001679183
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		S-4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-224102-01
		FILM NUMBER:		18730392

	BUSINESS ADDRESS:	
		STREET 1:		PIET HEINKADE 107
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1019 GM
		BUSINESS PHONE:		31 (0)20-2193000

	MAIL ADDRESS:	
		STREET 1:		PIET HEINKADE 107
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1019 GM

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Teva Pharmaceutical Finance Netherlands II B.V.
		CENTRAL INDEX KEY:			0001628587
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-224102-02
		FILM NUMBER:		18730393

	BUSINESS ADDRESS:	
		STREET 1:		PIET HEINKADE 107
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1019 GM
		BUSINESS PHONE:		31(0) 20-2193000

	MAIL ADDRESS:	
		STREET 1:		PIET HEINKADE 107
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1019 GM
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4
<SEQUENCE>1
<FILENAME>d558803ds4.htm
<DESCRIPTION>FORM S-4
<TEXT>
<HTML><HEAD>
<TITLE>Form S-4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on April 2, 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B><FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-4</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>TEVA&nbsp;PHARMACEUTICAL&nbsp;INDUSTRIES&nbsp;LIMITED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Additional Registrants Listed on Schedule A Hereto </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Israel</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>5 Basel Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>P.O. Box 3190 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Petach
Tikva, 4951033 Israel </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+972-3-926-7267</FONT></FONT></FONT>
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Teva Pharmaceuticals USA, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1090 Horsham Road </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>North
Wales, Pennsylvania 19454 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Attention: Deborah Griffin </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">(215)&nbsp;591-3000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Joshua
N. Korff, Esq. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ross M. Leff, Esq. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Kirkland&nbsp;&amp; Ellis LLP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>601 Lexington Avenue </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New
York, New York 10022-4675 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">446-4800</FONT> </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale of the securities to the public:</B> The exchange will occur as soon as practicable after the effective
date of this Registration Statement. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If the securities being registered on this form are being offered in connection with the formation of a holding
company and there is compliance with General Instruction G, check the following box:&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated filer, <FONT STYLE="white-space:nowrap">a&nbsp;non-accelerated&nbsp;filer,</FONT> a smaller reporting company, or an emerging growth company. See the definitions of
&#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2&nbsp;of</FONT> the Exchange Act. </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Exchange Act Rule <FONT STYLE="white-space:nowrap">13e-4(i)</FONT> (Cross-Border Issuer Tender Offer):&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Exchange Act Rule <FONT STYLE="white-space:nowrap">14d-1(d)</FONT> (Cross-Border Third-Party Tender Offer):&nbsp;&nbsp;&#9744; </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="7" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class&nbsp;of Securities<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount&nbsp;to be</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed Maximum</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate&nbsp;Offering&nbsp;Price(1)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registration Fee</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">6.000% Senior Notes due 2024</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$1,250,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$1,250,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$155,625</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Guarantees of 6.000% Senior Notes due 2024</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">(2)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">6.750% Senior Notes due 2028</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$1,250,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$1,250,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$155,625</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Guarantees of 6.750% Senior Notes due 2028</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">(2)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">3.250% Senior Notes due 2022</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">&#128;700,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">&#128;700,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$107,404(3)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Guarantees of 3.250% Senior Notes due 2022</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">(2)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">4.500% Senior Notes due 2025</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">&#128;900,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">&#128;900,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$138,091(3)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Guarantees of 4.500% Senior Notes due 2025</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">(2)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="7" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="7" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) promulgated under the Securities Act. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Pursuant to Rule 457(n), no additional registration fee is payable with respect to the guarantees. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">The amount of registration fee was calculated based on the rate reported by Bloomberg on March&nbsp;30, 2018 of $1.2324 = &#128;1.00. </TD></TR></TABLE>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman"><B>The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until this Registration Statement shall
become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule A </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exact Name of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Additional Registrants</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporation or</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Formation</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>I.R.S.&nbsp;Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">Netherlands</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEVA PHARMACEUTICAL FINANCE NETHERLANDS III B.V.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">Netherlands</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">N/A</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>*</B></TD>
<TD ALIGN="left" VALIGN="top"><B>All issuer registrants have the following principal executive office: </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Piet Heinkade 107 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1019 GM Amsterdam, Netherlands </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attention: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bibianne Bon </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>+31
<FONT STYLE="white-space:nowrap">(0)20-2193000</FONT> </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. The prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the
offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>Subject to Completion </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>Dated April 2, 2018 </B></FONT></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g558803g21e62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Teva Pharmaceutical Finance Netherlands III B.V. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exchange Offer for 6.000% Senior Notes due 2024 and 6.750% Senior Notes due 2028 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Teva Pharmaceutical Finance Netherlands II B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exchange Offer for 3.250% Senior Notes due 2022 and 4.500% Senior Notes due 2025 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Offering Price: 100% </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Teva Pharmaceutical Finance
Netherlands III B.V. (&#147;Teva Finance III&#148;) is offering, upon the terms and subject to the conditions set forth in this prospectus and the accompanying letter of transmittal, to exchange (i)&nbsp;an aggregate principal amount of up to
$1,125,000,000 of Teva Finance III&#146;s 6.000% Senior Notes due 2024 (which we refer to as the &#147;2024 Exchange Dollar Notes&#148;) for an equal principal amount of Teva Finance III&#146;s outstanding 6.000% Senior Notes due 2024 (which we
refer to as the &#147;2024 Original Dollar Notes&#148;), and (ii)&nbsp;an aggregate principal amount of up to $1,125,000,000 of Teva Finance III&#146;s 6.750% Senior Notes due 2028 (which we refer to as the &#147;2028 Exchange Dollar Notes&#148;
and, together with the 2024 Exchange Dollar Notes, the &#147;Exchange Dollar Notes&#148;) for an equal principal amount of Teva Finance III&#146;s 6.750% Senior Notes due 2028 (which we refer to as the &#147;2028 Original Dollar Notes&#148; and,
together with the 2024 Original Dollar Notes, the &#147;Original Dollar Notes&#148;). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Teva Pharmaceutical Finance Netherlands II B.V. (&#147;Teva Finance
II&#148; and, together with Teva Finance III, the &#147;Issuers&#148;) is offering, upon the terms and subject to the conditions set forth in this prospectus and the accompanying letter of transmittal, to exchange (i)&nbsp;an aggregate principal
amount of up to &#128;700,000,000 of Teva Finance II&#146;s 3.250% Senior Notes due 2022 (which we refer to as the &#147;2022 Exchange Euro Notes&#148;) for an equal principal amount of Teva Finance II&#146;s outstanding 3.250% Senior Notes due 2022
(which we refer to as the &#147;2022 Original Euro Notes&#148;), and (ii)&nbsp;an aggregate principal amount of up to &#128;900,000,000 of Teva Finance II&#146;s 4.500% Senior Notes due 2025 (which we refer to as the &#147;2025 Exchange Euro
Notes&#148; and, together with the 2022 Exchange Euro Notes, the &#147;Exchange Euro Notes&#148; and, together with the Exchange Dollar Notes, the &#147;Exchange Notes&#148;) for an equal principal amount of Teva Finance II&#146;s 4.500% Senior
Notes due 2025 (which we refer to as the &#147;2025 Original Euro Notes&#148; and, together with the 2022 Original Euro Notes, the &#147;Original Euro Notes&#148; and, together with the Original Dollar Notes, the &#147;Original Notes&#148;). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Terms of the Exchange Offer </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Expires 11:59
p.m., New York City time &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, unless extended. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">You may
withdraw tendered outstanding Original Notes any time before the expiration or termination of the exchange offer. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Not subject to any condition other than
that the exchange offer does not violate applicable law or any interpretation of the staff of the Securities and Exchange Commission (the &#147;SEC&#148;). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">We can amend or terminate the exchange offer. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">We will not receive
any proceeds from the exchange offer. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">The exchange of Original Notes for the Exchange Notes should not be a taxable exchange for United States federal
income tax purposes. See &#147;Certain Tax Considerations&#151;Certain United States Federal Income Tax Considerations.&#148; For a discussion of certain Dutch and Israeli tax considerations, see &#147;Certain Tax Considerations&#151;Certain Dutch
Tax Considerations&#148; and &#147;Certain Tax Considerations&#151;Certain Israeli Tax Considerations,&#148; respectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Terms of the
Exchange Notes </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">The Exchange Notes will be unsecured senior obligations of Teva Finance II or Teva Finance III, as applicable, which are indirect
subsidiaries of Teva Pharmaceutical Industries Limited (&#147;Teva&#148;), and the guarantees will be unsecured senior obligations of Teva. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">The 2024
Exchange Dollar Notes will mature on April&nbsp;15, 2024 and the 2028 Exchange Dollar Notes will mature on March&nbsp;1, 2028. The 2022 Exchange Euro Notes will mature on April&nbsp;15, 2022 and the 2025 Exchange Euro Notes will mature on
March&nbsp;1, 2025. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">The 2024 Exchange Dollar Notes will accrue interest at a rate per annum equal to 6.000% and will be payable semi-annually on each
April&nbsp;15 and October&nbsp;15, beginning on October&nbsp;15, 2018. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">The 2028 Exchange Dollar Notes will accrue interest at a rate per annum equal to
6.750% and will be payable semi-annually on each March&nbsp;1 and September&nbsp;1, beginning on September&nbsp;1, 2018. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">The 2022 Exchange Euro Notes will
accrue interest at a rate per annum equal to 3.250% and will be payable semi-annually on each April&nbsp;15 and October&nbsp;15, beginning on October&nbsp;15, 2018. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">The 2025 Exchange Euro Notes will accrue interest at a rate per annum equal to 4.500% and will be payable semi-annually on each March&nbsp;1 and
September&nbsp;1, beginning on September&nbsp;1, 2018. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">We may redeem the Exchange Notes in whole or in part from time to time. See &#147;Description of the
Exchange Dollar Notes&#148; and &#147;Description of the Exchange Euro Notes.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">The terms of the Exchange Notes are substantially identical to those of
the outstanding Original Notes, except the transfer restrictions, registration rights and additional interest provisions relating to the Original Notes do not apply to the Exchange Notes. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman"><B><I>For a discussion of the specific risks that you should consider before tendering your outstanding Original Notes in the exchange offer,
see &#147;<A HREF="#tx558803_6">Risk Factors</A>&#148; beginning on page 13 of this prospectus. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">We intend to apply to the Irish
Stock Exchange plc (the &#147;Irish Stock Exchange&#148;) for the Exchange Euro Notes to be admitted to the Official List and traded on the Global Exchange Market, which is the exchange regulated market of the Irish Stock Exchange. We do not intend
to list the Exchange Dollar Notes on any securities exchange or automated quotation system. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">Each broker-dealer that receives Exchange Notes
for its own account pursuant to the exchange offer must acknowledge that it will deliver a prospectus in connection with any resale of such Exchange Notes. By so acknowledging and by delivering a prospectus, a broker-dealer will not be deemed to
admit that it is an &#147;underwriter&#148; within the meaning of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). A broker dealer who acquired Original Notes as a result of market making or other trading activities may use
this prospectus, as supplemented or amended from time to time, in connection with any resales of the Exchange Notes. We have agreed that, for a period of up to 180 days after the closing of the exchange offer, we will make this prospectus available
for use in connection with any such resale. See &#147;Plan of Distribution.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">Neither the Securities and Exchange Commission nor any
state securities commission has approved or disapproved of the securities offered hereby or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained in this prospectus. We have not
authorized anyone to provide you with information different from that contained in this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy securities other than those specifically offered hereby or
an offer to sell any securities offered hereby in any jurisdiction where, or to any person whom, it is unlawful to make such offer or solicitation. The information contained in this prospectus is accurate only as of the date of this prospectus,
regardless of the time of delivery of this prospectus or issuing the Exchange Notes. </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx558803_1">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx558803_2">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">iii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx558803_3">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">iv</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx558803_4">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx558803_5">RATIO OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx558803_6">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx558803_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx558803_8">EXCHANGE OFFER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx558803_9">DESCRIPTION OF THE EXCHANGE DOLLAR NOTES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx558803_10">DESCRIPTION OF THE EXCHANGE EURO NOTES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx558803_11">CERTAIN TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx558803_12">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx558803_13">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx558803_14">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exchange offer is not being made to, nor will we accept surrenders for exchange from, holders of Original
Notes in any jurisdiction in which the exchange offer or the acceptance thereof would not be in compliance with the securities or blue sky laws of such jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> with respect to the Exchange
Notes. This prospectus, which forms part of the registration statement, does not contain all the information included in the registration statement, including its exhibits and schedules. For further information about us and the Exchange Notes, you
should refer to the registration statement and its exhibits and schedules. Statements we make in this prospectus about certain contracts or other documents are not necessarily complete. When we make such statements, we refer you to the copies of the
contracts or documents that are filed as exhibits to the registration statement, because those statements are qualified in all respects by reference to those exhibits. The registration statement, including the exhibits and schedules, is available at
the SEC&#146;s website at www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This prospectus incorporates important business and financial information about us that is not
included in or delivered with this document. This information is available to you at no cost, upon your request. You can request this information by writing or telephoning us at the following address:: Investor Relations, 5 Basel Street P.O. Box
3190, Petach Tikva, 4951033 Israel, telephone <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">number&nbsp;+972-3-926-7267.</FONT></FONT></FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>In order to ensure timely delivery, you must request the information no later than five business days before the expiration of the relevant
exchange offer. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx558803_1"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information that Teva files with or furnishes to the SEC after the date of this prospectus, and that is incorporated by reference herein, will
automatically update and supersede the information in this prospectus. You should review the SEC filings and reports that we incorporate by reference to determine if any of the statements in this prospectus or in any documents previously
incorporated by reference have been modified or superseded. We file annual&nbsp;and quarterly reports and other information with the SEC.&nbsp;You may read and copy such material at the public reference facilities maintained by the SEC at 100 F
Street, N.E., Room 1580, Washington, D.C. 20549, as well as at the SEC&#146;s regional offices. You may also obtain copies of such material from the SEC at prescribed rates by wiring to the Public Reference Section of the SEC, 100 F Street, N.E.,
Room 1580, Washington, D.C. 20549. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information on the public reference rooms.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC maintains an Internet website at http://www.sec.gov that contains reports, proxy, information statements and other material that
are filed through the SEC&#146;s Electronic Data Gathering, Analysis and Retrieval (&#147;EDGAR&#148;) system and filed electronically with the SEC. We began filing through the EDGAR system on October&nbsp;31, 2002. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our American Depositary Shares are quoted on the New York Stock Exchange under the symbol &#147;TEVA.&#148; You may inspect certain reports
and other information concerning us at the offices of the Financial Industry Regulatory Authority, 1735 K Street, N.W., Washington, D.C. 20006. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information about us is also available on our website at http://www.tevapharm.com. Such information on our website is not part of this
prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx558803_2"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus incorporates by reference important business and financial information about our company that is not included in or delivered
with this document. The information incorporated by reference is considered to be part of this prospectus, and later information that we file with the SEC will automatically update and supersede this information. Any statement contained in this
prospectus or in any document incorporated or deemed to be incorporated by reference into this prospectus that is modified or superseded by subsequently filed materials shall not be deemed, except as so modified or superseded, to constitute a part
of this prospectus. We incorporate by reference the documents set forth below that we have previously filed with the SEC, including all exhibits thereto, and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the
Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;) from now until the termination of the exchange offer: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Teva&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, filed with the SEC on February&nbsp;12, 2018; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Teva&#146;s Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on February&nbsp;1, 2018 (with respect to Item 1.01 and Item 9.01 only) and March&nbsp;14, 2018; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all documents filed by Teva pursuant to Sections 13(a), 13(c) 14 or 15(d) of the Exchange Act subsequent to the date of this prospectus until the date of the termination of the offering of securities made under this
prospectus (other than current reports furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of Form <FONT STYLE="white-space:nowrap">8-K).</FONT> </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You can obtain any of the documents incorporated by reference into this prospectus from the SEC&#146;s web site at the address described
above. You may also request a copy of these filings, at no cost, by writing or telephoning to the address and telephone set forth below. We will provide, without charge, upon written or oral request, copies of any or all of the documents
incorporated by reference into this prospectus (excluding exhibits to such documents unless such exhibits are specifically incorporated by reference therein). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should direct requests for documents to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Teva Pharmaceutical Industries Limited </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 Basel Street
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">P.O. Box 3190 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Petach Tikva
4951033 Israel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+972-3-926-7267</FONT></FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx558803_3"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The disclosure and analysis in the prospectus contains &#147;forward-looking statements,&#148; including statements that are predictive in
nature, or that depend upon or refer to future events or conditions, contain or incorporate by reference certain forward-looking statements. Forward-looking statements describe our current expectations or forecasts of future events. You can identify
these forward-looking statements by the use of words such as &#147;should,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;target,&#148; &#147;may,&#148; &#147;project,&#148; &#147;guidance,&#148; &#147;intend,&#148;
&#147;plan,&#148; &#147;believe&#148; and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance.&nbsp;Important factors that could cause or contribute to differences
between actual outcomes or results and those which are indicated in these statements include risks relating to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our generics medicines business, including: that we are substantially more dependent on this business, with its significant attendant risks, following our acquisition of Allergan&#146;s worldwide generic pharmaceuticals
business; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products;
price erosion relating to our generic products, both from competing products and increased regulation; delays in launches of new generic products; our ability to take advantage of high-value biosimilar opportunities; efforts of pharmaceutical
companies to limit the use of generics including through legislation and regulations; the difficulty and expense of obtaining licenses to proprietary technologies; returns, allowances and chargebacks; and investigations of the calculation of
wholesale prices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our specialty medicines business, including: competition for our specialty products, especially COPAXONE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, our leading medicine, which faces competition from
existing and potential additional generic versions and orally-administered alternatives; our ability to achieve expected results from investments in our product pipeline; competition from companies with greater resources and capabilities; and the
effectiveness of our patents and other measures to protect our intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result
in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our business and operations in general, including: failure to effectively execute the recently announced restructuring plan; uncertainties related to, and failure to achieve, the potential benefits and success of our
new senior management team and organizational structure; harm to our pipeline of future products due to the expected review of our Research&nbsp;&amp; Development programs; our ability to develop and commercialize additional pharmaceutical products;
potential additional adverse consequences following our resolution with the U.S. government of our Foreign Corrupt Practice Act investigation; compliance with sanctions and other trade control laws; manufacturing or quality control problems, which
may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain
key personnel; variations in intellectual property laws that may adversely affect our ability to manufacture our products; challenges associated with conducting business globally, including adverse effects of political or economic instability, major
hostilities or terrorism; significant sales to a limited number of customers in our U.S. market; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our
prospects and opportunities for growth if we sell assets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive
governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into Selling and Marketing practices; potential
liability for patent infringement; product liability claims; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax
liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update any forward-looking
statements or other information contained in this prospectus, whether as a result of new information, future events or otherwise. You are advised, however, to consult any additional disclosures we make in our Annual Reports on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> and our subsequently filed Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> that are filed with the SEC.
See &#147;Risk Factors.&#148; Other factors besides those listed here could also adversely affect us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">v </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx558803_4"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information from this prospectus or incorporated by reference and is therefore qualified in its entirety
by the more detailed information appearing elsewhere, or incorporated by reference, in this prospectus. It may not contain all the information that is important to you. We urge you to read carefully this entire prospectus and the other documents to
which it refers to understand fully the terms of the Exchange Notes. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless otherwise indicated or the context requires otherwise,
the following defined terms apply: References in this prospectus to &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148; or &#147;Teva&#148; refer to Teva Pharmaceutical Industries Limited and its subsidiaries. All references to
&#147;Teva Finance II&#148; refer to Teva Pharmaceutical Finance Netherlands II B.V., an indirect subsidiary of Teva. All references to &#147;Teva Finance III&#148; refer to Teva Pharmaceutical Finance Netherlands III B.V., an indirect subsidiary of
Teva. All references to the &#147;Issuers&#148; refer to Teva Finance II and Teva Finance III. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a global pharmaceutical company, committed to increasing access to high-quality healthcare to patients around the world. We operate
worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world. Our key strengths include our world-leading generic medicines expertise and portfolio, focused specialty
medicines portfolio and global infrastructure and scale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2017, we announced a new organizational structure and leadership
changes to enable strategic alignment across our portfolios, regions and functions. Under this new structure, our business will be integrated into one commercial organization, operating through three regions &#150; North America, Europe and Growth
Markets. Each region will manage our entire product portfolio, including generics, specialty <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">and&nbsp;over-the-counter&nbsp;(&#147;OTC&#148;).</FONT></FONT> We believe that the new
structure will enable stronger alignment and integration between Research&nbsp;&amp; Development, operations and commercial regions, allowing us to become a more agile, lean and profitable company. Prior to the implementation of our new
organizational structure, we operated our business and reported our financial results in two segments: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Generic Medicines</B>, which includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, such as tablets, capsules, injectables, inhalants, liquids, ointments and creams. This
segment includes our OTC business, a significant part of which is conducted through PGT Healthcare LLP, our consumer healthcare joint venture with The Procter&nbsp;&amp; Gamble Company, as well as our world-leading active pharmaceutical ingredient
manufacturing business. We are the leading generic drug company in the United States and Europe, and we have a significant presence in certain &#147;rest of the world&#148; markets. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Specialty Medicines</B>, which includes our core therapeutic areas of central nervous system medicines such as COPAXONE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;and AUSTEDO<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;and respiratory medicines such as ProAir<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;and QVAR<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Our specialty
medicines segment also includes other products, such as BENDEKA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;and GRANIX<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;in oncology. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to these two segments, we have other activities, primarily sales of third-party products for which we act as distributor in the
United States and in other countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva was incorporated in Israel on February&nbsp;13, 1944, and is the successor to a number of
Israeli corporations, the oldest of which was established in 1901. Our principal executive offices are located at 5 Basel </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Street, P.O. Box 3190, Petach Tikva 4951033, Israel, and our telephone number
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">is&nbsp;+972-3-926-7267.</FONT></FONT></FONT> Information about us is also available on our website at<U>&nbsp;http://www.tevapharm.com</U>. Such
information on our website is not part of this prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Teva Finance II </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance II is a Dutch private limited liability company that was formed on October&nbsp;16, 2013. Its address is Piet Heinkade 107, 1019
GM Amsterdam, Netherlands, telephone <FONT STYLE="white-space:nowrap">number&nbsp;+31&nbsp;(0)20-2193000.</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Teva Finance III
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance III is a Dutch private limited liability company that was formed on September&nbsp;21, 2015. Its address is Piet
Heinkade 107, 1019 GM Amsterdam, Netherlands, telephone <FONT STYLE="white-space:nowrap">number&nbsp;+31&nbsp;(0)20-2193000.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Organizational
Structure </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following diagram illustrates our simplified corporate structure: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g558803g83b10.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Issuer of 0.25% Convertible Senior Debentures due 2026 and 6.150% Senior Notes due 2036. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Guarantor of the Exchange Notes, 0.25% Convertible Senior Debentures due 2026, 6.150% Senior Notes due 2036, 2.950% Senior Notes due 2022, 3.650% Senior Notes due 2021, 2.250% Senior Notes due 2020, 3.650% Senior Notes
due 2021, 1.5% Notes due 2018, 1.250% Senior Notes due 2023, 1.875% Senior Notes due 2027, 0.375% Senior Notes due 2020, 1.125% Senior Notes due 2024, 1.625% Senior Notes due 2028, 1.700% Senior Notes due 2019, 2.200% Senior Notes due 2021, 2.800%
Senior Notes due 2023, 3.150% Senior Notes due 2026, 4.100% Senior Notes due 2046, 0.125% Notes due 2018, 0.500% Notes due 2022 and 1.000% Notes due 2025. </TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Borrower under the Senior Unsecured Revolving Credit Agreement, dated as of November&nbsp;16, 2015. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Issuer of 2.950% Senior Notes due 2022 and 3.650% Senior Notes due 2021. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Issuer of 2.250% Senior Notes due 2020. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Issuer of 3.650% Senior Notes due 2021. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Issuer of 1.5% Notes due 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Issuer of the Exchange Euro Notes, 1.250% Senior Notes due 2023, 1.875% Senior Notes due 2027, 0.375% Senior Notes due 2020, 1.125% Senior Notes due 2024 and 1.625% Senior Notes due 2028. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Issuer of the Exchange Dollar Notes, 1.700% Senior Notes due 2019, 2.200% Senior Notes due 2021, 2.800% Senior Notes due 2023, 3.150% Senior Notes due 2026, 4.100% Senior Notes due 2046; </TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Borrower under the Senior Unsecured Revolving Credit Agreement, dated as of November&nbsp;16, 2015. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Issuer of 0.125% Notes due 2018, 0.500% Notes due 2022 and 1.000% Notes due 2025. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Borrower under the Senior Unsecured Revolving Credit Agreement, dated as of November&nbsp;16, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">Borrower under the Senior Unsecured Revolving Credit Agreement, dated as of November&nbsp;16, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top">Borrower under the Senior Unsecured Revolving Credit Agreement, dated as of November&nbsp;16, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top">Borrower under the Senior Unsecured Revolving Credit Agreement, dated as of November&nbsp;16, 2015. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Exchange Offer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a brief summary of the terms of the exchange offers. For a more complete description of the exchange offer, see
&#147;Exchange Offer.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Original Notes </B></P></TD>
<TD>$1,250,000,000 aggregate principal amount of the 6.000% Senior Notes due 2024. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$1,250,000,000 aggregate principal amount of the 6.750% Senior Notes due 2028. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#128;700,000,000 aggregate principal amount of the 3.250% Senior Notes due 2022. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#128;900,000,000 aggregate principal amount of the 4.500% Senior Notes due 2025. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Exchange Notes </B></P></TD>
<TD>$1,250,000,000 in aggregate principal amount of 6.000% Senior Notes due 2024, the issuance of which will be registered under the Securities Act. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$1,250,000,000 in aggregate principal amount of 6.750% Senior Notes due 2028, the issuance of which will be registered under the Securities Act. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#128;700,000,000 in aggregate principal amount of 3.250% Senior Notes due 2022, the issuance of which will be registered under the Securities Act. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#128;900,000,000 in aggregate principal amount of 4.500% Senior Notes due 2025, the issuance of which will be registered under the Securities Act. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Exchange Offer </B></P></TD>
<TD>The Issuers are offering to exchange the Original Notes for a like principal amount at maturity of the Exchange Notes. The Original Dollar Notes may be exchanged only in minimum denominations of $200,000 and any integral multiple of $1,000 in
excess thereof. The Original Euro Notes may be exchanged only in minimum denominations of &#128;100,000 and any integral multiple of &#128;1,000 in excess thereof. The exchange offer is being made pursuant to registration rights agreements that the
Issuers entered into with the initial purchasers (the &#147;Registration Rights Agreements&#148;), which grant the initial purchasers and any subsequent holders of the Original Notes certain exchange and registration rights. This exchange offer is
intended to satisfy those exchange and registration rights with respect to the Original Notes. After the exchange offer is complete, holders of Original Notes will no longer be entitled to any exchange or registration rights with respect to their
Original Notes. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Resale of Exchange Notes </B></P></TD>
<TD>We believe that you can offer for resale, resell and otherwise transfer the Exchange Notes without complying with the registration and prospectus delivery requirements of the Securities Act so long as: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">you acquire the Exchange Notes in the ordinary course of business; </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">you are not participating, do not intend to participate, and have no arrangement or understanding with any person to participate, in the distribution of the Exchange Notes; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">you are not an affiliate of Teva; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">you are not a broker-dealer. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Expiration Date; Withdrawal of Tender </B></P></TD>
<TD>The exchange offer will expire 11:59 p.m., New York City time, on , 2018, or a later time if the Issuers choose to extend this exchange offer in their sole and absolute discretion. Holders of Original Notes may withdraw their tender of Original
Notes at any time prior to the expiration date. All outstanding Original Notes that are validly tendered and not validly withdrawn will be exchanged. Any Original Notes not accepted for exchange for any reason will be returned at the Issuers&#146;
expense as promptly as possible after the expiration or termination of the exchange offer. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Accrued Interest on the Exchange Notes and the Original Notes </B></P></TD>
<TD>The Exchange Notes will bear interest from March&nbsp;14, 2018 or from the most recent interest payment date to which interest has been paid on the applicable Original Notes. Holders of Original Notes that are accepted for exchange will be
deemed to have waived the right to receive any payment in respect of interest on such Original Notes accrued to the date of issuance of the Exchange Notes. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Conditions on the Exchange Offer </B></P></TD>
<TD>The Issuers&#146; obligation to accept for exchange, or to issue the Exchange Notes in exchange for, any Original Notes is subject to certain customary conditions, including the Issuers&#146; determination that the exchange offer does not
violate any law, statute, rule, regulation or interpretation by the Staff of the SEC or any regulatory authority or other foreign, federal, state or local government agency or court of competent jurisdiction, some of which the Issuers may waive. We
currently expect that each of the conditions will be satisfied and that no waivers will be necessary. See &#147;Exchange Offer&#151;Conditions on the Exchange Offer.&#148; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Procedures for Tendering Original Notes held in the Form of Book-Entry Interests </B></P></TD>
<TD>The Original Dollar Notes were issued as global securities and following issuance are held by The Bank of New York Mellon as custodian for The Depository Trust Company (&#147;DTC&#148;). The global securities represent 100% of the uncertificated
beneficial interests in Original Dollar Notes, at DTC. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Beneficial interests in the outstanding Original Dollar Notes, which are held by direct or indirect participants in DTC, are shown on, and transfers of the Original Dollar Notes can only be made through, records
maintained in book-entry form by DTC. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Original Euro Notes were issued as global securities and are held in book-entry form through Euroclear Bank SA/NV (&#147;Euroclear&#148;) and Clearstream Banking, <I>soci&eacute;t&eacute;</I> <I>anonyme</I>
(&#147;Clearstream&#148;). </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Holders may tender outstanding Original Notes by instructing their broker or bank to tender them on the holder&#146;s behalf. In some cases a holder may be asked to submit the letter of transmittal that may accompany
this prospectus. By tendering Original Notes a holder will be deemed to have acknowledged and agreed to be bound by the terms set forth under &#147;Exchange Offer.&#148; Outstanding Original Dollar Notes must be tendered in minimum denominations of
$200,000 and any integral multiple of $1,000 in excess thereof and outstanding Original Euro Notes must be tendered in minimum denominations of &#128;100,000 and any integral multiple of &#128;1,000 in excess thereof. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Holders of Original Dollar Notes through DTC:</I> If you wish to exchange your Original Dollar Notes and either you or your registered holder hold your Original Dollar Notes in book-entry form directly through DTC,
you must submit an instruction and follow the procedures for book-entry transfer as provided under &#147;The Exchange Offer&#151;Book-Entry Transfer.&#148; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Holders of Original Euro Notes through Euroclear and Clearstream:</I> If you wish to exchange your Original Euro Notes and either you or your registered holder hold your Original Euro Notes in book-entry form
directly through Euroclear or Clearstream, you should be aware that pursuant to their internal guidelines, Euroclear and Clearstream will automatically exchange your Original Euro Notes for Exchange Notes. <B>If you do not wish to participate in the
exchange offer, you must instruct Euroclear or Clearstream, as the case may be, to &#147;Take No Action&#148;</B>; otherwise your Original Euro Notes will automatically be tendered in the exchange offer, and you will be deemed to have agreed to be
bound by the terms of the letter of transmittal. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In order for a tender to be considered valid, the exchange agent must receive a confirmation of book-entry transfer of the outstanding Original Notes into the exchange agent&#146;s account at DTC (in the case of the
Original Dollar Notes) or Euroclear or Clearstream (in the case of the Original Euro Notes), under the procedure described in this prospectus under the heading &#147;Exchange Offer,&#148; on or before 11:59&nbsp;p.m., New York City time, on the
expiration date of the exchange offer. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Certain Tax Considerations </B></P></TD>
<TD>The exchange offer should not result in any income, gain or loss to the holders of Original Notes or to us for United States federal income tax purposes. See &#147;Certain Tax Considerations&#151;Certain United States Federal Income Tax
Considerations.&#148; For a discussion of certain Dutch and Israeli tax considerations, see &#147;Certain Tax Considerations&#151;Certain Dutch Tax Considerations&#148; and &#147;Certain Tax Considerations&#151;Certain Israeli Tax
Considerations,&#148; respectively. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds </B></P></TD>
<TD>We will not receive any proceeds from the issuance of the Exchange Notes in the exchange offer. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Exchange Agent </B></P></TD>
<TD>The Bank of New York Mellon is serving as the exchange agent for the exchange offer with respect to the Original Dollar Notes. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Bank of New York Mellon, London Branch, is serving as the exchange agent for the exchange offer for the Original Euro Notes. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consequences of Not Exchanging Original Notes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a holder does not exchange their Original Notes in the exchange offer, the Original Notes will continue to be subject to the restrictions
on transfer currently applicable to the Original Notes. In general, a holder of Original Notes may offer or sell Original Notes only: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if they are registered under the Securities Act and applicable state securities laws; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if they are offered or sold under an exemption from registration under the Securities Act and applicable state securities laws; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if they are offered or sold in a transaction not subject to the Securities Act and applicable state securities laws. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently intend to register the Original Notes under the Securities Act. Under some circumstances, however, holders of the Original Notes,
including holders who are not permitted to participate in the exchange offer or who may not freely resell Exchange Notes received in the exchange offer, may require the Issuers to file, and to cause to become effective, a shelf registration
statement covering resales of Original Notes by these holders. For more information regarding the consequences of not tendering Original Notes and the Issuers&#146; obligation to file a shelf registration statement, see &#147;Exchange
Offer&#151;Consequences of Failure to Exchange&#148; and &#147;Exchange Offer&#151;Shelf Registration.&#148; </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Terms of the Exchange Notes </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Issuers </P></TD>
<TD>For the Exchange Dollar Notes, Teva Pharmaceutical Finance Netherlands III B.V., which is an indirect, wholly owned subsidiary of Teva and has no assets or operations other than in connection with this offering and prior debt offerings.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For the Exchange Euro Notes, Teva Pharmaceutical Finance Netherlands II B.V., which is an indirect, wholly owned subsidiary of Teva and has no assets or operations other than in connection with this offering and prior
debt offerings. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Notes Offered </P></TD>
<TD>$1,250,000,000 aggregate principal amount of the 6.000% Senior Notes due 2024. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$1,250,000,000 aggregate principal amount of the 6.750% Senior Notes due 2028. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#128;700,000,000 aggregate principal amount of the 3.250% Senior Notes due 2022. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#128;900,000,000 aggregate principal amount of the 4.500% Senior Notes due 2025. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Maturity Date </P></TD>
<TD>The 2024 Exchange Dollar Notes will mature on April&nbsp;15, 2024. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The 2028 Exchange Dollar Notes will mature on March&nbsp;1, 2028. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The 2022 Exchange Euro Notes will mature on April&nbsp;15, 2022. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The 2025 Exchange Euro Notes will mature on March&nbsp;1, 2025. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Interest </P></TD>
<TD>Interest on the 2024 Exchange Dollar Notes will accrue at a rate of 6.000%&nbsp;per annum. Interest on the 2024 Exchange Dollar Notes will be payable semi-annually in cash in arrears on April&nbsp;15 and October&nbsp;15 of each year,
commencing&nbsp;October&nbsp;15, 2018. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Interest on the 2028 Exchange Dollar Notes will accrue at a rate of 6.750%&nbsp;per annum. Interest on the 2028 Exchange Dollar Notes will be payable semi-annually in cash in arrears on March&nbsp;1 and September&nbsp;1
of each year, commencing&nbsp;September 1, 2018. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Interest on the 2022 Exchange Euro Notes will accrue at a rate of 3.250%&nbsp;per annum. Interest on the 2022 Exchange Euro Notes will be payable semi-annually in cash in arrears on April&nbsp;15 and October&nbsp;15 of
each year, commencing&nbsp;October 15, 2018. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Interest on the 2025 Exchange Euro Notes will accrue at a rate of 4.500%&nbsp;per annum. Interest on the 2025 Exchange Euro Notes will be payable semi-annually in cash in arrears on March&nbsp;1 and September&nbsp;1 of
each year, commencing&nbsp;September 1, 2018. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Guarantees </P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Teva will irrevocably and unconditionally guarantee the punctual payment when due of the principal and interest, whether at maturity, upon redemption,
by acceleration or otherwise (including any additional amounts in respect of taxes as described in &#147;Description of the Exchange Dollar Notes&#151;Additional Tax Amounts&#148; and
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">
&#147;Description of the Exchange Euro Notes&#151;Additional Tax Amounts&#148;), on the Exchange Notes of each series. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Ranking </P></TD>
<TD>As indebtedness of Teva, the guarantees will rank: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">senior to the rights of creditors under any debt expressly subordinated to the guarantees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">equally with other unsecured debt of Teva from time to time outstanding other than any that is subordinated to the guarantees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectively junior to Teva&#146;s secured indebtedness up to the value of the collateral securing that indebtedness; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectively junior to the indebtedness and other liabilities of Teva&#146;s subsidiaries. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Optional Redemption </P></TD>
<TD>Teva Finance III may redeem the Exchange Dollar Notes of any series, in whole or in part, at any time or from time to time, upon at least 20 days&#146;, but not more than 60 days&#146;, prior notice. This redemption notice and the redemption
may, at Teva Finance III&#146;s discretion, be subject to one or more conditions precedent. The notes of each series will be redeemable at a redemption price equal to the greater of (1) 100% of the principal amount of the series of notes to be
redeemed and (2)&nbsp;the sum of the present values of the Remaining Scheduled Payments (as defined under &#147;Description of the Exchange Dollar Notes&#151;Optional Redemption by the Issuer&#148;) on the series of notes being redeemed discounted,
on a semi-annual basis (assuming a <FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months), at a rate equal to the sum of the Treasury Rate (as defined in &#147;Description of
the Exchange Dollar Notes&#151;Optional Redemption by the Issuer&#148;) plus 50 basis points, in the case of the 2024 Exchange Dollar Notes, and 50 basis points, in the case of the 2028 Exchange Dollar Notes, plus in each case accrued and unpaid
interest thereon, if any, to, but not including, the redemption date. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If we elect to redeem the 2024 Exchange Dollar Notes at any time on or after January&nbsp;15, 2024 (three months prior to the maturity date of the 2024 Exchange Dollar Notes) or the 2028 Exchange Dollar Notes at any
time on or after December&nbsp;1, 2027 (three months prior to the maturity date of the 2028 Exchange Dollar Notes), we may redeem the 2024 Exchange Dollar Notes and the 2028 Exchange Dollar Notes, in whole or in part, in each case upon at least 20
days&#146;, but not more than 60 days&#146;, prior notice at a redemption price equal to 100% of the principal amount of the notes then outstanding to be redeemed plus accrued and unpaid interest thereon, if any, to, but not including, the
redemption date. See &#147;Description of the Exchange Dollar Notes&#151;Optional Redemption.&#148; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Teva Finance II may redeem the Exchange Euro Notes of any series, in whole or in part, at any time or from time to time, upon
at least 20 days&#146;, but not more than 60 days&#146;, prior notice. This redemption notice and the redemption may, at Teva Finance II&#146;s discretion, be subject to one or more conditions precedent. The Exchange Euro
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">
Notes of each series will be redeemable at a redemption price equal to the greater of (1)&nbsp;100% of the principal amount of the series of notes to be redeemed and (2)&nbsp;the sum of the
present values of the Remaining Scheduled Payments (as defined in &#147;Description of the Exchange Euro Notes&#151;Optional Redemption by the Issuer&#148;) on the series of notes being redeemed discounted, on a semi-annual basis (assuming a <FONT
STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months), at the applicable Reinvestment Rate (as defined in &#147;Description of the Exchange Euro Notes &#151;Optional Redemption by
the Issuer&#148;), plus in each case accrued and unpaid interest thereon, if any, to, but not including, the redemption date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If we elect to redeem the 2022 Exchange Euro Notes at any time on or after January&nbsp;15, 2022 (three months prior to the maturity date of the 2022 Exchange Euro Notes) or the 2025 Exchange Euro Notes at any time on
or after December&nbsp;1, 2024 (three months prior to the maturity date of the 2025 Exchange Euro Notes), we may redeem the 2022 Exchange Euro Notes and the 2025 Exchange Euro Notes, in whole or in part, in each case upon at least 20 days&#146;, but
not more than 60&nbsp;days&#146;, prior notice at a redemption price equal to 100% of the principal amount of the notes then outstanding to be redeemed plus accrued and unpaid interest thereon, if any, to, but not including, the redemption date. See
&#147;Description of the Exchange Euro Notes &#151;Optional Redemption.&#148; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Tax Redemption </P></TD>
<TD>Teva Finance III and Teva may redeem all (but not part) of the Exchange Dollar Notes at any time, upon at least 20 days&#146;, but no more than 60 days&#146;, prior notice, at a redemption price equal to 100% of the aggregate principal amount of
such notes, plus accrued and unpaid interest, if any, to, but not including, the redemption date, if Teva Finance III or Teva would become obligated to pay certain additional amounts in respect of taxes as a result of certain changes in specified
tax laws or certain other circumstances. See &#147;Description of the Exchange Dollar Notes&#151;Tax Redemption.&#148; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Teva Finance II and Teva may redeem all (but not part) of the Exchange Euro Notes at any time, upon at least 20 days&#146;, but no more than 60 days&#146;, prior notice, at a redemption price equal to 100% of the
aggregate principal amount of such notes, plus accrued and unpaid interest, if any, to, but not including, the redemption date, if Teva Finance II or Teva would become obligated to pay certain additional amounts in respect of taxes as a result of
certain changes in specified tax laws or certain other circumstances. See &#147;Description of the Exchange Euro Notes &#151;Tax Redemption.&#148; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">No Prior Market </P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Exchange Notes will be a new class of securities for which there is currently no market. Although each initial purchaser of the Original Dollar
Notes has informed us that it intends to make a market in the Original Dollar Notes and each initial purchaser of the Original Euro Notes has informed us that it intends to make a market in the Original Euro Notes, the initial purchasers are not
obligated to do so, and may discontinue market-making activities at any time without notice. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">
Accordingly, we cannot assure you that a liquid market for the Exchange Notes will develop or be maintained. We do not intend to list the Exchange Dollar Notes on any U.S. securities exchange.
Application will be made to list the Exchange Euro Notes on the Official List of the Irish Stock Exchange and to admit the Exchange Euro Notes to trading on the Global Exchange Market. There are no assurances that the Exchange Euro Notes will be
admitted to the Official List of the Irish Stock Exchange. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>We will not receive any proceeds from the issuance of the Exchange Notes pursuant to the exchange offer. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </P></TD>
<TD>You should consider carefully all of the information set forth in this prospectus and, in particular, you should evaluate the specific factors discussed in the section entitled &#147;Risk Factors&#148; before deciding to invest in the Exchange
Notes. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx558803_5"></A>RATIO OF EARNINGS TO FIXED CHARGES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ratio of earnings to fixed charges in accordance with the generally accepted accounting principles in the United States of America for each
of the periods presented below was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ratio of earnings to fixed charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18.7<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom">)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The ratio of earnings to fixed charges was less than 1:1 for the fiscal year ended December&nbsp;31, 2017. In order to achieve a ratio of earnings to fixed charges of 1:1, we would have had to generate an additional
$18,380&nbsp;million in <FONT STYLE="white-space:nowrap">pre-tax</FONT> earnings in the fiscal year ended December&nbsp;31, 2017. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Issuers did not have any independent operations for the relevant periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx558803_6"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Exchange Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There may not
be liquid markets for the Exchange Notes, and you may not be able to sell your Exchange Notes at attractive prices or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Exchange Notes are new issues of securities for which there are currently no trading markets. Although one or more of the initial purchasers have advised us that they currently intend to make markets in the Original Notes, they are not obligated to
do so and may discontinue their market-making activities at any time without notice. We do not intend to apply for listing of the Exchange Dollar Notes on any exchange or any automated quotation system. Although application will be made to the Irish
Stock Exchange for the Exchange Euro Notes to be admitted to the Official List and to trading on the Global Exchange Market, an active market may not develop. If active markets for the Exchange Notes fails to develop or be sustained, the trading
prices of the Exchange Notes could fall, and even if active trading markets were to develop, the Exchange Notes could trade at prices that may be lower than their respective initial offering prices. The trading prices of the Exchange Notes will
depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prevailing interest rates and interest rate volatility; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the markets for similar securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our financial condition, results of operations and prospects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the publication of earnings estimates or other research reports and speculation in the press or investment community; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the anticipated results of acquisitions and divestitures; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in our industry and competition; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general market and economic conditions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, we cannot assure you that you will be
able to sell the Exchange Notes at attractive prices or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Exchange Euro Notes may not become, or remain, listed on the Irish Stock
Exchange. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Teva Finance II will, pursuant to the indenture governing the Exchange Euro Notes, agree to make an application to have the
Exchange Euro Notes listed on the Irish Stock Exchange and admitted to trading on the Global Exchange Market thereof within a reasonable period after the issue date and to use its efforts to maintain such listing as long as the Exchange Euro Notes
are outstanding, Teva Finance II cannot assure you that the Exchange Euro Notes will become, or remain, listed. If Teva Finance II cannot maintain the listing on the Irish Stock Exchange and the admission to trading on the Global Exchange Market
thereof or it becomes unduly burdensome to make or maintain such listing, Teva Finance II may cease to make or maintain such listing on the Irish Stock Exchange, provided that it will use reasonable best efforts to obtain and maintain the listing of
the Exchange Euro Notes on another securities exchange, although there can be no assurance that Teva Finance II will be able to do so. Although no assurance can be made as to the liquidity of the Exchange Euro Notes as a result of listing on the
Irish Stock Exchange or another recognized listing exchange for comparable issuers in accordance with the indenture, failure to be approved for listing or the delisting of the Exchange Euro Notes from Irish Stock Exchange or another listing exchange
in accordance with the indenture may have a material adverse effect on a holder&#146;s ability to resell Exchange Euro Notes in the secondary market. We do not intend to apply for the Exchange Euro Notes to be listed on any U.S. securities exchange
or to arrange for quotation on any automated dealer quotation system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A downgrade, suspension or withdrawal of the rating assigned by a rating agency to the Exchange Notes,
if any, could cause the liquidity or market values of the Exchange Notes to decline significantly. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you what
ratings will be assigned to the Exchange Notes. In addition, we cannot assure you that any rating so assigned will remain for any given period of time or that the rating will not be lowered or withdrawn entirely by the rating agency if in that
rating agency&#146;s judgment future circumstances relating to the basis of the rating, such as adverse changes in our business, so warrant. A downgrade of Teva&#146;s credit rating could negatively affect the liquidity or market values of the
Exchange Notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to refinance our indebtedness. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may need to refinance all or a portion of our indebtedness, including the Exchange Notes, before maturity. We cannot assure you that we will
be able to refinance any of our indebtedness on commercially reasonable terms or at all. We cannot assure you that we will be able to obtain sufficient funds to enable us to repay or refinance our debt obligations on commercially reasonable terms or
at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may incur additional indebtedness that may adversely affect our ability to meet our financial obligations under the Exchange Notes.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of the Exchange Notes do not impose any limitation on the ability of Teva, the Issuers or any of Teva&#146;s other
subsidiaries to incur additional unsecured debt. We may incur additional unsecured indebtedness in the future, which could have important consequences to holders of Exchange Notes, including that we could have insufficient cash to meet our financial
obligations, including our obligations under the Exchange Notes, and that our ability to obtain additional financing could be impaired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because
Teva and the Issuers are foreign entities, you may have difficulties enforcing your rights under the guarantees and under the Exchange Notes. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva is organized under the laws of Israel and certain of Teva&#146;s directors and officers reside outside of the United States. As a result,
service of process on them may be difficult or impossible to effect in the United States. Furthermore, a substantial portion of Teva&#146;s assets are located outside of the United States. Therefore, any judgment obtained in the United States
against us or any of our directors and officers may not be collectible within the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to various time limitations, an
Israeli court may declare a judgment rendered by a foreign court in a civil matter, including judgments awarding monetary or other damages in non civil matters, enforceable if it finds that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">the judgment was rendered by a court which was, according to the foreign country&#146;s law, competent to render it; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">the judgment is no longer appealable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">the obligation in the judgment is enforceable according to the rules relating to the enforceability of judgments in Israel and the substance of the judgment is not contrary to public policy in Israel; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">the judgment can be executed in the state in which it was given. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A foreign judgment will not
be declared enforceable by Israeli courts if it was given in a state, the laws of which do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases) or if its enforcement is likely to prejudice the sovereignty or
security of Israel. An Israeli court also will not declare a foreign judgment enforceable if it is proven to the Israeli court that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">the judgment was obtained by fraud; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">there was no due process; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">the judgment was given by a court not competent to render it according to the laws of private international law in Israel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">the judgment conflicts with another judgment that was given in the same matter between the same parties and which is still valid; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">at the time the action was brought to the foreign court a claim in the same matter and between the same parties was pending before a court or tribunal in Israel. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Issuers are organized under the laws of The Netherlands, their managing and supervisory directors reside outside the United States, and
all or a significant portion of the assets of such persons are, and substantially all of their assets are, located outside the United States. As a result, it may not be possible to effect service of process within the United States upon the Issuers
or any such person or to enforce against the Issuers or any such person judgments obtained in United States courts predicated upon the civil liability provisions of the federal securities laws of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because there is no treaty on the recognition and enforcement of judgments in civil and commercial matters between the United States and The
Netherlands, courts in The Netherlands will not recognize and enforce a judgment rendered by a United States court. For a United States judgment to be enforced in The Netherlands, a judgment creditor must bring proceedings before a competent court
in The Netherlands and seek a Dutch judgment enforcing the liability of the judgment debtor. If the party in whose favor such a final judgment by a United States court is rendered brings a new suit in a competent court in The Netherlands, that party
may submit to the Dutch court the final judgment that has been rendered in the United States. Based on the current practice of courts in The Netherlands, it appears that a final money judgment rendered by a United States federal or state court after
a substantive review of the merits (and not by mere &#147;default judgment&#148;) will be given effect by a Dutch court, without any <FONT STYLE="white-space:nowrap">re-examination</FONT> of the merits of the original judgment, provided that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">the judgment results from legal proceedings compatible with Dutch notions of due process; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">the judgment does not contravene public policy of the Netherlands; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">the jurisdiction of the relevant federal or state court in the United States has been based on internationally accepted principles of international civil law. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is doubt as to whether a Dutch court would accept jurisdiction and impose civil liability on the Issuers, their officers, directors or
persons of equivalent position in an original action brought in a court of competent jurisdiction in The Netherlands against the Issuers or such officers, directors or persons of equivalent position if such an action is predicated solely upon the
federal securities laws of the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The guarantees will effectively be subordinated to some of our existing and future indebtedness.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva will irrevocably and unconditionally guarantee the punctual payment when due of the principal of and interest, if any, on the
Exchange Notes. As indebtedness of Teva, the guarantees will be Teva&#146;s general, unsecured obligations and will rank equally in right of payment with all of Teva&#146;s existing and future unsubordinated, unsecured indebtedness. The guarantees
will be effectively subordinated to any existing and future secured indebtedness Teva may have up to the value of the collateral securing that indebtedness and structurally subordinated to any existing and future liabilities and other indebtedness
of our subsidiaries with respect to the assets of those subsidiaries. These liabilities may include debt securities, credit facilities, trade payables, guarantees, lease obligations, letter of credit obligations and other indebtedness. See
&#147;Description of the Exchange Dollar Notes&#151;Description of the Guarantees&#148; and &#147;Description of the Exchange Euro Notes&#151;Description of the Guarantees.&#148; The indentures governing the Exchange Notes do not restrict us or our
subsidiaries from incurring debt in the future, nor do the indentures limit the amount of indebtedness we can issue that is equal in right of payment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva may be subject to restrictions on receiving dividends and other payments from its subsidiaries.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#146;s income is derived in large part from its subsidiaries. Accordingly, Teva&#146;s ability to pay its obligations under
the guarantees depends in part on the earnings of its subsidiaries and the payment of those earnings to Teva, whether in the form of dividends, loans or advances. Such payment by Teva&#146;s subsidiaries to Teva may be subject to restrictions. The
indentures governing the Exchange Notes do not restrict Teva, the Issuers or Teva&#146;s other subsidiaries from entering into agreements that contain such restrictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An investment in the Exchange Notes by a purchaser whose home currency is not U.S. dollars or euros, as applicable, entails significant risks.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An investment in the Exchange Notes by a purchaser whose home currency is not U.S. dollars or euros, as applicable, entails
significant risks. These risks include the possibility of significant changes in rates of exchange between the holder&#146;s home currency and the U.S. dollar or euro, as applicable, and the possibility of the imposition or subsequent modification
of foreign exchange controls. These risks generally depend on factors over which we have no control, such as economic, financial and political events and the supply of and demand for the relevant currencies. In the past, rates of exchange between
the U.S. dollar or euro, as applicable, and certain currencies have been highly volatile, and each holder should be aware that volatility may occur in the future. Fluctuations in any particular exchange rate that have occurred in the past, however,
are not necessarily indicative of fluctuations in the rate that may occur during the terms of the Exchange Notes. Depreciation of the U.S. dollar or euro, as applicable, against the holder&#146;s home currency would result in a decrease in the
effective yield of the Exchange Notes, below its coupon rate and, in certain circumstances, could result in a loss to the holder. Investment in the Exchange Notes by a purchaser whose home currency is not U.S. dollars or euro, as applicable, may
also have important tax consequences. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The procedures for book-entry interests to be implemented through Euroclear or Clearstream may not be
adequate to ensure the timely exercise of your rights under the Exchange Euro Notes. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless and until Exchange Euro Notes in
definitive registered form are issued in exchange for global notes, owners of book-entry interests will not be considered owners or holders of the Exchange Euro Notes except in the limited circumstances provided in the indenture governing the
Exchange Euro Notes. The common depositary for Euroclear and Clearstream (or its nominee) will be the sole registered holder of the global notes representing the Exchange Euro Notes. After payment to the common depositary, we will have no
responsibility or liability for the payment of interest, principal or other amounts to the owners of book-entry interests. Accordingly, if you own a book-entry interest, you must rely on the procedures of Euroclear or Clearstream, as applicable, and
if you are not a participant in Euroclear or Clearstream, on the procedures of the participant through which you own your interest, to exercise any rights and obligations of a holder under the indenture governing the Exchange Euro Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unlike the holders of the Exchange Euro Notes themselves, owners of book-entry interests will not have the direct right to act upon our
solicitations for consents, requests for waivers or other actions from holders of the Exchange Euro Notes. Instead, if you own a book-entry interest, you will be permitted to act only to the extent you have received appropriate proxies to do so from
Euroclear or Clearstream. The procedures implemented for the granting of such proxies may not be sufficient to enable you to vote on any request actions on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, upon the occurrence of an event of default under the indenture governing the Exchange Euro Notes, if you own a book-entry interest,
you will be restricted to acting through Euroclear or Clearstream. The procedures to be implemented through Euroclear or Clearstream may not be adequate to ensure the timely exercise of rights under the Exchange Euro Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Exchange Notes have minimum specified denominations of $200,000 (in case of the Exchange Dollar
Notes) and &#128;100,000 (in case of the Exchange Euro Notes). </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Exchange Notes have minimum denominations of $200,000 (in case
of the Exchange Dollar Notes) and &#128;100,000 (in case of the Exchange Euro Notes) and multiples of $1,000 (in case of the Exchange Dollar Notes) and &#128;1,000 (in case of the Exchange Euro Notes) in excess thereof. It is therefore possible that
Exchange Notes may be traded in amounts that would cause a holder of Exchange Notes to hold a principal amount of less than $200,000 (in case of the Exchange Dollar Notes) and &#128;100,000 (in case of the Exchange Euro Notes) following such trade.
In such a case, a holder of Exchange Notes who holds a principal amount of less than $200,000 (in case of the Exchange Dollar Notes) and &#128;100,000 (in case of the Exchange Euro Notes) may not receive a definitive certificate in respect of such
holding (should definitive certificates be printed) and would need to purchase a principal amount of Exchange Notes such that its holding amounts to at least $200,000 (in case of the Exchange Dollar Notes) and &#128;100,000 (in case of the Exchange
Euro Notes). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In a lawsuit for payment on the Exchange Euro Notes, an investor may bear currency exchange risk. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture of the Exchange Euro Notes and the Exchange Euro Notes will be governed by the laws of the State of New York. Under New York law,
a New York state court rendering a judgment on the Exchange Euro Notes would be required to render the judgment in euros. The judgment would be converted into U.S. dollars, however, at the exchange rate prevailing on the date of entry of the
judgment. Consequently, in a lawsuit for payment on the Exchange Euro Notes, investors would bear currency exchange risk until a New York state court judgment is entered. A U.S. federal court sitting in New York with diversity jurisdiction over a
dispute arising in connection with the Exchange Euro Notes would apply the foregoing New York law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In courts outside of New York,
investors may not be able to obtain a judgment in a currency other than U.S. dollars. For example, a judgment for money in an action based on the Exchange Euro Notes in many other U.S. federal or state courts ordinarily would be enforced in the
United States only in U.S. dollars. The date used to determine the rate of conversion of euros into U.S. dollars would depend upon various factors, including which court renders the judgment and when the judgment is rendered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The exchange offer may be cancelled or delayed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have reserved the right to terminate or withdraw the exchange offer, including solely in respect of one or more series of the Original
Notes, in our sole discretion at any time and for any reason, subject to applicable law. Therefore, even if you properly submit a letter of instruction prior to the expiration date and otherwise comply with the terms and conditions of the exchange
offer, the exchange offer may not be consummated. Because of adjustments or other logistical challenges in exchanging Original Notes for Exchange Notes, among other things, the settlement of the exchange offer may be delayed. Accordingly, you may
have to wait longer than expected to receive your Exchange Notes, during which time you will not be able to effect transfers of your Original Notes or Exchange Notes you are to receive in the exchange offer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You must comply with the exchange offer procedures in order to receive new, freely tradable Exchange Notes. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delivery of Exchange Notes in exchange for Original Notes tendered and accepted for exchange pursuant to the exchange offer will be made only
if such tenders comply with the exchange offer procedures described herein. We are not required to notify you of defects or irregularities in tenders of Original Notes for exchange. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Some holders who exchange their Original Notes may be deemed to be underwriters, and these holders will be required to comply with the registration and
prospectus delivery requirements in connection with any resale transaction. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you exchange your Original Notes in the exchange
offer for the purpose of participating in a distribution of the Original Notes, you may be deemed to have received restricted securities and, if so, will be required to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comply with the registration and prospectus delivery requirements of the Securities Act in connection with any resale transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the exchange offer is not completed within a certain period after the issuance date of the respective Original Notes, the Issuers will incur
additional interest charges. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the exchange offer registration statement is not completed or is not declared
effective by the SEC within 365 days after the issuance date of the Original Notes, the interest rate will be increased, up to a maximum increase of (i) 0.25% per annum for the first <FONT STYLE="white-space:nowrap">90-day</FONT> period immediately
following such date and (ii)&nbsp;an additional 0.25% per annum with respect to each subsequent <FONT STYLE="white-space:nowrap">90-day</FONT> period, in each case until the exchange offer is completed or the becomes effective, up to a maximum total
increase of 0.50% per annum </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Retention of the Original Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you do not exchange your Original Notes, your Original Notes will continue to be subject to the existing transfer restrictions and you may be unable
to sell your Original Notes. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will only issue Exchange Notes in exchange for Original Notes that are validly tendered in
accordance with the procedures set forth in this prospectus. Therefore, you should carefully follow the instructions on how to tender your Original Notes. See &#147;The Exchange Offer&#151;Procedures for Tendering.&#148; We did not register the
Original Notes under the Securities Act, nor do we intend to do so following the exchange offer. If you do not exchange your Original Notes in the exchange offer, or if your Original Notes are not accepted for exchange, then, after we consummate the
exchange offer, you may continue to hold Original Notes that are subject to the existing transfer restrictions and may be transferred only in limited circumstances under the securities laws. If you do not exchange your Original Notes, you will lose
your right to have your Original Notes registered under the federal securities laws, except in limited circumstances. As a result, you will not be able to offer or sell Original Notes except in reliance on an exemption from, or in a transaction not
subject to, the Securities Act and applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we anticipate that most holders of Original Notes will elect
to exchange their Original Notes, we expect that the liquidity of the trading market for any Original Notes remaining after the completion of the exchange offer will be substantially reduced. Any Original Notes tendered and exchanged in the exchange
offer will reduce the aggregate number of Original Notes outstanding. Accordingly, the liquidity of the market for any Original Notes could be adversely affected and you may be unable to sell them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx558803_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This exchange offer is intended to satisfy our obligations under the Registration Rights Agreements. We will not receive any cash proceeds from
the issuance of the Exchange Notes. In consideration for issuing the Exchange Notes contemplated in this prospectus, we will receive the tendered outstanding Original Notes in like principal amount, the form and terms of which are substantially the
same as the form and terms of the Exchange Notes for which these Original Notes are exchanged, except as otherwise described in this prospectus. The Original Notes surrendered in exchange for the Exchange Notes will be retired and cancelled.
Accordingly, no additional debt will result from the exchange offer. We will bear the expense of the exchange offer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx558803_8"></A>EXCHANGE OFFER </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Purpose of the Exchange Offer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
exchange offer is designed to provide holders of Original Notes with an opportunity to acquire Exchange Notes which, unlike the Original Notes, will be freely transferable, subject to any restrictions on transfer imposed by state &#147;blue
sky&#148; laws and provided that the transferring holder is not our affiliate within the meaning of the Securities Act and, provided further that such holder acquired the Exchange Notes in the ordinary course of its business and is not engaged in,
and does not intend to engage in, a &#147;distribution&#148; of the Exchange Notes as such term is defined for purposes of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Original Dollar Notes were originally issued and sold on March&nbsp;14, 2018, to the initial purchasers, pursuant to the purchase
agreement, dated March&nbsp;7, 2018 and the Original Euro Notes were originally issued and sold on March&nbsp;14, 2018, to the initial purchasers, pursuant to the purchase agreement, dated March&nbsp;7, 2018. The Original Notes were issued and sold
in transactions not registered under the Securities Act in reliance upon the exemption provided by Section&nbsp;4(a)(2) of the Securities Act. The concurrent resales of the Original Notes by the initial purchasers to investors were done in reliance
upon the exemptions provided by Rule&nbsp;144A and Regulation&nbsp;S promulgated under the Securities Act. The Original Notes may not be reoffered, resold or transferred other than (i)&nbsp;to us or our subsidiaries, (ii)&nbsp;to a qualified
institutional buyer in compliance with Rule&nbsp;144A promulgated under the Securities Act, (iii)&nbsp;outside the United States to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> person within the meaning of Regulation&nbsp;S under the
Securities Act, (iv)&nbsp;pursuant to the exemption from registration provided by Rule&nbsp;144 promulgated under the Securities Act (if available) or (v)&nbsp;pursuant to an effective registration statement under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the original issuance and sale of the Original Notes, we entered into the Registration Rights Agreements, pursuant to which
we agreed to file with the SEC an exchange offer registration statement on an appropriate form under the Securities Act and offer to holders of Original Notes who are able to make certain representations the opportunity to exchange their Original
Notes for Exchange Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under existing interpretations by the Staff of the SEC as set forth in
<FONT STYLE="white-space:nowrap">no-action</FONT> letters issued to third parties in other transactions, the Exchange Notes would, in general, be freely transferable (other than in a distribution as noted above) after the exchange offer without
further registration under the Securities Act; provided, however, that in the case of broker-dealers participating in the exchange offer, a prospectus meeting the requirements of the Securities Act must be delivered by such broker-dealers in
connection with resales of the Exchange Notes. We have agreed to furnish a prospectus meeting the requirements of the Securities Act to any such broker-dealer for use in connection with any resale of any Exchange Notes acquired in the exchange
offer. A broker-dealer that delivers such a prospectus to purchasers in connection with such resales will be subject to certain of the civil liability provisions under the Securities Act and will be bound by the provisions of the Registration Rights
Agreements (including certain indemnification rights and obligations). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not intend to seek our own interpretation regarding the
exchange offer, and we cannot assure you that the staff of the SEC would make a similar determination with respect to the Exchange Notes as it has in other interpretations to third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of Original Notes that exchanges such Original Notes for Exchange Notes in the exchange offer will be deemed to have made certain
representations, including representations that (i)&nbsp;any Exchange Notes to be received by it will be acquired in the ordinary course of its business, (ii)&nbsp;it has no arrangement or understanding with any person to participate in the
distribution (within the meaning of the Securities Act) of Exchange Notes and (iii)&nbsp;it is not our affiliate as defined in Rule&nbsp;405 under the Securities Act, or if it is an affiliate, it will comply with the registration and prospectus
delivery requirements of the Securities Act to the extent applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the holder is not a broker-dealer, it will be required to
represent that it is not engaged in, and does not intend to engage in, the distribution of Original Notes or Exchange Notes. If the holder is a broker-dealer that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will receive Exchange Notes for its own account in exchange for Original Notes that were acquired as a result of market-making activities or other trading activities, it will be required to
acknowledge that it will deliver a prospectus in connection with any resale of such Exchange Notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms of the Exchange Offer; Period for Tendering
Outstanding Original Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the terms and subject to the conditions set forth in this prospectus, we will accept any and all
validly tendered Original Notes that were acquired pursuant to Rule&nbsp;144A or Regulation&nbsp;S, provided such tender has not been withdrawn prior to 11:59&nbsp;p.m., New York City time, on the expiration date of the exchange offer. The Original
Dollar Notes may be exchanged only in minimum denominations of $200,000 and any integral multiple of $1,000 in excess thereof. The Original Euro Notes may be exchanged only in minimum denominations of &#128;100,000 and any integral multiple of
&#128;1,000 in excess thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The form and terms of the Exchange Notes are the same as the form and terms of the outstanding Original
Notes except that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) the Exchange Notes will be registered under the Securities Act and will not have legends
restricting their transfer; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) the Exchange Notes will not contain the registration rights and liquidated damages
provisions contained in the outstanding Original Notes; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) interest on the Exchange Notes will accrue from the last
interest date on which interest was paid on your Original Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Exchange Notes will evidence the same debt as the Original Notes and will be
entitled to the benefits of the applicable Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to conduct the exchange offer in accordance with the applicable
requirements of the Exchange Act and the rules and regulations of the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be deemed to have accepted validly tendered Original
Notes when, as and if we have given oral or written notice of our acceptance to the relevant exchange agent. The exchange agents will act as agent for the tendering holders for the purpose of receiving the Exchange Notes from us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any tendered Original Notes are not accepted for exchange because of an invalid tender or the occurrence of specified other events set
forth in this prospectus, the certificates for any unaccepted Original Notes will be promptly returned, without expense, to the tendering holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders who tender Original Notes in the exchange offer will not be required to pay brokerage commissions or fees or transfer taxes with
respect to the exchange of Original Notes pursuant to the exchange offer. We will pay all charges and expenses, other than transfer taxes in certain circumstances, in connection with the exchange offer. See &#147;Fees and expenses&#148; and
&#147;Transfer taxes&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exchange offer will remain open for at least 20 business days. The term &#147;expiration date&#148;
will mean 11:59&nbsp;p.m., New York City time, on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, unless we, in our sole discretion, extend the exchange offer, in which case the term
&#147;expiration date&#148; will mean the latest date and time to which the exchange offer is extended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To extend the exchange offer,
prior to 9:00&nbsp;a.m., New York City time, on the next business day after the previously scheduled expiration date, we will: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) notify the exchange agents of any extension by oral notice (promptly confirmed in writing) or written notice, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) mail to the registered holders an announcement of any extension, and
issue a notice by press release or other public announcement before such expiration date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We reserve the right, in our sole discretion: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) if any of the conditions below under the heading &#147;&#151;Conditions of the Exchange Offer&#148; shall have not been
satisfied, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) to delay accepting any Original Notes, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) to extend the exchange offer, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) to terminate the exchange offer, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) to amend the terms of the exchange offer in any manner, provided however, that if we amend the exchange offer to make a
material change, including the waiver of a material condition, we will extend the exchange offer, if necessary, to keep the exchange offer open for at least five business days after such amendment or waiver; provided further, that if we amend the
exchange offer to change the percentage of Original Notes being exchanged or the consideration being offered, we will extend the exchange offer, if necessary, to keep the exchange offer open for at least ten business days after such amendment or
waiver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any delay in acceptance, extension, termination or amendment will be followed as promptly as practicable by oral or written notice to the
registered holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Procedures for Tendering Original Notes Through Brokers and Banks </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the Original Notes are represented by global notes, DTC, as depositary, or its nominee (in the case of the Original Dollar Notes) and a
common depository for Euroclear and Clearstream (in the case of the Original Euro Notes) is treated as the registered holder of the Original Notes and will be the only entity that can tender your Original Notes for Exchange Notes. Therefore, to
tender Original Notes subject to this exchange offer and to obtain Exchange Notes, you must instruct the institution where you keep your Original Notes to tender your Original Notes on your behalf so that they are received on or prior to the
expiration of this exchange offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The letter of transmittal that may accompany this prospectus may be used by you to give such
instructions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>YOU SHOULD CONSULT YOUR ACCOUNT REPRESENTATIVE AT THE BROKER OR BANK WHERE YOU KEEP YOUR ORIGINAL NOTES TO DETERMINE THE
PREFERRED PROCEDURE. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IF YOU WISH TO ACCEPT THIS EXCHANGE OFFER, PLEASE INSTRUCT YOUR BROKER OR ACCOUNT REPRESENTATIVE IN TIME FOR
YOUR ORIGINAL NOTES TO BE TENDERED BEFORE THE 11:59 PM (NEW YORK CITY TIME) DEADLINE ON&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deemed Representations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To participate in
the exchange offer, we require that you represent to us that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) you or any other person acquiring Exchange Notes in
exchange for your Original Notes in the exchange offer is acquiring them in the ordinary course of business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) neither
you nor any other person acquiring Exchange Notes in exchange for your Original Notes in the exchange offer is engaging in or intends to engage in a distribution of the Exchange Notes within the meaning of the federal securities laws; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) neither you nor any other person acquiring Exchange Notes in exchange for your Original Notes has an arrangement or
understanding with any person to participate in the distribution of Exchange Notes issued in the exchange offer; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) neither you nor any other person acquiring Exchange Notes in exchange
for your Original Notes is our &#147;affiliate&#148; as defined under Rule&nbsp;405 of the Securities Act; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5) if you
or another person acquiring Exchange Notes in exchange for your Original Notes is a broker-dealer and you acquired the Original Notes as a result of market-making activities or other trading activities, you acknowledge that you will deliver a
prospectus meeting the requirements of the Securities Act in connection with any resale of the Exchange Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>BY TENDERING YOUR
ORIGINAL NOTES YOU ARE DEEMED TO HAVE MADE THESE REPRESENTATIONS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broker-dealers who cannot make the representations in item&nbsp;(5)
of the paragraph above cannot use this exchange offer prospectus in connection with resales of the Exchange Notes issued in the exchange offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are our &#147;affiliate,&#148; as defined under Rule&nbsp;405 of the Securities Act, if you are a broker-dealer who acquired your
Original Notes in the initial offering and not as a result of market-making or trading activities, or if you are engaged in or intend to engage in or have an arrangement or understanding with any person to participate in a distribution of Exchange
Notes acquired in the exchange offer, you or that person: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) may not rely on the applicable interpretations of the Staff
of the SEC and therefore may not participate in the exchange offer; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) must comply with the registration and
prospectus delivery requirements of the Securities Act or an exemption therefrom when reselling the Original Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may tender some
or all of your Original Notes in this exchange offer. The Original Dollar Notes may be exchanged only in minimum denominations of $200,000 and any integral multiple of $1,000 in excess thereof. The Original Euro Notes may be exchanged only in
minimum denominations of &#128;100,000 and any integral multiple of &#128;1,000 in excess thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you tender your outstanding
Original Notes and we accept them, the tender will be a binding agreement between you and us as described in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The method
of delivery of outstanding Original Notes and all other required documents to the exchange agent is at your election and risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
decide all questions about the validity, form, eligibility, acceptance and withdrawal of tendered Original Notes, and our reasonable determination will be final and binding on you. We reserve the absolute right to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) reject any and all tenders of any particular Original Note not properly tendered; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) refuse to accept any Original Note if, in our reasonable judgment or the judgment of our counsel, the acceptance would be
unlawful; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) waive any defects or irregularities or conditions of the exchange offer as to any particular Original
Notes before the expiration of the offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our interpretation of the terms and conditions of the exchange offer will be final and binding
on all parties. You must cure any defects or irregularities in connection with tenders of Original Notes as we will reasonably determine. Neither we, the exchange agents, the trustee nor any other person will incur any liability for failure to
notify you or any defect or irregularity with respect to your tender of Original Notes. If we waive any terms or conditions pursuant to (3)&nbsp;above with respect to a noteholder, we will extend the same waiver to all noteholders with respect to
that term or condition being waived. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Procedures for Brokers and Custodian Banks; DTC ATOP Account </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to accept this exchange offer on behalf of a holder of Original Dollar Notes held through DTC you must submit or cause your DTC
participant to submit an Agent&#146;s Message as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exchange agent, on our behalf will seek to establish an Automated
Tender Offer Program (&#147;ATOP&#148;) account with respect to the outstanding Original Notes at DTC promptly after the delivery of this prospectus. Any financial institution that is a DTC participant, including your broker or bank, may make
book-entry tender of outstanding Original Dollar Notes by causing the book-entry transfer of such Original Dollar Notes into our ATOP account in accordance with DTC&#146;s procedures for such transfers. Concurrently with the delivery of Original
Dollar Notes, an Agent&#146;s Message in connection with such book-entry transfer must be transmitted by DTC to, and received by, the exchange agent on or prior to 11:59 pm, New York City Time on the expiration date. The confirmation of a book entry
transfer into the ATOP account as described above is referred to herein as a &#147;Book-Entry Confirmation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term
&#147;Agent&#146;s Message&#148; means a message transmitted by the DTC participants to DTC, and thereafter transmitted by DTC to the exchange agent, forming a part of the Book-Entry Confirmation which states that DTC has received an express
acknowledgment from the participant in DTC described in such Agent&#146;s Message stating that such participant and beneficial holder agree to be bound by the terms of this exchange offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Agent&#146;s Message must include the following information: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) name of the beneficial owner tendering such Original Dollar Notes; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) account number of the beneficial owner tendering such Original Dollar Notes; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) principal amount of Original Dollar Notes tendered by such beneficial owner; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) a confirmation that the beneficial holder of the Original Dollar Notes tendered has made the representations for our
benefit set forth under &#147;&#151;Deemed Representations&#148; above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Procedures for Tendering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have forwarded to you, along with this prospectus, a letter of transmittal relating to this exchange offer. Because all of the Original
Notes are held in book-entry accounts maintained by the exchange agent at DTC, Euroclear and Clearstream, a holder need not submit a letter of transmittal. However, all holders who exchange their Original Notes for Exchange Notes in accordance with
procedures outlined below will be deemed to have acknowledged receipt of, and agreed to be bound by, and to have made all of the representations and warranties contained in the letter of transmittal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of Original Dollar Notes hold their notes through DTC. Holders of Original Euro Notes hold their notes through Euroclear or
Clearstream. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To tender in the exchange offer, a holder must comply with the following procedures, as applicable: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Holders of Original Dollar Notes through DTC:</I> If you wish to exchange your Original Dollar Notes and either you or your registered holder hold your Original Dollar Notes in book-entry form directly through DTC,
you must submit an instruction and follow the procedures for book-entry transfer as provided under &#147;&#151;Book-Entry Transfer.&#148; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Holders of Original Euro Notes through Euroclear or Clearstream</I>: If you wish to exchange your Original
Euro Notes and either you or your registered holder hold your Original Euro Notes in book-entry form directly through Euroclear or Clearstream, you should be aware that pursuant to their internal guidelines, Euroclear and Clearstream will
automatically exchange your Original Notes for exchange notes. <B>If you</B> <B>do not wish to participate in the exchange offer, you</B> <B>must instruct</B> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
<B>Euroclear or Clearstream as the case may be, to &#147;Take No Action&#148;</B>; otherwise your Original Notes will automatically be tendered in the exchange offer, and you will be deemed to
have agreed to be bound by the terms of the letter of transmittal. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only a registered holder of record of Original Notes
may tender Original Notes in the exchange offer. If you are a beneficial owner of Original Notes that are registered in the name of a broker, dealer, commercial bank, trust company or other nominee, you may request your respective broker, dealer,
commercial bank, trust company or other nominee to effect the above transactions for you. Alternatively, if you are a beneficial owner and you wish to act on your own behalf in connection with the exchange offer, you must either make appropriate
arrangements to register ownership of the Original Notes in your name or obtain a properly completed bond power from the registered holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tender by a holder that is not withdrawn before expiration of the exchange offer will constitute an agreement between the holder and us in
accordance with the terms and subject to the conditions set forth in this prospectus and in the letter of transmittal. If a holder tenders less than all of the Original Notes held by the holder, the tendering holder should so indicate. The amount of
Original Notes delivered to the applicable exchange agent will be deemed to have been tendered unless otherwise indicated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The method of
delivery of Original Notes, the letter of transmittal and all other required documents or transmission of an agent&#146;s message, as described under &#147;&#151;Book-Entry Transfer,&#148; to the applicablw exchange agent is at the election and risk
of the holder. Rather than mail these items, we recommend that holders use an overnight or hand delivery service. In all cases, holders should allow sufficient time to assume delivery to the exchange agent before expiration of the exchange offer.
Holders should not send the letter of transmittal or Original Notes to us. Delivery of documents to DTC, Euroclear or Clearstream in accordance with their respective procedures will not constitute delivery to the applicable exchange agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer of registered ownership may take considerable time and may not be completed prior to the expiration date. If the applicable
letter of transmittal is signed by the record holder(s) of the Original Notes tendered, the signature must correspond with the name(s) written on the face of the original note without alteration, enlargement or any change whatsoever. If a letter of
transmittal is signed by the participant in DTC or Euroclear or Clearstream, as applicable, the signature must correspond with the name as it appears on the security position listing as the holder of the Original Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A signature on a letter of transmittal or a notice of withdrawal must be guaranteed by a member firm of a registered national securities
exchange or of the Financial industry Regulatory Authority, a commercial bank or trust company having an office or correspondent in the United States or &#147;an eligible guarantor institution&#148; within the meaning of Rule <FONT
STYLE="white-space:nowrap">17Ad-15</FONT> under the Exchange Act unless the Original Notes tendered pursuant thereto are tendered: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by a registered holder who has not completed the box entitled &#147;Special Registration Instructions&#148; or &#147;Special Delivery Instructions&#148; on the letter of transmittal; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for the account of an eligible institution. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a letter of transmittal is signed by a person
other than the registered holder of any Original Notes, the Original Notes must be endorsed or accompanied by a properly completed bond power. The bond power must be signed by the registered holder as the registered holder&#146;s name appears on the
Original Notes and an eligible institution must guarantee the signature on the bond power. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a letter of transmittal or any Original
Notes or bond powers are signed by trustees, executors, administrators, guardians, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact,</FONT></FONT> officers of corporations or others acting in a fiduciary or
representative capacity, these persons should so indicate when signing. Unless we waive this requirement, they should also submit evidence satisfactory to us of their authority to deliver the letter of transmittal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will determine in our sole discretion all questions as to the validity, form,
eligibility, including time of receipt, acceptance and withdrawal of tendered Original Notes. Our determination will be final and binding. We reserve the absolute right to reject any Original Notes not properly tendered or any Original Notes the
acceptance of which would, in the opinion of our counsel, be unlawful. We also reserve the right to waive any defects, irregularities or conditions of tender as to particular Original Notes. Our interpretation of the terms and conditions of the
exchange offer, including the instructions in the letter of transmittal, will be final and binding on all parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless waived, any
defects or irregularities in connection with tenders of Original Notes must be cured within the time that we determine. Although we intend to notify holders of defects or irregularities with respect to tenders of Original Notes, neither we, the
exchange agents, the trustee, nor any other person will incur any liability for failure to give notification. Tenders of Original Notes will not be deemed made until those defects or irregularities have been cured or waived. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Original Notes received by either exchange agent that are not properly tendered and as to which the defects or irregularities have not been
cured or waived will be returned by such exchange agent without cost to the tendering holder, unless otherwise provided in the letter of transmittal, as soon as practicable following the expiration date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we reserve the right in our sole discretion to (a)&nbsp;purchase or make offers for any Original Notes that remain outstanding
subsequent to the expiration date, and (b)&nbsp;to the extent permitted by applicable law, purchase Original Notes in the open market, in privately negotiated transactions or otherwise. The terms of any such purchases or offers may differ from the
terms of the exchange offer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Transfer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exchange agent for the Original Dollar Notes has established an account with respect to the Original Dollar Notes at DTC for the purpose of
facilitating the exchange offer. Any financial institution that is a participant in DTC&#146;s system may make book-entry delivery of Original Dollar Notes by causing DTC to transfer such Original Dollar Notes into the exchange agent&#146;s DTC
account in accordance with DTC&#146;s Automated Tender Offer Program procedures for such transfer. Pursuant to their internal guidelines, Euroclear and Clearstream will automatically exchange Original Notes for Exchange Notes on behalf of the
holders of the Original Notes. <B>If they do not wish to participate in the exchange offer, the registered holder of Original Notes on the records of Euroclear or Clearstream must instruct Euroclear or Clearstream as the case may be, to &#147;Take
No Action&#148;;</B> otherwise such Original Notes will be tendered in the exchange offer, and the holder of such notes will be deemed to have agreed to be bound by the terms of the letter of transmittal. The exchange for Original Notes so tendered
will only be made after a timely confirmation of a book-entry transfer of Original Notes into the exchange agent&#146;s account, and timely receipt by the exchange agent of an agent&#146;s message. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;agent&#146;s message&#148; means a message transmitted by DTC, Euroclear or Clearstream as the case may be, and received by the
applicable exchange agent and forming part of the confirmation of a book-entry transfer, which states that DTC has received an express or deemed acknowledgment from a participant tendering Original Notes and that the participant has received and
agrees to be bound by the terms of the letter of transmittal, and that we may enforce that agreement against the participant. Delivery of an agent&#146;s message will also constitute an acknowledgement from the tendering participant that the
representations contained in the appropriate letter of transmittal and described below are true and correct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>BY SENDING AN
AGENT&#146;S MESSAGE TO DTC, EUROCLEAR OR CLEARSTREAM, AS APPLICABLE, A PARTICIPANT IS DEEMED TO HAVE CERTIFIED THAT THE BENEFICIAL HOLDER FOR WHOM NOTES ARE BEING TENDERED HAS BEEN PROVIDED WITH A COPY OF THIS PROSPECTUS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The delivery of Original Notes through DTC, Euroclear or Clearstream and any transmission of
an Agent&#146;s Message through ATOP, is at the election and risk of the person tendering Original Notes. We will ask the applicable exchange agent to instruct DTC to promptly return those Original Notes, if any, that were tendered through ATOP but
were not accepted by us, to the DTC participant that tendered such Original Notes on behalf of holders of the Original Notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Acceptance of
Outstanding Original Notes for Exchange; Delivery of Exchange Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will accept validly tendered Original Notes when the conditions
to the exchange offer have been satisfied or we have waived them. We will have accepted your validly tendered Original Notes when we have given oral or written notice to the applicable exchange agent. The applicable exchange agent will act as agent
for the tendering holders for the purpose of receiving the Exchange Notes from us. If we do not accept any tendered Original Notes for exchange by book-entry transfer because of an invalid tender or other valid reason, we will credit the Notes to an
account maintained with DTC, Euroclear or Clearstream promptly after the exchange offer terminates or expires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE AGENT&#146;S
MESSAGE MUST BE TRANSMITTED TO THE EXCHANGE AGENT ON OR BEFORE 11:59 PM, NEW YORK CITY TIME, ON THE EXPIRATION DATE. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withdrawal Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may withdraw your tender of outstanding Original Notes at any time before 11:59&nbsp;p.m., New York City time, on the expiration date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a withdrawal to be effective, you should contact your bank or broker where your Original Notes are held and have them send an ATOP notice
of withdrawal (in the case of Original Notes held through DTC) or on electronic instruction (in the case of Original Notes held through Euroclear or Clearstream) so that it is received by the applicable exchange agent before 11:59&nbsp;p.m., New
York City time, on the expiration date. Such notice of withdrawal must: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) specify the name of the person that tendered
the Original Notes to be withdrawn; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) identify the Original Notes to be withdrawn, including the CUSIP number or ISIN
number (as applicable) and principal amount at maturity of the Original Notes; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) specify the name and number of an
account at the DTC, Euroclear or Clearstream (as applicable) to which your withdrawn Original Notes can be credited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will decide all questions as to
the validity, form and eligibility of the notices and our determination will be final and binding on all parties. Any tendered Original Notes that you withdraw will not be considered to have been validly tendered. We will promptly return any
outstanding Original Notes that have been tendered but not exchanged, or credit them to the DTC Euroclear or Clearstream account (as applicable). You may <FONT STYLE="white-space:nowrap">re-tender</FONT> properly withdrawn Original Notes by
following one of the procedures described above before the expiration date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conditions of the Exchange Offer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision of the exchange offer, or any extension of the exchange offer, we will not be required to accept for
exchange, or to issue Exchange Notes in exchange for, any outstanding Original Notes and may terminate the exchange offer (whether or not any Original Notes have been accepted for exchange) or amend the exchange offer, if any of the following
conditions has occurred or exists and such condition has not been waived by us in our sole reasonable discretion or satisfied, prior to the expiration date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any statute, rule, regulation, order or injunction has been sought, proposed, introduced, enacted, promulgated or
deemed applicable to the exchange offer or any of the transactions contemplated by the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
exchange offer by any governmental authority, domestic or foreign or if there is threatened, instituted or pending any action or proceeding before, or any injunction, order or decree issued by,
any court or governmental agency or other governmental regulatory or administrative agency or commission: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) seeking to restrain or prohibit the making or completion of the exchange offer or any other transaction contemplated by the
exchange offer, or assessing or seeking any damages as a result of this transaction; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) resulting in a material delay
in our ability to accept for exchange or exchange some or all of the Original Notes in the exchange offer; or </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any action has been taken, proposed or threatened, by any governmental authority, domestic or foreign, that, in our sole reasonable judgment, would (a)&nbsp;directly or indirectly result in any of the consequences
referred to in clauses&nbsp;(1) or (2)&nbsp;above, (b)&nbsp;result in the holders of Exchange Notes having obligations with respect to resales and transfers of Exchange Notes which are greater than those described in the interpretation of the SEC
referred to above, or (c)&nbsp;otherwise make it inadvisable to proceed with the exchange offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any of the following has occurred: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) any general suspension of or general
limitation on prices for, or trading in, securities on any national securities exchange or in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) any limitation by a governmental authority which adversely affects our ability to complete the transactions contemplated by
the exchange offer; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) a declaration of a banking moratorium or any suspension of payments in respect of banks in the
United States or any limitation by any governmental agency or authority which adversely affects the extension of credit; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) a commencement of a war, armed hostilities or other similar international calamity directly or indirectly involving the
United States, or, in the case of any of the preceding events existing at the time of the commencement of the exchange offer, a material acceleration or worsening of these calamities; or </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any change, or any development involving a prospective change, has occurred or been threatened in our business, financial condition, operations or prospects and those of our subsidiaries taken as a whole that is or may
be adverse to us, or we have become aware of facts that have or may have an adverse impact on the value of the Original Notes or the Exchange Notes, which in our sole reasonable judgment in any case makes it inadvisable to proceed with the exchange
offer and/or with such acceptance for exchange or with such exchange; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">there shall occur a change in the current interpretation by the Staff of the SEC which permits the Exchange Notes issued pursuant to the exchange offer in exchange for Original Notes to be offered for resale, resold and
otherwise transferred by holders thereof (other than broker-dealers and any such holder which is our affiliate within the meaning of Rule&nbsp;405 promulgated under the Securities Act) without compliance with the registration and prospectus delivery
provisions of the Securities Act, provided that such Exchange Notes are acquired in the ordinary course of such holders&#146; business and such holders have no arrangement or understanding with any person to participate in the distribution of such
Exchange Notes; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any law, statute, rule or regulation shall have been adopted or enacted which, in our reasonable judgment, would impair our ability to proceed with the exchange offer; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a stop order shall have been issued by the SEC or any state securities authority suspending the effectiveness of the registration statement, or proceedings shall have been initiated or, to our knowledge, threatened for
that purpose, or any governmental approval has not been obtained, which approval we shall, in our sole reasonable discretion, deem necessary for the consummation of the exchange offer as contemplated hereby; or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we have received an opinion of counsel experienced in such matters to the effect that there exists any actual or threatened legal impediment (including a default or prospective default under an agreement, indenture or
other instrument or obligation to which we are a party or by which we are bound) to the consummation of the transactions contemplated by the exchange offer. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we determine in our sole reasonable discretion that any of the foregoing events or conditions has occurred or exists and has not been
satisfied, we may, subject to applicable law, terminate the exchange offer (whether or not any Original Notes have been accepted for exchange) or may waive any such condition or otherwise amend the terms of the exchange offer in any respect. If such
waiver or amendment constitutes a material change to the exchange offer, we will promptly disclose such waiver or amendment by means of a prospectus supplement that will be distributed to the registered holders of the Original Notes and will extend
the exchange offer to the extent required by <FONT STYLE="white-space:nowrap">Rule&nbsp;14e-1</FONT> promulgated under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These conditions are for our sole benefit and we may assert them regardless of the circumstances giving rise to any of these conditions, or we
may waive them, in whole or in part, in our sole reasonable discretion, provided that we will not waive any condition with respect to an individual holder of Original Notes unless we waive that condition for all such holders. Any reasonable
determination made by us concerning an event, development or circumstance described or referred to above will be final and binding on all parties. Our failure at any time to exercise any of the foregoing rights will not be a waiver of our rights and
each such right will be deemed an ongoing right which may be asserted at any time before the expiration of the exchange offer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange Agent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bank of New York Mellon has been appointed as Exchange Dollar Notes Exchange Agent in connection with the exchange offer for the Original
Dollar Notes. Questions and requests for assistance, as well as requests for additional copies of this prospectus or of the letter of transmittal, should be directed to the Exchange Agent at its offices at The Bank of New York Mellon, 101 Barclay
Street, Floor 7- East New York, NY 10286, attention Global Corporate Trust Administration &#150; Teva. The Exchange Dollar Note Exchange Agent&#146;s telephone number is (212) 815-5587 and facsimile number is (212) 815-2830. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bank of New York Mellon. London Branch has been appointed as Exchange Euro Notes Exchange Agent in connection with the exchange offer for
the Euro Notes. Questions and requests for assistance, as well as requests for additional copies of this prospectus or of the letter of transmittal, should be directed to the Euro Note Exchange Agent at its offices at The Bank of New York Mellon,
London Branch, One Canada Square, London E145AL United Kingdom, attention Debt Restructuring Services. The Euro Note Exchange Agent&#146;s telephone number is +44&nbsp;(0) 1202 689644, facsimile number is +44 (0) 207 964 2728,
E-mail&nbsp;debtrestructuring@bnymellon.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fees and Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal solicitation for the Original Dollar Notes is being made through DTC by The Bank of New York Mellon, as Exchange Dollar Notes
Exchange Agent, and the principal solicitation for the Original Euro Notes is being made through Euroclear and Clearstream by The Bank of New York Mellon, London Branch, as Exchange Euro Notes Exchange Agent. We will pay each exchange agents&#146;
customary fees for its services, reimburse each exchange agent for its reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with the provisions of these services and
pay other registration expenses, including registration and filing fees, fees and expenses of compliance with federal securities and state blue sky securities laws, printing expenses, messenger and delivery services and telephone, fees and
disbursements to our counsel, application and filing fees and any fees and disbursements to our independent certified public accountants. We will not make any payment to brokers, dealers, or others soliciting acceptances of the exchange offer except
for reimbursement of mailing expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional solicitations may be made by telephone, facsimile or in person by our and our
authorized agents&#146; respective officers, employees and by persons so engaged by the exchange agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting Treatment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Exchange Notes will be recorded at the same carrying value as the existing Original Notes, as reflected in our accounting records on the
date of exchange. Accordingly, neither Teva, the Issuers or any of their subsidiaries will recognize any gain or loss for accounting purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you tender outstanding
Original Notes for exchange you will not be obligated to pay any transfer taxes. However, if you instruct us to register Exchange Notes in the name of, or request that your Original Notes not tendered or not accepted in the exchange offer be
returned to, a person other than the registered tendering holder, you will be responsible for paying any transfer tax owed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>YOU MAY
SUFFER ADVERSE CONSEQUENCES IF YOU FAIL TO EXCHANGE OUTSTANDING ORIGINAL NOTES. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you do not tender your outstanding Original Notes,
you will not have any further registration rights, except for the rights described in the Registration Rights Agreements and described above, and your Original Notes will continue to be subject to the provisions of the indentures governing the
Original Notes regarding transfer and exchange of the Original Notes and the restrictions on transfer of the Original Notes imposed by the Securities Act and state securities laws when we complete the exchange offer. These transfer restrictions are
required because the Original Notes were issued under an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, if you do not tender your Original
Notes in the exchange offer, your ability to sell or otherwise transfer your Original Notes could be adversely affected. Once we have completed the exchange offer, holders who have not tendered notes will not continue to be entitled to any increase
in interest rate that the indentures governing the Original Notes provides for if we do not complete the exchange offer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consequences of Failure to
Exchange </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Original Notes that are not exchanged for Exchange Notes pursuant to the exchange offer will remain restricted
securities. Accordingly, the Original Notes may be resold only: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) to us upon redemption thereof or otherwise; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) so long as the outstanding securities are eligible for resale pursuant to Rule&nbsp;144A, to a person inside the United
States who is a qualified institutional buyer within the meaning of Rule&nbsp;144A under the Securities Act in a transaction meeting the requirements of Rule&nbsp;144A, in accordance with Rule&nbsp;144 under the Securities Act, or pursuant to
another exemption from the registration requirements of the Securities Act, which other exemption is based upon an opinion of counsel reasonably acceptable to us; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) outside the United States to a foreign person in a transaction meeting the requirements of Rule&nbsp;904 under the
Securities Act; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) pursuant to an effective registration statement under the Securities Act, in each case in
accordance with any applicable securities laws of any state of the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shelf Registration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registration Rights Agreements also require that we file&nbsp;a shelf registration statement if: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) the Issuers and the Guarantor determine that the registration of the Exchange Notes is not available or may not be
completed as soon as practicable after the last exchange date because it would violate any applicable law or applicable interpretations of the SEC; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) a holder participating in the exchange offer does not receive Exchange Notes on the date of the exchange that may be sold
without restriction under state and federal securities laws (other than due solely </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
to the status of such holder as an affiliate of the applicable Issuer within the meaning of the Securities Act) and notifies the applicable Issuer within 30 days after such holder first becomes
aware of such restrictions; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) the exchange offer is not for any reason completed within the applicable periods set forth
in the Registration Rights Agreements; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) the applicable Issuer receives a written request from any Initial Purchaser
representing that it holds Original Notes that are or were ineligible to be exchanged in the exchange offer; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also register the
Exchange Notes under the securities laws of jurisdictions that holders may request before offering or selling notes in a public offering. We do not intend to register Exchange Notes in any jurisdiction unless a holder requests that we do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Original Notes may be subject to restrictions on transfer until: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) a person other than a broker-dealer has exchanged the Original Notes in the exchange offer; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) a broker-dealer has exchanged the Original Notes in the exchange offer and sells them to a purchaser that receives a
prospectus from the broker-dealer on or before the sale; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) the Original Notes are sold under an effective shelf
registration statement that we have filed; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) the Original Notes are sold to the public under Rule 144 of the
Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx558803_9"></A>DESCRIPTION OF THE EXCHANGE DOLLAR NOTES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We issued the Original Dollar Notes and will issue the Exchange Dollar Notes pursuant to a senior indenture, as supplemented by a supplemental
indenture, each dated as of March&nbsp;14, 2018, by and among Teva Finance III, Teva and The Bank of New York Mellon, as trustee. The terms of the Exchange Dollar Notes include those stated in the Indenture and, except as specified below, those made
part of such indenture by reference to the Trust&nbsp;Indenture Act of 1939, as amended (the &#147;Trust&nbsp;Indenture Act&#148;). The Exchange Dollar Notes are subject to all such terms pursuant to the provisions of the indenture, and Holders of
the Exchange Dollar Notes are referred to the Indenture and the Trust&nbsp;Indenture Act for a statement thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a
summary of the material provisions of the indenture. Because this is a summary, it may not contain all the information that is important to you. You should read the indenture in its entirety. Copies of the indenture are available as described under
&#147;Incorporation of Certain Documents by Reference.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we refer to Teva or the guarantor in this section, we refer only to
Teva Pharmaceutical Industries Limited, an Israeli corporation. When we refer to Teva Finance III or the issuer in this section, we refer to Teva Pharmaceutical Finance Netherlands III B.V., an indirect, wholly-owned subsidiary of Teva organized as
a Dutch private limited liability company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this section, we refer to the senior indenture referenced in the first paragraph of this
section, as supplemented, as &#147;the indenture&#148;; we refer to the 2024 Exchange Dollar Notes as the 2024 notes and the 2028 Exchange Dollar Notes as the 2028 notes; and when we refer to the 2024 notes and the 2028 notes, each as a series of
notes and, collectively, as the &#147;notes,&#148; we refer to the Exchange Dollar Notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Brief Description of the Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initially be limited to: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$1,250,000,000 aggregate principal amount of the 2024 notes; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$1,250,000,000 aggregate principal amount of the 2028 notes; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">subject to reopening of the
notes at the discretion of the issuer; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">accrue interest at a rate of: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">6.000% on the 2024 notes, payable semi-annually in arrears on April&nbsp;15 and October&nbsp;15 of each year, beginning on October&nbsp;15, 2018; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">6.750% on the 2028 notes, payable semi-annually in arrears on March&nbsp;1 and September&nbsp;1 of each year, beginning on September&nbsp;1, 2018; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">constitute general unsecured obligations of the issuer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be redeemable (in addition to being redeemable as set forth below under &#147;&#151;Tax Redemption&#148;) at the
option of Teva Finance III at any time at the greater of (1) 100% of the principal amount of the series of notes to be redeemed or (2)&nbsp;the sum of the present values of the Remaining Scheduled Payments (as defined below) on the series of notes
being redeemed discounted, on a semi-annual basis (assuming a <FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months), at a rate equal to the sum of the Treasury Rate (as
defined below) plus 50 basis points, in the case of the 2024 notes, or 50 basis points, in the case of the 2028 notes, plus in each case accrued and unpaid interest thereon, if any (including additional interest, if any), to, but not including, the
redemption date; provided that if the issuer redeems the notes of any series on or after the applicable Par Call Date (as defined below) for such series, the redemption price </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
for such notes will be equal to 100% of the aggregate principal amount of such notes being redeemed, plus accrued and unpaid interest thereon, if any (including additional interest, if any), to,
but not including, the redemption date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">are due on: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">April&nbsp;15, 2024, in the case of the 2024 notes; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">March&nbsp;1, 2028, in the case of the 2028 notes; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">in each case, unless earlier redeemed by
the issuer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture does not contain any financial covenants or restrictions on the amount of additional indebtedness that Teva,
Teva Finance III or any of Teva&#146;s other subsidiaries may incur except as described in &#147;&#151;Certain Covenants&#148; below. The indenture does not protect you in the event of a highly leveraged transaction or change of control of Teva or
Teva Finance III. The notes do not contain any sinking fund provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance III may, without the consent of the holders, issue
additional notes of any series under the indenture with the same terms (except for the issue date, issue price and, in some cases, the first payment of interest or interest accruing prior to the issue date of such additional notes) and with the same
CUSIP number as the notes of such series offered hereby in an unlimited aggregate principal amount; provided that if the additional notes of a series are not fungible with the notes of such series for United States federal income tax purposes, such
additional notes will have a separate CUSIP number. We may also from time to time repurchase notes in open market purchases or negotiated transactions without giving prior notice to holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may present definitive registered notes for registration of transfer and exchange, without service charge, at our office or agency in New
York City, which shall initially be the office or agency of the trustee in New York City. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of the Guarantees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva will irrevocably and unconditionally guarantee the punctual payment when due, whether at maturity, upon redemption, by acceleration or
otherwise, of the principal of and premium and interest (including any additional amounts in respect of taxes as provided herein), if any, on the notes of each series as well as all other amounts due and payable under the indenture. The respective
guarantees will be enforceable by the trustee, the holders of the applicable notes and their successors, transferees and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each
guarantee will be an unsecured senior obligation of Teva. As indebtedness of Teva, each guarantee will rank: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">senior to the rights of creditors under indebtedness expressly subordinated to the guarantee (at December&nbsp;31, 2017, Teva had no subordinated indebtedness outstanding); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">equally with other unsecured indebtedness of Teva from time to time outstanding other than any that is subordinated to the guarantee (at December&nbsp;31, 2017, Teva had approximately $32.5&nbsp;billion of senior
unsecured indebtedness outstanding); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectively junior to Teva&#146;s secured indebtedness up to the value of the collateral securing that indebtedness (at December&nbsp;31, 2017, Teva had no secured indebtedness outstanding); and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectively junior to the indebtedness and other liabilities of Teva&#146;s subsidiaries (at December&nbsp;31, 2017, Teva&#146;s subsidiaries, other than finance subsidiaries, had a <I>de minimis</I> amount of
indebtedness outstanding). </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment of Interest and Principal </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest on the Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2024 notes will bear interest at the rate of 6.000% per year, payable semi-annually in arrears on April&nbsp;15 and October&nbsp;15 of each
year, beginning October&nbsp;15, 2018, to the holders of record at the close of business on the preceding April&nbsp;1 and October&nbsp;1, respectively, whether or not a Business Day (as defined below). The 2028 notes will bear interest at the rate
of 6.750% per year, payable semi-annually in arrears on&nbsp;March 1 and September 1&nbsp;of each year, beginning September&nbsp;1, 2018, to the holders of record at the close of business on the preceding February&nbsp;15 and August&nbsp;15,
respectively, whether or not a Business Day. If an interest payment date for the notes falls on a day that is not a Business Day, interest will be payable on the next succeeding Business Day with the same force and effect as if made on such interest
payment date and no interest shall accrue thereon on account of such delay. Interest on the notes will be computed on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year comprised of twelve
<FONT STYLE="white-space:nowrap">30-day</FONT> months, and will accrue from March&nbsp;14, 2018, or from the most recent interest payment date to which interest has been paid to, but not including, the next interest payment date. Additional interest
may accrue on the notes in certain circumstances pursuant to the Registration Rights Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Business Day&#148; means a day
other than (i)&nbsp;a Saturday or Sunday, (ii)&nbsp;a day on which banks in New York, New York are authorized or obligated by law or executive order to remain closed or (iii)&nbsp;a day on which the trustee&#146;s corporate trust office is closed
for business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mechanics of Payment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided below, Teva Finance III will pay interest on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the global registered notes to The Depository Trust Company (&#147;DTC&#148;) in immediately available funds; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any definitive registered notes having an aggregate principal amount of $5,000,000 or less by check mailed to the holders of these notes; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any definitive registered notes having an aggregate principal amount of more than $5,000,000 by wire transfer in immediately available funds at the election of the holders of these notes. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At maturity, Teva Finance III will pay interest on the definitive registered notes at our office or agency in New York City, which initially
will be the office or agency of the trustee in New York City. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance III will pay principal and premium, if any, on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the global registered notes to DTC in immediately available funds; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any definitive registered notes at our office or agency in New York City, which initially will be the office or agency of the trustee in New York City. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference to payments of interest in this section, unless the context otherwise requires, refer to the payment of interest and additional
amounts in respect to taxes, if any. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Optional Redemption by the Issuer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuer may redeem the notes of any series, in whole or in part, at any time or from time to time, on at least 20 days&#146;, but not more
than 60 days&#146;, prior notice delivered to the registered address of each holder of the relevant notes, with a copy of such notice delivered to the trustee. The redemption prices will be equal to the greater of (1) 100% of the principal amount of
the series of notes to be redeemed or (2)&nbsp;the sum of the present values of the Remaining Scheduled Payments (as defined below) on the series of notes being redeemed discounted, on a semi-annual basis (assuming a
<FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months), using a discount rate equal to the sum of the Treasury Rate (as defined below) plus 50 basis points, in the case of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2024 notes, and 50 basis points, in the case of the 2028 notes, plus in each case accrued and unpaid interest thereon, if any (including additional interest, if any), to, but not including, the
redemption date; provided that if the issuer redeems the notes of any series on or after the applicable Par Call Date for such series, the redemption price for such notes will be equal to 100% of the aggregate principal amount of such notes being
redeemed, plus accrued and unpaid interest thereon, if any (including additional interest, if any), to, but not including, the redemption date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of any redemption of any series of notes in connection with a corporate transaction (including an equity offering, an incurrence of
indebtedness or a change of control) may, at the issuer&#146;s discretion, be given prior to the completion thereof and any such redemption or notice may, at the issuer&#146;s discretion, be subject to one or more conditions precedent, including,
but not limited to, completion of the related transaction. If such redemption or purchase is so subject to satisfaction of one or more conditions precedent, such notice shall describe each such condition, and such notice may be rescinded or the
redemption date delayed in the event that any or all such conditions shall not have been satisfied by the redemption date. In addition, the issuer may provide in such notice that payment of the redemption price and performance of its obligations
with respect to such redemption may be performed by another person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Comparable Treasury Issue&#148; means the United States
Treasury security selected by an Independent Investment Banker as having a maturity comparable to the remaining term to the Par Call Date of the applicable series of notes to be redeemed that would be utilized, at the time of selection and in
accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term to the Par Call Date of such series of notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Comparable Treasury Price&#148; means, with respect to any redemption date, (1)&nbsp;the average of the Reference Treasury Dealer
Quotations for such redemption date after excluding the highest and lowest of such Reference Treasury Dealer Quotations or (2)&nbsp;if the Independent Investment Banker obtains fewer than five such Reference Treasury Dealer Quotations, the average
of all such quotations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Independent Investment Banker&#148; means one of the Reference Treasury Dealers appointed by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Par Call Date&#148; means (i)&nbsp;with respect to the 2024 notes, January&nbsp;15, 2024 (the date that is three months prior to the
maturity date of such notes) and (ii)&nbsp;with respect to the 2028 notes, December&nbsp;1, 2027 (the date that is three months prior to the maturity date of such notes). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Reference Treasury Dealer&#148; means each of Barclays Capital Inc., BNP Paribas Securities Corp., Citigroup Global Markets Inc., Credit
Suisse Securities (USA) LLC, HSBC Securities (USA) Inc. and Merrill Lynch, Pierce Fenner&nbsp;&amp; Smith Incorporated and their respective successors. If any of the foregoing shall cease to be a Primary Treasury Dealer, we will substitute another
nationally recognized investment banking firm that is a Primary Treasury Dealer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Reference Treasury Dealer Quotations&#148; means,
with respect to each Reference Treasury Dealer and any redemption date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its
principal amount) quoted in writing to the Independent Investment Banker by such Reference Treasury Dealer at 3:30 p.m., New York City time, on the third Business Day preceding such redemption date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Remaining Scheduled Payments&#148; means, with respect to each note to be redeemed, the remaining scheduled payments of principal of and
interest on such note as if redeemed on the applicable Par Call Date. If the applicable redemption date is not an interest payment date with respect to such note, the amount of the next succeeding scheduled interest payment on such note will be
reduced by the amount of interest accrued on such note to such redemption date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Treasury Rate&#148; means, with respect to any redemption date, the rate per year
equal to the semi-annual equivalent yield to maturity (computed as of the second Business Day immediately preceding such redemption date) of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage
of its principal amount) equal to the Comparable Treasury Price for such redemption date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On and after the redemption date, interest will
cease to accrue on the applicable series of notes or any portion of such series as is called for redemption (unless we default in the payment of the redemption price and accrued interest). On or prior to the redemption date, we will deposit with a
paying agent (or the trustee) money sufficient to pay the redemption price of and accrued interest on the notes to be redeemed on such date. If less than all of the notes of such series are to be redeemed, the notes of such series to be redeemed
shall be selected by the trustee on a pro rata basis, by lot or by such method as the trustee shall deem fair and appropriate and subject to the rules of the applicable depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of the notes do not prevent Teva, Teva Finance III or any of Teva&#146;s other subsidiaries from purchasing notes on the open
market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Covenants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Limitations on Secured Debt</I>. If Teva or any of its subsidiaries creates, incurs, assumes or suffers to exist any lien on any of its
property (including a subsidiary&#146;s stock or debt) to secure other debt, Teva will secure the notes on the same basis for so long as such other debt is so secured, unless, after giving effect to such lien, the aggregate amount of the secured
debt then outstanding (not including debt secured by liens permitted below) plus the value of all sale and leaseback transactions described in paragraph (3)&nbsp;of &#147;&#151;Limitations on Sales and Leasebacks&#148; below would not exceed 10% of
Teva&#146;s Consolidated Net Worth. The restrictions do not apply to the following liens: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">liens existing as of the date when Teva Finance III first issues such series of notes pursuant to the indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">liens on property created, incurred or assumed prior to, at the time of or within 120 days after the date of acquisition, completion of construction or completion of improvement of such property to secure all or part of
the cost of acquiring, constructing or improving all or any part of such property; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">landlord&#146;s, material men&#146;s, carriers&#146;, workmen&#146;s, repairmen&#146;s or other like liens arising in the ordinary course of business in respect of obligations which are not overdue or which are being
contested in good faith in appropriate proceedings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">liens existing on any property of a corporation or other entity at the time it became or becomes a subsidiary of Teva (provided that the lien has not been created or assumed in contemplation of that corporation or other
entity becoming a subsidiary of Teva); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">liens securing debt owing by a subsidiary to Teva or to one or more of its subsidiaries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">liens in favor of any governmental authority of any jurisdiction securing the obligation of Teva or any of its subsidiaries pursuant to any contract or payment owed to that entity pursuant to applicable laws,
regulations or statutes; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any extension, renewal, substitution or replacement of the foregoing, provided that the principal amount is not increased and that such lien is not extended to other property. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Consolidated Net Worth&#148; means the stockholders&#146; equity of the guarantor and its consolidated subsidiaries, as shown on the
audited consolidated balance sheet of the guarantor&#146;s latest annual report to stockholders, prepared in accordance with accounting principles generally accepted in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Limitations on Sales and Leasebacks</I>. Teva will not, and will not permit any
subsidiary to, enter into any sale and leaseback transaction covering any property after the date when Teva Finance III first issues such series of notes pursuant to the indenture unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">the sale and leaseback transaction: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top">involves a lease for a period, including renewals, of not more than five years; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top">occurs within 270 days after the date of acquisition, completion of construction or completion of improvement of such property; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top">is with Teva or one of its subsidiaries; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Teva or any subsidiary, within 270 days after the sale and leaseback transaction shall have occurred, applies or causes to be applied an amount equal to the value of the property so sold and leased back at the time of
entering into such arrangement to the prepayment, repayment, redemption, reduction or retirement of any indebtedness of Teva or any subsidiary that is not subordinated to the notes and that has a stated maturity of more than twelve months; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Teva or any subsidiary would be entitled pursuant to the exceptions under &#147;&#151;Limitations on Secured Debt&#148; above to create, incur, issue or assume indebtedness secured by a lien in the property without
equally and ratably securing the notes. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Certain Other Covenants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture contains certain other covenants regarding, among other matters, corporate existence and reports to holders of notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Tax Amounts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither Teva
Finance III, as the issuer, nor Teva, as the guarantor, will withhold or deduct from payments made with respect to the notes of any series on account of any present or future Taxes unless such withholding or deduction is required by law. The term
&#147;Taxing Jurisdiction&#148; as used herein means with respect to the notes, The Netherlands, Israel or any jurisdiction where a successor to Teva Finance III or Teva is incorporated or organized or considered to be a resident, if other than The
Netherlands or Israel, respectively, or any jurisdiction through which payments will be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Taxes&#148; means, with respect to
payments on the notes, all taxes, withholdings, duties, assessments or governmental charges of whatever nature imposed or levied by or on behalf of any Taxing Jurisdiction or any political subdivision thereof or any authority or agency therein or
thereof having power to tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Teva Finance III or Teva is required to withhold or deduct on account of any such Taxes
from any payment made under or with respect to the notes, Teva Finance III or Teva, as the case may be, will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withhold or deduct such amounts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay such additional tax amounts so that the net amount received by each holder or beneficial owner of the relevant notes, including those additional tax amounts, will equal the amount that such holder or beneficial
owner would have received if such Taxes had not been required to be withheld or deducted; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay the full amount withheld or deducted to the relevant tax or other authority in accordance with applicable law, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except that no such additional amounts will be payable in respect of any note: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent that such Taxes are imposed or levied by reason of such holder (or the beneficial owner) having
some present or former connection with the Taxing Jurisdiction other than the mere holding (or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
beneficial ownership) of such note or receiving principal or interest payments on the notes (including but not limited to citizenship, nationality, residence, domicile, or the existence of a
business, permanent establishment, a dependent agent, a place of business or a place of management present or deemed present in the Taxing Jurisdiction); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">in respect of any Taxes that would not have been so withheld or deducted but for the failure by the holder or the beneficial owner of the notes to make a declaration of
<FONT STYLE="white-space:nowrap">non-residence,</FONT> or any other claim or filing for exemption to which it is entitled or otherwise comply with any reasonable certification, identification, information, documentation or other reporting
requirement concerning nationality, residence, identity or connection with the Taxing Jurisdiction if (a)&nbsp;compliance is required by applicable law, regulation, administrative practice or treaty as a precondition to exemption from all or part of
the Taxes, (b)&nbsp;the holder (or beneficial owner) is able to comply with these requirements without undue hardship and (c)&nbsp;we have given the holders (or beneficial owners) at least 30 calendar days prior notice that they will be required to
comply with such requirement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">to the extent that such Taxes are imposed by reason of any estate, inheritance, gift, sales, transfer or personal property taxes imposed with respect to the notes, except as otherwise provided in the indenture;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top">to the extent that any such Taxes would not have been imposed but for the presentation of such notes, where presentation is required, for payment on a date more than 30 days after the date on which such payment became
due and payable or the date on which payment thereof is duly provided for, whichever is later, except to the extent that the holder would have been entitled to additional tax amounts had the notes been presented for payment on any date during such <FONT
STYLE="white-space:nowrap">30-day</FONT> period; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top">in respect of any Taxes imposed under Sections 1471-1474 of the Internal Revenue Code of 1986, as amended, any applicable U.S. Treasury Regulations promulgated thereunder, or any judicial or administrative
interpretations of any of the foregoing; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6)</TD>
<TD ALIGN="left" VALIGN="top">any combination of items 1 through 5 above. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance III, as the issuer, and Teva, as the
guarantor, will pay any present or future stamp, court or documentary taxes or any other excise or property taxes, charges or similar levies that arise from the execution, delivery, enforcement or registration of the notes of any series or any other
document or instrument in relation thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Redemption </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes of any series may be redeemed as a whole, but not in part, at the option of Teva Finance III, Teva or any successor to Teva Finance
III or Teva, as the case may be, at any time prior to maturity, upon the giving of not less than 20 days&#146; nor more than 60 days&#146; notice of tax redemption to the trustee and the holders of the applicable series of notes, if Teva Finance III
or Teva determines that, as a result of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any change in or amendment to the laws, or any regulations or rulings promulgated under the laws of the Taxing Jurisdiction or any political subdivision or taxing authority of or in the Taxing Jurisdiction affecting
taxation, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any change in official position regarding the application or interpretation of the laws, regulations or rulings referred to above, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which change or amendment becomes effective or, in the case of a change in official position, is announced on or after the issuance of such series of notes,
Teva Finance III, Teva or any successor to Teva Finance III or Teva, as the case may be, is or will become obligated to pay additional tax amounts with respect to the notes, as described above under &#147;&#151;Additional Tax Amounts,&#148; provided
that Teva Finance III or Teva (or any of their respective successors) determines that such obligation cannot be avoided by Teva Finance III or Teva (or any of their respective successors), as the case may be, taking reasonable measures available to
it. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redemption price will be equal to 100% of the principal amount of the applicable series
of notes plus accrued and unpaid interest, if any (including additional interest, if any), to, but not including, the date fixed for redemption. The date and the applicable redemption price will be specified in the notice of tax redemption, which
notice will be given not earlier than 90 days prior to the earliest date on which Teva Finance III (or its successor) or, as the case may be, Teva (or its successor) would be obligated to pay such additional tax amounts if a payment in respect of
the relevant notes were actually due on such date. The notes can be redeemed if, at the time such notice of redemption is given, such obligation to pay such additional tax amounts remains in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to giving the notice of a tax redemption, Teva Finance III, Teva or any successor to Teva Finance III or Teva, as the case may be, will
deliver to the trustee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a certificate signed by a duly authorized officer stating that Teva Finance III, Teva or any successor to Teva Finance III or Teva, as the case may be, is entitled to effect the redemption and setting forth a statement
of facts showing that the conditions precedent to the right of Teva Finance III, Teva or any successor to Teva Finance III or Teva, as the case may be, to so redeem have occurred; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an opinion of independent legal counsel of recognized standing to that effect based on the statement of facts. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the following
constitutes an event of default under the indenture with respect to each series of notes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Teva Finance III&#146;s failure to pay when due the principal and premium, if any, on such series of notes issued under the indenture at maturity or upon redemption; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Teva Finance III&#146;s failure to pay an installment of interest (including additional amounts and additional interest, in each case, if any) on such series of notes issued under the indenture for 30 days after the
date when due; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Teva&#146;s failure to perform its obligations under its guarantees under the indenture relating to such series of notes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">except as permitted by the indenture, the related guarantee by Teva shall be held in any final, <FONT STYLE="white-space:nowrap">non-appealable</FONT> judicial proceeding to be unenforceable or invalid or shall cease
for any reason to be in full force and effect or Teva, or any person acting on behalf of the Teva, shall deny or disaffirm its obligations under that guarantee; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Teva&#146;s or Teva Finance III&#146;s failure to perform or observe any other term, covenant or agreement contained in the indenture or the relevant notes issued under it for a period of 60 days after written notice of
such failure, requiring Teva or Teva Finance III, as the case may be, to remedy the same, shall have been given to Teva or Teva Finance III, as the case may be, by the trustee or to Teva or Teva Finance III, as the case may be, and the trustee by
the holders of at least 25% in aggregate principal amount of such series of notes then outstanding; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Teva&#146;s or Teva Finance III&#146;s default under any Indebtedness (as defined below) for money borrowed by it, the aggregate outstanding principal amount of which is in an amount in excess of $250&nbsp;million, for
a period of 30 days after written notice to Teva Finance III by the trustee or to Teva Finance III and the trustee by holders of at least 25% in aggregate principal amount of the relevant notes then outstanding, which default: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">is caused by Teva or Teva Finance III&#146;s, as the case may be, failure to pay when due principal or interest on such Indebtedness by the end of the applicable grace period, if any, unless such Indebtedness is
discharged; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results in the acceleration of such Indebtedness, unless such acceleration is waived, cured, rescinded or annulled; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Teva or Teva Finance III&#146;s bankruptcy, insolvency or reorganization. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture provides that the trustee shall (other than in the case of (7)&nbsp;above,
which shall result in the notes of a series becoming immediately due and payable), within 90 days of the occurrence of a default under the indenture, give to the registered holders of the notes of such series notice of all defaults that have
occurred and are continuing known to it, but the trustee shall be protected in withholding such notice if it, in good faith, determines that the withholding of such notice is in the best interest of such registered holders, except in the case of a
default in the payment of the principal of or interest on, any of the notes when due or in the payment of any redemption or repurchase obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default under the indenture shall occur and be continuing, the trustee or the holders of at least 25% in aggregate principal
amount of the notes of such series affected then outstanding may declare the principal amount of such series of notes due and payable, together with accrued and unpaid interest, if any (including additional interest, if any), and then the trustee
may, at its discretion, proceed to protect and enforce the rights of the holders of such series of notes by appropriate judicial proceedings. Such declaration may be rescinded or annulled with the written consent of the holders of a majority in
aggregate principal amount of such series of notes then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture contains a provision entitling the trustee, subject to
the duty of the trustee during default to act with the required standard of care, to be indemnified to its satisfaction by the holders of the notes before proceeding to exercise any right or power under the indenture at the request of such holders.
The indenture provides that, subject to the conditions set forth therein, the holders of a majority in aggregate principal amount of the notes of a series then outstanding shall have the right to direct the time, method, and place of conducting any
proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee with respect to such series of notes by the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance III will be required to furnish annually to the trustee a statement as to its compliance with all conditions and covenants under
the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Indebtedness&#148; means, with respect to any person: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">any liability for borrowed money, or evidenced by an instrument for the payment of money, or incurred in connection with the acquisition of any property, services or assets (including securities), or relating to a
capitalized lease obligation, other than accounts payable or any other indebtedness to trade creditors created or assumed by such person in the ordinary course of business in connection with the obtaining of materials or services; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">obligations under exchange rate contracts or interest rate protection agreements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">any obligations to reimburse Teva Finance III of any letter of credit, surety bond, performance bond or other guarantee of contractual performance; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">any liability of another person of the type referred to in clause (1), (2) or (3)&nbsp;which has been assumed or guaranteed by such person; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">any obligations described in clauses (1)&nbsp;through (3) secured by any mortgage, pledge, lien or other encumbrance existing on property which is owned or held by such person, regardless of whether the indebtedness or
other obligation secured thereby shall have been assumed by such person. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Assumption </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance III may, without the consent of the holders of the notes, consolidate with, merge into or transfer all or substantially all of
its respective assets to any other corporation, limited liability company, partnership, joint venture, association, joint stock company or trust organized under the laws of The Netherlands, in the case of Teva Finance III, provided that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the successor entity assumes all of the obligations of Teva Finance III under the indenture and the notes; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at the time of such transaction, no event of default, and no event which, after notice or lapse of time, would become an event of default, shall have happened and be continuing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the indenture, Teva may, without the consent of the holders of notes, consolidate with, merge into or transfer all or
substantially all of its assets to any other corporation, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the successor corporation assumes all of the obligations of Teva under the indenture and the notes; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at the time of such transaction, no event of default, and no event which, after notice or lapse of time, would become an event of default, shall have happened and be continuing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture provides that so long as any notes are outstanding, all of Teva Finance III&#146;s capital stock or membership interests, as
applicable, will be owned directly or indirectly by Teva or its successor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modifications and Amendments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes Requiring Approval of Each Affected Holder </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture provides that it cannot be modified or amended without the written consent or the affirmative vote of the holder of each note
affected by such change to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change the maturity of the principal of or any installment of interest on such note; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the principal amount of or interest on such note; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change the currency of payment of that note or interest thereon; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impair the right to institute suit for the enforcement of any payment on or with respect to such note; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">modify Teva Finance III&#146;s obligations to maintain an office or agency in New York City; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">modify Teva&#146;s obligation to own, directly or indirectly, all of Teva Finance III&#146;s outstanding capital stock or membership interests, as applicable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">modify the redemption provisions of the indenture in a manner adverse to the holders of such series of notes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">modify the applicable guarantee in a manner adverse to the holders of such series of notes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the percentage in aggregate principal amount of outstanding notes of such series necessary to modify or amend the indenture or to waive any past default; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the percentage in aggregate principal amount of notes of a series outstanding required for the adoption of a resolution. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes Requiring Majority Approval </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described above, the indenture may be modified or amended with the written consent of the holders of at least a majority in aggregate
principal amount of the series of notes affected at the time outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes Requiring No Approval </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture or the notes may be modified or amended by Teva Finance III, Teva and the trustee, without the consent of the holder of any note
of a given series, for the purposes of, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">securing any series of notes or confirming and evidencing the release of security when such security is not required under the indenture; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adding to Teva or Teva Finance III&#146;s covenants for the benefit of the holders of the notes; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">surrendering any right or power conferred upon Teva or Teva Finance III; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">providing for the assumption of Teva or Teva Finance III&#146;s obligations to the holders of the notes of such series in the case of a merger, consolidation, conveyance, transfer or lease; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">complying with the requirements of the SEC in order to effect or maintain the qualification of the indenture under the Trust Indenture Act of 1939, as amended; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">curing any ambiguity, supplying any omission or correcting any defective provision contained in the indenture; provided that such modification or amendment does not, in the good faith opinion of Teva Finance III&#146;s
managing and supervisory directors, adversely affect the interests of the holders of notes in any material respect; and provided, further, that any amendment made solely to conform the provisions of the indenture to the description of the notes
contained in the offering memorandum will not be deemed to adversely affect the interests of the holders of the notes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evidencing the assumption by Teva (or any successor) of all obligations and release of the issuer; provided that no event of default under the indenture shall have occurred and be continuing; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evidencing the acceptance of appointment by a successor trustee; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adding guarantors or <FONT STYLE="white-space:nowrap">co-obligors</FONT> to a series or releasing guarantors in accordance with the indenture; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make such provisions as may be necessary to issue any exchange notes issued in exchange for notes pursuant to a registration rights agreement or similar agreement; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adding or modifying any other provisions which Teva Finance III or Teva, as the case may be, and the trustee may deem necessary or desirable and which will not adversely affect the interests of the holders of notes.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Satisfaction and Discharge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance III and Teva may satisfy and discharge their obligations under the indenture with respect to any series of notes while the notes
remain outstanding if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all outstanding notes with respect to such series issued under the indenture have become due and payable at their scheduled maturity; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all outstanding notes issued under the indenture with respect to such series have been called for redemption, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and, in either case, Teva Finance III has deposited with the trustee an amount sufficient to pay and discharge all outstanding notes of such series issued
under the indenture on the date of their scheduled maturity or the scheduled date of redemption, as the case may be. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture is and the notes will be governed by, and construed in accordance with, the law of the State of New York. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee and Paying Agent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Bank of New York Mellon has been appointed by us as trustee, paying agent, transfer agent, registrar and custodian with regard to the notes
of each series. The Bank of New York Mellon or its affiliates may from time to time in the future provide banking and other services to us in the ordinary course of their business. The Bank of New York Mellon shall be under no obligation to exercise
any of the trusts or powers vested in it by the indenture at the request, order or direction of any of the holders of the notes of a series pursuant to the indenture, unless such holders shall have offered to the trustee security or indemnity
satisfactory to it against the costs, expenses and liabilities which might be incurred therein or thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx558803_10"></A>DESCRIPTION OF THE EXCHANGE EURO NOTES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We issued the Original Euro Notes and will issue the Exchange Euro Notes pursuant to a a senior indenture dated as of March&nbsp;14, 2018, by
and among Teva Finance II, Teva and The Bank of New York Mellon, as trustee, as supplemented by a supplemental indenture, dated as of March&nbsp;14, 2018, by and among Teva Finance II, Teva, The Bank of New York Mellon, as trustee, and The Bank of
New York Mellon, London Branch, as paying agent. The terms of the Exchange Euro Notes include those stated in the indenture and, except as specified below, those made part of such Indenture by reference to the Trust&nbsp;Indenture Act. The Exchange
Euro Notes are subject to all such terms pursuant to the provisions of the indenture, and Holders of the Exchange Euro Notes are referred to the indenture and the Trust&nbsp;Indenture Act for a statement thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material provisions of the indenture. Because this is a summary, it may not contain all the information that
is important to you. You should read the indenture in its entirety. Copies of the indenture are available as described under &#147;Incorporation of Certain Documents by Reference.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we refer to Teva or the guarantor in this section, we refer only to Teva Pharmaceutical Industries Limited, an Israeli corporation. When
we refer to Teva Finance II or the issuer in this section, we refer to Teva Pharmaceutical Finance Netherlands II B.V., an indirect, wholly-owned subsidiary of Teva organized as a Dutch private limited liability company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this section, we refer to the senior indenture referenced in the first paragraph of this section, as supplemented, as &#147;the
indenture&#148;; we refer to the 2022 Exchange Euro Notes as the 2022 notes and the 2025 Exchange Euro Notes as the 2025 notes; and when we refer to the 2022 notes and the 2025 notes, each as a series of notes and, collectively, as the
&#147;notes,&#148; we refer to the Exchange Euro Notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Brief Description of the Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initially be limited to: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#128;700,000,000 aggregate principal amount of the 2022 notes; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#128;900,000,000 aggregate principal amount of the 2025 notes; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">subject to reopening of the
notes at the discretion of the issuer; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">accrue interest at a rate of: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3.250% on the 2022 notes, payable semi-annually in arrears on April&nbsp;15 and October&nbsp;15 of each year, beginning on October&nbsp;15, 2018; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">4.500% on the 2025 notes, payable semi-annually in arrears on March&nbsp;1 and September&nbsp;1 of each year, beginning on September&nbsp;1, 2018; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">constitute general unsecured obligations of the issuer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be redeemable (in addition to being redeemable as set forth below under &#147;&#151;Tax Redemption&#148;) at the
option of Teva Finance II at any time at the greater of (1) 100% of the principal amount of the series of notes to be redeemed or (2)&nbsp;the sum of the present values of the Remaining Scheduled Payments (as defined below) on the series of notes
being redeemed discounted, on a semi-annual basis (assuming a <FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months), at the applicable Reinvestment Rate (as defined below),
plus in each case accrued and unpaid interest thereon, if any (including additional interest, if any), to, but not including, the redemption date; provided that if the issuer redeems the notes of any
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
series on or after the applicable Par Call Date (as defined below) for such series, the redemption price for such notes will be equal to 100% of the aggregate principal amount of such notes being
redeemed, plus accrued and unpaid interest thereon, if any (including additional interest, if any), to, but not including, the redemption date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">are due on: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">April&nbsp;15, 2022, in the case of the 2022 notes; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">March&nbsp;1, 2025, in the case of the 2025 notes; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">in each case, unless earlier redeemed by
the issuer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture does not contain any financial covenants or restrictions on the amount of additional indebtedness that Teva,
Teva Finance II or any of Teva&#146;s other subsidiaries may incur except as described in &#147;&#151;Certain Covenants&#148; below. The indenture does not protect you in the event of a highly leveraged transaction or change of control of Teva or
Teva Finance II. The notes do not contain any sinking fund provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance II may, without the consent of the holders, issue
additional notes of any series under the indenture with the same terms (except for the issue date, issue price and, in some cases, the first payment of interest or interest accruing prior to the issue date of such additional notes) and with the same
ISIN number as the notes of such series offered hereby in an unlimited aggregate principal amount; provided that if the additional notes of a series are not fungible with the notes of such series for United States federal income tax purposes, such
additional notes will have a separate ISIN number. Any additional debt securities having such similar terms, together with the notes, could be considered part of the same series of notes under the indenture; provided that, in the case of any notes
represented by global notes, for so long as may be required by the Securities Act or the procedures of the common depositary, Euroclear or Clearstream (or a successor or clearing system), such additional notes will be represented by one or more
separate global notes in accordance with the terms of the indenture and subject to applicable transfer or other restrictions. We may also from time to time repurchase notes in open market purchases or negotiated transactions without giving prior
notice to holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Application has been made to the Irish Stock Exchange plc to list the notes on the Official List of the Irish Stock
Exchange and to admit the notes to trading on the Global Exchange Market thereof. The application to list the notes on the Official List of the Irish Stock Exchange and to admit the notes to trading on the Global Exchange Market may not be approved
and settlement is not conditioned on obtaining such listing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Description of the Guarantees </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva will irrevocably and unconditionally guarantee the punctual payment when due, whether at maturity, upon redemption, by acceleration or
otherwise, of the principal of and premium and interest (including any additional amounts in respect of taxes as provided herein), if any, on the notes of each series as well as all other amounts due and payable under the indenture. The respective
guarantees will be enforceable by the trustee, the holders of the applicable notes and their successors, transferees and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each
guarantee will be an unsecured senior obligation of Teva. As indebtedness of Teva, each guarantee will rank: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">senior to the rights of creditors under indebtedness expressly subordinated to the guarantee (at December&nbsp;31, 2017, Teva had no subordinated indebtedness outstanding); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">equally with other unsecured indebtedness of Teva from time to time outstanding other than any that is subordinated to the guarantee (at December&nbsp;31, 2017, Teva had approximately $32.5&nbsp;billion of senior
unsecured indebtedness outstanding); </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectively junior to Teva&#146;s secured indebtedness up to the value of the collateral securing that indebtedness (at December&nbsp;31, 2017, Teva had no secured indebtedness outstanding); and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectively junior to the indebtedness and other liabilities of Teva&#146;s subsidiaries (at December&nbsp;31, 2017, Teva&#146;s subsidiaries, other than finance subsidiaries, had a <I>de minimis</I> amount of
indebtedness outstanding). </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payment of Interest and Principal </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest on the Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2022 notes will bear interest at the rate of 3.250% per year, payable semi-annually in arrears on April&nbsp;15 and October&nbsp;15 of each
year, beginning October&nbsp;15, 2018, to the holders of record at the close of business on the preceding April&nbsp;1 and October&nbsp;1, respectively, whether or not a Business Day (as defined below). The 2025 notes will bear interest at the rate
of 4.500% per year, payable semi-annually in arrears on March&nbsp;1 and September&nbsp;1 of each year, beginning September&nbsp;1, 2018, to the holders of record at the close of business on the preceding February&nbsp;15 and August&nbsp;15,
respectively, whether or not a Business Day. If an interest payment date for the notes falls on a day that is not a Business Day, interest will be payable on the next succeeding Business Day with the same force and effect as if made on such interest
payment date and no interest shall accrue thereon on account of such delay. Interest on the notes will be computed on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year comprised of twelve
<FONT STYLE="white-space:nowrap">30-day</FONT> months, and will accrue from March&nbsp;14, 2018, or from the most recent interest payment date to which interest has been paid to, but not including, the next interest payment date. Additional interest
may accrue on the notes in certain circumstances pursuant to the Registration Rights Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Business Day&#148; means any day on
which commercial banks and foreign exchange markets are open for business in New York and London; provided that, for purposes of payments on the notes, a &#147;Business Day&#148; must be a day on which the Trans-European Automated Real-Time Gross
Settlement Express Transfer System (TARGET) is operating. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mechanics of Payment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments on the notes represented by global notes will be made through the principal paying agent. Payments on the notes will be made in euros
at the specified office or agency of the principal paying agent; provided that all such payments with respect to notes represented by one or more global notes deposited with and registered in the name of the common depositary or its nominee for the
accounts of Euroclear and Clearstream, will be by wire transfer of immediately available funds to the account specified in writing by the holder or holders thereof to the common depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, at our option, if physical notes (as defined below under &#147;Provisions Relating to the Notes While Represented by the Global
Notes&#148;) are issued, we may make payments by wire transfer to the account specified by the holder or holders thereof as notified to the principal paying agent in writing at least 15 days prior to such payment date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference to payments of interest in this section, unless the context otherwise requires, refer to the payment of interest and additional
amounts in respect to taxes, if any. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Optional Redemption by the Issuer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuer may redeem the notes of any series, in whole or in part, at any time or from time to time, on at least 20 days&#146;, but not more
than 60 days&#146;, prior notice delivered to the registered address of each holder of the relevant notes, with a copy of such notice delivered to the trustee and the paying agent. The redemption prices will be equal to the greater of (1) 100% of
the principal amount of the series of notes to be redeemed or (2)&nbsp;the sum of the present values of the Remaining Scheduled Payments (as defined below) on the series of notes being </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
redeemed discounted, on a semi-annual basis (assuming a <FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months), at the
applicable Reinvestment Rate (as defined below), plus in each case accrued and unpaid interest thereon, if any (including additional interest, if any), to, but not including, the redemption date; provided that if the issuer redeems the notes of any
series on or after the applicable Par Call Date for such series, the redemption price for such notes will be equal to 100% of the aggregate principal amount of such notes being redeemed, plus accrued and unpaid interest thereon, if any (including
additional interest, if any), to, but not including, the redemption date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of any redemption of any series of notes in connection
with a corporate transaction (including an equity offering, an incurrence of indebtedness or a change of control) may, at the issuer&#146;s discretion, be given prior to the completion thereof and any such redemption or notice may, at the
issuer&#146;s discretion, be subject to one or more conditions precedent, including, but not limited to, completion of the related transaction. If such redemption or purchase is so subject to satisfaction of one or more conditions precedent, such
notice shall describe each such condition, and such notice may be rescinded or the redemption date delayed in the event that any or all such conditions shall not have been satisfied by the redemption date. In addition, the issuer may provide in such
notice that payment of the redemption price and performance of its obligations with respect to such redemption may be performed by another person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Independent Investment Banker&#148; means a bank appointed by Teva Finance II which is a primary European government security dealer,
and any of its successors, or a market maker in pricing corporate bond issues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Par Call Date&#148; means (i)&nbsp;with respect to
the 2022 notes, January&nbsp;15, 2022 (the date that is three months prior to the maturity date of such notes) and (ii)&nbsp;with respect to the 2025 notes, December&nbsp;1, 2024 (the date that is three months prior to the maturity date of such
notes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Reference Bund&#148; means, with respect to the 2022 notes, the 0.000% Federal Government Bond of Bundesrepublik
Deutschland due April&nbsp;8, 2022, with ISIN DE0001141752 and, with respect to the 2025 notes, the 0.500% Federal Government Bond of Bundesrepublik Deutschland due February&nbsp;15, 2025, with ISIN DE0001102374. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Reference Dealers&#148; means the Independent Investment Banker and each of the three other banks selected by Teva Finance II which are
primary European government security dealers, and their respective successors, or market makers in pricing corporate bond issues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Reinvestment Rate&#148; means, with respect to the 2022 notes, 0.500%, and, with respect to the 2025 notes, 0.500%, plus, in each case,
the greater of (i)&nbsp;the average of the four quotations given by the Reference Dealers of the <FONT STYLE="white-space:nowrap">mid-market</FONT> semi-annual yield to maturity of the Reference Bund at 11:00 a.m. (Central European time
(&#147;CET&#148;)) on the fourth Business Day preceding such redemption date and if the Reference Bund is no longer outstanding, a Similar Security will be chosen by the Independent Investment Banker at 11:00 a.m. (CET) on the third Business Day in
London preceding such redemption date, quoted in writing by the Independent Investment Banker to Teva Finance II and (ii)&nbsp;zero. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Remaining Scheduled Payments&#148; means, with respect to each note to be redeemed, the remaining scheduled payments of principal of and
interest on such note as if redeemed on the applicable Par Call Date. If the applicable redemption date is not an interest payment date with respect to such note, the amount of the next succeeding scheduled interest payment on such note will be
reduced by the amount of interest accrued on such note to such redemption date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Similar Security&#148; means a reference bond or
reference bonds issued by the German Federal Government having an actual or interpolated maturity comparable with the Par Call Date of the applicable series of notes to be redeemed that would be utilized, at the time of selection and in accordance
with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the Par Call Date of such series of notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On and after the redemption date, interest will cease to accrue on the applicable series of
notes or any portion of such series as is called for redemption (unless we default in the payment of the redemption price and accrued interest). On or prior to the redemption date, we will deposit with the paying agent money sufficient to pay the
redemption price of and accrued interest on the notes to be redeemed on such date. If less than all of the notes of such series are to be redeemed, the notes to be redeemed of such series shall be selected by the trustee on a pro rata basis, by lot
or by such method as the trustee shall deem fair and appropriate and subject to the rules of the applicable depositary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of the
notes do not prevent Teva, Teva Finance II or any of Teva&#146;s other subsidiaries from purchasing notes on the open market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain Covenants
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Limitations on Secured Debt</I>. If Teva or any of its subsidiaries creates, incurs, assumes or suffers to exist any lien on
any of its property (including a subsidiary&#146;s stock or debt) to secure other debt, Teva will secure the notes on the same basis for so long as such other debt is so secured, unless, after giving effect to such lien, the aggregate amount of the
secured debt then outstanding (not including debt secured by liens permitted below) plus the value of all sale and leaseback transactions described in paragraph (3)&nbsp;of &#147;&#151;Limitations on Sales and Leasebacks&#148; below would not exceed
10% of Teva&#146;s Consolidated Net Worth. The restrictions do not apply to the following liens: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">liens existing as of the date when Teva Finance II first issues such series of notes pursuant to the indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">liens on property created, incurred or assumed prior to, at the time of or within 120 days after the date of acquisition, completion of construction or completion of improvement of such property to secure all or part of
the cost of acquiring, constructing or improving all or any part of such property; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">landlord&#146;s, material men&#146;s, carriers&#146;, workmen&#146;s, repairmen&#146;s or other like liens arising in the ordinary course of business in respect of obligations which are not overdue or which are being
contested in good faith in appropriate proceedings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">liens existing on any property of a corporation or other entity at the time it became or becomes a subsidiary of Teva (provided that the lien has not been created or assumed in contemplation of that corporation or other
entity becoming a subsidiary of Teva); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">liens securing debt owing by a subsidiary to Teva or to one or more of its subsidiaries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">liens in favor of any governmental authority of any jurisdiction securing the obligation of Teva or any of its subsidiaries pursuant to any contract or payment owed to that entity pursuant to applicable laws,
regulations or statutes; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any extension, renewal, substitution or replacement of the foregoing, provided that the principal amount is not increased and that such lien is not extended to other property. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Consolidated Net Worth&#148; means the stockholders&#146; equity of the guarantor and its consolidated subsidiaries, as shown on the
audited consolidated balance sheet of the guarantor&#146;s latest annual report to stockholders, prepared in accordance with accounting principles generally accepted in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Limitations on Sales and Leasebacks</I>. Teva will not, and will not permit any subsidiary to, enter into any sale and leaseback
transaction covering any property after the date when Teva Finance II first issues such series of notes pursuant to the indenture unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">the sale and leaseback transaction: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top">involves a lease for a period, including renewals, of not more than five years; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top">occurs within 270 days after the date of acquisition, completion of construction or completion of improvement of such property; or </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top">is with Teva or one of its subsidiaries; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Teva or any subsidiary, within 270 days after the sale and leaseback transaction shall have occurred, applies or causes to be applied an amount equal to the value of the property so sold and leased back at the time of
entering into such arrangement to the prepayment, repayment, redemption, reduction or retirement of any indebtedness of Teva or any subsidiary that is not subordinated to the notes and that has a stated maturity of more than twelve months; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Teva or any subsidiary would be entitled pursuant to the exceptions under &#147;&#151;Limitations on Secured Debt&#148; above to create, incur, issue or assume indebtedness secured by a lien in the property without
equally and ratably securing the notes. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Certain Other Covenants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture contains certain other covenants regarding, among other matters, corporate existence and reports to holders of notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Tax Amounts </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither
Teva Finance II, as the issuer, nor Teva, as the guarantor, will withhold or deduct from payments made with respect to the notes of any series on account of any present or future Taxes unless such withholding or deduction is required by law. The
term &#147;Taxing Jurisdiction&#148; as used herein means with respect to the notes, The Netherlands, Israel or any jurisdiction where a successor to Teva Finance II or Teva is incorporated or organized or considered to be a resident, if other than
The Netherlands or Israel, respectively, or any jurisdiction through which payments will be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Taxes&#148; means, with respect
to payments on the notes, all taxes, withholdings, duties, assessments or governmental charges of whatever nature imposed or levied by or on behalf of any Taxing Jurisdiction or any political subdivision thereof or any authority or agency therein or
thereof having power to tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Teva Finance II or Teva is required to withhold or deduct on account of any such Taxes
from any payment made under or with respect to the notes, Teva Finance II or Teva, as the case may be, will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withhold or deduct such amounts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay such additional tax amounts so that the net amount received by each holder or beneficial owner of the relevant notes, including those additional tax amounts, will equal the amount that such holder or beneficial
owner would have received if such Taxes had not been required to be withheld or deducted; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay the full amount withheld or deducted to the relevant tax or other authority in accordance with applicable law, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except that no such additional amounts will be payable in respect of any note: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">to the extent that such Taxes are imposed or levied by reason of such holder (or the beneficial owner) having some present or former connection with the Taxing Jurisdiction other than the mere holding (or beneficial
ownership) of such note or receiving principal or interest payments on the notes (including but not limited to citizenship, nationality, residence, domicile, or the existence of a business, permanent establishment, a dependent agent, a place of
business or a place of management present or deemed present in the Taxing Jurisdiction); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in respect of any Taxes that would not have been so withheld or deducted but for the failure by the holder or the
beneficial owner of the notes to make a declaration of <FONT STYLE="white-space:nowrap">non-residence,</FONT> or any other claim </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
or filing for exemption to which it is entitled or otherwise comply with any reasonable certification, identification, information, documentation or other reporting requirement concerning
nationality, residence, identity or connection with the Taxing Jurisdiction if (a)&nbsp;compliance is required by applicable law, regulation, administrative practice or treaty as a precondition to exemption from all or part of the Taxes,
(b)&nbsp;the holder (or beneficial owner) is able to comply with these requirements without undue hardship and (c)&nbsp;we have given the holders (or beneficial owners) at least 30 calendar days prior notice that they will be required to comply with
such requirement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">to the extent that such Taxes are imposed by reason of any estate, inheritance, gift, sales, transfer or personal property taxes imposed with respect to the notes, except as otherwise provided in the indenture;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top">to the extent that any such Taxes would not have been imposed but for the presentation of such notes, where presentation is required, for payment on a date more than 30 days after the date on which such payment became
due and payable or the date on which payment thereof is duly provided for, whichever is later, except to the extent that the holder would have been entitled to additional tax amounts had the notes been presented for payment on any date during such <FONT
STYLE="white-space:nowrap">30-day</FONT> period; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top">in respect of any Taxes imposed under Sections 1471-1474 of the Internal Revenue Code of 1986, as amended, any applicable U.S. Treasury Regulations promulgated thereunder, or any judicial or administrative
interpretations of any of the foregoing; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6)</TD>
<TD ALIGN="left" VALIGN="top">any combination of items 1 through 5 above. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance II, as the issuer, and Teva, as the
guarantor, will pay any present or future stamp, court or documentary taxes or any other excise or property taxes, charges or similar levies that arise from the execution, delivery, enforcement or registration of the notes of any series or any other
document or instrument in relation thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Redemption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes of any series may be redeemed as a whole, but not in part, at the option of Teva Finance II, Teva or any successor to Teva Finance II
or Teva, as the case may be, at any time prior to maturity, upon the giving of not less than 20 days&#146; nor more than 60 days&#146; notice of tax redemption to the trustee and the holders of the applicable series of notes, if Teva Finance II or
Teva determines that, as a result of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any change in or amendment to the laws, or any regulations or rulings promulgated under the laws of the Taxing Jurisdiction or any political subdivision or taxing authority of or in the Taxing Jurisdiction affecting
taxation, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any change in official position regarding the application or interpretation of the laws, regulations or rulings referred to above, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which change or amendment becomes effective or, in the case of a change in official position, is announced on or after the issuance of such series of notes,
Teva Finance II, Teva or any successor to Teva Finance II or Teva, as the case may be, is or will become obligated to pay additional tax amounts with respect to the notes, as described above under &#147;&#151;Additional Tax Amounts,&#148; provided
that Teva Finance II or Teva (or any of their respective successors) determines that such obligation cannot be avoided by Teva Finance II or Teva (or any of their respective successors), as the case may be, taking reasonable measures available to
it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redemption price will be equal to 100% of the principal amount of the applicable series of notes plus accrued and unpaid
interest, if any (including additional interest, if any), to, but not including, the date fixed for redemption. The date and the applicable redemption price will be specified in the notice of tax redemption, which notice will be given not earlier
than 90 days prior to the earliest date on which Teva Finance II (or its successor) or, as the case may be, Teva (or its successor) would be obligated to pay such additional tax amounts if a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment in respect of the relevant notes were actually due on such date. The notes can be redeemed if, at the time such notice of redemption is given, such obligation to pay such additional tax
amounts remains in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to giving the notice of a tax redemption, Teva Finance II, Teva or any successor to Teva Finance II or
Teva, as the case may be, will deliver to the trustee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a certificate signed by a duly authorized officer stating that Teva Finance II, Teva or any successor to Teva Finance II or Teva, as the case may be, is entitled to effect the redemption and setting forth a statement of
facts showing that the conditions precedent to the right of Teva Finance II, Teva or any successor to Teva Finance II or Teva, as the case may be, to so redeem have occurred; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an opinion of independent legal counsel of recognized standing to that effect based on the statement of facts. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Events of Default </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the
following constitutes an event of default under the indenture with respect to each series of notes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Teva Finance II&#146;s failure to pay when due the principal and premium, if any, on such series of notes issued under the indenture at maturity or upon redemption; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Teva Finance II&#146;s failure to pay an installment of interest (including additional amounts and additional interest, in each case, if any) on such series of notes issued under the indenture for 30 days after the date
when due; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Teva&#146;s failure to perform its obligations under its guarantees under the indenture relating to such series of notes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">except as permitted by the indenture, the related guarantee by Teva shall be held in any final, <FONT STYLE="white-space:nowrap">non-appealable</FONT> judicial proceeding to be unenforceable or invalid or shall cease
for any reason to be in full force and effect or Teva, or any person acting on behalf of the Teva, shall deny or disaffirm its obligations under that guarantee; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Teva&#146;s or Teva Finance II&#146;s failure to perform or observe any other term, covenant or agreement contained in the indenture or the relevant notes issued under it for a period of 60 days after written notice of
such failure, requiring Teva or Teva Finance II, as the case may be, to remedy the same, shall have been given to Teva or Teva Finance II, as the case may be, by the trustee or to Teva or Teva Finance II, as the case may be, and the trustee by the
holders of at least 25% in aggregate principal amount of such series of notes then outstanding; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Teva&#146;s or Teva Finance II&#146;s default under any Indebtedness (as defined below) for money borrowed by it, the aggregate outstanding principal amount of which is in an amount in excess of $250&nbsp;million, for a
period of 30 days after written notice to Teva Finance II by the trustee or to Teva Finance II and the trustee by holders of at least 25% in aggregate principal amount of the relevant notes then outstanding, which default: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">is caused by Teva or Teva Finance II&#146;s, as the case may be, failure to pay when due principal or interest on such Indebtedness by the end of the applicable grace period, if any, unless such Indebtedness is
discharged; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results in the acceleration of such Indebtedness, unless such acceleration is waived, cured, rescinded or annulled; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Teva or Teva Finance II&#146;s bankruptcy, insolvency or reorganization. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture
provides that the trustee shall (other than in the case of (7)&nbsp;above, which shall result in the notes of a series becoming immediately due and payable), within 90 days of the occurrence of a default under the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indenture, give to the registered holders of the notes of such series notice of all defaults that have occurred and are continuing known to it, but the trustee shall be protected in withholding
such notice if it, in good faith, determines that the withholding of such notice is in the best interest of such registered holders, except in the case of a default in the payment of the principal of or interest on, any of the notes when due or in
the payment of any redemption or repurchase obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default under the indenture shall occur and be continuing, the
trustee or the holders of at least 25% in aggregate principal amount of the notes of such series affected then outstanding may declare the principal amount of such series of notes due and payable, together with accrued and unpaid interest, if any
(including additional interest, if any), and then the trustee may, at its discretion, proceed to protect and enforce the rights of the holders of such series of notes by appropriate judicial proceedings. Such declaration may be rescinded or annulled
with the written consent of the holders of a majority in aggregate principal amount of such series of notes then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
indenture contains a provision entitling the trustee, subject to the duty of the trustee during default to act with the required standard of care, to be indemnified to its satisfaction by the holders of the notes before proceeding to exercise any
right or power under the indenture at the request of such holders. The indenture will provide that, subject to the conditions set forth therein, the holders of a majority in aggregate principal amount of the notes of a series then outstanding shall
have the right to direct the time, method, and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee with respect to such series of notes by the indenture. Teva Finance
II will be required to furnish annually to the trustee a statement as to its compliance with all conditions and covenants under the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Indebtedness&#148; means, with respect to any person: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">any liability for borrowed money, or evidenced by an instrument for the payment of money, or incurred in connection with the acquisition of any property, services or assets (including securities), or relating to a
capitalized lease obligation, other than accounts payable or any other indebtedness to trade creditors created or assumed by such person in the ordinary course of business in connection with the obtaining of materials or services; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">obligations under exchange rate contracts or interest rate protection agreements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">any obligations to reimburse Teva Finance II of any letter of credit, surety bond, performance bond or other guarantee of contractual performance; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">any liability of another person of the type referred to in clause (1), (2) or (3)&nbsp;which has been assumed or guaranteed by such person; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">any obligations described in clauses (1)&nbsp;through (3) secured by any mortgage, pledge, lien or other encumbrance existing on property which is owned or held by such person, regardless of whether the indebtedness or
other obligation secured thereby shall have been assumed by such person. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Consolidation, Merger or Assumption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance II may, without the consent of the holders of the notes, consolidate with, merge into or transfer all or substantially all of its
respective assets to any other corporation, limited liability company, partnership, joint venture, association, joint stock company or trust organized under the laws of The Netherlands, in the case of Teva Finance II, provided that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the successor entity assumes all of the obligations of Teva Finance II under the indenture and the notes; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at the time of such transaction, no event of default, and no event which, after notice or lapse of time, would become an event of default, shall have happened and be continuing. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the indenture, Teva may, without the consent of the holders of notes,
consolidate with, merge into or transfer all or substantially all of its assets to any other corporation provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the successor corporation assumes all of the obligations of Teva under the indenture and the notes; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at the time of such transaction, no event of default, and no event which, after notice or lapse of time, would become an event of default, shall have happened and be continuing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture provides that so long as any notes are outstanding, all of Teva Finance II&#146;s capital stock or membership interests, as
applicable, will be owned directly or indirectly by Teva or its successor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modifications and Amendments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes Requiring Approval of Each Affected Holder </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture provides that it cannot be modified or amended without the written consent or the affirmative vote of the holder of each note
affected by such change to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change the maturity of the principal of or any installment of interest on such note; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the principal amount of or interest on such note; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change the currency of payment of that note or interest thereon; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impair the right to institute suit for the enforcement of any payment on or with respect to such note; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">modify Teva&#146;s obligation to own, directly or indirectly, all of Teva Finance II&#146;s outstanding capital stock or membership interests, as applicable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">modify the redemption provisions of the indenture in a manner adverse to the holders of such series of notes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">modify the applicable guarantee in a manner adverse to the holders of such series of notes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the percentage in aggregate principal amount of outstanding notes of such series necessary to modify or amend the indenture or to waive any past default; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the percentage in aggregate principal amount of notes of a series outstanding required for the adoption of a resolution. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes Requiring Majority Approval </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described above, the indenture may be modified or amended with the written consent of the holders of at least a majority in
aggregate principal amount of the series of notes affected at the time outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes Requiring No Approval </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture or the notes may be modified or amended by Teva Finance II, Teva and the trustee, without the consent of the holder of any note
of a given series, for the purposes of, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">securing any series of notes or confirming and evidencing the release of security when such security is not required under the indenture; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adding to Teva or Teva Finance II&#146;s covenants for the benefit of the holders of the notes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">surrendering any right or power conferred upon Teva or Teva Finance II; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">providing for the assumption of Teva or Teva Finance II&#146;s obligations to the holders of the notes of such series in the case of a merger, consolidation, conveyance, transfer or lease; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">complying with the requirements of the SEC in order to effect or maintain the qualification of the indenture under the Trust Indenture Act of 1939, as amended; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">curing any ambiguity, supplying any omission or correcting any defective provision contained in the indenture; provided that such modification or amendment does not, in the good faith opinion of Teva Finance II&#146;s
managing and supervisory directors, adversely affect the interests of the holders of notes in any material respect; and provided, further, that any amendment made solely to conform the provisions of the indenture to the description of the notes
contained in the offering memorandum will not be deemed to adversely affect the interests of the holders of the notes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evidencing the assumption by Teva (or any successor) of all obligations and release of the issuer; provided that no event of default under the indenture shall have occurred and be continuing; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evidencing the acceptance of appointment by a successor trustee; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adding guarantors or <FONT STYLE="white-space:nowrap">co-obligors</FONT> to a series or releasing guarantors in accordance with the indenture; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make such provisions as may be necessary to issue any exchange notes issued in exchange for notes pursuant to a registration rights agreement or similar agreement; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adding or modifying any other provisions which Teva Finance II or Teva, as the case may be, and the trustee may deem necessary or desirable and which will not adversely affect the interests of the holders of notes.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Satisfaction and Discharge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance II and Teva may satisfy and discharge their obligations under the indenture with respect to any series of notes while the notes
remain outstanding if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all outstanding notes with respect to such series issued under the indenture have become due and payable at their scheduled maturity; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all outstanding notes issued under the indenture with respect to such series have been called for redemption, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and, in either case, Teva Finance II has deposited with the trustee an amount sufficient to pay and discharge all outstanding notes of such series issued
under the indenture on the date of their scheduled maturity or the scheduled date of redemption, as the case may be. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Governing Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture is and the notes will be governed by, and construed in accordance with, the law of the State of New York. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Concerning the Trustee and Paying Agent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bank of New York Mellon has been appointed by us as trustee, paying agent, transfer agent and registrar with regard to the notes of each
series. The Bank of New York Mellon, London Branch, has been appointed by us as the paying agent with respect to the notes of each series and act as common depositary. The Bank of New York Mellon, The Bank of New York Mellon, London Branch or their
affiliates may from time to time in the future provide banking and other services to us in the ordinary course of their business. The Bank of New York Mellon and The Bank of New York Mellon, London Branch shall be under no obligation to exercise any
of the trusts or powers vested in them by the indenture at the request, order or direction of any of the holders of the notes of a series pursuant to the indenture, unless such holders shall have offered to the trustee and the paying agent security
or indemnity satisfactory to them against the costs, expenses and liabilities which might be incurred therein or thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx558803_11"></A>CERTAIN TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain United States Federal Income Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of certain United States federal income tax considerations relating to the exchange of Original Notes for Exchange
Notes in the exchange offer. It does not contain a complete analysis of all the potential tax considerations relating to the exchange. This summary is limited to holders of Original Notes who hold the Original Notes as &#147;capital assets&#148; (in
general, assets held for investment). Special situations, such as the following, are not addressed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax consequences to holders who may be subject to special tax treatment, such as <FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities, dealers in securities or currencies, banks, other financial institutions,
insurance companies, regulated investment companies, traders in securities that elect to use a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting for their securities holdings or
corporations that accumulate earnings to avoid United States federal income tax; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax consequences to persons holding notes as part of a hedging, integrated, constructive sale or conversion transaction or a straddle or other risk reduction transaction; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax consequences to holders whose &#147;functional currency&#148; is not the United States dollar; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax consequences to persons who hold Original Notes through a partnership or similar pass-through entity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax consequences to U.S. expatriates or entities covered by the anti-inversion rules under the Code, persons who actually or constructively own more than 10% of our stock by vote or value, persons subject to the base
erosion and anti-abuse tax, or holders who are members of an &#147;expanded group&#148; or modified expanded group&#148; with the issuers within the meaning of Treasury Regulations under Code Section&nbsp;355; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">United States federal gift tax, estate tax or alternative minimum tax consequences, if any; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any state, local or <FONT STYLE="white-space:nowrap">non-United</FONT> States tax consequences. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity treated as a partnership for U.S. federal income tax purposes holds Original Notes, the tax treatment of a partner will generally
depend upon the status of the partner and the activities of the partnership. If an investor is a partnership or a partner in a partnership holding Original Notes, such investor should his, her or its tax advisors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion below is based upon the provisions of the Internal Revenue Code of 1986, as amended, existing and proposed Treasury regulations
promulgated thereunder, and rulings, judicial decisions and administrative interpretations thereunder, as of the date hereof. Those authorities may be changed, perhaps retroactively, so as to result in United States federal income tax consequences
different from those discussed below. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consequences of Tendering Original Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exchange of your Original Notes for Exchange Notes in the exchange offer should not constitute an exchange for United States federal income
tax purposes because the Exchange Notes should not be considered to differ materially in kind or extent from the Original Notes. Accordingly, the exchange offer should have no United States federal income tax consequences to you if you exchange your
Original Notes for Exchange Notes. For example, there should be no change in your tax basis and your holding period should carry over to the Exchange Notes. In addition, the United States federal income tax consequences of holding and disposing of
your Exchange Notes should be the same as those applicable to your Original Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The preceding discussion of certain </B>United
States<B> federal income tax considerations of the exchange offer is for general information only and is not tax advice. Accordingly, each investor should consult its</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B>own tax advisor as to particular tax consequences to it of exchanging Original Notes for Exchange Notes, including the applicability and effect of any state, local or foreign tax laws, and of
any proposed changes in applicable laws. </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom558803_15"></A>Certain Dutch Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a discussion of certain material Netherlands income tax consequences applicable to a holder of Original Notes relating to the
exchange of the Original Notes for the Exchange Notes. This discussion does not purport to describe all possible tax considerations or consequences that may be relevant to holder of Original Notes and does not purport to deal with the tax
consequences applicable to all categories of investors, some of which (such as trusts or similar arrangements) may be subject to special rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is included for general information purposes only. In view of its general nature, this discussion should be treated with
corresponding caution. Holders of Original Notes should consult with their own tax advisors with regard to the tax consequences of the exchange offer in their particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section does not apply to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">holders of Original Notes if such holders, and in the case of individuals, his/her partner or certain of their relatives by blood or marriage in the direct line (including foster children), have a substantial interest
or deemed substantial interest in us under The Netherlands Income Tax Act 2001 (in Dutch: &#147;<I>Wet inkomstenbelasting 2001</I>&#148;). Generally speaking, a holder of securities in a company is considered to hold a substantial interest in such
company, if such holder alone or, in the case of individuals, together with his/her partner (as defined in The Netherlands Income Tax Act 2001), directly or indirectly, holds (i)&nbsp;an interest of 5% or more of the total issued and outstanding
capital of that company or of 5% or more of the issued and outstanding capital of a certain class of shares of that company; or (ii)&nbsp;rights to acquire, directly or indirectly, such interest; or (iii)&nbsp;certain profit sharing rights in that
company that relate to 5% or more of the company&#146;s annual profits and/or to 5% or more of the company&#146;s liquidation proceeds. A deemed substantial interest may arise if a substantial interest (or part thereof) in a company has been
disposed of, or is deemed to have been disposed of, on a non-recognition basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pension funds, fiscal investment institutions (in Dutch: &#147;<I>fiscale beleggingsinstellingen</I>&#148;), exempt investment institutions (in Dutch: &#147;<I>vrijgestelde beleggingsinstellingen</I>&#148;) (as defined
in The Netherlands Corporate Income Tax Act 1969; in Dutch: &#147;<I>Wet op de vennootschapsbelasting 1969</I>&#148;) and other entities that are, in whole or in part, not subject to or exempt from Netherlands corporate income tax;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">holders of Original Notes who are individuals for whom the Original Notes or any benefit derived from the Original Notes are a remuneration or deemed to be a remuneration for activities performed by such holders or
certain individuals related to such holders (as defined in The Netherlands Income Tax Act 2001); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entities which are resident of Aruba, Curacao or Sint Maarten that have an enterprise which is carried on through a permanent establishment or permanent representative on Bonaire, Sint Eustatius or Saba and the Original
Notes are attributable to such permanent establishment or representative. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, this summary only
addresses Netherlands national tax legislation and published regulations, whereby The Netherlands means the part of the Kingdom of The Netherlands located in Europe, as in effect on the date hereof and as interpreted in published case law until this
date, without prejudice to any amendment introduced at a later date and implemented with or without retroactive effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Please
consult your own tax advisor regarding The Netherlands and non-Netherlands tax considerations of the acquisition, ownership, and disposition of the Exchange Notes.</I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holders who do not exchange their Original Notes for Exchange Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder who does not exchange its Original Note for an Exchange Note pursuant to the exchange offer will not recognize any gain or loss for
Netherlands income tax purposes, upon consummation of the exchange offer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holders who exchange their Original Notes for Exchange Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since it cannot be excluded that the exchange of an Original Note for an Exchange Note pursuant to the exchange offer constitutes a taxable
exchange for Netherlands income tax purposes, the subsections below will describe The Netherlands income tax consequences for holders who exchange their Original Notes for Exchange Notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Netherlands Resident Entities</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally
speaking, if the holder of Original Notes is an entity that is a resident or deemed to be a resident of The Netherlands for Netherlands corporate income tax purposes (&#147;Netherlands Resident Entity&#148;), any income under the Original Notes or
any gain or loss realized pursuant to the exchange offer is subject to Netherlands corporate income tax at a rate of 20% with respect to taxable profits up to &#128;200,000 and 25% with respect to taxable profits in excess of that amount. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Netherlands Resident Individuals</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a
holder of Original Notes is an individual, resident or deemed to be a resident of The Netherlands for Netherlands income tax purposes (&#147;Netherlands Resident Individual&#148;), any income under the Original Notes or any gain or loss realized
pursuant to the exchange offer is taxable at the progressive income tax rates (with a maximum of 51.95%), if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top">the Original Notes are attributable to an enterprise from which the holder of Original Notes derives a share of the profit, whether as an entrepreneur or as a person who has a co-entitlement to the net worth (in Dutch:
&#147;medegerechtigd tot het vermogen&#148;) of such enterprise without being a shareholder (as defined in The Netherlands Income Tax Act 2001); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top">the holder of Original Notes is considered to perform activities with respect to the Original Notes that go beyond ordinary asset management (in Dutch: &#147;<I>normaal, actief vermogensbeheer</I>&#148;) or derives
benefits from the notes that are taxable as benefits from other activities (in Dutch: &#147;<I>resultaat uit overige werkzaamheden</I>&#148;). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the above-mentioned conditions i. and ii. do not apply to the Netherlands Resident Individual holding the Original Notes, the Original
Notes are recognized as investment assets and included as such in Netherlands Resident Individual&#146;s net investment base (in Dutch &#147;<I>rendementsgrondslag</I>&#148;). Such holder will be taxed annually on a deemed, variable return of the
fair market value of the investment assets less the allowable liabilities at the beginning of the calendar year (1&nbsp;January) at an income tax rate of 30%. A tax free allowance may be available. Actual income, gains or losses in respect of the
Original Notes are not subject to Netherlands income tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the net investment assets on January&nbsp;1, 2018, a deemed return between
2.02% and 5.38% (depending on the amount of such holder&#146;s net investment assets on January&nbsp;1, 2018) will be applied. The deemed variable return will be adjusted annually. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Non-residents of The Netherlands</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
holder of Original Notes that is neither a Netherlands Resident Entity nor a Netherlands Resident Individual will not be subject to Netherlands taxes on income or capital gains in respect of any income under the Original Notes or in respect of any
gain or loss realized pursuant to the exchange offer; provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such holder does not have an interest in an enterprise or deemed enterprise (as defined in The Netherlands Income
Tax Act 2001 and The Netherlands Corporate Income Tax Act 1969) which, in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
whole or in part, is either effectively managed in The Netherlands or carried on through a permanent establishment, a deemed permanent establishment or a permanent representative in The
Netherlands and to which enterprise or part of an enterprise the Original Notes are attributable; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top">in the event the holder is an individual, such holder does not carry out any activities in The Netherlands with respect to the Original Notes that go beyond ordinary asset management and does not derive, or is deemed to
derive, benefits from the Original Notes that are taxable as benefits from other activities in The Netherlands. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please
consult your own tax advisor concerning the exchange of an Original Note for an Exchange Note pursuant to the exchange offer in light of your particular circumstances under The Netherlands national tax laws and published regulations and the laws of
any other taxing jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom558803_16"></A>Certain Israeli Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following is a summary of certain material Israeli tax considerations relating to the ownership of the Original Notes and/or the
Exchange Notes by holders who are not residents of the State of Israel for Israeli tax purposes. It is not, however, a complete analysis of all the potential tax considerations that may be applicable to all potential holders. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The following discussion is for general information purposes only. It is also applicable to beneficial owners of the Original Notes and/or
Exchange Notes. Holders of the Original Notes should consult their own tax advisors with respect to the application of Israeli income tax laws to their particular situations as well as any tax consequences arising under any <FONT
STYLE="white-space:nowrap">non-Israeli</FONT> taxing jurisdiction or under any applicable tax treaty. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Israeli Tax Liability on Interest Payable
by Teva to <FONT STYLE="white-space:nowrap">Non-Israeli</FONT> Residents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An individual is subject to tax on interest at a reduced
rate of up to 25%. The reduced rate is not available to an individual, if interest expenses are claimed as tax deductions with respect to the notes, if the individual is a &#147;substantial shareholder,&#148; (&#147;substantial shareholder&#148; for
these purposes is a shareholder who holds directly or indirectly, including with others, at least 10% of any means of control in the company), if there is a special relationship between the individual and the company paying out the interest (unless
certain conditions are met), or if the interest is a business income of the individual. In such cases, the individual will be subject to tax on the interest at his marginal tax rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Corporate entities are subject to corporate tax on their interest income. The corporate tax rate is currently 23%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Israeli</FONT> residents are required to file an income tax return in Israel if they have Israeli sourced
interest income, unless the full amount of tax was withheld. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Withholding Taxes on Interest Payable by Teva to
<FONT STYLE="white-space:nowrap">Non-Israeli</FONT> Residents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An Israeli company paying interest on a note denominated in a
foreign currency to an individual who is a <FONT STYLE="white-space:nowrap">non-Israeli</FONT> resident is required to withhold tax at a rate of 25%, except for (i)&nbsp;interest paid to a &#147;substantial shareholder&#148; (as defined above), or
(ii)&nbsp;interest paid to an employee, a service provider or a supplier of such Israeli company, who are subject to withholding tax according to the highest marginal tax rate applicable to individuals. Tax liability with respect to interest paid to
<FONT STYLE="white-space:nowrap">non-Israeli</FONT> residents by an Israeli company may be reduced under an applicable tax treaty. To benefit from such reduced rate under an applicable tax treaty, such
<FONT STYLE="white-space:nowrap">non-Israeli</FONT> residents should file an Israeli tax return based on such lower rate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An Israeli company paying interest on a similar note to a corporate entity will be subject
to withholding tax in accordance with the applicable corporate tax rate for the year in which the interest is paid, such rate is currently 23%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aforementioned might only apply if Teva as a guarantor pays interest on the notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Original Issue Discount</I>. For Israeli income tax purposes, any principal amount reflecting original issue discount is generally treated
in the same manner as interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent notes are redeemed by Teva as described under &#147;Description of the Exchange Dollar
Notes &#151;Tax Redemption,&#148; and &#147;Description of the Exchange Euro Notes&#151;Tax Redemption,&#148; holders of notes will be required to present withholding tax exemption certificates issued by the Israeli Tax Authority to prevent
withholding on account of Israeli taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva, Teva Finance II and Teva Finance III have agreed to pay certain additional amounts in
connection with withholding taxes or deductions that may be imposed by Israeli or Dutch authorities. See under &#147;Description of the Exchange Dollar Notes &#151;Additional Tax Amounts,&#148; and &#147;Description of the Exchange Euro Notes&#151;
Additional Tax Amounts.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx558803_12"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each broker-dealer that receives Exchange Notes for its own account pursuant to the exchange offer must acknowledge that it will deliver a
prospectus in connection with any resale of Exchange Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, as it may be amended or supplemented from time to time, may
be used by a broker-dealer in connection with resales of Exchange Notes received in exchange for Original Notes if the Original Notes were acquired as a result of market-making activities or other trading activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to make this prospectus, as amended or supplemented, available to any broker-dealer to use in connection with any such resale
for a period of at least 180 days after the expiration date. In addition, until (90 days after the date of this prospectus), all broker-dealers effecting transactions in the Exchange Notes may be required to deliver a prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not receive any proceeds from any sale of Exchange Notes by broker-dealers. Exchange Notes received by broker-dealers for their own
account pursuant to the exchange offer may be sold from time to time in one or more transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in negotiated transactions; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through the writing of options on the Exchange Notes or a combination of such methods of resale. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These resales may be made: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at market prices prevailing at the time of resale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at prices related to such prevailing market prices; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at negotiated prices. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any such resale may be made directly to purchasers or to or through
brokers or dealers. Brokers or dealers may receive compensation in the form of commissions or concessions from any such broker-dealer or the purchasers of any such Exchange Notes. An &#147;underwriter&#148; within the meaning of the Securities Act
includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any broker-dealer that resells Exchange Notes that were received by it for its own account pursuant to the exchange offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any broker or dealer that participates in a distribution of such Exchange Notes. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any profit
on any resale of Exchange Notes and any commissions or concessions received by any persons may be deemed to be underwriting compensation under the Securities Act. The letter of transmittal states that, by acknowledging that it will deliver and by
delivering a prospectus, a broker-dealer will not be deemed to admit that it is an &#147;underwriter&#148; within the meaning of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a period of not less than 180 days after the expiration of the exchange offer we will promptly send additional copies of this prospectus
and any amendment or supplement to this prospectus to any broker-dealer that requests those documents in the letter of transmittal. We have agreed to pay all expenses incident to performance of our obligations in connection with the exchange offer,
other than commissions or concessions of any brokers or dealers. We will indemnify the holders of the Exchange Notes (including any broker-dealers) against certain liabilities, including liabilities under the Securities Act, and will contribute to
payments that they may be required to make as a result thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx558803_13"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain legal matters with respect to United States and New York law with respect to the validity of the Exchange Notes will be passed upon for
the Issuers by Kirkland&nbsp;&amp; Ellis LLP, New York, New York. Certain legal matters with respect to Israeli law with respect to the validity of the Exchange Notes will be passed upon for Teva by Tulchinsky Stern Marciano Cohen
Levitski&nbsp;&amp; Co., Israel. Certain legal matters with respect to Dutch law will be passed upon for the Issuers by Van Doorne N.V., Netherlands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx558803_14"></A>EXPERTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements and management&#146;s assessment of the effectiveness of internal control over financial reporting (which is included
in management&#146;s report on internal control over financial reporting) incorporated in this prospectus by reference to the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Teva Pharmaceutical Industries Limited for the year
ended December&nbsp;31, 2017, have been so incorporated in reliance on the reports of Kesselman&nbsp;&amp; Kesselman, an independent registered public accounting firm in Israel and a member of PricewaterhouseCoopers International Limited, given on
the authority of said firm as experts in auditing and accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g558803g94y08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exchange Offer for </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Teva Pharmaceutical Finance Netherlands III B.V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$1,250,000,000 6.000% Senior Notes due 2024 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$1,250,000,000 6.750% Senior Notes due 2028 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Teva Pharmaceutical Finance Netherlands II B.V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>&#128;700,000,000 3.250% Senior Notes due 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>&#128;900,000,000 4.500% Senior Notes due 2025 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not authorized any dealer, salesperson or other person to give any information or represent anything to you other than the information contained in
this prospectus. You may not rely on unauthorized information or representations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus does not offer to sell or ask for offers to buy any of
the securities in any jurisdiction where it is unlawful, where the person making the offer is not qualified to do so, or to any person who cannot legally be offered the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this prospectus is current only as of the date on its cover, and may change after that date. For any time after the cover date of this
prospectus, we do not represent that our affairs are the same as described or that the information in this prospectus is correct, nor do we imply those things by delivering this prospectus or selling securities to you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Until&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;, 2018, all dealers that
effect transactions in these securities, whether or not participating in the exchange offer may be required to deliver a prospectus. This is in addition to the dealers&#146; obligations to deliver a prospectus when acting as underwriters and with
respect to their unsold allotments or subscriptions. </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;20.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Indemnification of Directors and Officers </B></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><I>Teva Pharmaceutical Industries Limited</I><B>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Israeli Companies Law, 5759-1999 (the &#147;Companies Law&#148;) provides that a company may not exempt or indemnify a director or
an executive officer (each an &#147;Officer&#148;), or enter into an insurance contract, which would provide coverage for any liability incurred as a result of any of the following: (i)&nbsp;a breach by the Officer of his or her duty of loyalty
unless, with respect to insurance coverage or indemnification, due to a breach of his or her duty of loyalty to the company committed in good faith and with reasonable grounds to believe that such act would not prejudice the interests of the
company; (ii)&nbsp;a breach by the Officer of his or her duty of care to the company committed intentionally or recklessly; (iii)&nbsp;any act or omission done with the intent of unlawfully realizing personal gain; or (iv)&nbsp;a fine, monetary
sanction, forfeit or penalty imposed upon an Officer. In addition, the Companies Law provides that Officers can only be exempted in advance with respect to liability for damages caused as a result of a breach of their duty of care to the company
(but not for such breaches committed intentionally or recklessly, as noted above, or in connection with a distribution (as defined in the Companies Law)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#146;s Articles of Association include provisions under which Officers of Teva are or may be insured, exempted or indemnified against
liability which they may incur in their capacities as such, subject to the Companies Law. Articles 102 through 105 of Teva&#146;s Articles of Association provide as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">102.</TD>
<TD ALIGN="left" VALIGN="top">Subject to the provisions of applicable law, the Company shall be entitled to engage in a contract for insurance of the liability of any Officer of the Company, in whole or in part, in respect of any liability or
expense imposed on an Officer or expended by him or her as a result of any action which was performed by said Officer in his or her capacity as an Officer of the Company for which insurance may be provided under applicable law, including in respect
of any liability imposed on any Officer with respect to any of the following: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Breach of a duty of care <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> the Company or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> another person; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Breach of a duty of loyalty <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> the Company, provided that the Officer acted in good faith and had reasonable grounds to
believe that the action in question would not adversely affect the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Financial liability which shall be imposed upon said Officer in favor of another person as a result of any action which was performed by said Officer in his or her capacity as an Officer of the Company; including (c1) A
payment which said Officer is obligated to make to an injured party as set forth in Section&nbsp;52(54)(a)(1)(a) of the Securities Law and expenses that said Officer incurred in connection with a proceeding under Chapters H&#146;3, H&#146;4 or
I&#146;1 of the Securities Law , including reasonable legal expenses, which term includes attorney fees, or in connection with Article D of Chapter Four of Part Nine of the Companies Law. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">103.</TD>
<TD ALIGN="left" VALIGN="top">Subject to the provisions of applicable law, the Company shall be entitled to indemnify post factum and/or undertake in advance to indemnify any Officer of the Company, as a result of any liability or an expense imposed
on him or her or expended by him or her as a result of any action which was performed by said Officer in his or her capacity as an Officer of the Company, in respect of any liability or expense for which indemnification may be provided under
applicable law, including in respect of any liability or an expense imposed on the Officer as follows: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial liability imposed upon said Officer in favor of another person by virtue of a decision by a court of
law, including a decision by way of settlement or a decision in arbitration which has been </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
confirmed by a court of law, provided that the undertaking to indemnify in advance shall be limited to events which, in the opinion of the Board of Directors of the Company, are foreseeable, in
light of the Company&#146;s activities at the time that the undertaking to indemnify was given, and shall further be limited to amounts or criteria that the Board of Directors has determined to be reasonable under the circumstances, and provided
further that in the undertaking to indemnify in advance the events that the Board of Directors believes to be foreseeable in light of the Company&#146;s activities at the time that the undertaking to indemnify was given are mentioned, as is the
amount or criteria that the Board of Directors determined to be reasonable under the relevant circumstances, including (a1) A payment which said Officer is obligated to make to an injured party as set forth in Section&nbsp;52(54)(a)(1)(a) of the
Securities Law and expenses that said Officer incurred in connection with a proceeding under Chapters H&#146;3, H&#146;4 or I&#146;1 of the Securities Law, including reasonable legal expenses, which term includes attorney fees, or in connection with
Article D of Chapter Four of Part Nine of the Companies Law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">reasonable litigation expenses, including attorney fees, expended by the Officer as a result of an inquiry or a proceeding conducted in respect of such Officer by an authority authorized to conduct same, which was
concluded without the submission of an indictment against said Officer and without any financial penalty being imposed on said Officer instead of a criminal proceeding (as such term is defined in the Companies Law), or which was concluded without
the submission of an indictment against said Officer with a financial penalty being imposed on said Officer instead of a criminal proceeding, in respect of a criminal charge which does not require proof of criminal intent or in connection with a
financial sanction; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">reasonable litigation expenses, including attorney fees, which said Officer shall have expended or shall have been obligated to expend by a court of law, in any proceedings which shall have been filed against said
Officer by or on behalf of the Company or by another person, or with regard to any criminal charge of which said Officer was acquitted, or with regard to any criminal charge of which said Officer was convicted which does not require proof of
criminal intent. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">104.</TD>
<TD ALIGN="left" VALIGN="top">Subject to the provisions of applicable law, the Company shall be entitled, in advance, to exempt any Officer of the Company from liability, in whole or in part, with regard to damage incurred as a result of the breach
of duty of care <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">105.</TD>
<TD ALIGN="left" VALIGN="top">Notwithstanding the foregoing, the Company shall be entitled to insure, indemnify and exempt from liability any Officer of the Company to the fullest extent permitted by applicable law. Accordingly, (i)&nbsp;any
amendment to the Companies Law, the Securities Law or any other applicable law expanding the right of any Officer to be insured, indemnified or exempted from liability in comparison to the provisions of these Articles shall, to the extent permitted
by applicable law, immediately apply to the fullest extent permitted by applicable law, and (ii)&nbsp;any amendment to the Companies Law, the Securities Law or any other applicable law adversely affecting the right of any Officer to be insured,
indemnified or exempted from liability in comparison to the provision of these Articles shall not be in effect post factum and shall not affect the Company&#146;s obligation or ability to insure, indemnify or exempt from liability an Officer for any
act or omission occurring prior to such amendment, unless otherwise provided by applicable law. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to indemnification
and release agreements, Teva releases its Officers from liability and indemnifies them to the fullest extent permitted by law and the Articles. Under these agreements, Teva undertakes to indemnify each Officer for monetary liabilities imposed by a
court judgment (including a settlement or an arbitrator&#146;s award that were approved by a court), provided that such undertaking (i)&nbsp;shall be limited to matters that are connected or otherwise related to certain events or circumstances set
forth therein, and (ii)&nbsp;shall not exceed $200&nbsp;million in the aggregate per Officer. Under Israeli law, indemnification is subject to other limitations, including those described above. Subject to applicable law, Teva may also indemnify its
Officers following specific events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#146;s Officers are also covered by directors&#146; and officers&#146; liability insurance. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Teva Pharmaceutical Finance Netherlands II B.V. and Teva Pharmaceutical Finance
Netherlands III B.V. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the laws of the Netherlands, indemnification by a company of its officers and directors for liability
incurred in their capacity as such is not permitted where the liability results from the gross negligence or willful malfeasance of the officers or directors. Subject to the foregoing, the general meeting of shareholders of the Netherlands BVs can
grant an indemnity or an annual discharge to a managing director of the Netherlands BVs. As for the indemnity, article 16(3) of the articles of association of the Netherlands BVs provides that &#147;the remuneration and the other employment
conditions of each managing director are determined by the general meeting.&#148; As for the annual discharge, the relevant clauses of Article 21 of the articles of association of each of the Netherlands BVs provide as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The general meeting adopts the financial statements. The management board adopts the annual report. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Adoption of the financial statements does not discharge a managing director, unless the provisions of paragraph 3 apply. By separate
resolution the general meeting can discharge a managing director for the management conducted in the financial year in question, insofar as that management is apparent from the financial statements or has been made known to the general meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. If all the shareholders are also managing directors of the Company, signing of the financial statements by all the managing directors also
serves as adoption of the financial statements, provided that all the parties entitled to attend meetings have been given the opportunity to take note of the drafted financial statements and have agreed to this manner of adoption. Adoption of the
financial statements in this manner discharges the managing directors. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;21.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits and Financial Statement Schedules </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Memorandum of Association of Teva Pharmaceutical Industries Limited <SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex32.htm">Amendment to Memorandum of Association of Teva Pharmaceutical Industries Limited <SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP>
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex33.htm">Articles of Association of Teva Pharmaceutical Industries Limited <SUP STYLE="font-size:85%; vertical-align:top">(4)(5)</SUP> </A></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex34.htm">Articles of Association of Teva Pharmaceutical Finance Netherlands II B.V.<SUP STYLE="font-size:85%; vertical-align:top"> (6)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.5*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex35.htm">Deed of Incorporation of Teva Pharmaceutical Finance Netherlands II B.V.<SUP STYLE="font-size:85%; vertical-align:top"> (6)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex36.htm">Deed of Incorporation, including the Articles of Association of Teva Pharmaceutical Finance Netherlands III B.V.<SUP STYLE="font-size:85%; vertical-align:top"> (6)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312515389926/d80198dex99a.htm">Amended and Restated Deposit Agreement, dated as of November&nbsp;
5, 2012, among Teva Pharmaceutical Industries Limited, JPMorgan Chase Bank N.A., as depositary, and the holders from time to time of shares <SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119380516002720/e614709_ex99-a2.htm">Amendment No.&nbsp;1, dated as of February&nbsp;
29, 2016, to the Amended and Restated Deposit Agreement, including form of American Depositary Receipt <SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312515397375/d12632dex42.htm">Form of share certificate for the 7.00% mandatory convertible preferred shares <SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518082582/d550834dex45.htm">Senior Indenture, dated as of March&nbsp;
14, 2018, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee <SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></A><SUP
STYLE="font-size:85%; vertical-align:top"></SUP></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518082582/d550834dex46.htm">First Supplemental Senior Indenture, dated as of March&nbsp;
14, 2018, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited, The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London Branch, as paying agent, including the form of 3.250% Senior Notes
 due 2022 and 4.500% Senior Notes due 2025 <SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP> </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518082582/d550834dex41.htm">Senior Indenture, dated as of March&nbsp;
14, 2018, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee <SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518082582/d550834dex42.htm">First Supplemental Senior Indenture, dated as of March&nbsp;
14, 2018, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee, including the form of 6.000% Senior Notes due 2024 and 6.750% Senior Notes due 2028 <SUP
STYLE="font-size:85%; vertical-align:top">(13)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518082582/d550834dex48.htm">Registration Rights Agreement, dated as of March&nbsp;
14, 2018, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited and the initial purchasers party thereto <SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518082582/d550834dex44.htm">Registration Rights Agreement, dated as of March&nbsp;
14, 2018, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and the initial purchasers party thereto <SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312506016240/dex41.htm">Senior Indenture, dated as of January&nbsp;
31, 2006, by and among Teva Pharmaceutical Finance Company LLC, Teva Pharmaceutical Industries Limited and The Bank of New York, as trustee <SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312506016240/dex42.htm">First Supplemental Senior Indenture, dated as of January&nbsp;
31, 2006, by and among Teva Pharmaceutical Finance Company LLC, Teva Pharmaceutical Industries Limited and The Bank of New York, as trustee, including the form of 0.25% Convertible Senior Debentures due 2026 <SUP
STYLE="font-size:85%; vertical-align:top">(17)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312506016240/dex43.htm">Second Supplemental Senior Indenture, dated as of January&nbsp;
31, 2006, by and among Teva Pharmaceutical Finance Company LLC, Teva Pharmaceutical Industries Limited and The Bank of New York, as trustee, including the form of 6.150% Senior Notes due 2036 <SUP STYLE="font-size:85%; vertical-align:top">(18)</SUP>
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312511306761/d252883dex41.htm">Senior Indenture, dated as of November&nbsp;
10, 2011, by and among Teva Pharmaceutical Finance IV, LLC, Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee <SUP STYLE="font-size:85%; vertical-align:top">(19)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312512506295/d455114dex42.htm">Second Supplemental Senior Indenture, dated as of December&nbsp;
18, 2012, by and among Teva Pharmaceutical Finance IV, LLC, Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee, including the form of 2.950% Senior Notes due 2022 <SUP STYLE="font-size:85%; vertical-align:top">(20)</SUP>
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312511306761/d252883dex43.htm">Senior Indenture, dated as of November&nbsp;
10, 2011, by and among Teva Pharmaceutical Finance Company B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee <SUP STYLE="font-size:85%; vertical-align:top">(21)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312511306761/d252883dex44.htm">First Supplemental Senior Indenture, dated as of November&nbsp;
10, 2011, by and among Teva Pharmaceutical Finance Company B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee, including the form of 3.650% Senior Notes due 2021 <SUP STYLE="font-size:85%; vertical-align:top">(22)
</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312512506295/d455114dex44.htm">Second Supplemental Senior Indenture, dated as of December&nbsp;
18, 2012, by and among Teva Pharmaceutical Finance Company B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee, including the form of 2.250% Senior Notes due 2020 <SUP STYLE="font-size:85%; vertical-align:top">(23)
</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312511306761/d252883dex45.htm">Senior Indenture, dated as of November&nbsp;
10, 2011, by and among Teva Pharmaceutical Finance IV B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee <SUP STYLE="font-size:85%; vertical-align:top">(24)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312511306761/d252883dex46.htm">First Supplemental Senior Indenture, dated as of November&nbsp;
10, 2011, by and among Teva Pharmaceutical Finance IV B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee, including the form of 3.650% Senior Notes due 2021<SUP STYLE="font-size:85%; vertical-align:top">(25)</SUP>
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312512181187/d339314dex41.htm">Permanent Global Certificate, dated as of April&nbsp;25, 2012, and the Terms of the CHF 450,000,000 1.5&nbsp;per cent Notes due 2018 <SUP
STYLE="font-size:85%; vertical-align:top">(26)</SUP> </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312512181187/d339314dex42.htm">Guarantee, dated as of April&nbsp;
25, 2012, by Teva Pharmaceutical Industries Limited <SUP STYLE="font-size:85%; vertical-align:top">(27)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312515113855/d899515dex41.htm">Senior Indenture, dated as of March&nbsp;
31, 2015, by and among Teva Pharmaceutical Industries Limited, Teva Pharmaceutical Finance Netherlands II B.V. and The Bank of New York Mellon, as trustee <SUP STYLE="font-size:85%; vertical-align:top">(28)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312515113855/d899515dex42.htm">Supplemental Senior Indenture, dated as of March&nbsp;
31, 2015, by and among Teva Pharmaceutical Industries Limited, Teva Pharmaceutical Finance Netherlands II B.V., The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London branch, as principal paying agent, including the form of 1.250%
 Senior Notes due 2023 and the form of 1.875% Senior Notes due 2027 <SUP STYLE="font-size:85%; vertical-align:top">(29)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.24</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312516656602/d220765dex42.htm">Second Supplemental Senior Indenture, dated as of July&nbsp;
25, 2016, by and among Teva Pharmaceutical Industries Limited, Teva Pharmaceutical Finance Netherlands II B.V., The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London branch, as principal paying agent, including the form of 0.375%
 Senior Notes due 2020, the form of 1.125% Senior Notes due 2024 and the form of 1.625% Senior Notes due 2028 <SUP STYLE="font-size:85%; vertical-align:top">(30)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312516653824/d334267dex41.htm">Senior Indenture, dated as of July&nbsp;
21, 2016, by and among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee <SUP STYLE="font-size:85%; vertical-align:top">(31)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.26</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312516653824/d334267dex42.htm">First Supplemental Senior Indenture, dated as of July&nbsp;
21, 2016, by and among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee, including the form of the form of 1.700% Senior Notes due 2019, the form of 2.200% Senior Notes
 due 2021, the form of 2.800% Senior Notes due 2023, the form of 3.150% Senior Notes due 2026 and the form of 4.100% Senior Notes due 2046 <SUP STYLE="font-size:85%; vertical-align:top">(32)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.27</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312516661692/d202899dex41.htm">Permanent Global Certificate, dated as of July&nbsp;28, 2016, and the Terms of the CHF 300,000,000 0.125&nbsp;per cent Notes due 2018 <SUP
STYLE="font-size:85%; vertical-align:top">(33)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.28</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312516661692/d202899dex42.htm">Permanent Global Certificate, dated as of July&nbsp;28, 2016, and the Terms of the CHF 350,000,000 0.500&nbsp;per cent Notes due 2022 <SUP
STYLE="font-size:85%; vertical-align:top">(34)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.29</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312516661692/d202899dex43.htm">Permanent Global Certificate, dated as of July&nbsp;28, 2016, and the Terms of the CHF 350,000,000 1.000&nbsp;per cent Notes due 2025 <SUP
STYLE="font-size:85%; vertical-align:top">(35)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.36</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312516661692/d202899dex44.htm">Guarantee, dated as of July&nbsp;28, 2016, by Teva Pharmaceutical Industries Limited (relating to the 2018 Notes) <SUP
STYLE="font-size:85%; vertical-align:top">(36)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.31</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312516661692/d202899dex45.htm">Guarantee, dated as of July&nbsp;28, 2016, by Teva Pharmaceutical Industries Limited (relating to the 2022 Notes) <SUP
STYLE="font-size:85%; vertical-align:top">(37)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.32</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312516661692/d202899dex46.htm">Guarantee, dated as of July&nbsp;28, 2016, by Teva Pharmaceutical Industries Limited (relating to the 2025 Notes) <SUP
STYLE="font-size:85%; vertical-align:top">(38)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.33</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Other long-term debt instruments: The registrant hereby undertakes to provide the Securities and Exchange Commission with copies upon request.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex51.htm">Opinion of Kirkland&nbsp;&amp; Ellis LLP </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>5.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex52.htm">Opinion of Van Doorne N.V. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>5.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex53.htm">Opinion of Tulchinsky Stern Marciano Cohen Levitski&nbsp;&amp; Co. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312515380854/d67104dex992.htm">Senior Unsecured Revolving Credit Agreement, dated as of November&nbsp;
16, 2015, by and among Teva Pharmaceutical Industries Limited, as guarantor, Teva Pharmaceuticals USA, Inc., Teva Capital Services Switzerland GmbH, Teva Finance Services B.V., Teva Finance Services II B.V., Teva Pharmaceutical Finance Netherlands III B.V.,
 as borrowers, Citibank, N.A., as administrative agent, and the lenders party thereto <SUP STYLE="font-size:85%; vertical-align:top">(39)</SUP> </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex108.htm">Amendment, dated as of July&nbsp;21, 2016, to the Senior Unsecured Revolving Credit Agreement, dated as of November&nbsp;
16, 2015, by and among Teva Pharmaceutical Industries Limited, as guarantor, Teva Pharmaceuticals USA, Inc., Teva Capital Services Switzerland GmbH, Teva Finance Services B.V., Teva Finance Services II B.V., Teva Pharmaceutical Finance Netherlands III B.V.,
 as borrowers, Citibank, N.A., as administrative agent, and the lenders party thereto <SUP STYLE="font-size:85%; vertical-align:top">(40)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312517288195/d457069dex991.htm">Amendment, dated as of September&nbsp;18, 2017, to the Senior Unsecured Revolving Credit Agreement, dated as of November&nbsp;
16, 2015, by and among Teva Pharmaceutical Industries Limited, as guarantor, Teva Pharmaceuticals USA, Inc., Teva Capital Services Switzerland GmbH, Teva Finance Services B.V., Teva Finance Services II B.V., Teva Pharmaceutical Finance Netherlands III B.V.,
 as borrowers, Citibank, N.A., as administrative agent, and the lenders party thereto <SUP STYLE="font-size:85%; vertical-align:top">(41)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518029309/d522623dex101.htm">Amendment, dated as of February&nbsp;
1, 2018, to the Senior Unsecured Revolving Credit Agreement, dated as of November 16, 2015, by and among Teva Pharmaceutical Industries Limited, as guarantor, Teva Pharmaceuticals USA, Inc., Teva Capital Services Switzerland GmbH, Teva Finance Services
 B.V., Teva Finance Services II B.V., Teva Pharmaceutical Finance Netherlands III B.V., as borrowers, Citibank, N.A., as administrative agent, and the lenders party thereto <SUP STYLE="font-size:85%; vertical-align:top">(42)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312515266181/d53544dex992.htm">Stockholders Agreement, dated August&nbsp;2, 2016, by and between Allergan plc and Teva Pharmaceutical Industries Limited <SUP
STYLE="font-size:85%; vertical-align:top">(43)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1020.htm">Employment Agreement, dated September&nbsp;7, 2017, between Teva Pharmaceutical Industries Limited and K&aring;re Schultz <SUP
STYLE="font-size:85%; vertical-align:top">(44)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1021.htm">Employment Agreement, dated January&nbsp;15, 2014, between Teva Pharmaceutical Industries Limited and Erez Vigodman <SUP
STYLE="font-size:85%; vertical-align:top">(45)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1022.htm">Employment Agreement, dated as of February&nbsp;6, 2017, between Teva Pharmaceutical Industries Limited and Yitzhak Peterburg <SUP
STYLE="font-size:85%; vertical-align:top">(46)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1023.htm">Employment Agreement, dated as of August&nbsp;7, 2008, between Teva Pharmaceutical Industries Limited and Eyal Desheh <SUP
STYLE="font-size:85%; vertical-align:top">(47)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1024.htm">Addendum to Employment Agreement between Teva Pharmaceutical Industries Limited and Eyal Desheh, dated as of August&nbsp;7, 2008 <SUP
STYLE="font-size:85%; vertical-align:top">(48)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1025.htm">Amendment to Employment Agreement between Teva Pharmaceutical Industries Limited and Eyal Desheh, dated as of October 2012 <SUP
STYLE="font-size:85%; vertical-align:top">(49)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1026.htm">Termination Agreement, dated as of January&nbsp;22, 2018, between Teva Pharmaceutical Industries Limited and Eyal Desheh <SUP
STYLE="font-size:85%; vertical-align:top">(50)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1027.htm">Employment Agreement, dated as of February&nbsp;8, 2018, between Teva Pharmaceuticals USA, Inc. and Michael McClellan <SUP
STYLE="font-size:85%; vertical-align:top">(51)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1028.htm">Letter Agreement, dated as of July&nbsp;19, 2017, between Teva Pharmaceuticals USA, Inc. and Michael McClellan <SUP
STYLE="font-size:85%; vertical-align:top">(52)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1029.htm">Letter Agreement, dated as of September&nbsp;19, 2017, between Teva Pharmaceuticals USA, Inc. and Michael McClellan <SUP
STYLE="font-size:85%; vertical-align:top">(53)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1030.htm">Letter Agreement, dated as of April&nbsp;26, 2017, between Teva Pharmaceuticals USA, Inc. and Michael McClellan <SUP
STYLE="font-size:85%; vertical-align:top">(54)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1031.htm">Amended and Restated Employment Agreement, dated as of February&nbsp;
7, 2018, between Teva Pharmaceuticals USA, Inc. and Carlo de Notaristefani <SUP STYLE="font-size:85%; vertical-align:top">(55)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1032.htm">Employment Agreement, dated as of June&nbsp;18, 2017, between Teva Pharmaceuticals USA, Inc. and Hafrun Fridriksdottir <SUP
STYLE="font-size:85%; vertical-align:top">(56) </SUP></A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1033.htm">Letter Agreement, dated as of February&nbsp;21, 2016, between Teva Pharmaceuticals USA, Inc. and Hafrun Fridriksdottir <SUP
STYLE="font-size:85%; vertical-align:top">(57)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1034.htm">Letter Agreement, dated as of December&nbsp;1, 2016, between Teva Pharmaceuticals USA, Inc. and Hafrun Fridriksdottir <SUP
STYLE="font-size:85%; vertical-align:top">(58)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1035.htm">Letter Agreement, dated as of November&nbsp;7, 2016, between Teva Pharmaceuticals USA, Inc. and Hafrun Fridriksdottir <SUP
STYLE="font-size:85%; vertical-align:top">(59)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.24</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1036.htm">Letter Agreement, dated as of July&nbsp;28, 2015, between Teva Pharmaceutical Industries Limited and Hafrun Fridriksdottir <SUP
STYLE="font-size:85%; vertical-align:top">(60) </SUP></A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1037.htm">Employment Agreement, dated as of December&nbsp;22, 2013, between Teva Pharmaceutical Industries Limited and Mark Sabag <SUP
STYLE="font-size:85%; vertical-align:top">(61)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.26</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1038.htm">Letter Agreement, dated as of June 2017, between Teva Pharmaceutical Industries Limited and Mark Sabag <SUP
STYLE="font-size:85%; vertical-align:top">(62)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.27</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1039.htm">Employment Agreement, dated as of December&nbsp;21, 2011, between Teva Pharmaceuticals Europe B.V. and Rob Koremans <SUP
STYLE="font-size:85%; vertical-align:top">(63)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.28</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1040.htm">First Amendment to Employment Agreement between Teva Pharmaceuticals Europe B.V. and Rob Koremans, dated as of October&nbsp;30, 2012 <SUP
STYLE="font-size:85%; vertical-align:top">(64)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.29</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1041.htm">Second Amendment to Employment Agreement between Teva Pharmaceuticals Europe B.V. and Rob Koremans, dated as of January&nbsp;12, 2015 <SUP
STYLE="font-size:85%; vertical-align:top">(65)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.30</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1042.htm">Third Amendment to Employment Agreement between Teva Pharmaceuticals Europe B.V. and Rob Koremans, dated as of September&nbsp;18, 2017 <SUP
STYLE="font-size:85%; vertical-align:top">(66)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.31</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1043.htm">Termination Agreement, dated as of January&nbsp;25, 2018, between Teva Pharmaceuticals Europe B.V. and Rob Koremans <SUP
STYLE="font-size:85%; vertical-align:top">(67)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.32</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1044.htm">Amended and Restated Employment Agreement, dated as of May&nbsp;22, 2015, between Teva Pharmaceutical Industries Limited and Dr.&nbsp;
Michael Hayden <SUP STYLE="font-size:85%; vertical-align:top">(68)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.33</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1045.htm">Letter Agreement, dated as of May&nbsp;8, 2012, between Teva Pharmaceutical Industries Limited and Dr.&nbsp;Michael Hayden <SUP
STYLE="font-size:85%; vertical-align:top">(69)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.34</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1046.htm">2017 Form Bonus Letter Agreement, applicable to Rob Koremans, Dr.&nbsp;
Michael Hayden, Hafrun Fridriksdottir, Carlo de Notaristefani, Eyal Desheh and Mark Sabag <SUP STYLE="font-size:85%; vertical-align:top">(70)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.35</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312517198533/d281982d6k.htm#toc281982_31">Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan <SUP STYLE="font-size:85%; vertical-align:top">(71)
</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.36</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312517198533/d281982d6k.htm#toc281982_32">Teva Pharmaceutical Industries Limited 2017 Executive Incentive Compensation Plan <SUP STYLE="font-size:85%; vertical-align:top">(72)
</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.37</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1049.htm">Teva Pharmaceuticals USA, Inc. Supplemental Deferred Compensation Plan <SUP STYLE="font-size:85%; vertical-align:top">(73)</SUP>
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.38</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1050.htm">Teva Pharmaceuticals USA, Inc. Defined Contribution Supplemental Executive Retirement Plan <SUP STYLE="font-size:85%; vertical-align:top">(74)
</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.39</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1051.htm">Form of Indemnification and Release Agreement <SUP STYLE="font-size:85%; vertical-align:top">(75)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.40</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1052.htm">Form Director Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected
 2015, 2016 and 2017 grants <SUP STYLE="font-size:85%; vertical-align:top">(76)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.41</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1053.htm">Hafrun Fridriksdottir Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable
 to selected 2016 grants <SUP STYLE="font-size:85%; vertical-align:top">(77)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.42</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1054.htm">K&aring;re Schultz Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to
 November&nbsp;3, 2017 grant <SUP STYLE="font-size:85%; vertical-align:top">(78)</SUP> </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.43</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1055.htm">Carlo de Notaristefani Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable
 to May&nbsp;18, 2017 grant <SUP STYLE="font-size:85%; vertical-align:top">(79)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.44</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1056.htm">Form Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2016
 grants made to Michael McClellan and Hafrun Fridriksdottir and selected 2017 grants made to Michael McClellan <SUP STYLE="font-size:85%; vertical-align:top">(80)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.45</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1057.htm">Hafrun Fridriksdottir Substitute Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan
 applicable to August&nbsp;2, 2016 stock option grant <SUP STYLE="font-size:85%; vertical-align:top">(81)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.46</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1058.htm">Hafrun Fridriksdottir Substitute Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan
 applicable to August&nbsp;2, 2016 restricted stock unit grant <SUP STYLE="font-size:85%; vertical-align:top">(82)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.47</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1059.htm">Form Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2015
 grants made to Michael McClellan <SUP STYLE="font-size:85%; vertical-align:top">(83)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.48</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1060.htm">Form Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2017
 grants made to Mark Sabag, Michael Hayden, Carlo de Notaristefani, Eyal Desheh, Rob Koremans, Hafrun Fridriksdottir, Yitzhak Peterburg and K&aring;re Schultz <SUP STYLE="font-size:85%; vertical-align:top">(84)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.49</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1061.htm">Form Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2016
 grants made to Mark Sabag, Carlo de Notaristefani, Erez Vigodman, Eyal Desheh, Rob Koremans and Michael Hayden <SUP STYLE="font-size:85%; vertical-align:top">(85)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1062.htm">Form Award Agreement under the Teva Pharmaceutical Industries Limited 2010 Long-Term Equity-Based Incentive Plan applicable to selected 2015
 grants made to Mark Sabag, Carlo de Notaristefani, Erez Vigodman, Eyal Desheh, Rob Koremans and Michael Hayden <SUP STYLE="font-size:85%; vertical-align:top">(86)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.51</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1063.htm">Form Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2018
 grants made to K&aring;re Schultz, Michael McClellan, Mark Sabag, Carlo de Notaristefani and Hafrun Fridriksdottir <SUP STYLE="font-size:85%; vertical-align:top">(87)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1064.htm">2018 Form Bonus Letter Agreement <SUP STYLE="font-size:85%; vertical-align:top">(88)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.53</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1065.htm">Michael McClellan Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to September&nbsp;18,
 2017 grant <SUP STYLE="font-size:85%; vertical-align:top">(89)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.54</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1066.htm">Settlement Agreement and Mutual Releases Agreement, dated as of January&nbsp;
31, 2018, by and between Teva Pharmaceutical Industries Ltd. and Allergan plc <SUP STYLE="font-size:85%; vertical-align:top">(90)</SUP> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>12.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex121.htm">Computation of Ratio of Earnings to Fixed Charges </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.0*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex210.htm">Subsidiaries of Teva Pharmaceutical Industries Limited </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex231.htm">Consent of Kesselman&nbsp;&amp; Kesselman </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex51.htm">Consent of Kirkland&nbsp;&amp; Ellis LLP (included in Exhibit 5.1) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex52.htm">Consent of Van Doorne N.V. (included in Exhibit 5.2) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex53.htm">Consent of Tulchinsky Stern Marciano Cohen Levitski&nbsp;&amp; Co. (included in Exhibit 5.3) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#sig">Power of Attorney of Teva Pharmaceutical Industries Limited, Teva Pharmaceutical Finance Netherlands II B.V. and Teva Pharmaceutical Finance Netherlands III B.V. (including on the signature pages of this Registration Statement)
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>25.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex251.htm">Statement of Eligibility of The Bank of New York Mellon, as trustee with respect to the Teva Pharmaceutical Finance Netherlands II B.V. Senior Indenture dated as of March&nbsp;14, 2018 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>25.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex252.htm">Statement of Eligibility of The Bank of New York Mellon, as trustee with respect to the Teva Pharmaceutical Finance Netherlands III B.V. Senior Indenture dated as of March&nbsp;14, 2018
</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex991.htm">Letter of Transmittal for the &#128;700,000,000 3.250% Senior Notes due 2022 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex992.htm">Letter of Transmittal for the &#128;900,000,000 4.500% Senior Notes due 2025 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex993.htm">Letter of Transmittal for the 1,250,000,000 6.000% Senior Notes due 2024</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d558803dex994.htm">Letter of Transmittal for the 1,250,000,000 6.750% Senior Notes due 2028 </A></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Filed herewith </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">English translation or summary from Hebrew original, which is the official version. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 3.1 to Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Reg. <FONT STYLE="white-space:nowrap">No.&nbsp;33-15736).</FONT> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 3.2 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">English translation or summary from Hebrew original, which is the official version, except as to Exhibit A thereto, the official version of which is in English. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 3.3 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">English translation or summary from Dutch original, which is the official version. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit (a)&nbsp;to Registration Statement on Form <FONT STYLE="white-space:nowrap">F-6</FONT> filed on November&nbsp;30, 2015 (Reg.
<FONT STYLE="white-space:nowrap">No.&nbsp;333-208239).</FONT> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Post-Effective Amendment to Registration Statement on Form <FONT STYLE="white-space:nowrap">F-6</FONT> filed on February&nbsp;29, 2016 (Reg.
<FONT STYLE="white-space:nowrap">No.&nbsp;333-208239).</FONT> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.2 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on December&nbsp;8, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.5 to Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on March&nbsp;14, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.6 to Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on March&nbsp;14, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.1 to Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on March&nbsp;14, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.2 to Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on March&nbsp;14, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.8 to Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on March&nbsp;14, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.4 to Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on March&nbsp;14, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.1 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on January&nbsp;31, 2006. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.2 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on January&nbsp;31, 2006. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.3 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on January&nbsp;31, 2006. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.1 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on November&nbsp;10, 2011. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.2 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on December&nbsp;18, 2012. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.3 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on November&nbsp;10, 2011. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.4 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on November&nbsp;10, 2011. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">23.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.4 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on December&nbsp;18, 2012. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">24.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.5 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on November&nbsp;10, 2011. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">25.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.6 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on November&nbsp;10, 2011. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">26.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.1 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on April&nbsp;25, 2012. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">27.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.2 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on April&nbsp;25, 2012. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">28.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.1 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on March&nbsp;31, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">29.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.2 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on March&nbsp;31, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">30.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.2 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on July&nbsp;25, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">31.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.1 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on July&nbsp;21, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">32.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.2 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on July&nbsp;21, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">33.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.1 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on July&nbsp;28, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">34.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.2 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on July&nbsp;28, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">35.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.3 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on July&nbsp;28, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">36.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.4 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on July&nbsp;28, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">37.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.5 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on July&nbsp;28, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">38.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 4.6 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on July&nbsp;28, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">39.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 99.2 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on November&nbsp;18, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">40.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.8 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">41.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 99.1 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on September&nbsp;19, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">42.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.1 to Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on February&nbsp;1, 2018 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">43.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 99.2 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed on July&nbsp;28, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">44.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.20 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">45.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.21 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">46.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.22 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">47.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.23 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">48.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.24 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">49.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.25 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">50.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.26 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">51.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.27 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">52.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.28 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">53.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.29 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">54.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.30 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">55.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.31 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">56.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.32 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">57.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.33 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">58.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.34 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">59.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.35 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">60.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.36 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">61.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.37 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">62.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.38 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">63.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.39 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">64.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.40 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">65.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.41 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">66.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.42 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">67.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.43 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">68.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.44 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">69.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.45 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">70.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.46 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">71.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit A to Proxy Statement filed on June&nbsp;8, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">72.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit B to Proxy Statement filed on June&nbsp;8, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">73.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.49 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">74.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.50 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">75.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.51 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">76.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.52 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">77.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.53 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">78.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.54 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">79.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.55 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">80.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.56 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">81.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.57 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">82.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.58 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">83.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.59 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">84.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.60 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">85.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.61 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">86.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.62 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">87.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.63 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">88.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.64 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">89.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.65 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">90.</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to Exhibit 10.66 to Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;12, 2018. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;22.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Undertakings. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned registrants hereby undertake: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">To file, during any period in which offers or sales are being made, a post-effective amendment to this prospectus: </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(i) to include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the
Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20&nbsp;percent change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in
the effective registration statement; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(iii) to include any material information with respect to the plan of distribution not
previously disclosed in the registration statement or any material change to such information in the registration statement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">To remove from the registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">That, for purposes of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration
statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no
statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration
statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such
document immediately prior to such date of first use. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">That, for the purpose of determining liability of the registrants under the Securities Act to any purchaser in the initial distribution of the securities: The undersigned registrants undertake that in a primary offering
of securities of the undersigned registrants pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the
following communications, the undersigned registrants will each be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(i) any preliminary prospectus or prospectus of the undersigned registrants relating to the offering required to be filed pursuant to Rule 424;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(ii) any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
the undersigned registrants; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(iii) the portion of any other free writing prospectus relating to the offering containing
material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrants; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(iv)
any other communication that is an offer in the offering made by the undersigned registrants to the purchaser. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">That, for purposes of determining any liability under the Securities Act, each filing of the registrant&#146;s annual report pursuant to Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended
(and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended) that is incorporated by reference in this registration statement shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrants pursuant to the provisions described in Item 20, or
otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top">To respond to requests for information that is incorporated by reference into the prospectus pursuant to Items 4, 10(b), or 11 or 13 of this form, within one business day of receipt of such request, and to send the
incorporated documents by first-class mail or other equally prompt means. This includes information contained in documents filed subsequent to the date of the registration statement through the date of responding to the request. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">To supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it
became effective. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the City of Petach Tikva, Israel, on April 2, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Deborah Griffin</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Deborah Griffin</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President and Chief</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Accounting Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person whose signature appears below constitutes and appoints K&aring;re Schultz, Michael McClellan, David Stark and Deborah Griffin and
each of them singly, his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution and resubstitution, for him or her and in his or her name,
place and stead, in any and all capacities, to sign any and all (i)&nbsp;amendments (including post-effective amendments) and additions to this registration statement and (ii)&nbsp;any and all additional registration statements pursuant to Rule
462(b) of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to each said <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agents full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents or either of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dr.&nbsp;Sol&nbsp;J.&nbsp;Barer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Chairman</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April 2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Dr.&nbsp;Sol&nbsp;J.&nbsp;Barer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ K&aring;re Schultz</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">President and Chief Executive Officer and Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April 2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">K&aring;re Schultz</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Michael McClellan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Vice President and Chief</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Financial Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April 2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Michael McClellan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Deborah Griffin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President and Chief</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounting Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Accounting Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April 2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Deborah Griffin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Rosemary A. Crane</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April 2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Rosemary A. Crane</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Amir Elstein</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April 2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Amir Elstein</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Murray A. Goldberg</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April 2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Murray A. Goldberg</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jean-Michel Halfon</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April 2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jean-Michel Halfon</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Gerald M. Lieberman</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April 2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Gerald M. Lieberman</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Galia Maor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April 2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Galia Maor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Roberto A. Mignone</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April 2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Roberto A. Mignone</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dr.&nbsp;Perry&nbsp;D. Nisen</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April 2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Dr.&nbsp;Perry&nbsp;D. Nisen</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Nechemia (Chemi) J. Peres</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April 2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Nechemia (Chemi) J. Peres</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dan S. Suesskind</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April 2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Dan S. Suesskind</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Gabrielle Sulzberger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April 2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Gabrielle Sulzberger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Deborah Griffin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Authorized U.S. Representative</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April 2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Deborah Griffin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in The Netherlands on April 2, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEVA PHARMACEUTICAL FINANCE</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">NETHERLANDS II B.V.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceuticals Europe B.V.,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its Managing
Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Vrhovec</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Vrhovec</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ John Nason</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">John Nason</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person whose signature appears below constitutes and appoints K&aring;re Schultz, Michael McClellan, David Stark and Deborah Griffin and
each of them singly, his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution and resubstitution, for him or her and in his or her name,
place and stead, in any and all capacities, to sign any and all (i)&nbsp;amendments (including post-effective amendments) and additions to this registration statement and (ii)&nbsp;any and all additional registration statements pursuant to Rule
462(b) of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to each said <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agents full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents or either of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Nason</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Managing Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April&nbsp;2,&nbsp;2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">John Nason</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Vrhovec</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Managing Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April&nbsp;2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Vrhovec</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Deborah Griffin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Authorized U.S. Representative</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">April&nbsp;2, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Deborah Griffin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in The Netherlands on April 2, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEVA PHARMACEUTICAL FINANCE</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">NETHERLANDS III B.V.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceuticals Europe B.V.,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its
Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Vrhovec</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Vrhovec</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ John Nason</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">John Nason</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person whose signature appears below constitutes and appoints K&aring;re Schultz, Michael McClellan, David Stark and Deborah Griffin and
each of them singly, his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution and resubstitution, for him or her and in his or her name,
place and stead, in any and all capacities, to sign any and all (i)&nbsp;amendments (including post-effective amendments) and additions to this registration statement and (ii)&nbsp;any and all additional registration statements pursuant to Rule
462(b) of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to each said <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agents full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents or either of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John&nbsp;Nason</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">John&nbsp;Nason</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>April&nbsp;2, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David&nbsp;Vrhovec</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">David&nbsp;Vrhovec</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>April&nbsp;2, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Deborah&nbsp;Griffin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Deborah&nbsp;Griffin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Authorized&nbsp;U.S.&nbsp;Representative</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>April&nbsp;2, 2018</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>2
<FILENAME>d558803dex34.htm
<DESCRIPTION>EX-3.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CERTIFIED COPY </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Deed of amendment of the articles of association <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Deed dated 14&nbsp;November 2013 </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>NOTE ABOUT TRANSLATION: </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This document is an English translation of a document prepared in Dutch. In preparing this document, an attempt has been made to translate as literally as
possible without jeopardizing the overall continuity of the text. Inevitably, however, differences may occur in translation and if they do, the Dutch text will govern by law. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In this translation, Dutch legal concepts are expressed in English terms and not in their original Dutch terms. The concepts concerned may not be identical
to concepts described by the English terms as such terms may be understood under the laws of other jurisdictions. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DEED OF
AMENDMENT OF THE ARTICLES OF ASSOCIATION OF </U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V. </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the fourteenth day of November two thousand and thirteen appears before me, Jan Willem Schenk, <FONT STYLE="white-space:nowrap">civil-law</FONT> notary
practising in the city of Amsterdam (the Netherlands): Anglig&eacute;ne Nyre&eacute; Beatrice Servania, born on Curacao, on the eighteenth day of August nineteen hundred and seventy-three, with office address at Prins Bernhardplein 200, 1097 JB
Amsterdam (the Netherlands). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The appearer declares that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><B>the General Meeting of Teva Pharmaceutical Finance Netherlands II B.V., a</B> private company with limited liability, registered in Amsterdam, the Netherlands, with the trade register under number 59012161,
hereinafter referred to as: the <B>&#147;Company&#148;. </B>The Company resolved on twelfth day of November two thousand thirteen to: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">to reduce the Company&#146;s capital without making repayments and consequently to withdraw part of the share capital without repayments; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">amend the Company&#146;s articles of association and adopt them again partially; and </TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">to authorise the person appearing to have this deed executed, which resolutions are evidenced by the shareholders&#146; resolution signed on the twelfth day of November two thousand thirteen attached to the original
copy of this deed, a copy which will be attached to this original copy. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">the articles of association of the company were drawn up by deed of incorporation executed by me, the notary, on the sixteenth day of November two thousand and thirteen and not amended since then. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The person appearing declared that, in implementation of the aforementioned resolution to amend the articles of association according to article 3 paragraph
1, she amended the Company&#146;s articles of association and to adopt again in their entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s capital consists of one or
more ordinary shares, each share having a nominal value of one euro (EUR 1.00). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Final statements. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Today, before the present amendment to the articles of associations enters into effect, the subscribed capital of the Company amounts to two million euros (EUR 2,000,000.00) divided into two thousand (2,000) shares with
a nominal value of one thousand euros (EUR 1,000.00) each, hereinafter referred to as: the &#147;<B>Shares&#148;.</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">As a result of the entry into effect of the present amendment to the articles of association, the subscribed capital of the company will be reduced by reducing the amount of the Shares by means of the present amendment
to the articles of association and by simultaneously joining the Shares, as a consequence of which the subscribed capital of the Company consist of two thousand (2,000) shares with a nominal value of one euro (EUR 1.00) and consequently one thousand
nine hundred (1,900) shares with a nominal value of one euro (EUR1.00). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">After the aforementioned capital reduction and cancellation of the shares, the subscribed capital of the Company amounts to one hundred euros (EUR 100), consisting of one hundred (100)&nbsp;shares of one euro (EUR
1.00). </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>End of deed </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The person
appearing has identified herself to me, the <FONT STYLE="white-space:nowrap">civil-law</FONT> notary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In witness whereof this Deed was executed in one
original copy in Amsterdam on the date first written above. Before this Deed was read out in full, the substance of this Deed was stated and explained to the person appearing. She then stated that she had taken note of the content of this deed in a
timely manner, agreed to that content and did not require a full reading of this Deed. Immediately after a limited reading of this Deed it was signed by the person appearing and by me, the <FONT STYLE="white-space:nowrap">civil-law</FONT> notary.
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>NOTE ABOUT TRANSLATION: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This document is an English translation of a document prepared in Dutch. In preparing this document, an attempt has been made to translate as literally as
possible without jeopardizing the overall continuity of the text. Inevitably, however, differences may occur in translation and if they do, the Dutch text will govern by law. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In this translation, Dutch legal concepts are expressed in English terms and not in their original Dutch terms. The concepts concerned may not be identical
to concepts described by the English terms as such terms may be understood under the laws of other jurisdictions. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DEED OF
AMENDMENT OF THE ARTICLES OF ASSOCIATION OF </U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V. </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the fourteenth day of November two thousand and thirteen appears before me, Jan Willem Schenk, <FONT STYLE="white-space:nowrap">civil-law</FONT> notary
practising in the city of Amsterdam (the Netherlands): Anglig&eacute;ne Nyre&eacute; Beatrice Servania, born on Curacao, on the eighteenth day of August nineteen hundred and seventy-three, with office address at Prins Bernhardplein 200, 1097 JB
Amsterdam (the Netherlands). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The appearer declares that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><B>the General Meeting of Teva Pharmaceutical Finance Netherlands II B.V., a</B> private company with limited liability, registered in Amsterdam, the Netherlands, with the trade register under number 59012161,
hereinafter referred to as: the <B>&#147;Company&#148;. </B>The Company resolved on twelfth day of November two thousand thirteen to: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">to reduce the Company&#146;s capital without making repayments and consequently to withdraw part of the share capital without repayments; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">amend the Company&#146;s articles of association and adopt them again partially; and </TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">to authorise the person appearing to have this deed executed, which resolutions are evidenced by the shareholders&#146; resolution signed on the twelfth day of November two thousand thirteen attached to the original
copy of this deed, a copy which will be attached to this original copy. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">the articles of association of the company were drawn up by deed of incorporation executed by me, the notary, on the sixteenth day of November two thousand and thirteen and not amended since then. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The person appearing declared that, in implementation of the aforementioned resolution to amend the articles of association according to article 3 paragraph
1, she amended the Company&#146;s articles of association and to adopt again in their entirety as follows: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s capital consists of one or
more ordinary shares, each share having a nominal value of one euro (EUR 1.00). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Final statements. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Today, before the present amendment to the articles of associations enters into effect, the subscribed capital of the Company amounts to two million euros (EUR 2,000,000.00) divided into two thousand (2,000) shares with
a nominal value of one thousand euros (EUR 1,000.00) each, hereinafter referred to as: the &#147;<B>Shares&#148;.</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">As a result of the entry into effect of the present amendment to the articles of association, the subscribed capital of the company will be reduced by reducing the amount of the Shares by means of the present amendment
to the articles of association and by simultaneously joining the Shares, as a consequence of which the subscribed capital of the Company consist of two thousand (2,000) shares with a nominal value of one euro (EUR 1.00) and consequently one thousand
nine hundred (1,900) shares with a nominal value of one euro (EUR1.00). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">After the aforementioned capital reduction and cancellation of the shares, the subscribed capital of the Company amounts to one hundred euros (EUR 100), consisting of one hundred (100)&nbsp;shares of one euro (EUR
1.00). </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>End of deed </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The person
appearing has identified herself to me, the <FONT STYLE="white-space:nowrap">civil-law</FONT> notary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In witness whereof this Deed was executed in one
original copy in Amsterdam on the date first written above. Before this Deed was read out in full, the substance of this Deed was stated and explained to the person appearing. She then stated that she had taken note of the content of this deed in a
timely manner, agreed to that content and did not require a full reading of this Deed. Immediately after a limited reading of this Deed it was signed by the person appearing and by me, the <FONT STYLE="white-space:nowrap">civil-law</FONT> notary.
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Continuous text as per November 14, 2013 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>NAME AND REGISTERED OFFICE. </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 1 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><B></B>The Company&#146;s name is:<B> Teva Pharmaceutical Finance Netherlands II B.V.</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The Company has its registered office in Amsterdam. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><B>Objects</B>. </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 2 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s objects are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">to incorporate, in any manner to participate in, to manage and to supervise businesses, companies and other legal entities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">to finance businesses, companies and other legal entities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">to borrow, including the lending and raising of funds, to issue bonds, debentures or other securities, and to enter into related agreements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">to give advice and to provide services to businesses, companies and other legal entities with which the Company is affiliated in a group, and to third parties; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top">to issue guarantees, to commit the Company and to encumber assets of the Company for the benefit of businesses, companies and other legal entities with which the Company is affiliated in a group and for the benefit of
third parties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top">to make periodical payments, including the conclusion and performance of annuity and other standing right agreements, whether or not in the context of a pension provision; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top">to invest capital and to invest moneys in real property, shares and bonds, to buy and sell real property, securities and other goods, to manage pension funds and to perform all the work and develop projects that may be
conducive to achieving the above objects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">h.</TD>
<TD ALIGN="left" VALIGN="top">to perform all kinds of industrial, financial and commercial activities; as well as any and all things that are related or may be conducive to the above, all of this in the broadest sense of the word. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Share capital.</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 3 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s capital consists of one or more ordinary shares, each share having a nominal value of one euro (&#128;&nbsp;1.00). </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">All the shares are registered and are numbered consecutively from 1 onwards. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The identifying number of a share serves as a designation. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">At least one voting share is held by a party other than the Company and otherwise than for the account of the Company or one of the Company&#146;s subsidiaries. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Share ownership. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 4 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">No obligations under the law of obligations are attached to the share ownership, within the meaning of Section&nbsp;2:192a (1)&nbsp;of the Dutch Civil Code. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">No requirements are attached to the share ownership, within the meaning of Section&nbsp;2:192b(1) of the Dutch Civil Code. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The voting right, the right to receive distributions and the right to attend meetings are suspended during any period in which a shareholder fails to fulfil an obligation under these Articles of Association or does not
meet a requirement under these Articles of Association. If a shareholder cannot exercise the rights referred to in the preceding sentence, the suspension ends if the Company has not within three (3)&nbsp;months after a request to that effect from
the shareholder designated prospective purchasers to whom he can transfer all his shares with due observance of the provisions of these Articles of Association. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">A suspension of rights ends if none of the shareholders can exercise the voting right as a result of the suspension. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Shareholders&#146; register. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 5 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board keeps a register in which the names, addresses and <FONT STYLE="white-space:nowrap">e-mail</FONT> addresses of all the shareholders are recorded, stating the date on which they
acquired the shares, the date of acknowledgement or service, the type or the designation of the shares, and the amount paid up on each share. If a shareholder is not bound by an obligation or requirement under these Articles of Association within
the meaning of Section&nbsp;2:192(1) of the Dutch Civil Code or by a price determination arrangement in these Articles of Association within the meaning of Section&nbsp;2:192a(2) of the Dutch Civil Code, that fact must be stated. If no voting right
is attached to shares pursuant to an arrangement in these Articles of Association on the grounds of Section&nbsp;2:228(5) of the Dutch Civil Code, the shares are registered as <FONT STYLE="white-space:nowrap">non-voting</FONT> shares. The names and
addresses of parties that have a usufruct or pledge in respect of shares must be recorded in the register, stating the date on which they acquired the right, the date of acknowledgement or service, and also stating which rights attached to the
shares are vested in them. The register must state the names and addresses of the holders of depositary receipts for shares that carry the right to attend meetings, stating the date on which the right to attend meetings was attached to their
depositary receipts and the date of acknowledgement or service. Insofar as share certificates may be issued, this will be recorded in the Articles of Association. The issue and withdrawal of a share certificate must also be recorded in the
shareholders&#146; register. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Shareholders and other parties whose data are recorded in the register pursuant to paragraph 1 of this Article must provide the management board in a timely manner with the information required. If an electronic address
is also notified for the purpose of being recorded in the shareholders&#146; register, that notification also constitutes consent to be sent all notifications and statements and notices convening meetings in an electronic form. In these Articles of
Association &#147;in writing&#148; means: by post, by fax, by <FONT STYLE="white-space:nowrap">e-mail</FONT> or by any other customary means of communication by means of which text can be transmitted. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The register must be updated on a regular basis. Any discharge from liability granted for payments not yet made must also be recorded in the register. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">On request the Company&#146;s management board must provide a shareholder, a usufructuary, a pledgee and a holder of a depositary receipt for a share that carries the right to attend meetings in or pursuant to these
Articles of Association for no consideration with an excerpt from the register regarding his right to a share or a depositary receipt. If the share is subject to a usufruct or a pledge, the excerpt must state who has the rights referred to in
Sections 2:197, 2:198 and 2:227 of the Dutch Civil Code. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board must make the register available at the Company&#146;s office for inspection by the shareholders, the usufructuaries and the pledgees who have the rights referred to in
Section&nbsp;2:227(2) of the Dutch Civil Code and the holders of depositary receipts issued for shares that carry the right to attend meetings in or pursuant to these Articles of Association. The information in the register regarding not fully <FONT
STYLE="white-space:nowrap">paid-up</FONT> shares is available for public inspection; a copy of or excerpt from that information is provided at no more than cost. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Share certificates. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 6 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No share certificates may be issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Issue of shares and <FONT
STYLE="white-space:nowrap">pre-emptive</FONT> right. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 7 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Shares may be issued only by resolution of the general meeting, insofar as the general meeting has not transferred that power to another body within the Company. The general meeting may revoke that transfer. The price
and the other conditions of issue are determined in the decision to issue shares. The price may not be below par. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Each shareholder, with the exception of the Company if it is the holder of shares in its own capital, has a <FONT STYLE="white-space:nowrap">pre-emptive</FONT> right on the issue of shares pro rata to the aggregate
value of his shares. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The provisions of paragraph 2 apply accordingly to the granting of rights to purchase shares but do not apply to the issue of shares to someone who exercises a previously acquired right to purchase shares.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The <FONT STYLE="white-space:nowrap">pre-emptive</FONT> right can be limited or excluded, each time for one single issue, by the body authorised to issue shares. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The issue of a share furthermore requires a deed intended for that purpose, executed before a <FONT STYLE="white-space:nowrap">civil-law</FONT> notary practising in the Netherlands, to which deed the Company and the
persons acquiring shares must be parties. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">A share premium may only be paid when shares are issued or with the approval of the body that is authorised to decide to issue shares. Every time a share premium is paid this body can decide that the paid share premium
or a part thereof will be added as a share premium reserve for shares of one type or designation. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Payment on shares. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 8 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">On the purchase of a share its nominal value must be paid up. It may be stipulated that the nominal value or part of that value need not be paid until a specified period of time has passed or until the management board
calls in that amount. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Payment on a share must be made in cash, except insofar as another contribution has been agreed on. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Payment in a currency other than that in which the nominal value is denominated may be made only with the permission of the Company&#146;s management board. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Shares held by the Company in its own capital. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 9 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company may not purchase shares in its own capital on the issue of shares. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board decides on the acquisition and sale of shares in the Company&#146;s capital. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The Company may acquire shares in its own capital or depositary receipts for those shares only insofar as they have been paid up in full and only with due observance of the relevant provisions of the law.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">Acquisition and sale by the Company of shares in its own capital or depositary receipts for those shares must take place with due observance of the provisions of Article 14. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">No vote may be cast at the General Meeting in respect of a share or a depositary receipt for a share that belongs to the Company or to a subsidiary of the Company. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Reduction of capital. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 10 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The General Meeting may decide to reduce the issued capital by withdrawing shares or by reducing the value of shares by amendment to these Articles of Association. In that resolution the shares to which the resolution
relates must be designated and the implementation of the resolution must be regulated. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Capital reduction must otherwise take place with due observance of the provisions of the law. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Usufruct.
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 11 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">A usufruct may be created on a share. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The voting right attached to a share is vested in the usufructuary if that right has been granted to him by law or with due observance of the statutory provisions. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Pledge. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 12 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Shares may be pledged. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The voting right attached to the pledged shares is vested in the shareholder. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Contrary to the preceding paragraph the voting right is vested in the pledgee if that was determined on the creation of the pledge, whether or not subject to a condition precedent, or if that is later agreed on in
writing between the shareholder and the pledgee, and the transmission of the voting right has been approved by the General Meeting. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Transfer of shares and restricted rights. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article
13 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The transfer of a share or the creation or transfer of a restricted right to a share requires a deed intended for that purpose and executed before a civil-law notary practising in the Netherlands, to which deed the
party that transfers the shares and the party that acquires the shares must be parties. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Unless the Company itself is a party to the legal act, the rights attached to the share cannot be exercised until the Company has acknowledged the legal act or the deed has been served on the Company in accordance with
the relevant provisions of the law, or the Company has acknowledged the legal act of its own accord by registering it in the shareholders&#146; register in accordance with the relevant provisions of the law. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Share transfer restrictions. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 14 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No legal or statutory restrictions are referred to in Section&nbsp;2:195 of the Dutch Civil Code apply to a transfer of shares in the share capital of the
Company as long as there is a sole shareholder. In case there is more than one shareholder then the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">legal or the statutory restrictions, as referred to in
Section&nbsp;2:195 of the Dutch Civil </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Code, will applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Management board. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 15 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board consists of one or more managing directors. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The number of managing directors is determined by the general meeting. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Appointment Suspension and
removal from office Remuneration. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 16 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The managing directors are appointed by the general meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Each managing director may be suspended and removed from office by the general meeting at any time. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The remuneration and the other employment conditions of each managing director are determined by the general meeting. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The general meeting may give a managing director the title of Chief Executive. The general meeting may withdraw that title at any time. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Management task; decision-making; absence or inability to act. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 17 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board is entrusted with the management of the Company. In performing its task the management board must focus on the interest of the Company and the business affiliated with it.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The management board shall comply with the instructions of the General Meeting. The Management board shall comply with the instructions of the General Meeting unless these are contrary to the interest of the Company and
the business affiliated with it. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">All resolutions of the management board are adopted by an absolute majority of the votes cast. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">Resolutions of the Company&#146;s management board may also be adopted in writing rather than at a meeting, provided that that is done by a unanimous vote of all the managing directors in office. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">If a managing director is absent or unable to act, the other managing director(s) is/are temporarily entrusted with the management of the Company. If all the managing directors or the sole managing director is/are
absent or unable to act, the person appointed for that purpose by the general meeting is temporarily entrusted with the management of the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">A managing director may not participate in the deliberations and decision-making, if with respect to the matter concerned he has a direct or indirect personal interest that conflicts with the interests of the Company
and the business affiliated with it. If, as a result hereof, the management board cannot make a decision, the board is still authorised to do so. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Representation. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 18 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board is authorised to represent the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">In addition to the provisions of paragraph 1, two (2)&nbsp;managing directors acting jointly, or one managing director together with a proxyholder, are authorised to represent the Company. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board may appoint officers with a general or limited power of representation. Each of them represents the Company with due observance of the limits imposed on that power. Their titles are
determined by the Company&#146;s management board. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Approval of resolutions of the management board. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 19 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The general meeting is authorised to submit resolutions to its approval. Such resolutions must be clearly described and must be notified to the management board in writing. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The absence of the approval referred to in this Article does not affect the power of representation of the management board or the managing directors. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Financial statements. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 20 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The financial year coincides with the calendar year. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Each year, within five (5)&nbsp;months after the end of the financial year, unless that term is extended by no more than six (6)&nbsp;months by the general meeting on the grounds of special circumstances, the
Company&#146;s management board must draw up financial statements and make them available for inspection by the shareholders at the Company&#146;s office. Within that period the Company&#146;s management board must also make the annual report
available for inspection by the shareholders, unless Sections 2:396(7) or 2:403 of the Dutch Civil Code apply. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The financial statements must be signed by the managing directors; if the signature of one or more of them is missing, that fact and the reason must be stated. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The Company must give instruction to have the financial statements audited by an accountant who is authorised by law, unless the Company is exempted from doing so by law. The general meeting is authorised to give that
instruction. If it fails to do so, the management board has that authority. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The instruction to audit the financial statements can be withdrawn for valid reasons by the general meeting and by the party that gave the instruction. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">The accountant who has audited the financial statements reports on his audit to the management board. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">The Company must ensure that the drafted financial statements, the annual report and the information that must be added to them pursuant to Section&nbsp;2:392(1) of the Dutch Civil Code are available at its office from
the convening of the general meeting at which they are to be addressed. The shareholders and the other parties entitled to attend meetings can inspect the documents there and obtain free copies of those documents. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top">If the Company has been exempted from the obligation referred to in paragraph 4, the general meeting may nevertheless decide that the obligation to audit will be complied with or that another form of assessment of the
financial statements and financial accounts will be performed. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Adoption of the financial statements; discharge; publication.
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 21 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The general meeting adopts the financial statements. </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The management board adopts the annual
report. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Adoption of the financial statements does not discharge a managing director, unless the provisions of paragraph 3 apply. By separate resolution the general meeting can discharge a managing director for the management
conducted in the financial year in question, insofar as that management is apparent from the financial statements or has been made known to the general meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">If all the shareholders are also managing directors of the Company, signing of the financial statements by all the managing directors also serves as adoption of the financial statements, provided that all the parties
entitled to attend meetings have been given the opportunity to take note of the drafted financial statements and have agreed to this manner of adoption. Adoption of the financial statements in this manner discharges the managing directors.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The Company is required to publish its financial statements within eight (8)&nbsp;days after their adoption, unless a statutory exemption applies. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Profit. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 22 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The general meeting is authorised to allocate the profit determined by the adoption of the financial statements and to decide on distributions insofar as its equity exceeds the reserves that must be maintained by law or
pursuant to these Articles of Association. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">A resolution pertaining to distribution has no consequences until the management board has given its approval. The management board may withhold its approval only if it knows or reasonably ought to foresee that the
Company will not be able to continue to pay its immediately payable debts after the distribution. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">If the Company cannot continue to pay its immediately payable debts after a distribution, the managing directors who knew or reasonably ought to have foreseen that at the time of the distribution are jointly and
severally liable towards the Company for the deficit resulting from the distribution, plus the statutory interest from the day of the distribution. Section&nbsp;2:248(5) of the Dutch Civil Code applies accordingly. A managing director who proves
that he or she is not to blame for the distribution made by the Company and that he or she has not been negligent in taking measures to ward off the consequences is not bound. A person who received the distribution while he knew or reasonably ought
to have foreseen that the Company would be unable after the distribution to continue to pay its immediately payable debts is required to pay the deficit resulting from the distribution, up to the amount of the value of the distribution received by
him, plus the statutory interest from the day of the distribution. If the managing directors have paid the claim pursuant to the first sentence, the payment referred to in the fourth sentence is made to the managing directors pro rata to the part
that has been paid by each of the managing directors. The debtor does not have the right of <FONT STYLE="white-space:nowrap">set-off</FONT> in respect of a debt on the grounds of the first or fourth sentence. This paragraph does not apply to
distributions in the form of shares in the Company&#146;s capital or additional payment on not fully paid shares. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">For the purposes of paragraph 3 a person who determined or <FONT STYLE="white-space:nowrap">co-determined</FONT> the Company&#146;s policy is put on a par with a managing director as if he were a managing director. The
claim cannot be filed against the administrator appointed by the court. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">In calculating each distribution the shares held by the Company in its own capital are not counted. In calculating the amount that will be paid on each share only the amount of the obligatory payments on the nominal
value of the shares is taken into account. It is possible to depart from the provision of the second sentence of this paragraph with the approval of all the shareholders. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">A shareholder&#146;s claim regarding a distribution of profits expires five (5)&nbsp;years after the day of the resolution to distribute the profit. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>General meeting. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 23 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">During each financial year at least one general meeting must be held or at least once a resolution must be adopted without a meeting being held in accordance with Article 28, unless the financial statements have been
adopted in accordance with the provisions of Article 23(3). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2. Other general meetings will be held as often as the Company&#146;s management board considers necessary. The
management board is authorised to convene a general meeting. The management board is required to convene a general meeting if one or more shareholders solely or jointly representing at least <FONT STYLE="white-space:nowrap">one-hundredth</FONT>
(1/100th) of the issued capital request(s) the convening of a general meeting in writing, accurately stating the subjects to be addressed. The management board must take the necessary measures to ensure that the general meeting can be held within
four (4)&nbsp;weeks after the request, unless a compelling interest of the Company so opposes. If the management board fails to comply with the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">request, the shareholders referred to in the second sentence can be authorised at their request by the preliminary relief judge of the court to convene the general meeting. For the purposes of this paragraph,
shareholders are put on a par with other persons who have the right to attend meetings. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Each person entitled to attend meetings is authorised to attend and address the general meeting in person or by written proxy. The requirement of a written power of attorney is met if the power of attorney has been
drawn up in an electronic form. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">A general meeting must be convened by means of convening notices sent to the addresses of the shareholders and other parties entitled to attend meetings as recorded in the register referred to in Article 5 of these
Articles of Association. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">With the approval of a person entitled to attend meetings, the meeting can also be convened by readable and reproducible message sent in an electronic form to the address that he has made known to the Company for that
purpose. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">The convening notices must state the subjects to be addressed. Participation in and voting at a general meeting is possible using an electronic means of communication if that is stated in the convening notices.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">The meeting must be convened no later than on the eighth (8th) day before the day of the meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top">The general meetings are held in the municipality in which the Company has its registered office under these Articles of Association. The general meeting appoints its own chairperson. Until that moment the meeting is
chaired by a managing director or, if no managing director is present, by the most senior person present at the meeting in terms of age. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top">The managing directors have an advisory vote in that capacity at the general meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top">If shares, restricted rights to shares or depositary receipts issued for shares form part of a community of property, the joint owners can be represented towards the Company only by one person to be designated in
writing. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Depositary receipts for shares. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 24 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of depositary receipts for shares do not have
the right to attend meetings. <B><U> </U></B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Persons entitled to attend meetings.</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 25 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The right to attend meetings vests in shareholders,
in shareholders who because of a usufruct or pledge have no voting rights and in usufructuaries and pledges who have voting rights. Usufructuaries and pledgees who have no voting rights do not have the right to attend meetings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>General meeting; different agenda; term; location. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 26 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Provided that all the persons entitled to attend meetings have agreed and the managing directors have been given the opportunity prior to the decision-making to advise, resolutions can be adopted within the meaning of
Sections 2:224(2), 2:225 and 2:226(3) of the Dutch Civil Code. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board must keep notes of the resolutions adopted. If the Company&#146;s management board is not represented at the meeting, a copy of the resolution that is adopted is presented to the
Company&#146;s management board by or on behalf of the chairperson as soon as possible after the meeting. The records are available at the Company&#146;s office for inspection by the shareholders and other persons who have the right to attend
meetings. On request, each of them is provided with a copy of or excerpt from those notes at no more than cost. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Decision-making.
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 27 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Each share carries the right to cast one vote. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Each shareholder is authorised, either in person or by written proxy, by means of an electronic means of communication to take part in the general meeting, to address the meeting and to exercise the voting right, unless
one or more of those rights is/are not vested in a shareholder in accordance with the provisions of these Articles of Association. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">For the purposes of paragraph 2 it is a minimum requirement that the shareholder can be identified, can directly take part in the business transacted at the meeting and can exercise the voting right by the electronic
means of communication. The person entitled to attend meetings can furthermore take part in the deliberations via the electronic means of communication. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board may stipulate further conditions for the use of the electronic means of communication referred to in this Article, which conditions must be stated in the convening notices.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The requirement of a written proxy is met if the proxy has been recorded in an electronic form. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">Insofar as no greater majority is prescribed by law or in these Articles of Association, all resolutions are adopted by an absolute majority of the votes cast. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">If a vote is equally divided, the proposal has been rejected. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Decision-making without a meeting being
held. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 28 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Decisions may also be made otherwise than at a meeting, provided that all the persons entitled to attend meetings have given their approval for that manner of decision-making. That approval can also be given in an
electronic form. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Votes are cast in writing. The requirement of a written vote is also met if the decision has been recorded in writing or electronically, stating the manner in which each of the shareholders votes, and has been signed by
all the persons entitled to attend meetings. The votes may also be cast in an electronic form. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The managing directors are given the opportunity to advise prior to the decision-making. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Amendment to these Articles of Association and winding up. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 29 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Resolutions to amend these Articles of Association, to wind up the Company or to effect a legal merger or legal demerger or division may be adopted by the general meeting only by a majority of at least <FONT
STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the votes cast at a meeting at which at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the issued capital is represented, unless the law requires a larger majority or quorum.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">If the capital referred to in paragraph 1 is not represented, a new meeting must be convened, to be held within one (1)&nbsp;month after the first meeting, but no sooner than eight (8)&nbsp;days thereafter, at which,
irrespective of the capital then represented, the resolutions referred to in paragraph 1 can be adopted by a majority of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the votes cast, unless the law requires a larger majority
or quorum. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The notices convening that new meeting must state that a second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) meeting is involved, with due observance of the provisions of Section&nbsp;2:230(3) of the Dutch
Civil Code. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">If a proposal to amend the Articles of Association or to wind up the Company will be made to the general meeting, that must always be stated in the notices convening the general meeting and, if an amendment to these
Articles of Association is involved, a copy of the proposal containing the proposed amendment verbatim must be made available at the Company&#146;s office for inspection by shareholders until the end of the meeting. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">A resolution to amend these Articles of Association that specifically detracts from any right of shareholders of a specific designation or type, can be adopted only with the approval of all the shareholders and other
persons entitled to attend meetings whose rights are affected by the amendment to the Articles of Association. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">When these Articles of Association are amended the following requirement, obligation or regulations may not be imposed against the shareholder&#146;s will, including subject to conditions or time limit:
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">obligations related to the law of obligations, attached to the ownership of all the shares or shares of a specific designation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">the attachment of requirements to the ownership of shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">provisions that a shareholder is required to offer and transfer his shares or part of his shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">deviating from the price determination rules within the meaning of Section&nbsp;2:192(3) of the Dutch Civil Code. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Liquidation. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 30 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">If the Company is wound up by resolution of the general meeting, the general meeting appoints one or more persons who will be entrusted with the liquidation of the Company&#146;s affairs. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">During the liquidation the provisions of these Articles of Association continue to apply to the extent possible. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Any amount remaining after payment of the debts is paid and transferred to the shareholders pro rata to the joint value of each person&#146;s shares. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The provisions of Part 1, Book 2, of the Dutch Civil Code also apply to the liquidation. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Other powers.
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 31 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The general meeting has all the powers
not granted to the management board or other parties within the limits stipulated by law and by these Articles of Association. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Disputes procedure. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 32 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disputes between shareholders within the meaning of
Section&nbsp;1, Part 8, Book 2 of the Dutch Civil Code are settled in the first instance by the District Court for the Company&#146;s registered office as provided for in Section&nbsp;2:336(3) of the Dutch Civil Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.5
<SEQUENCE>3
<FILENAME>d558803dex35.htm
<DESCRIPTION>EX-3.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">20130066/JS/AS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>IN THIS
TRANSLATION AN ATTEMPT HAS BEEN MADE TO BE AS LITERAL AS POSSIBLE WITHOUT JEOPARDISING THE OVERALL CONTINUITY. INEVITABLY, DIFFERENCES MAY OCCUR IN TRANSLATION, AND IF SO THE DUTCH TEXT WILL BY LAW GOVERN. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEED OF INCORPORATION OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This sixteenth day of October two thousand and thirteen, before me, mr. Jan Willem Anton Schenk, a <FONT STYLE="white-space:nowrap">civil-law</FONT> notary in
Amsterdam, personally appeared: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anglig&eacute;ne Nyre&eacute; Beatrice Servania, born on Curacao, on the eighteenth day of August nineteen hundred and
seventy-three, with office address at Prins Bernhardplein 200, 1097 JB Amsterdam (the Netherlands), in this respect acting as written proxy of attorney granted by: <B>Teva Pharmaceuticals Finance Netherlands B.V., </B>a private company with limited
liability, with its registered office in Utrecht and its principal place of business at Computerweg 10, 3542 DR in Utrecht, registered in the trade register of the Chambers of Commerce under number 30175193, referred to below as the
<B>&#147;Incorporator&#148;;</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The person appearing, acting in her aforesaid capacity, stated that she incorporated a private limited liability company
governed by following Articles of Association: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>NAME AND REGISTERED OFFICE.</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 1 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s name is: <B>Teva Pharmaceutical Finance Netherlands II B.V.</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The Company has its registered office in Amsterdam. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>OBJECTS. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 2 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s objects are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">to incorporate, in any manner to participate in, to manage and to supervise businesses, companies and other legal entities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">to finance businesses, companies and other legal entities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">to borrow, including the lending and raising of funds, to issue bonds, debentures or other securities, and to enter into related agreements; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">to give advice and to provide services to businesses, companies and other legal entities with which the Company is affiliated in a group, and to third parties; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top">to issue guarantees, to commit the Company and to encumber assets of the Company for the benefit of businesses, companies and other legal entities with which the Company is affiliated in a group and for the benefit of
third parties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top">to make periodical payments, including the conclusion and performance of annuity and other standing right agreements, whether or not in the context of a pension provision; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top">to invest capital and to invest moneys in real property, shares and bonds, to buy and sell real property, securities and other goods, to manage pension funds and to perform all the work and develop projects that may be
conducive to achieving the above objects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">h.</TD>
<TD ALIGN="left" VALIGN="top">to perform all kinds of industrial, financial and commercial activities; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as well as any and all things that
are related or may be conducive to the above, all of this in the broadest sense of the word. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SHARE CAPITAL. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 3 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s capital consists of one or more ordinary shares, each share having a nominal value of one thousand euro (&#128;&nbsp;1,000). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">All the shares are registered and are numbered consecutively from 1 onwards. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The identifying number of a share serves as a designation. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">At least one voting share is held by a party other than the Company and otherwise than for the account of the Company or one of the Company&#146;s subsidiaries. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SHARE OWNERSHIP. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 4 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">No obligations under the law of obligations are attached to the share ownership, within the meaning of Section&nbsp;2:192a (1)&nbsp;of the Dutch Civil Code. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">No requirements are attached to the share ownership, within the meaning of Section&nbsp;2:192b(1) of the Dutch Civil Code. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The voting right, the right to receive distributions and the right to attend meetings are suspended during any period in which a shareholder fails to fulfil an obligation under these Articles of Association or does not
meet a requirement under these Articles of Association. If a shareholder cannot exercise the rights referred to in the preceding sentence, the suspension ends if the Company has not within three (3)&nbsp;months after a request to that effect from
the shareholder designated prospective purchasers to whom he can transfer all his shares with due observance of the provisions of these Articles of Association. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">A suspension of rights ends if none of the shareholders can exercise the voting right as a result of the suspension. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SHAREHOLDERS&#146; REGISTER. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 5 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board keeps a register in which the names, addresses and <FONT STYLE="white-space:nowrap">e-mail</FONT> addresses of all the shareholders are recorded, stating the date on which they
acquired the shares, the date of acknowledgement or service, the type or the designation of the shares, and the amount paid up on each share. If a shareholder is not bound by an obligation or requirement under these Articles of Association within
the meaning of Section&nbsp;2:192(1) of the Dutch Civil Code or by a price determination arrangement in these Articles of Association within the meaning of Section&nbsp;2:192a(2) of the Dutch Civil Code, that fact must be stated. If no voting right
is attached to shares pursuant to an arrangement in these Articles of Association on the grounds of Section&nbsp;2:228(5) of the Dutch Civil Code, the shares are registered as <FONT STYLE="white-space:nowrap">non-voting</FONT> shares. The names and
addresses of parties that have a usufruct or pledge in respect of shares must be recorded in the register, stating the date on which they acquired the right, the date of acknowledgement or service, and also stating which rights attached to the
shares are vested in them. The register must state the names and addresses of the holders of depositary receipts for shares that carry the right to attend meetings, stating the date on which the right to attend meetings was attached to their
depositary receipts and the date of acknowledgement or service. Insofar as share certificates may be issued, this will be recorded in the Articles of Association. The issue and withdrawal of a share certificate must also be recorded in the
shareholders&#146; register. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Shareholders and other parties whose data are recorded in the register pursuant to paragraph 1 of this Article must provide the management board in a timely manner with the information required. If an electronic address
is also notified for the purpose of being recorded in the shareholders&#146; register, that notification also constitutes consent to be sent all notifications and statements and notices convening meetings in an electronic form. In these Articles of
Association &#147;in writing&#148; means: by post, by fax, by <FONT STYLE="white-space:nowrap">e-mail</FONT> or by any other customary means of communication by means of which text can be transmitted. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The register must be updated on a regular basis. Any discharge from liability granted for payments not yet made must also be recorded in the register. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">On request the Company&#146;s management board must provide a shareholder, a usufructuary, a pledgee and a holder of a depositary receipt for a share that carries the right to attend meetings in or pursuant to these
Articles of Association for no consideration with an excerpt from the register regarding his right to a share or a depositary receipt. If the share is subject to a usufruct or a pledge, the excerpt must state who has the rights referred to in
Sections 2:197, 2:198 and 2:227 of the Dutch Civil Code. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board must make the register available at the Company&#146;s office for inspection by the shareholders, the usufructuaries and the pledgees who have the rights referred to in
Section&nbsp;2:227(2) of the Dutch Civil Code and the holders of depositary receipts issued for shares that carry the right to attend meetings in or pursuant to these Articles of Association. The information in the register regarding not fully <FONT
STYLE="white-space:nowrap">paid-up</FONT> shares is available for public inspection; a copy of or excerpt from that information is provided at no more than cost. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SHARE CERTIFICATES. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 6 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No share certificates may be issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ISSUE OF SHARES AND <FONT
STYLE="white-space:nowrap">PRE-EMPTIVE</FONT> RIGHT. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 7 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Shares may be issued only by resolution of the general meeting, insofar as the general meeting has not transferred that power to another body within the Company. The general meeting may revoke that transfer. The price
and the other conditions of issue are determined in the decision to issue shares. The price may not be below par. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Each shareholder, with the exception of the Company if it is the holder of shares in its own capital, has a <FONT STYLE="white-space:nowrap">pre-emptive</FONT> right on the issue of shares pro rata to the aggregate
value of his shares. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The provisions of paragraph 2 apply accordingly to the granting of rights to purchase shares but do not apply to the issue of shares to someone who exercises a previously acquired right to purchase shares.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The <FONT STYLE="white-space:nowrap">pre-emptive</FONT> right can be limited or excluded, each time for one single issue, by the body authorised to issue shares. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The issue of a share furthermore requires a deed intended for that purpose, executed before a <FONT STYLE="white-space:nowrap">civil-law</FONT> notary practising in the Netherlands, to which deed the Company and the
persons acquiring shares must be parties. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">A share premium may only be paid when shares are issued or with the approval of the body that is authorised to decide to issue shares. Every time a share premium is paid this body can decide that the paid share premium
or a part thereof will be added as a share premium reserve for shares of one type or designation. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>PAYMENT ON SHARES. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 8 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">On the purchase of a share its nominal value must be paid up. It may be stipulated that the nominal value or part of that value need not be paid until a specified period of time has passed or until the management board
calls in that amount. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Payment on a share must be made in cash, except insofar as another contribution has been agreed on. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Payment in a currency other than that in which the nominal value is denominated may be made only with the permission of the Company&#146;s management board. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SHARES HELD BY THE COMPANY IN ITS OWN CAPITAL. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 9 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company may not purchase shares in its own capital on the issue of shares. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board decides on the acquisition and sale of shares in the Company&#146;s capital. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The Company may acquire shares in its own capital or depositary receipts for those shares only insofar as they have been paid up in full and only with due observance of the relevant provisions of the law.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">Acquisition and sale by the Company of shares in its own capital or depositary receipts for those shares must take place with due observance of the provisions of Article 14. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">No vote may be cast at the General Meeting in respect of a share or a depositary receipt for a share that belongs to the Company or to a subsidiary of the Company. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>REDUCTION OF CAPITAL. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 10 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The General Meeting may decide to reduce the issued capital by withdrawing shares or by reducing the value of shares by amendment to these Articles of Association. In that resolution the shares to which the resolution
relates must be designated and the implementation of the resolution must be regulated. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Capital reduction must otherwise take place with due observance of the provisions of the law. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>USUFRUCT.
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 11 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">A usufruct may be created on a share. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The voting right attached to a share is vested in the usufructuary if that right has been granted to him by law or with due observance of the statutory provisions. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>PLEDGE. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 12 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Shares may be pledged. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The voting right attached to the pledged shares is vested in the shareholder. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Contrary to the preceding paragraph the voting right is vested in the pledgee if that was determined on the creation of the pledge, whether or not subject to a condition precedent, or if that is later agreed on in
writing between the shareholder and the pledgee, and the transmission of the voting right has been approved by the General Meeting. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>TRANSFER OF SHARES AND RESTRICTED RIGHTS. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article
13 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The transfer of a share or the creation or transfer of a restricted right to a share requires a deed intended for that purpose and executed before a civil-law notary practising in the Netherlands, to which deed the
party that transfers the shares and the party that acquires the shares must be parties. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Unless the Company itself is a party to the legal act, the rights attached to the share cannot be exercised until the Company has acknowledged the legal act or the deed has been served on the Company in accordance with
the relevant provisions of the law, or the Company has acknowledged the legal act of its own accord by registering it in the shareholders&#146; register in accordance with the relevant provisions of the law. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SHARE TRANSFER RESTRICTIONS. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 14 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No legal or statutory restrictions are referred to in Section&nbsp;2:195 of the Dutch Civil Code apply to a transfer of shares in the share capital of the
Company as long as there is a sole shareholder. In case there is more than one shareholder then the legal or the statutory restrictions, as referred to in Section&nbsp;2:195 of the Dutch Civil Code, will applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>MANAGEMENT BOARD. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 15 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board consists of one or more managing directors. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The number of managing directors is determined by the general meeting. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>APPOINTMENT SUSPENSION AND
REMOVAL FROM OFFICE REMUNERATION. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 16 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The managing directors are appointed by the general meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Each managing director may be suspended and removed from office by the general meeting at any time. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The remuneration and the other employment conditions of each managing director are determined by the general meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The general meeting may give a managing director the title of Chief Executive. The general meeting may withdraw that title at any time. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>MANAGEMENT TASK; DECISION-MAKING; ABSENCE OR INABILITY TO ACT. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Article 17 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board is entrusted with the management of the Company. In performing its task the management board must focus on the interest of the Company and the business affiliated with it.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The management board shall comply with the instructions of the General Meeting. The Management board shall comply with the instructions of the General Meeting unless these are contrary to the interest of the Company and
the business affiliated with it. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">All resolutions of the management board are adopted by an absolute majority of the votes cast. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">Resolutions of the Company&#146;s management board may also be adopted in writing rather than at a meeting, provided that that is done by a unanimous vote of all the managing directors in office. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">If a managing director is absent or unable to act, the other managing director(s) is/are temporarily entrusted with the management of the Company. If all the managing directors or the sole managing director is/are
absent or unable to act, the person appointed for that purpose by the general meeting is temporarily entrusted with the management of the Company. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">A managing director may not participate in the deliberations and decision-making, if with respect to the matter concerned he has a direct or indirect personal interest that conflicts with the interests of the Company
and the business affiliated with it. If, as a result hereof, the management board cannot make a decision, the board is still authorised to do so. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>REPRESENTATION. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 18 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board is authorised to represent the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">In addition to the provisions of paragraph 1, two (2)&nbsp;managing directors acting jointly, or one managing director together with a proxyholder, are authorised to represent the Company. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board may appoint officers with a general or limited power of representation. Each of them represents the Company with due observance of the limits imposed on that power. Their titles are
determined by the Company&#146;s management board. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>APPROVAL OF RESOLUTIONS OF THE MANAGEMENT BOARD. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 19 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The general meeting is authorised to submit resolutions to its approval. Such resolutions must be clearly described and must be notified to the management board in writing. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The absence of the approval referred to in this Article does not affect the power of representation of the management board or the managing directors. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>FINANCIAL STATEMENTS. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 20 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The financial year coincides with the calendar year. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Each year, within five (5)&nbsp;months after the end of the financial year, unless that term is extended by no more than six (6)&nbsp;months by the general meeting on the grounds of special circumstances, the
Company&#146;s management board must draw up financial statements and make them available for inspection by the shareholders at the Company&#146;s office. Within that period the Company&#146;s management board must also make the annual report
available for inspection by the shareholders, unless Sections 2:396(7) or 2:403 of the Dutch Civil Code apply. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The financial statements must be signed by the managing directors; if the signature of one or more of them is missing, that fact and the reason must be stated. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The Company must give instruction to have the financial statements audited by an accountant who is authorised by law, unless the Company is exempted from doing so by law. The general meeting is authorised to give that
instruction. If it fails to do so, the management board has that authority. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The instruction to audit the financial statements can be withdrawn for valid reasons by the general meeting and by the party that gave the instruction. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">The accountant who has audited the financial statements reports on his audit to the management board. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">The Company must ensure that the drafted financial statements, the annual report and the information that must be added to them pursuant to Section&nbsp;2:392(1) of the Dutch Civil Code are available at its office from
the convening of the general meeting at which they are to be addressed. The shareholders and the other parties entitled to attend meetings can inspect the documents there and obtain free copies of those documents. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top">If the Company has been exempted from the obligation referred to in paragraph 4, the general meeting may nevertheless decide that the obligation to audit will be complied with or that another form of assessment of the
financial statements and financial accounts will be performed. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ADOPTION OF THE FINANCIAL STATEMENTS; DISCHARGE; PUBLICATION.
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 21 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The general meeting adopts the financial statements. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The management board
adopts the annual report. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Adoption of the financial statements does not discharge a managing director, unless the provisions of paragraph 3 apply. By separate resolution the general meeting can discharge a managing director for the management
conducted in the financial year in question, insofar as that management is apparent from the financial statements or has been made known to the general meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">If all the shareholders are also managing directors of the Company, signing of the financial statements by all the managing directors also serves as adoption of the financial statements, provided that all the parties
entitled to attend meetings have been given the opportunity to take note of the drafted financial statements and have agreed to this manner of adoption. Adoption of the financial statements in this manner discharges the managing directors.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The Company is required to publish its financial statements within eight (8)&nbsp;days after their adoption, unless a statutory exemption applies. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>PROFIT. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 22 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The general meeting is authorised to allocate the profit determined by the adoption of the financial statements and to decide on distributions insofar as its equity exceeds the reserves that must be maintained by law or
pursuant to these Articles of Association. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">A resolution pertaining to distribution has no consequences until the management board has given its approval. The management board may withhold its approval only if it knows or reasonably ought to foresee that the
Company will not be able to continue to pay its immediately payable debts after the distribution. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the Company cannot continue to pay its immediately payable debts after a distribution, the managing directors
who knew or reasonably ought to have foreseen that at the time of the distribution are jointly and severally liable towards the Company for the deficit resulting from the distribution, plus the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">statutory interest from the day of the distribution. Section&nbsp;2:248(5) of the Dutch Civil Code applies accordingly. A managing director who proves that he or she is not to blame for the distribution made by the
Company and that he or she has not been negligent in taking measures to ward off the consequences is not bound. A person who received the distribution while he knew or reasonably ought to have foreseen that the Company would be unable after the
distribution to continue to pay its immediately payable debts is required to pay the deficit resulting from the distribution, up to the amount of the value of the distribution received by him, plus the statutory interest from the day of the
distribution. If the managing directors have paid the claim pursuant to the first sentence, the payment referred to in the fourth sentence is made to the managing directors pro rata to the part that has been paid by each of the managing directors.
The debtor does not have the right of <FONT STYLE="white-space:nowrap">set-off</FONT> in respect of a debt on the grounds of the first or fourth sentence. This paragraph does not apply to distributions in the form of shares in the Company&#146;s
capital or additional payment on not fully paid shares. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">For the purposes of paragraph 3 a person who determined or <FONT STYLE="white-space:nowrap">co-determined</FONT> the Company&#146;s policy is put on a par with a managing director as if he were a managing director. The
claim cannot be filed against the administrator appointed by the court. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">In calculating each distribution the shares held by the Company in its own capital are not counted. In calculating the amount that will be paid on each share only the amount of the obligatory payments on the nominal
value of the shares is taken into account. It is possible to depart from the provision of the second sentence of this paragraph with the approval of all the shareholders. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">A shareholder&#146;s claim regarding a distribution of profits expires five (5)&nbsp;years after the day of the resolution to distribute the profit. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>GENERAL MEETING. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 23 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">During each financial year at least one general meeting must be held or at least once a resolution must be adopted without a meeting being held in accordance with Article 28, unless the financial statements have been
adopted in accordance with the provisions of Article 23(3). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">2. Other general meetings will be held as often as the Company&#146;s management board considers necessary. The management board is authorised to convene a general meeting. The management board is required to convene a
general meeting if one or more shareholders solely or jointly representing at least <FONT STYLE="white-space:nowrap">one-hundredth</FONT> (1/100th) of the issued capital request(s) the convening of a general meeting in writing, accurately stating
the subjects to be addressed. The management board must take the necessary measures to ensure that the general meeting can be held within four (4)&nbsp;weeks after the request, unless a compelling interest of the Company so opposes. If the
management board fails to comply with the request, the shareholders referred to in the second sentence can be authorised at their request by the preliminary relief judge of the court to convene the general meeting. For the purposes of this
paragraph, shareholders are put on a par with other persons who have the right to attend meetings. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Each person entitled to attend meetings is authorised to attend and address the general meeting in person or by written proxy. The requirement of a written power of attorney is met if the power of attorney has been
drawn up in an electronic form. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">A general meeting must be convened by means of convening notices sent to the addresses of the shareholders and other parties entitled to attend meetings as recorded in the register referred to in Article 5 of these
Articles of Association. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">With the approval of a person entitled to attend meetings, the meeting can also be convened by readable and reproducible message sent in an electronic form to the address that he has made known to the Company for that
purpose. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">The convening notices must state the subjects to be addressed. Participation in and voting at a general meeting is possible using an electronic means of communication if that is stated in the convening notices.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">The meeting must be convened no later than on the eighth (8th) day before the day of the meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top">The general meetings are held in the municipality in which the Company has its registered office under these Articles of Association. The general meeting appoints its own chairperson. Until that moment the meeting is
chaired by a managing director or, if no managing director is present, by the most senior person present at the meeting in terms of age. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top">The managing directors have an advisory vote in that capacity at the general meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top">If shares, restricted rights to shares or depositary receipts issued for shares form part of a community of property, the joint owners can be represented towards the Company only by one person to be designated in
writing. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>DEPOSITARY RECEIPTS FOR SHARES. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 24 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of depositary receipts for shares do not have
the right to attend meetings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>PERSONS ENTITLED TO ATTEND MEETINGS. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 25 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The right to attend meetings vests in shareholders,
in shareholders who because of a usufruct or pledge have no voting rights and in usufructuaries and pledges who have voting rights. Usufructuaries and pledgees who have no voting rights do not have the right to attend meetings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>GENERAL MEETING; DIFFERENT AGENDA; TERM; LOCATION. </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 26 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Provided that all the persons entitled to attend meetings have agreed and the managing directors have been given the opportunity prior to the decision-making to advise, resolutions can be adopted within the meaning of
Sections 2:224(2), 2:225 and 2:226(3) of the Dutch Civil Code. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board must keep notes of the resolutions adopted. If the Company&#146;s management board is not represented at the meeting, a copy of the resolution that is adopted is presented to the
Company&#146;s management board by or on behalf of the chairperson as soon as possible after the meeting. The records are available at the Company&#146;s office for inspection by the shareholders and other persons who have the right to attend
meetings. On request, each of them is provided with a copy of or excerpt from those notes at no more than cost. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>DECISION-MAKING.
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 27 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Each share carries the right to cast one vote. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Each shareholder is authorised, either in person or by written proxy, by means of an electronic means of communication to take part in the general meeting, to address the meeting and to exercise the voting right, unless
one or more of those rights is/are not vested in a shareholder in accordance with the provisions of these Articles of Association. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">For the purposes of paragraph 2 it is a minimum requirement that the shareholder can be identified, can directly take part in the business transacted at the meeting and can exercise the voting right by the electronic
means of communication. The person entitled to attend meetings can furthermore take part in the deliberations via the electronic means of communication. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board may stipulate further conditions for the use of the electronic means of communication referred to in this Article, which conditions must be stated in the convening notices.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The requirement of a written proxy is met if the proxy has been recorded in an electronic form. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">Insofar as no greater majority is prescribed by law or in these Articles of Association, all resolutions are adopted by an absolute majority of the votes cast. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">If a vote is equally divided, the proposal has been rejected. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>DECISION-MAKING WITHOUT A MEETING BEING
HELD. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 28 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Decisions may also be made otherwise than at a meeting, provided that all the persons entitled to attend meetings have given their approval for that manner of decision-making. That approval can also be given in an
electronic form. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Votes are cast in writing. The requirement of a written vote is also met if the decision has been recorded in writing or electronically, stating the manner in which each of the shareholders votes, and has been signed by
all the persons entitled to attend meetings. The votes may also be cast in an electronic form. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The managing directors are given the opportunity to advise prior to the decision-making. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>AMENDMENT TO
THESE ARTICLES OF ASSOCIATION AND WINDING UP. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 29 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Resolutions to amend these Articles of Association, to wind up the Company or to effect a legal merger or legal demerger or division may be adopted by the general meeting only by a majority of at least <FONT
STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the votes cast at a meeting at which at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the issued capital is represented, unless the law requires a larger majority or quorum.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">If the capital referred to in paragraph 1 is not represented, a new meeting must be convened, to be held within one (1)&nbsp;month after the first meeting, but no sooner than eight (8)&nbsp;days thereafter, at which,
irrespective of the capital then represented, the resolutions referred to in paragraph 1 can be adopted by a majority of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the votes cast, unless the law requires a larger majority
or quorum. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The notices convening that new meeting must state that a second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) meeting is involved, with due observance of the provisions of Section&nbsp;2:230(3) of the Dutch
Civil Code. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">If a proposal to amend the Articles of Association or to wind up the Company will be made to the general meeting, that must always be stated in the notices convening the general meeting and, if an amendment to these
Articles of Association is involved, a copy of the proposal containing the proposed amendment verbatim must be made available at the Company&#146;s office for inspection by shareholders until the end of the meeting. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">A resolution to amend these Articles of Association that specifically detracts from any right of shareholders of a specific designation or type, can be adopted only with the approval of all the shareholders and other
persons entitled to attend meetings whose rights are affected by the amendment to the Articles of Association. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">When these Articles of Association are amended the following requirement, obligation or regulations may not be imposed against the shareholder&#146;s will, including subject to conditions or time limit:
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">obligations related to the law of obligations, attached to the ownership of all the shares or shares of a specific designation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">the attachment of requirements to the ownership of shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">provisions that a shareholder is required to offer and transfer his shares or part of his shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">deviating from the price determination rules within the meaning of Section&nbsp;2:192(3) of the Dutch Civil Code. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>LIQUIDATION. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 30 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">If the Company is wound up by resolution of the general meeting, the general meeting appoints one or more persons who will be entrusted with the liquidation of the Company&#146;s affairs. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">During the liquidation the provisions of these Articles of Association continue to apply to the extent possible. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Any amount remaining after payment of the debts is paid and transferred to the shareholders pro rata to the joint value of each person&#146;s shares. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The provisions of Part 1, Book 2, of the Dutch Civil Code also apply to the liquidation. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>OTHER POWERS.
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 31 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The general meeting has all the powers
not granted to the management board or other parties within the limits stipulated by law and by these Articles of Association. <B><U> </U></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>DISPUTES PROCEDURE. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 32 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disputes between shareholders within the meaning of Section&nbsp;1, Part 8, Book 2 of the Dutch Civil Code are settled in the first instance by the District
Court for the Company&#146;s registered office as provided for in Section&nbsp;2:336(3) of the Dutch Civil Code. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>CODE, FIRST FINANCIAL YEAR.
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article 33 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s first financial year
runs from the date of incorporation until the thirty-first of December two thousand and thirteen. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>FINAL STATEMENTS. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The person appearing, acting in her aforesaid capacity, finally stated that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">on the incorporation two thousand (2,000) shares were issued. The issued share capital amounts to two million euro (EUR 2,000,000). The Incorporator takes part for all the shares. The shares are issued at their par
value; </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">the managing directors to be appointed are: <B>Theodorus Jacobus Andriessen, </B>born in Nieuwer-Amstel, the
Netherlands, on the twenty sixth day of January nineteen hundred and fifty, with office address at Computerweg 10, 3542 DR Utrecht; and <B>Gertjan Noordermeer, </B>born in Weesp, the Netherlands, on the sixth day of January nineteen hundred sixty
four, with office address at Computerweg 10, 3542 DR Utrecht. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">the costs involved in the incorporation will be paid by the Company. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>End of deed.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The person appearing has identified herself to me, the <FONT STYLE="white-space:nowrap">civil-law</FONT> notary. In witness whereof this Deed
was executed in one original copy in Amsterdam on the date first above written. Before this Deed was read out in full, the substance of this Deed was stated and explained to the person appearing. She then stated that she had taken note of the
content of this deed in a timely manner, agreed to that content and did not require a full reading of this Deed. Immediately after a limited reading of this Deed it was signed by the person appearing and by me, the
<FONT STYLE="white-space:nowrap">civil-law</FONT> notary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.6
<SEQUENCE>4
<FILENAME>d558803dex36.htm
<DESCRIPTION>EX-3.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>JWS/AS/2015.444 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In this translation an
attempt has been made to be as literal as possible without jeopardising the overall continuity. Inevitably, differences may occur in translation, and if so the Dutch text will by law govern.</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DEED OF INCORPORATION OF TEVA PHARMACEUTICAL FINANCE NETHERLANDS III B.V. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This the twenty-first of September two thousand fifteen, appears before me, Jan Willem Anton Schenk, <FONT STYLE="white-space:nowrap">civil-law</FONT> notary
in Amsterdam, the Netherlands: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ren&eacute;e Martha Meijer, born in Nijmegen, the Netherlands, on the first of February nineteen hundred <FONT
STYLE="white-space:nowrap">ninety-one,</FONT> with office address at Prins Bernhardplein 200, 1097 JB Amsterdam, the Netherlands, in this respect acting as authorised representative of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Teva Pharmaceuticals Finance Netherlands B.V., </B>a private company with limited liability incorporated under the laws of the Netherlands, having its
registered office in Amsterdam, the Netherlands, and its business office at Piet Heinkade 107, 1019 GM Amsterdam, the Netherlands, registered with the trade register of the Chambers of Commerce under number 30175193 (the
<B>&#147;Incorporator&#148;).</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The person appearing, acting as aforementioned, has declared the following: The Incorporator hereby incorporates a
private company with limited liability (<I>&#145;een besloten vennootschap met beperkte aansprakelijkheid&#146;)</I> under Dutch law with the following articles of association: <B> </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLES OF ASSOCIATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CHAPTER I. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Name, registered office, objects. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 1 Name and
office. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s name is: <B>Teva Pharmaceutical Finance Netherlands III B.V.</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The Company has its registered office in Amsterdam. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 2. Objects. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s objects are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">to incorporate, in any manner to participate in, to manage and to supervise businesses, companies and other legal entities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">to finance businesses, companies and other legal entities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">to borrow, including the lending and raising of funds, to issue bonds, debentures or other securities, and to enter into related agreements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">to give advice and to provide services to businesses, companies and other legal entities with which the Company is affiliated in a group, and to third parties; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top">to issue guarantees, to commit the Company and to encumber assets of the Company for the benefit of businesses, companies and other legal entities with which the Company is affiliated in a group and for the benefit of
third parties; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top">to make periodical payments, including the conclusion and performance of annuity and other standing right agreements, whether or not in the context of a pension provision; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top">to invest capital and to invest moneys in real property, shares and bonds, to buy and sell real property, securities and other goods, to manage pension funds and to perform all the work and develop projects that may be
conducive to achieving the above objects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">h.</TD>
<TD ALIGN="left" VALIGN="top">to perform all kinds of industrial, financial and commercial activities; </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as well as any and all things that
are related or may be conducive to the above, all of this in the broadest sense of the word. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CHAPTER II. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital. Register. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 3. Share capital. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s capital consists of one or more ordinary shares, each share having a nominal value of one United States Dollar (USD 1.00). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">All the shares are registered and are numbered consecutively from 1 onwards. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The identifying number of a share serves as a designation. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">At least one voting share is held by a party other than the Company and otherwise than for the account of the Company or one of the Company&#146;s subsidiaries. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 4. Share ownership. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">No obligations under the law of obligations are attached to the share ownership, within the meaning of Section&nbsp;2:192a (1)&nbsp;of the Dutch Civil Code. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">No requirements are attached to the share ownership, within the meaning of Section&nbsp;2:192b(1) of the Dutch Civil Code. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The voting right, the right to receive distributions and the right to attend meetings are suspended during any period in which a shareholder fails to fulfil an obligation under these Articles of Association or does not
meet a requirement under these Articles of Association. If a shareholder cannot exercise the rights referred to in the preceding sentence, the suspension ends if the Company has not within three (3)&nbsp;months after a request to that effect from
the shareholder designated prospective purchasers to whom he can transfer all his shares with due observance of the provisions of these Articles of Association. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">A suspension of rights ends if none of the shareholders can exercise the voting right as a result of the suspension. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 5. Shareholders&#146; register. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company&#146;s management board keeps a register in which the names, addresses and <FONT
STYLE="white-space:nowrap">e-mail</FONT> addresses of all the shareholders are recorded, stating the date on which they acquired the shares, the date of acknowledgement or service, the type or the designation of the shares, and the amount paid up on
each share. If a shareholder is not bound by an obligation or requirement under these Articles of Association within the meaning of Section&nbsp;2:192(1) of the Dutch Civil Code or by a price determination arrangement in these Articles of
Association within the meaning of Section&nbsp;2:192a(2) of the Dutch Civil Code, that fact must be stated. If no voting right is attached to shares </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
pursuant to an arrangement in these Articles of Association on the grounds of Section&nbsp;2:228(5) of the Dutch Civil Code, the shares are registered as
<FONT STYLE="white-space:nowrap">non-voting</FONT> shares. The names and addresses of parties that have a usufruct or pledge in respect of shares must be recorded in the register, stating the date on which they acquired the right, the date of
acknowledgement or service, and also stating which rights attached to the shares are vested in them. The register must state the names and addresses of the holders of depositary receipts for shares that carry the right to attend meetings, stating
the date on which the right to attend meetings was attached to their depositary receipts and the date of acknowledgement or service. Insofar as share certificates may be issued, this will be recorded in the Articles of Association. The issue and
withdrawal of a share certificate must also be recorded in the shareholders&#146; register. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Shareholders and other parties whose data are recorded in the register pursuant to paragraph 1 of this Article must provide the management board in a timely manner with the information required. If an electronic address
is also notified for the purpose of being recorded in the shareholders&#146; register, that notification also constitutes consent to be sent all notifications and statements and notices convening meetings in an electronic form. In these Articles of
Association &#147;in writing&#148; means: by post, by fax, by <FONT STYLE="white-space:nowrap">e-mail</FONT> or by any other customary means of communication by means of which text can be transmitted. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The register must be updated on a regular basis. Any discharge from liability granted for payments not yet made must also be recorded in the register. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">On request the Company&#146;s management board must provide a shareholder, a usufructuary, a pledgee and a holder of a depositary receipt for a share that carries the right to attend meetings in or pursuant to these
Articles of Association for no consideration with an excerpt from the register regarding his right to a share or a depositary receipt. If the share is subject to a usufruct or a pledge, the excerpt must state who has the rights referred to in
Sections 2:197, 2:198 and 2:227 of the Dutch Civil Code. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board must make the register available at the Company&#146;s office for inspection by the shareholders, the usufructuaries and the pledgees who have the rights referred to in
Section&nbsp;2:227(2) of the Dutch Civil Code and the holders of depositary receipts issued for shares that carry the right to attend meetings in or pursuant to these Articles of Association. The information in the register regarding not fully <FONT
STYLE="white-space:nowrap">paid-up</FONT> shares is available for public inspection; a copy of or excerpt from that information is provided at no more than cost. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CHAPTER III. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance of shares. Own shares. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 6. Share certificates. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No share certificates may
be issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 7. Issue of shares and <FONT STYLE="white-space:nowrap">pre-emptive</FONT> right. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Shares may be issued only by resolution of the general meeting, insofar as the general meeting has not transferred that power to another body within the Company. The general meeting may revoke that transfer. The price
and the other conditions of issue are determined in the decision to issue shares. The price may not be below par. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Each shareholder, with the exception of the Company if it is the holder of shares in its own capital, has a <FONT STYLE="white-space:nowrap">pre-emptive</FONT> right on the issue of shares pro rata to the aggregate
value of his shares. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The provisions of paragraph 2 apply accordingly to the granting of rights to purchase shares but do not apply to the issue of shares to someone who exercises a previously acquired right to purchase shares.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The <FONT STYLE="white-space:nowrap">pre-emptive</FONT> right can be limited or excluded, each time for one single issue, by the body authorised to issue shares. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The issue of a share furthermore requires a deed intended for that purpose, executed before a <FONT STYLE="white-space:nowrap">civil-law</FONT> notary practising in the Netherlands, to which deed the Company and the
persons acquiring shares must be parties. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">A share premium may only be paid when shares are issued or with the approval of the body that is authorised to decide to issue shares. Every time a share premium is paid this body can decide that the paid share premium
or a part thereof will be added as a share premium reserve for shares of one type or designation. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 8. Payment on shares. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">On the purchase of a share its nominal value must be paid up. It may be stipulated that the nominal value or part of that value need not be paid until a specified period of time has passed or until the management board
calls in that amount. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Payment on a share must be made in cash, except insofar as another contribution has been agreed on. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Payment in a currency other than that in which the nominal value is denominated may be made only with the permission of the Company&#146;s management board. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 9. Shares held by the Company in its own capital. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company may not purchase shares in its own capital on the issue of shares. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board decides on the acquisition and sale of shares in the Company&#146;s capital. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The Company may acquire shares in its own capital or depositary receipts for those shares only insofar as they have been paid up in full and only with due observance of the relevant provisions of the law.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">Acquisition and sale by the Company of shares in its own capital or depositary receipts for those shares must take place with due observance of the provisions of Article 14. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">No vote may be cast at the General Meeting in respect of a share or a depositary receipt for a share that belongs to the Company or to a subsidiary of the Company. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CHAPTER IV. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital reduction. Rights in rem. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 10.
Reduction of capital. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The General Meeting may decide to reduce the issued capital by withdrawing shares or by reducing the value of shares by amendment to these Articles of Association. In that resolution the shares to which the resolution
relates must be designated and the implementation of the resolution must be regulated. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Capital reduction must otherwise take place with due observance of the provisions of the law. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 11.
Usufruct. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">A usufruct may be created on a share. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The voting right attached to a share is vested in the usufructuary if that right has been granted to him by law or with due observance of the statutory provisions. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 12. Pledge. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Shares may be pledged. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The voting right attached to the pledged shares is vested in the shareholder. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Contrary to the preceding paragraph the voting right is vested in the pledgee if that was determined on the creation of the pledge, whether or not subject to a condition precedent, or if that is later agreed on in
writing between the shareholder and the pledgee, and the transmission of the voting right has been approved by the General Meeting. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CHAPTER V. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Transfer restrictions. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 13. Transfer of shares and restricted rights. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The transfer of a share or the creation or transfer of a restricted right to a share requires a deed intended for that purpose and executed before a <FONT STYLE="white-space:nowrap">civil-law</FONT> notary practising in
the Netherlands, to which deed the party that transfers the shares and the party that acquires the shares must be parties. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Unless the Company itself is a party to the legal act, the rights attached to the share cannot be exercised until the Company has acknowledged the legal act or the deed has been served on the Company in accordance with
the relevant provisions of the law, or the Company has acknowledged the legal act of its own accord by registering it in the shareholders&#146; register in accordance with the relevant provisions of the law. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 14. Share transfer restrictions. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No legal or
statutory restrictions are referred to in Section&nbsp;2:195 of the Dutch Civil Code apply to a transfer of shares in the share capital of the Company as long as there is a sole shareholder. In case there is more than one shareholder then the legal
or the statutory restrictions, as referred to in Section&nbsp;2:195 of the Dutch Civil Code, will applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CHAPTER VI. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Management Board. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 15. Management board.
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board consists of one or more managing directors. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The number of managing directors is determined by the general meeting. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 16 Appointment Suspension and removal from office Remuneration. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The managing directors are appointed by the general meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Each managing director may be suspended and removed from office by the general meeting at any time. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The remuneration and the other employment conditions of each managing director are determined by the general meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The general meeting may give a managing director the title of Chief Executive. The general meeting may withdraw that title at any time. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 17. Management task; decision-making; absence or inability to act. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board is entrusted with the management of the Company. In performing its task the management board must focus on the interest of the Company and the business affiliated with it.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The management board shall comply with the instructions of the General Meeting. The Management board shall comply with the instructions of the General Meeting unless these are contrary to the interest of the Company and
the business affiliated with it. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">All resolutions of the management board are adopted by an absolute majority of the votes cast. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">Resolutions of the Company&#146;s management board may also be adopted in writing rather than at a meeting, provided that that is done by a unanimous vote of all the managing directors in office. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">If a managing director is absent or unable to act, the other managing director(s) is/are temporarily entrusted with the management of the Company. If all the managing directors or the sole managing director is/are
absent or unable to act, the person appointed for that purpose by the general meeting is temporarily entrusted with the management of the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">A managing director may not participate in the deliberations and decision-making, if with respect to the matter concerned he has a direct or indirect personal interest that conflicts with the interests of the Company
and the business affiliated with it. If, as a result hereof, the management board cannot make a decision, the board is still authorised to do so. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 18. Representation. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board is authorised to represent the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">In addition to the provisions of paragraph 1, two (2)&nbsp;managing directors acting jointly, or one managing director together with a proxyholder, are authorised to represent the Company. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board may appoint officers with a general or limited power of representation. Each of them represents the Company with due observance of the limits imposed on that power. Their titles are
determined by the Company&#146;s management board. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 19. Approval of resolutions of the management board. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The general meeting is authorised to submit resolutions to its approval. Such resolutions must be clearly described and must be notified to the management board in writing. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The absence of the approval referred to in this Article does not affect the power of representation of the management board or the managing directors. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CHAPTER VII. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annual accounts. Profits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 20. Financial statements. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The financial year coincides with the calendar year. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Each year, within five (5)&nbsp;months after the end of the financial year, unless that term is extended by no more than six (6)&nbsp;months by the general meeting on the grounds of special circumstances, the
Company&#146;s management board must draw up financial statements and make them available for inspection by the shareholders at the Company&#146;s office. Within that period the Company&#146;s management board must also make the annual report
available for inspection by the shareholders, unless Sections 2:396(7) or 2:403 of the Dutch Civil Code apply. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The financial statements must be signed by the managing directors; if the signature of one or more of them is missing, that fact and the reason must be stated. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The Company must give instruction to have the financial statements audited by an accountant who is authorised by law, unless the Company is exempted from doing so by law. The general meeting is authorised to give that
instruction. If it fails to do so, the management board has that authority. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The instruction to audit the financial statements can be withdrawn for valid reasons by the general meeting and by the party that gave the instruction. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">The accountant who has audited the financial statements reports on his audit to the management board. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">The Company must ensure that the drafted financial statements, the annual report and the information that must be added to them pursuant to Section&nbsp;2:392(1) of the Dutch Civil Code are available at its office from
the convening of the general meeting at which they are to be addressed. The shareholders and the other parties entitled to attend meetings can inspect the documents there and obtain free copies of those documents. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top">If the Company has been exempted from the obligation referred to in paragraph 4, the general meeting may nevertheless decide that the obligation to audit will be complied with or that another form of assessment of the
financial statements and financial accounts will be performed. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 21. Adoption of the financial statements; discharge; publication.
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The general meeting adopts the financial statements. The management board adopts the annual report. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Adoption of the financial statements does not discharge a managing director, unless the provisions of paragraph 3 apply. By separate resolution the general meeting can discharge a managing director for the management
conducted in the financial year in </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">question, insofar as that management is apparent from the financial statements or has
been made known to the general meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">If all the shareholders are also managing directors of the Company, signing of the financial statements by all the managing directors also serves as adoption of the financial statements, provided that all the parties
entitled to attend meetings have been given the opportunity to take note of the drafted financial statements and have agreed to this manner of adoption. Adoption of the financial statements in this manner discharges the managing directors.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The Company is required to publish its financial statements within eight (8)&nbsp;days after their adoption, unless a statutory exemption applies. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 22. Profit. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The general meeting is authorised to allocate the profit determined by the adoption of the financial statements and to decide on distributions insofar as its equity exceeds the reserves that must be maintained by law or
pursuant to these Articles of Association. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">A resolution pertaining to distribution has no consequences until the management board has given its approval. The management board may withhold its approval only if it knows or reasonably ought to foresee that the
Company will not be able to continue to pay its immediately payable debts after the distribution. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">If the Company cannot continue to pay its immediately payable debts after a distribution, the managing directors who knew or reasonably ought to have foreseen that at the time of the distribution are jointly and
severally liable towards the Company for the deficit resulting from the distribution, plus the statutory interest from the day of the distribution. Section&nbsp;2:248(5) of the Dutch Civil Code applies accordingly. A managing director who proves
that he or she is not to blame for the distribution made by the Company and that he or she has not been negligent in taking measures to ward off the consequences is not bound. A person who received the distribution while he knew or reasonably ought
to have foreseen that the Company would be unable after the distribution to continue to pay its immediately payable debts is required to pay the deficit resulting from the distribution, up to the amount of the value of the distribution received by
him, plus the statutory interest from the day of the distribution. If the managing directors have paid the claim pursuant to the first sentence, the payment referred to in the fourth sentence is made to the managing directors pro rata to the part
that has been paid by each of the managing directors. The debtor does not have the right of <FONT STYLE="white-space:nowrap">set-off</FONT> in respect of a debt on the grounds of the first or fourth sentence. This paragraph does not apply to
distributions in the form of shares in the Company&#146;s capital or additional payment on not fully paid shares. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">For the purposes of paragraph 3 a person who determined or <FONT STYLE="white-space:nowrap">co-determined</FONT> the Company&#146;s policy is put on a par with a managing director as if he were a managing director. The
claim cannot be filed against the administrator appointed by the court. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">In calculating each distribution the shares held by the Company in its own capital are not counted. In calculating the amount that will be paid on each share only the amount of the obligatory payments on the nominal
value of the shares is taken into account. It is possible to depart from the provision of the second sentence of this paragraph with the approval of all the shareholders. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">A shareholder&#146;s claim regarding a distribution of profits expires five (5)&nbsp;years after the day of the resolution to distribute the profit. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CHAPTER VIII. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Meeting. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 23. General meeting. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">During each financial year at least one general meeting must be held or at least once a resolution must be adopted without a meeting being held in accordance with Article 28, unless the financial statements have been
adopted in accordance with the provisions of Article 23(3). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">2. Other general meetings will be held as often as the Company&#146;s management board considers necessary. The management board is authorised to convene a general meeting. The management board is required to convene a
general meeting if one or more shareholders solely or jointly representing at least <FONT STYLE="white-space:nowrap">one-hundredth</FONT> (1/100th) of the issued capital request(s) the convening of a general meeting in writing, accurately stating
the subjects to be addressed. The management board must take the necessary measures to ensure that the general meeting can be held within four (4)&nbsp;weeks after the request, unless a compelling interest of the Company so opposes. If the
management board fails to comply with the request, the shareholders referred to in the second sentence can be authorised at their request by the preliminary relief judge of the court to convene the general meeting. For the purposes of this
paragraph, shareholders are put on a par with other persons who have the right to attend meetings. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Each person entitled to attend meetings is authorised to attend and address the general meeting in person or by written proxy. The requirement of a written power of attorney is met if the power of attorney has been
drawn up in an electronic form. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">A general meeting must be convened by means of convening notices sent to the addresses of the shareholders and other parties entitled to attend meetings as recorded in the register referred to in Article 5 of these
Articles of Association. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">With the approval of a person entitled to attend meetings, the meeting can also be convened by readable and reproducible message sent in an electronic form to the address that he has made known to the Company for that
purpose. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">The convening notices must state the subjects to be addressed. Participation in and voting at a general meeting is possible using an electronic means of communication if that is stated in the convening notices.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">The meeting must be convened no later than on the eighth (8th) day before the day of the meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top">The general meetings are held in the municipality in which the Company has its registered office under these Articles of Association. The general meeting appoints its own chairperson. Until that moment the meeting is
chaired by a managing director or, if no managing director is present, by the most senior person present at the meeting in terms of age. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top">The managing directors have an advisory vote in that capacity at the general meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top">If shares, restricted rights to shares or depositary receipts issued for shares form part of a community of property, the joint owners can be represented towards the Company only by one person to be designated in
writing. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 24. Depositary receipts for shares. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of depositary receipts for shares do not have the right to attend meetings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 25. Persons entitled to attend meetings. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
right to attend meetings vests in shareholders, in shareholders who because of a usufruct or pledge have no voting rights and in usufructuaries and pledges who have voting rights. Usufructuaries and pledgees who have no voting rights do not have the
right to attend meetings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 26. General meeting; different agenda; term; location. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Provided that all the persons entitled to attend meetings have agreed and the managing directors have been given the opportunity prior to the decision-making to advise, resolutions can be adopted within the meaning of
Sections 2:224(2), 2:225 and 2:226(3) of the Dutch Civil Code. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board must keep notes of the resolutions adopted. If the Company&#146;s management board is not represented at the meeting, a copy of the resolution that is adopted is presented to the
Company&#146;s management board by or on behalf of the chairperson as soon as possible after the meeting. The records are available at the Company&#146;s office for inspection by the shareholders and other persons who have the right to attend
meetings. On request, each of them is provided with a copy of or excerpt from those notes at no more than cost. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 27.
Decision-making. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Each share carries the right to cast one vote. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Each shareholder is authorised, either in person or by written proxy, by means of an electronic means of communication to take part in the general meeting, to address the meeting and to exercise the voting right, unless
one or more of those rights is/are not vested in a shareholder in accordance with the provisions of these Articles of Association. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">For the purposes of paragraph 2 it is a minimum requirement that the shareholder can be identified, can directly take part in the business transacted at the meeting and can exercise the voting right by the electronic
means of communication. The person entitled to attend meetings can furthermore take part in the deliberations via the electronic means of communication. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s management board may stipulate further conditions for the use of the electronic means of communication referred to in this Article, which conditions must be stated in the convening notices.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The requirement of a written proxy is met if the proxy has been recorded in an electronic form. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">Insofar as no greater majority is prescribed by law or in these Articles of Association, all resolutions are adopted by an absolute majority of the votes cast. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">If a vote is equally divided, the proposal has been rejected. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 28. Decision-making without a
meeting being held. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Decisions may also be made otherwise than at a meeting, provided that all the persons entitled to attend meetings have given their approval for that manner of decision-making. That approval can also be given in an
electronic form. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Votes are cast in writing. The requirement of a written vote is also met if the decision has been recorded in writing or electronically, stating the manner in which each of the shareholders votes, and has been signed by
all the persons entitled to attend meetings. The votes may also be cast in an electronic form. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The managing directors are given the opportunity to advise prior to the decision-making. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CHAPTER IX.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment of the articles of association. Dissolution. Liquidation. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 29. Amendment to these Articles of Association and winding up. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Resolutions to amend these Articles of Association, to wind up the Company or to effect a legal merger or legal demerger or division may be adopted by the general meeting only by a majority of at least <FONT
STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the votes cast at a meeting at which at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the issued capital is represented, unless the law requires a larger majority or quorum.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">If the capital referred to in paragraph 1 is not represented, a new meeting must be convened, to be held within one (1)&nbsp;month after the first meeting, but no sooner than eight (8)&nbsp;days thereafter, at which,
irrespective of the capital then represented, the resolutions referred to in paragraph 1 can be adopted by a majority of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the votes cast, unless the law requires a larger majority
or quorum. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The notices convening that new meeting must state that a second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) meeting is involved, with due observance of the provisions of Section&nbsp;2:230(3) of the Dutch
Civil Code. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">If a proposal to amend the Articles of Association or to wind up the Company will be made to the general meeting, that must always be stated in the notices convening the general meeting and, if an amendment to these
Articles of Association is involved, a copy of the proposal containing the proposed amendment verbatim must be made available at the Company&#146;s office for inspection by shareholders until the end of the meeting. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">A resolution to amend these Articles of Association that specifically detracts from any right of shareholders of a specific designation or type, can be adopted only with the approval of all the shareholders and other
persons entitled to attend meetings whose rights are affected by the amendment to the Articles of Association. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">When these Articles of Association are amended the following requirement, obligation or regulations may not be imposed against the shareholder&#146;s will, including subject to conditions or time limit:
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">obligations related to the law of obligations, attached to the ownership of all the shares or shares of a specific designation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">the attachment of requirements to the ownership of shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">provisions that a shareholder is required to offer and transfer his shares or part of his shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">deviating from the price determination rules within the meaning of Section&nbsp;2:192(3) of the Dutch Civil Code. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 30. Liquidation. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">If the Company is wound up by resolution of the general meeting, the general meeting appoints one or more persons who will be entrusted with the liquidation of the Company&#146;s affairs. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">During the liquidation the provisions of these Articles of Association continue to apply to the extent possible. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Any amount remaining after payment of the debts is paid and transferred to the shareholders pro rata to the joint value of each person&#146;s shares. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The provisions of Part 1, Book 2, of the Dutch Civil Code also apply to the liquidation. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 31. Other
powers.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The general meeting has all the powers not granted to the management board or other parties within the limits stipulated by law and by these
Articles of Association. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Article 32. Disputes procedure. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disputes between shareholders within the meaning of Section&nbsp;1, Part 8, Book 2 of the Dutch Civil Code are settled in the first instance by the District
Court for the Company&#146;s registered office as provided for in Section&nbsp;2:336(3) of the Dutch Civil Code. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Final provision. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The first financial year of the Company shall run up to and including the thirty-first of December two thousand fifteen. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Final statements. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, the person appearing, acting
as aforementioned, declares: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">at the incorporation the issued share capital amounts to one hundred United States Dollar (USD 100.00); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">the Incorporator is participating in the issued capital for one hundred (100)&nbsp;shares, numbered 1 up to and including 100; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">the issue takes place at par value; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">the issued share capital of the Company has been paid up in cash. The Company accepts the payments on the shares issued on the incorporation. Payment will be in euro, however payment in foreign currency is permitted;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top">the Company binds itself to bear the costs in relation to this incorporation; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top">the following entity will be appointed as the first member of the Management Board of the Company: </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Teva Pharmaceuticals Europe B.V., </B>a private company with limited liability incorporated under the laws of the Netherlands, having its
registered office in Amsterdam, the Netherlands, and its business office at Piet Heinkade 107, 1019 GM Amsterdam, the Netherlands, registered with the trade register of the Chambers of Commerce under number 30110625. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Power of Attorney. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The original or a copy of the Power
of Attorney as mentioned in the heading of this deed is attached to this deed as an <I><U>Annex</U></I><I>.</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conclusion deed. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The person appearing is known to me, <FONT STYLE="white-space:nowrap">civil-law</FONT> notary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This deed is executed in Amsterdam, the Netherlands on the date mentioned in the heading of this deed. After the substance of this deed and an explanation
thereon have been stated to the person appearing, the person appearing has declared to have taken notice of the contents of this deed and to consent thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately after those parts of the deed that the law requires to be read out have been read out, this deed is signed by the person appearing and by me, <FONT
STYLE="white-space:nowrap">civil-law</FONT> notary.at eleven hours. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>d558803dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g558803logo.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">601 Lexington Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, NY 10022</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(212) <FONT STYLE="white-space:nowrap">446-4800</FONT></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.kirkland.com</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Facsimile:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(212) <FONT
STYLE="white-space:nowrap">446-4900</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">April&nbsp;2, 2018 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Industries Limited </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5 Basel Street, Petach
Tikva 4951033 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Israel </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Re: <U>Registration
Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT></U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are issuing this opinion letter in our capacity as special counsel for (i)&nbsp;Teva Pharmaceutical Finance Netherlands II B.V.
(&#147;<U>Teva Finance II</U>&#148;) and Teva Pharmaceutical Finance Netherlands III B.V. (&#147;<U>Teva Finance III</U>&#148; and, together with Teva Finance II, the &#147;<U>Issuers</U>&#148;), each a Dutch private limited liability company, and
(ii)&nbsp;Teva Pharmaceutical Industries Limited (the &#147;<U>Guarantor</U>&#148; and, together with the Issuers, the &#147;<U>Registrants</U>&#148;), an Israeli corporation. This opinion letter is being delivered in connection with the proposed
registration by the Registrants of (i) $1,250,000,000 in aggregate principal amount of Teva Finance III&#146;s 6.000% Senior Notes due 2024 (the &#147;<U>2024 Exchange Dollar Notes</U>&#148;), (ii) $1,250,000,000 in aggregate principal amount of
Teva Finance III&#146;s 6.750% Senior Notes due 2028 (the &#147;<U>2028 Exchange Dollar Notes</U>&#148; and, together with the 2024 Exchange Dollar Notes, the &#147;<U>Exchange Dollar Notes</U>&#148;), (iii) &#128;700,000,000 in aggregate principal
amount of Teva Finance II&#146;s 3.250% Senior Notes due 2022 (the &#147;<U>2022 Exchange Euro Notes</U>&#148;), and (iv) &#128;900,000,000 in aggregate principal amount of Teva Finance II&#146;s 4.500% Senior Notes due 2025 (the &#147;<U>2025
Exchange Euro Notes</U>&#148; and, together with the 2022 Exchange Euro Notes, the &#147;<U>Exchange Euro Notes</U>&#148; and, together with the Exchange Dollar Notes, the &#147;<U>Exchange Notes</U>&#148;), to be guaranteed (the
&#147;<U>Guarantees</U>&#148;) by the Guarantor, pursuant to a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> filed on or about the date hereof with the Securities and Exchange Commission (the
&#147;<U>Commission</U>&#148;) under the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;). Such Registration Statement, as amended or supplemented, is hereinafter referred to as the &#147;<U>Registration
Statement.</U>&#148; The Exchange Dollar Notes are to be issued pursuant to an Indenture (the &#147;<U>Dollar Base Indenture</U>&#148;), dated as of March&nbsp;14, 2018, as supplemented by the First Supplemental Indenture (the &#147;<U>Dollar
Supplemental Indenture</U>&#148; and, together with the Dollar Base Indenture, the &#147;<U>Dollar Indenture</U>&#148;), dated as of March&nbsp;14, 2018, in each case, by and among Teva Finance III, the Guarantor and The Bank of New York Mellon, as
trustee (the &#147;<U>Trustee</U>&#148;). The Exchange Euro Notes are to be issued pursuant to an Indenture (the &#147;<U>Euro Base Indenture</U>&#148;), dated as of March&nbsp;14, 2018, by and among Teva Finance II, the Guarantor and the Trustee,
as supplemented by the First Supplemental Indenture (the &#147;<U>Euro Supplemental Indenture</U>&#148; and, together with the Euro Base Indenture, the &#147;<U>Euro Indenture</U>&#148; and, together with the Dollar Indenture, the
&#147;<U>Indentures</U>&#148;), dated as of March&nbsp;14, 2018, by and among, Teva Finance II, the Guarantor, the Trustee and The Bank of New York Mellon, London Branch, as paying agent. The 2024 Exchange Dollar Notes are to be issued in exchange
for and in replacement of Teva Finance III&#146;s 6.000% Senior Notes due 2024 (the &#147;<U>2024 Original Dollar Notes</U>&#148;) and the 2028 Exchange Dollar Notes are to be issued in exchange for and in replacement of Teva Finance III&#146;s
6.750% Senior Notes due 2028 (the &#147;<U>2028 Original Dollar Notes</U>&#148; and, together with the 2024 Original Dollar Notes, the &#147;<U>Original Dollar Notes</U>&#148;). The 2022 Exchange Euro Notes are to be issued in exchange for and in
replacement of Teva Finance II&#146;s 3.250% Senior Notes due 2022 (the &#147;<U>2022 Original Euro Notes</U>&#148;) and the 2025 Exchange Euro Notes are to be issued in exchange for and in replacement of Teva Finance II&#146;s 4.500% Senior Notes
due 2025 (the &#147;<U>2025 Original Euro Notes</U>&#148; and, together with the 2022 Original Euro Notes, the &#147;<U>Original Euro Notes</U>&#148; and, together with the Original Dollar Notes, the &#147;<U>Original Notes</U>&#148;). </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Beijing &nbsp;&nbsp;&nbsp;&nbsp;Boston&nbsp;&nbsp;&nbsp;&nbsp;
Chicago&nbsp;&nbsp;&nbsp;&nbsp; Hong&nbsp;Kong&nbsp;&nbsp;&nbsp;&nbsp; Houston&nbsp;&nbsp;&nbsp;&nbsp; London&nbsp;&nbsp;&nbsp;&nbsp; Los&nbsp;Angeles&nbsp;&nbsp;&nbsp;&nbsp; Munich&nbsp;&nbsp;&nbsp;&nbsp; Palo&nbsp;Alto&nbsp;&nbsp;&nbsp;&nbsp;
San&nbsp;Francisco&nbsp;&nbsp;&nbsp;&nbsp; Shanghai&nbsp;&nbsp;&nbsp;&nbsp; Washington,&nbsp;D.C. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g558803logo2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Industries Limited </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;2, 2018 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In that connection, we have examined originals, or copies certified or otherwise identified
to our satisfaction, of such documents, corporate records and other instruments as we have deemed necessary for the purposes of this opinion, including (i)&nbsp;the Indentures, (ii)&nbsp;the Registration Statement, (iii)&nbsp;the Registration Rights
Agreement, dated as of March&nbsp;14, 2018, by and among Teva Finance III, the Guarantor, Barclays Capital Inc., BNP Paribas Securities Corp., Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, HSBC Securities (USA) Inc. and Merrill
Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, as representative of the initial purchasers named therein, (iv)&nbsp;the Registration Rights Agreement, dated as of March&nbsp;14, 2018, by and among Teva Finance II, the Guarantor, Barclays Bank
PLC, BNP Paribas, Citigroup Global Markets Limited, Credit Suisse Securities (Europe) Limited, HSBC Bank plc and Merrill Lynch International, as representative of the initial purchasers named therein, and (v)&nbsp;forms of the Exchange Notes and the
Guarantees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this opinion, we have assumed the authenticity of all documents submitted to us as originals, the conformity
to the originals of all documents submitted to us as copies and the authenticity of the originals of all documents submitted to us as copies. We have also assumed the genuineness of the signatures of persons signing all documents in connection with
which this opinion is rendered, the authority of such persons signing on behalf of the parties thereto and the due authorization, execution and delivery of all documents by the parties thereto. As to any facts material to the opinions expressed
herein that we have not independently established or verified, we have relied upon statements and representations of officers and other representatives of the Issuers and the Guarantor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinion expressed below is subject to the qualifications that we express no opinion as to the applicability of, compliance with, or effect
of (i)&nbsp;any bankruptcy, insolvency, reorganization, fraudulent transfer, fraudulent conveyance, moratorium or other similar law affecting the enforcement of creditors&#146; rights generally, (ii)&nbsp;general principals of equity (regardless of
whether enforcement is considered in a proceeding in equity or at law) and (iii)&nbsp;public policy considerations that may limit the rights of parties to obtain certain remedies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing qualifications, assumptions and limitations and the further limitations set forth below, we are of the
opinion that when (i)&nbsp;the Registration Statement becomes effective, (ii)&nbsp;the Indentures have been duly qualified under the Trust Indenture Act of 1939, as amended, and (iii)&nbsp;the Exchange Notes and the Guarantees have been duly
executed and authenticated in accordance with the provisions of the Indentures and duly delivered to holders of the Original Notes in exchange for the Original Notes and the guarantees related thereto pursuant to the exchange offer described in the
Registration Statement (assuming the due authorization and execution of the Exchange Notes and the Guarantees by the Issuers and the Guarantor and the due delivery of the Exchange Notes and the Guarantees by the Issuers and the Guarantor to holders
of the Original Notes in exchange for the Original Notes and the guarantees related thereto), the Exchange Notes will be validly issued under the Indentures and will be binding obligations of the Issuers and the Guarantees will be validly issued
under the Indentures and will be binding obligations of the Guarantor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion as Exhibit 5.1 to
the Registration Statement. We also consent to the reference to our firm under the heading &#147;Legal Matters&#148; in the Registration Statement. In giving this consent, we do not thereby admit that we are in the category of persons whose consent
is required under Section&nbsp;7 of the Securities Act of the rules and regulations of the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our advice on every legal issue
addressed in this letter is based exclusively on the internal laws of the State of New York and represents our opinion as to how that issue would be resolved were it to be considered by the </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g558803logo2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Industries Limited </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;2, 2018 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
highest court in the jurisdiction which enacted such laws. The manner in which any particular issue relating to the opinions would be treated in any actual court case would depend in part on
facts and circumstances particular to the case and would also depend on how the court involved chose to exercise the wide discretionary authority generally available to it. None of the opinions or other advice contained in this letter considers or
covers any foreign or state securities (or &#147;blue sky&#148;) laws or regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is limited to the specific issues
addressed herein, and no opinion may be inferred or implied beyond that expressly stated herein. This opinion speaks only as of the date hereof and we assume no obligation to revise or supplement this opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also assumed that the execution and delivery of the Indentures and the Exchange Notes and the performance by the Issuers and the
Guarantor of their obligations thereunder do not and will not violate, conflict with or constitute a default under any agreement or instrument to which any Registrant is bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is furnished to you in connection with the filing of the Registration Statement and in accordance with the requirements of Item
601(b)(5)(i) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated under the Securities Act, and is not to be used, circulated, quoted or otherwise relied upon for any other purposes. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Kirkland&nbsp;&amp; Ellis LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">KIRKLAND&nbsp;&amp; ELLIS LLP</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>6
<FILENAME>d558803dex52.htm
<DESCRIPTION>EX-5.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Jachthavenweg 121&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1081 KM Amsterdam</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">P.O. Box 75265&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Teva Pharmaceutical Finance Netherlands II B.V.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1070 AG Amsterdam</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Teva Pharmaceutical Finance Netherlands III B.V.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">the Netherlands&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">c/o Teva Pharmaceutical Industries Limited</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5 Basel Street</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">P.O. Box 3190</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">T +31 20 6789 123&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Petach Tikva 49131 Israel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">F +31 20 6789 589&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">29 March 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Our&nbsp;ref.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">40.00.1994</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Subject</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> re: Teva Pharmaceutical Finance Netherlands II</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">B.V. and Teva Pharmaceutical Finance Netherlands III B.V.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sirs, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as
Dutch legal advisers to Teva Pharmaceutical Finance Netherlands II B.V. and Teva Pharmaceutical Finance Netherlands III B.V., each a Dutch private limited liability company (each a <B>Dutch Company</B>), in connection with the preparation and filing
of the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> by Teva Pharmaceutical Industries Limited, an Israeli corporation (<B>Teva</B>) and the Dutch Companies (the <B>Registration Statement</B>), with the Securities and
Exchange Commission pursuant to the Securities Act of 1933 (the <B>Act</B>), on or about the date hereof, for the purpose of providing for the registration of senior notes (the <B>Exchange Notes</B>), guaranteed by Teva, to be issued pursuant to the
Indentures (as defined in Schedule 2 (<I>Documents</I>)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of this opinion, we have examined and relied only on the documents listed in
Schedule 2 (<I>Documents</I>) and Schedule 3 (<I>Corporate Documents</I>), which shall form part of this opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The documents listed in Schedule 2 are
referred to as the <B>Documents </B>and the documents listed in Schedule 3 as the <B>Corporate Documents</B>. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>page </I><I></I>
2<I>
 </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">29.03.2018 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise defined in this opinion (including Schedule 1) or unless the context otherwise requires,
words and expressions defined in the Documents shall have the same meanings when used in this opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with such examination and in giving
this opinion, we have assumed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">the genuineness of the signatures to the Documents and the Corporate Documents, the authenticity and completeness of the Documents and the Corporate Documents submitted to us as originals, the conformity to the original
documents of the Documents and Corporate Documents submitted to us as copies and the authenticity and completeness of those original documents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">the due incorporation and valid existence of, the corporate power and authority of and the due authorization and execution of the Documents by, each of the parties thereto (other than the Dutch Companies) under any
applicable law (other than Dutch law); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">the due compliance with all matters of, and the validity, binding effect and enforceability of the Documents under, any applicable law (other than Dutch law) and in any jurisdiction (other than the Netherlands) in which
an obligation under the Documents falls to be performed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">the due authorization and due execution by each Dutch Company of the Documents submitted to and examined by us in draft in the form of those drafts; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">that no party to the Documents is controlled by or otherwise connected with a person, organisation or country which is subject to United Nations, European Union or Dutch sanctions implemented or effective in the
Netherlands under or pursuant to the Sanction Act 1977 (<I>Sanctiewet 1977</I>), the Economic Offences Act (<I>Wet economische delicten</I>), the General Customs Act (<I>Algemene Douanewet</I>) or Regulations of the European Union;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">that no Dutch Company takes deposits or other repayable funds from the public within the meaning of the European Regulation No.&nbsp;575/2013 on prudential requirements for credit institutions and investment firms and
the Exchange Notes will not be offered in the Netherlands; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">that the execution of and performance under the Documents by a Dutch Company are not prohibited or affected by contractual restrictions or obligations binding on that Dutch Company; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top">that any foreign law which may apply with respect to any of the Documents or the transactions contemplated thereby does not affect this opinion. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is only given with respect to Dutch law in force as at the date hereof and as generally interpreted on the basis of <FONT
STYLE="white-space:nowrap">case-law</FONT> published at the date hereof. We do not express any opinion on: (i)&nbsp;matters of fact or the completeness or accuracy of the representations or warranties made pursuant to the Documents,
(ii)&nbsp;matters of foreign law, international law (including the law of the European Union to the extent not directly applicable in the Netherlands), tax law (except for any specific tax opinions contained herein) and anti-trust and competition
law (including the law of the European Union in respect of antitrust and </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>page </I>
3<I>
 </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">29.03.2018 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
competition), and (iii)&nbsp;commercial, accounting or <FONT STYLE="white-space:nowrap">non-legal</FONT> matters or on the ability of the parties to meet their financial or other obligations
under the Documents. We do not assume any obligation to advise the Dutch Companies (or any other person entitled to rely on this Opinion Letter) of subsequent changes in Dutch law or in the interpretation thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on and subject to the foregoing and subject to the qualifications set out below and matters of fact, documents or events not disclosed to us, we express
the following opinion: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">When Exchange Notes have been duly authorized, executed, authenticated, issued and delivered in accordance with the relevant Indenture, such Exchange Notes will, as a matter of Dutch law, constitute valid and binding
obligations of the relevant Dutch Company, enforceable against that Dutch Company in accordance with its terms. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinion expressed above
is subject to the following qualifications: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top">Our opinions expressed herein are subject to and limited by (i)&nbsp;Dutch or foreign laws and regulations applicable to Insolvency Proceedings, including laws and regulations of general application relating to or
affecting the rights of creditors or secured creditors and (ii)&nbsp;the provisions of the Insolvency Regulation. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top">The term &#147;enforceable&#148; used in the opinion above means that the obligations assumed by the relevant party under the relevant document are of a type which the Dutch courts generally enforce and does not mean
that those obligations will be necessarily enforced in accordance with their terms under all circumstances. In particular, the availability in the Dutch courts of remedies, such as injunction and specific performance is at the discretion of the
Dutch courts. The enforcement in the Netherlands of the Documents is subject to the Dutch rules of civil procedure as applied by the Dutch courts. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top">Foreign currency amounts claimed in a Dutch Insolvency Proceeding will be converted into euro for enforcement purposes at the rate prevailing at the commencement of such Dutch Insolvency Proceeding. In addition, foreign
currency amounts may have to be converted into euro for enforcement purposes. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top">Under the Dutch rules on fraudulent preference, the validity of a transaction (such as the execution of an agreement or the giving of guarantees or security) entered into by a Dutch Company may be contested. In
particular if a transaction entered into by a Dutch Company is prejudicial to the interests of its creditors, the validity of such transaction may in certain circumstances be contested by such creditors or the public receiver in an Insolvency
Proceeding of that Dutch Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top">Pursuant to the Dutch Act on Financial Supervision (<I>Wet op het financieel toezicht</I>) persons, firms or companies (regardless of where they are domiciled) may only provide intermediary services in The Netherlands
in respect of the Exchange Notes if they are licensed by the Netherlands Authority for the Financial Markets (<I>Autoriteit Financi&euml;le Markten</I>) or exempt from such license requirement. </TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>page </I>4<I> </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">29.03.2018 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. By giving our
consent, we do not admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is being delivered to you for your information in connection with the above matter and addresses matters only as of the date hereof. This opinion
is strictly limited to the matters stated herein and is not to be read as extending by implication to any other matters in connection with the Documents or the Corporate Documents or otherwise. This opinion is given subject to and may only be relied
upon by you on the express conditions that (i)&nbsp;Van Doorne N.V. is the party issuing this opinion, (ii)&nbsp;any liability of individual persons or legal entities involved in the services provided by or on behalf of Van Doorne N.V. is expressly
excluded (<I>uitgesloten</I>), (iii) in respect of Dutch legal concepts, which are expressed in this opinion in English terms, the original Dutch terms will prevail, (iv)&nbsp;this opinion and the opinions given herein are governed by Dutch law,
(v)&nbsp;all disputes arising from or in connection with this opinion must be submitted to the exclusive jurisdiction of, and will be exclusively decided by, the competent court in Amsterdam, the Netherlands, without prejudice to the right of appeal
and appeal to the Supreme Court, and (vi)&nbsp;the aggregate liability of Van Doorne N.V. (and the individual persons and legal entities involved in the services provided by or on behalf of Van Doorne N.V) in respect of this opinion towards the
Dutch Companies and any other person will be limited to the amount which can be claimed under the professional liability insurance(s) taken out by Van Doorne N.V., increased by the amount which Van Doorne N.V. has to bear as their own risk pursuant
to the terms of such insurance(s). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Yours faithfully,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>/s/ Van Doorne N.V.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Van Doorne N.V.</B></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>page </I>5<I> </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">29.03.2018 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS AND INTERPRETATION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1</B></TD>
<TD ALIGN="left" VALIGN="top"><B>INTERPRETATION </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Any reference in this opinion to a &#147;person&#148; includes any individual person, firm, partnership, company, corporation, government agency or administrative body or any other legal entity. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Any reference in this opinion made to the laws of the Netherlands or Dutch law or to the Netherlands in a geographical sense, should be read as: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">a reference to the laws as in effect in that part of the Kingdom of the Netherlands that is located in Continental Europe (<I>Europese deel van Nederland</I>); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">a reference to the geographical part of the Kingdom of the Netherlands that is located in Continental Europe. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DEFINITIONS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In this opinion: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Insolvency Proceeding</B> means a bankruptcy (<I>faillissement</I>), a (provisional) suspension of payment (<I>(voorlopige) surseance van
betaling</I>) or any other Dutch or foreign insolvency proceeding howsoever named (including without limitation any insolvency proceeding referred to in the Insolvency Regulation or in Annex A to the Insolvency Regulation); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Insolvency Regulation</B> means the Regulation (EU) 2015/848 of the European Parliament and of the Council of 20&nbsp;May 2015 on insolvency
proceedings (recast).<B> </B> </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>page </I>6<I> </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">29.03.2018 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DOCUMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">A copy of the signed Registration Statement dated on or about the date hereof; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">a signed copy of the indenture, dated 14 March 2018 and made between Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon as Trustee; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">a signed copy of a supplemental indenture, dated 14&nbsp;March 2018 and made between Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited, The Bank of New York Mellon as Trustee and
The Bank of New York Mellon, London Branch as Principal Paying Agent; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">a signed copy of the indenture, dated 14&nbsp;March 2018 and made between Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon as Trustee;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">a signed copy of a supplemental indenture, dated 14&nbsp;March 2018 and made between Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon as Trustee,
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">the indentures referred to in subparagraphs (b)&nbsp;up to and including (e)&nbsp;above herein referred to as the
<B>Indentures</B>. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>page </I>7<I> </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">29.03.2018 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE DOCUMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">A copy of the deed of incorporation of (i)&nbsp;Teva Pharmaceutical Finance Netherlands II B.V. dated 16&nbsp;October 2013 and Teva Pharmaceutical Finance Netherlands III B.V. dated 21&nbsp;September 2015;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">a copy of (i)&nbsp;the articles of association of Teva Pharmaceutical Finance Netherlands II B.V. dated 14&nbsp;November 2013 and (ii)&nbsp;the articles of association of Teva Pharmaceutical Finance Netherlands III B.V.
as included in its Deed of Incorporation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">an extract in respect of each Dutch Company from the Commercial Register, each dated the date of this opinion. </TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.3
<SEQUENCE>7
<FILENAME>d558803dex53.htm
<DESCRIPTION>EX-5.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.3 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g558803dsp049.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">* Member of the N. Y. Bar Association </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">April&nbsp;2, 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Industries
Limited </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Finance Netherlands II B.V. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Finance Netherlands III B.V. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Teva
Pharmaceutical Industries Limited </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5 Basel Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">P.O. Box
3190 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Petach Tikva 4951033 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Israel </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Re: <U>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT></U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 1 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g558803dsp050.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as Israeli counsel for Teva Pharmaceutical Industries Limited, an Israeli corporation
(&#147;<U>Teva</U>&#148; or the &#147;<U>Guarantor</U>&#148;), in connection with the preparation and filing by Teva with the United States Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (the
&#147;<U>Act</U>&#148;), of the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (the &#147;<U>Registration Statement</U>&#148;) by Teva; Teva Pharmaceutical Finance Netherlands II B.V., a Dutch private limited liability
company (&#147;<U>Teva Netherlands II</U>&#148;), and Teva Pharmaceutical Finance Netherlands III B.V., a Dutch private limited liability company (&#147;<U>Teva Netherlands III</U>&#148;). This opinion letter is being delivered in connection with
the proposed registration: (A)&nbsp;by Teva Finance III of (i)&nbsp;up to $1,125,000,000 in aggregate principal amount of Teva Finance III&#146;s 6.000% Senior Notes due 2024; and (ii)&nbsp;up to $1,125,000,000 in aggregate principal amount of Teva
Finance III&#146;s 6.750% Senior Notes due 2028 (the &#147;<U>Exchange Dollar Notes</U>&#148;) for an equal principal amount of Teva Finance III&#146;s 6.000% Senior Notes due 2024 and Teva Finance III&#146;s 6.750% Senior Notes due 2028 (the
&#147;<U>Original Dollar Notes</U>&#148;); and (B)&nbsp;by Teva Finance II of (i)&nbsp;up to &#128;700,000,000 in aggregate principal amount of Teva Finance II&#146;s 3.250% Senior Notes due 2022; and (ii)&nbsp;up to &#128;900,000,000 in aggregate
principal amount of Teva Finance II&#146;s 4.500% Senior Notes due 2025 (the &#147;<U>Exchange Euro Notes</U>&#148;, and, together with the Exchange Dollar Notes, the &#147;<U>Exchange Notes</U>&#148;) for an equal principal amount of Teva Finance
II&#146;s outstanding 3.250% Senior Notes due 2022 and Teva Finance II&#146;s 4.500% Senior Notes due 2025 (the &#147;<U>Original Euro Notes</U>&#148;, and, together with the Original Dollar Notes, the &#147;<U>Original Notes</U>&#148;), to be
guaranteed (the &#147;<U>Guarantees</U>&#148;) by the Guarantor, pursuant to the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Exchange Notes are to be issued in exchange
for and in replacement of the Original Notes and are subject to the exchange offer pursuant to the Registration Statement. The Exchange Notes are being issued pursuant to a senior indenture dated as of March&nbsp;14, 2018, as supplemented by a
Supplemental Indenture (such indenture, as so supplemented, the &#147;<U>Indenture</U>&#148;), dated as of March&nbsp;14, 2018, among Teva Finance III, Teva Finance II, Teva, The Bank of New York Mellon, as trustee (the &#147;<U>Trustee</U>&#148;),
and, with respect to the Exchange Euro Notes, also The Bank of New York Mellon, London Branch, as principal agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the opinions
hereinafter expressed, we have examined originals or copies, certified and otherwise identified to our satisfaction, of such documents, corporate records, certificates of public officials and other instruments as we have deemed necessary as a basis
for the opinions expressed herein. Insofar as the opinions expressed herein involve factual matters, we have relied (without independent factual investigation), to the extent we deemed proper or necessary, upon certificates of, and other
communications with, officers and employees of Teva and upon certificates of public officials. We have also considered such questions of Israeli law as we have deemed relevant and necessary as a basis for the opinions hereinafter expressed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In making our examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents
submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or facsimile copies and the authenticity of the originals of such copies and the legal capacity and due authenticity of all
persons executing such documents. We have assumed the same to have been properly given and to be accurate, and we have assumed the truth of all facts communicated to us by Teva, and have assumed that all consents, minutes and protocols of meetings
of Teva&#146;s board of directors and shareholders which have been provided to us are true, accurate and have been properly prepared in accordance with Teva&#146;s incorporation documents and all applicable laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with all of the opinions expressed below, we have assumed that, at or prior to the time of the delivery of any such Exchange Note, (i)&nbsp;the
Exchange Notes have been specifically authorized and approved for issuance and sale by Teva by all necessary corporate action, and such authorization shall not have been modified or rescinded (ii)&nbsp;the Exchange Notes will be issued, sold and
delivered as contemplated by the relevant underwriting agreement, if applicable, and the Registration Statement; (iii)&nbsp;Teva has received the consideration provided for in the necessary corporate action and, if applicable, the underwriting
agreements; (iv)&nbsp;the Registration Statement (including any post-effective amendments) is effective under the Act, and such effectiveness shall not have been terminated or rescinded; and (v)&nbsp;there shall not have occurred any change in law
affecting the validity or enforceability of any such Exchange Note. We have also assumed that none of the terms of any Exchange Note to be established subsequent to the date hereof, nor the issuance and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g558803dsp051.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">delivery of such Exchange Note, nor the compliance by Teva with the terms of such Exchange Note will violate any applicable
law or will result in a violation of any provision of any instrument or agreement then binding upon the relevant company (including Teva), or any restriction imposed by any court or governmental body having jurisdiction over Teva. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinions expressed below are based upon our consideration of only those statutes, rules and regulations of the State of Israel which, in our experience,
are normally applicable to the proposed registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on and subject to the foregoing, we are of the opinion that necessary corporate proceedings
by Teva have been duly taken to authorize the issuance of the Exchange Notes and, when and if the Exchange Notes and the Guarantees have been duly executed and authenticated in accordance with the provisions of the Indenture and duly delivered to
holders of the Original Notes in exchange for the Original Notes and the guarantees related thereto pursuant to the exchange offer, the Exchange Notes will be validly issued, under the Indenture and will be binding obligations of the Guarantor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not purport to be expert on the laws of any jurisdiction other than the laws of the State of Israel, and we express no opinion herein as to the effect
of any other laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. By giving our consent, we do not admit
that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations issued or promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is being delivered to you for your information in connection with the above matter and addresses matters only as of the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Very truly yours, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Tulchinsky
Stern Marciano Cohen Levitski&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tulchinsky Stern Marciano Cohen Levitski&nbsp;&amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Law Offices </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>8
<FILENAME>d558803dex121.htm
<DESCRIPTION>EX-12.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-12.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 12.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(U.S. dollars in millions, except ratios)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Earnings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pre-tax</FONT> income from continuing operations before
adjustments for minority interests in consolidated subsidiaries or income or loss from equity investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed charges, as below</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest capitalized, less amortization of capitalized interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fixed Charges</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest costs (expensed and capitalized) and amortization of issuance costs relating to
long-term debentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rentals &#150; <FONT STYLE="white-space:nowrap">one-third</FONT> of rental expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ratio of Earnings to Fixed Charges</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.0
<SEQUENCE>9
<FILENAME>d558803dex210.htm
<DESCRIPTION>EX-21.0
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.0</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.0 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a list of subsidiaries of the Company as of December&nbsp;31, 2017, omitting some subsidiaries which, considered in the
aggregate, would not constitute a significant subsidiary. Teva Pharmaceutical Industries, Ltd. is not a subsidiary of any other entity. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Name of Subsidiary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Jurisdiction of Organization</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">AbZ-Pharma</FONT> GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Germany</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actavis Pharma Holding 4 ehf</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Iceland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arrow International Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Malta</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTER LAB PHARMACEUTICA, S.A. de C.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Mexico</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratorio Chile S.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chile</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medis ehf.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Iceland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mepha Schweiz AG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merckle GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Germany</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Norton (Waterford) Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Ireland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Norton Healthcare Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">United Kingdom</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pharmachemie Holding B.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Netherlands</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PLIVA HRVATSKA d.o.o.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Croatia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plus Chemicals, branch of Teva Pharmaceuticals International GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ratiopharm Arzneimittel Vertriebs-GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Austria</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ratiopharm GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Germany</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ratiopharm Oy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Finland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teva API B.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Netherlands</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teva API Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">United States</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teva Canada Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Canada</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teva Czech Industries s.r.o</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Czech Republic</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teva Finance Services II B.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Curacao</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teva GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Germany</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teva Italia S.r.l</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Italy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teva Limited Liability Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Russia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEVA OPERATIONS POLAND</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Poland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teva Pharma S.L</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Spain</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Industries Ltd</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Israel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEVA Pharmaceutical Works Private Limited Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Hungary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teva Pharmaceuticals International GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teva Pharmaceuticals USA, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">United States</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teva Sant&eacute; SAS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">France</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teva Takeda Pharma Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Japan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teva Takeda Yakuhin Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Japan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teva UK Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">United Kingdom</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>d558803dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g558803g0327082700035.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the incorporation by reference in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> of Teva Pharmaceutical
Industries Limited of our reports dated February&nbsp;12, 2018 relating to the financial statements, financial statement Schedule II &#150; Valuation and Qualifying Accounts and the effectiveness of internal control over financial reporting, which
appear in Teva Pharmaceutical Industries Limited Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017. We also consent to the reference to us under the heading &#147;Experts&#148; in such
Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Kesselman&nbsp;&amp; Kesselman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certified Public Accountants (lsr.) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A member firm of
PricewaterhouseCoopers International Limited </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tel-Aviv,</FONT> Israel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 2, 2018 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-25.1
<SEQUENCE>11
<FILENAME>d558803dex251.htm
<DESCRIPTION>EX-25.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-25.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 25.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">T-1</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENT OF
ELIGIBILITY </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE TRUST INDENTURE ACT OF 1939 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>THE BANK OF
NEW YORK MELLON </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of trustee as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>New York</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">13-5160382</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Jurisdiction of incorporation</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>if not a U.S. national bank)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>identification no.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>225 Liberty Street, New York, N.Y.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>10286</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip code)</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of obligor as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Netherlands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>identification no.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Piet Heinkade 107</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1019 GM Amsterdam, Netherlands</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip code)</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL INDUSTRIES LIMITED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of obligor as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Israel</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>identification no.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>5 Basel Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P.O. Box 3190</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Petach
Tikva, 4951033 Israel</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip code)</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3.250% Senior Notes due 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Guarantees of 3.250% Senior Notes due 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4.500% Senior Notes due 2025 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Guarantees of 4.500% Senior Notes due 2025 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Title of the indenture securities) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>General information. Furnish the following information as to the Trustee: </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Name and address of each examining or supervising authority to which it is subject. </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:19.10pt; display:inline; font-size:8pt; font-family:Times New Roman; ">Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Address</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Superintendent of the Department of Financial Services of the State of New York</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One State Street, New York, N.Y.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">10004-1417,
and Albany, N.Y. 12223</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Federal Reserve Bank of New York</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">33 Liberty Street, New York, N.Y. 10045</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Federal Deposit Insurance Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">550 17<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Street, NW</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20429</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Clearing House Association L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 Broad Street</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">New York, N.Y.
10004</P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Whether it is authorized to exercise corporate trust powers. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Yes. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Affiliations with Obligor. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>If the obligor is an affiliate of the trustee, describe
each such affiliation. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>List of Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Exhibits identified in parentheses below, on file with the
Commission, are incorporated herein by reference as an exhibit hereto, pursuant to Rule <FONT STYLE="white-space:nowrap">7a-29</FONT> under the Trust Indenture Act of 1939 (the &#147;Act&#148;) and 17 C.F.R. 229.10(d). </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">A copy of the Organization Certificate of The Bank of New York Mellon (formerly known as The Bank of New York, itself formerly Irving Trust Company) as now in effect, which contains the authority to commence business
and a grant of powers to exercise corporate trust powers. (Exhibit 1 to Amendment No.&nbsp;1 to Form <FONT STYLE="white-space:nowrap">T-1</FONT> filed with Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;33-6215,</FONT> Exhibits 1a
and 1b to Form <FONT STYLE="white-space:nowrap">T-1</FONT> filed with Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;33-21672,</FONT> Exhibit 1 to Form <FONT STYLE="white-space:nowrap">T-1</FONT> filed with Registration Statement <FONT
STYLE="white-space:nowrap">No.&nbsp;33-29637,</FONT> Exhibit 1 to Form <FONT STYLE="white-space:nowrap">T-1</FONT> filed with Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-121195</FONT> and Exhibit 1 to Form <FONT
STYLE="white-space:nowrap">T-1</FONT> filed with Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-152735).</FONT> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">A copy of the existing <FONT STYLE="white-space:nowrap">By-laws</FONT> of the Trustee (Exhibit 4 to Form <FONT STYLE="white-space:nowrap">T-1</FONT> filed with Registration Statement
<FONT STYLE="white-space:nowrap">No.&nbsp;333-207042).</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">The consent of the Trustee required by Section&nbsp;321(b) of the Act (Exhibit 6 to Form <FONT STYLE="white-space:nowrap">T-1</FONT> filed with Registration Statement
<FONT STYLE="white-space:nowrap">No.&nbsp;333-188382).</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">A copy of the latest report of condition of the Trustee published pursuant to law or to the requirements of its supervising or examining authority. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Act, the trustee, The Bank of New York Mellon, a corporation organized and existing under the laws of the
State of New York, has duly caused this statement of eligibility to be signed on its behalf by the undersigned, thereunto duly authorized, all in the City of New York, and State of New York, on the 23rd day of March, 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">THE&nbsp;BANK&nbsp;OF&nbsp;NEW&nbsp;YORK MELLON</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Wanda Camacho</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Wanda Camacho</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: &nbsp;&nbsp;Vice President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT 7 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Consolidated&nbsp;Report&nbsp;of&nbsp;Condition&nbsp;of </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THE BANK OF NEW YORK MELLON </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">of
225 Liberty Street, New York, N.Y. 10286 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">And Foreign and Domestic Subsidiaries, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a member of the Federal Reserve System, at the close of business December&nbsp;31, 2017, published in accordance with a call made by the Federal Reserve Bank
of this District pursuant to the provisions of the Federal Reserve Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B></B>Dollar&nbsp;amounts&nbsp;in&nbsp;thousands<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and balances due from depository institutions:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noninterest-bearing balances and currency and coin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,671,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest-bearing balances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,042,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Held-to-maturity</FONT></FONT>
securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,315,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale</FONT></FONT>
securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,943,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal funds sold and securities purchased under agreements to resell:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal funds sold in domestic offices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities purchased under agreements to resell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,998,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans and lease financing receivables:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans and leases held for sale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans and leases held for investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,491,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LESS: Allowance for loan and lease losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans and leases held for investment, net of allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,358,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trading assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,358,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Premises and fixed assets (including capitalized leases)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,388,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other real estate owned</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments in unconsolidated subsidiaries and associated companies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">585,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct and indirect investments in real estate ventures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,390,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">834,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,419,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297,305,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">In domestic offices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,898,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noninterest-bearing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,656,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest-bearing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,242,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">In foreign offices, Edge and Agreement subsidiaries, and IBFs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,992,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noninterest-bearing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,485,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest-bearing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,507,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal funds purchased and securities sold under agreements to repurchase:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal funds purchased in domestic offices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,917,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities sold under agreements to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,401,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trading liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,775,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other borrowed money:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(includes mortgage indebtedness and obligations under capitalized leases)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,542,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Not applicable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Not applicable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subordinated notes and debentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">515,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,284,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,324,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>EQUITY CAPITAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perpetual preferred stock and related surplus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,135,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surplus (exclude all surplus related to preferred stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,764,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retained earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,872,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-1,140,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other equity capital components</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total bank equity capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,631,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncontrolling (minority) interests in consolidated subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,981,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and equity capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297,305,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, Michael Santomassimo, Chief Financial Officer of the above-named bank do hereby declare
that this Report of Condition is true and correct to the best of my knowledge and belief. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-right:13%; font-size:10pt; font-family:Times New Roman" ALIGN="right">Michael Santomassimo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-right:13%; font-size:10pt; font-family:Times New Roman" ALIGN="right">Chief Financial Officer </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the undersigned directors, attest to the correctness of this statement of resources and liabilities. We declare that it has been examined
by us, and to the best of our knowledge and belief has been prepared in conformance with the instructions and is true and correct. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles W. Scharf</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Samuel C. Scott</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Joseph J. Echevarria</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-25.2
<SEQUENCE>12
<FILENAME>d558803dex252.htm
<DESCRIPTION>EX-25.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-25.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 25.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">T-1</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENT OF
ELIGIBILITY </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE TRUST INDENTURE ACT OF 1939 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>THE BANK OF
NEW YORK MELLON </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of trustee as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>New York</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">13-5160382</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Jurisdiction of incorporation</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>if not a U.S. national bank)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>identification no.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>225 Liberty Street, New York, N.Y.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>10286</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip code)</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS III B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of obligor as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Netherlands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>identification no.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Piet Heinkade 107</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1019 GM Amsterdam, Netherlands</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip code)</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL INDUSTRIES LIMITED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of obligor as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Israel</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>identification no.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>5 Basel Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P.O. Box 3190</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Petach
Tikva, 4951033 Israel</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip code)</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6.000% Senior Notes due 2024 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Guarantees of 6.000% Senior Notes due 2024 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6.750% Senior Notes due 2028 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Guarantees of 6.750% Senior Notes due 2028 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Title of the indenture securities) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>General information. Furnish the following information as to the Trustee: </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Name and address of each examining or supervising authority to which it is subject. </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:19.10pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:26.20pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Address</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Superintendent of the Department of Financial Services of the State of New York</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One State Street, New York, N.Y.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">10004-1417,
and Albany, N.Y. 12223</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Federal Reserve Bank of New York</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">33 Liberty Street, New York, N.Y. 10045</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Federal Deposit Insurance Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">550 17<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Street, NW</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20429</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Clearing House Association L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 Broad Street</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">New York, N.Y.
10004</P></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Whether it is authorized to exercise corporate trust powers. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Yes. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Affiliations with Obligor. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>If the obligor is an affiliate of the trustee, describe
each such affiliation.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>List of Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Exhibits identified in parentheses below, on file with the
Commission, are incorporated herein by reference as an exhibit hereto, pursuant to Rule <FONT STYLE="white-space:nowrap">7a-29</FONT> under the Trust Indenture Act of 1939 (the &#147;Act&#148;) and 17 C.F.R. 229.10(d). </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">A copy of the Organization Certificate of The Bank of New York Mellon (formerly known as The Bank of New York, itself formerly Irving Trust Company) as now in effect, which contains the authority to commence business
and a grant of powers to exercise corporate trust powers. (Exhibit 1 to Amendment No.&nbsp;1 to Form <FONT STYLE="white-space:nowrap">T-1</FONT> filed with Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;33-6215,</FONT> Exhibits 1a
and 1b to Form <FONT STYLE="white-space:nowrap">T-1</FONT> filed with Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;33-21672,</FONT> Exhibit 1 to Form <FONT STYLE="white-space:nowrap">T-1</FONT> filed with Registration Statement <FONT
STYLE="white-space:nowrap">No.&nbsp;33-29637,</FONT> Exhibit 1 to Form <FONT STYLE="white-space:nowrap">T-1</FONT> filed with Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-121195</FONT> and Exhibit 1 to Form <FONT
STYLE="white-space:nowrap">T-1</FONT> filed with Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-152735).</FONT> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">A copy of the existing <FONT STYLE="white-space:nowrap">By-laws</FONT> of the Trustee (Exhibit 4 to Form <FONT STYLE="white-space:nowrap">T-1</FONT> filed with Registration Statement
<FONT STYLE="white-space:nowrap">No.&nbsp;333-207042).</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">The consent of the Trustee required by Section&nbsp;321(b) of the Act (Exhibit 6 to Form <FONT STYLE="white-space:nowrap">T-1</FONT> filed with Registration Statement
<FONT STYLE="white-space:nowrap">No.&nbsp;333-188382).</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">A copy of the latest report of condition of the Trustee published pursuant to law or to the requirements of its supervising or examining authority. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Act, the trustee, The Bank of New York Mellon, a corporation organized and existing under the laws of the
State of New York, has duly caused this statement of eligibility to be signed on its behalf by the undersigned, thereunto duly authorized, all in the City of New York, and State of New York, on the 23rd day of March, 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">THE&nbsp;BANK&nbsp;OF&nbsp;NEW&nbsp;YORK MELLON</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Wanda Camacho</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Wanda Camacho</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Vice President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT 7 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Consolidated&nbsp;Report&nbsp;of&nbsp;Condition&nbsp;of </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THE BANK OF NEW YORK MELLON </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">of
225 Liberty Street, New York, N.Y. 10286 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">And Foreign and Domestic Subsidiaries, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a member of the Federal Reserve System, at the close of business December&nbsp;31, 2017, published in accordance with a call made by the Federal Reserve Bank
of this District pursuant to the provisions of the Federal Reserve Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B></B>Dollar&nbsp;amounts&nbsp;in&nbsp;thousands<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and balances due from depository institutions:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noninterest-bearing balances and currency and coin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,671,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest-bearing balances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,042,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Held-to-maturity</FONT></FONT>
securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,315,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale</FONT></FONT>
securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,943,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal funds sold and securities purchased under agreements to resell:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal funds sold in domestic offices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities purchased under agreements to resell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,998,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans and lease financing receivables:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans and leases held for sale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans and leases held for investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,491,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LESS: Allowance for loan and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">lease losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans and leases held for investment, net of allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,358,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trading assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,358,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Premises and fixed assets (including capitalized leases)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,388,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other real estate owned</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments in unconsolidated subsidiaries and associated companies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">585,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct and indirect investments in real estate ventures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,390,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">834,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,419,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297,305,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">In domestic offices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,898,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noninterest-bearing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,656,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest-bearing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,242,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">In foreign offices, Edge and Agreement subsidiaries, and IBFs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,992,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noninterest-bearing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,485,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest-bearing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,507,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal funds purchased and securities sold under agreements to repurchase:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal funds purchased in domestic</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">offices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,917,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities sold under agreements to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,401,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trading liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,775,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other borrowed money:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(includes mortgage indebtedness and obligations under capitalized leases)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,542,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Not applicable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Not applicable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subordinated notes and debentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">515,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,284,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,324,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>EQUITY CAPITAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perpetual preferred stock and related</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">surplus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,135,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surplus (exclude all surplus related to preferred stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,764,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retained earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,872,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-1,140,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other equity capital components</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total bank equity capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,631,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncontrolling (minority) interests in</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">consolidated subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,981,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and equity capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297,305,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, Michael Santomassimo, Chief Financial Officer of the above-named bank do hereby declare
that this Report of Condition is true and correct to the best of my knowledge and belief. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Michael Santomassimo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Chief Financial Officer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the
undersigned directors, attest to the correctness of this statement of resources and liabilities. We declare that it has been examined by us, and to the best of our knowledge and belief has been prepared in conformance with the instructions and is
true and correct. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles&nbsp;W.&nbsp;Scharf</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Samuel C. Scott</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Joseph J. Echevarria</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>13
<FILENAME>d558803dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LETTER OF TRANSMITTAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>With respect to the Exchange Offer Regarding the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#128;700,000,000 3.250% Senior Notes due 2022 issued by Teva Pharmaceutical Finance Netherlands II B.V. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE EXCHANGE OFFER WILL EXPIRE AT 11:59 PM, NEW YORK CITY TIME, ON &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, UNLESS
EXTENDED </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deliver to: The Bank of New York Mellon, London Branch (the &#147;<U>Exchange Agent</U>&#148;) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>By Facsimile (Eligible Institutions</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Only)</I>: +44 (0) 207 964 2728</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(provide call back telephone number on</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">fax cover sheet for confirmation)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>By Mail, Overnight Courier or Hand:</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The Bank of New York Mellon, London Branch</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">One Canada Square London E14 5AL</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tel: +44 (0) 1202 689 644</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fax: +44
(0) 20 7694 2728</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">email: <U>debtrestructuring@bnymellon.com</U></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DELIVERY OF THIS INSTRUMENT TO AN ADDRESS OTHER THAN AS SET FORTH ABOVE OR TRANSMISSION OF INSTRUCTIONS VIA A FACSIMILE
NUMBER OTHER THAN THE ONE LISTED ABOVE WILL NOT CONSTITUTE A VALID DELIVERY. THE INSTRUCTIONS ACCOMPANYING THIS LETTER OF TRANSMITTAL SHOULD BE READ CAREFULLY BEFORE THIS LETTER OF TRANSMITTAL IS COMPLETED. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To My Broker or Account Representative: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, the
undersigned, hereby acknowledge receipt of the Prospectus, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 (the &#147;<U>Prospectus</U>&#148;) of Teva Pharmaceutical Finance Netherlands II B.V., a private company
with limited liability incorporated under Dutch law (the &#147;<U>Issuer</U>&#148;), and this Letter of Transmittal and the instructions hereto with respect to the Issuer&#146;s exchange offer of an aggregate principal amount of up to
&#128;700,000,000 of the Issuer&#146;s 3.250% Senior Notes due 2022 (the &#147;<U>2022 Exchange Euro Notes</U>) for an equal principal amount of its outstanding 3.250% Senior Notes due 2022 (the &#147;<U>2022 Original Euro Notes</U>&#148;), which
have been registered under the United States Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), set forth therein (the &#147;<U>Exchange Offer</U>&#148;). I understand that the Exchange Offer must be accepted on or prior to
11:59 PM, New York City Time, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter instructs
you as to action to be taken by you relating to the Exchange Offer with respect to the 2022 Original Euro Notes held by you for the account of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate face amount of the 2022 Original Euro Notes held by you for the account of the undersigned is (FILL IN AMOUNT):
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of the 2022 Original Euro Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the Exchange Offer,
the undersigned hereby instructs you (CHECK APPROPRIATE BOX): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; TO TENDER the following 2022 Original Euro Notes held by you for the account of the
undersigned (INSERT PRINCIPAL AMOUNT AT MATURITY OF 2022 ORIGINAL EURO NOTES TO BE TENDERED, IF ANY): &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (must be in minimum denominations of &#128;100,000 and
integral multiples of &#128;1,000 in excess thereof). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; NOT TO TENDER any 2022 Original Euro Notes held by you for the account of the undersigned.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned instructs you to tender the 2022 Original Euro Notes held by you for the account of the undersigned, the undersigned
hereby represents for the benefit of the Issuer and you that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The undersigned is acquiring the 2022 Exchange Euro Notes, for which the 2022 Original Euro Notes will be exchanged, in the ordinary course of its business; </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Neither the undersigned nor any other person acquiring 2022 Exchange Euro Notes in exchange for the undersigned&#146;s 2022 Original Euro Notes in the Exchange Offer is engaging in or intends to engage in a distribution
of the 2022 Exchange Euro Notes within the meaning of the federal securities laws of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The undersigned is not engaged in, and does not intend to engage in, and does not have an arrangement or understanding with any person to participate in, the &#147;distribution&#148; (as defined in the Securities Act)
of 2022 Exchange Euro Notes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The undersigned is not an &#147;affiliate,&#148; as defined under Rule 405 of the Securities Act, of the Issuer; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The undersigned is not a broker-dealer and does not engage in, and does not intend to engage in, a distribution of the 2022 Original Euro Notes or the 2022 Exchange Euro Notes. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the Issuer accepts the tender of the 2022 Original Euro Notes, this Letter of Transmittal is a binding agreement between the undersigned and the Issuer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Issuer reserves the absolute right to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">reject any and all tenders of any particular 2022 Original Euro Notes not properly tendered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">refuse to accept any 2022 Original Euro Notes if, in its reasonable judgment or the judgment of its counsel, the acceptance would be unlawful; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">waive any defects or irregularities or conditions of the Exchange Offer as to any particular 2022 Original Euro Notes before the expiration of the offer. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the undersigned is a broker-dealer, and acquired the 2022 Original Euro Notes for its own account as a result of market making activities or other trading
activities, the undersigned represents that it will deliver a prospectus meeting the requirements of the Securities Act in connection with any resale of 2022 Exchange Euro Notes received in respect of such 2022 Original Euro Notes pursuant to the
Exchange Offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned also authorizes you to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">confirm that the undersigned has made such representations; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">take such other action as necessary under the Prospectus to effect the valid tender of such 2022 Original Euro Notes. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges that any person participating in the Exchange Offer for the purpose of distributing the 2022 Exchange Euro Notes must comply with
the registration and prospectus delivery requirements of the Securities Act in connection with a secondary resale transaction of the 2022 Exchange Euro Notes acquired by such person and cannot rely on the position of the Staff of the Securities and
Exchange Commission set forth in <FONT STYLE="white-space:nowrap">no-action</FONT> letters that are discussed in the section of the Prospectus entitled &#147;Exchange Offer.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Exchange Offer is subject to certain conditions, described in the Prospectus in the section entitled &#147;The Exchange Offer&#151;Conditions of the
Exchange Offer.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of beneficial owner(s): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signatures:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name&nbsp;(please&nbsp;print):&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone&nbsp;Number):&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Taxpayer&nbsp;Identification&nbsp;or&nbsp;Social&nbsp;Security&nbsp;Number:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signatures:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Because all of the 2022 Original Euro Notes are held in book-entry accounts maintained by the Exchange
Agent through Euroclear Bank S.A./N.V. as operator of the Euroclear System (&#147;<U>Euroclear</U>&#148;) or Clearstream Banking, </B><B><I>soci</I></B><B></B><B><I>&eacute;</I></B><B></B><B><I>t</I></B><B></B><B><I>&eacute;</I></B><B></B><B><I>
</I></B><B></B><B><I>anonyme</I></B><B> (&#147;<U>Clearstream</U>&#148;), a holder need not manually execute this Letter of Transmittal, provided, however, that tenders of 2022 Original Euro Notes must be effected in accordance with the procedures
mandated by Euroclear or Clearstream, as the case may be. However, all holders who exchange their 2022 Original Euro Notes for 2022 Exchange Euro Notes in accordance with the procedures outlined in the Prospectus will be deemed to have acknowledged
receipt of, and agreed to be bound by, and to have made all of the representations and warranties contained in the Letter of Transmittal. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>YOUR BANK OR BROKER CAN ASSIST YOU IN COMPLETING THIS FORM. THE INSTRUCTIONS INCLUDED WITH THIS LETTER OF TRANSMITTAL MUST BE FOLLOWED.
QUESTIONS AND REQUESTS FOR ASSISTANCE OR FOR ADDITIONAL COPIES OF THE PROSPECTUS AND THIS LETTER OF TRANSMITTAL MAY BE DIRECTED TO THE EXCHANGE AGENT. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter of Transmittal is to be used if certificates of 2022 Original Euro Notes are to be forwarded herewith. Delivery of documents to a
book-entry transfer facility does not constitute delivery to the Exchange Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Holder&#148; with respect to the Exchange
Offer means any person in whose name 2022 Original Euro Notes are registered on the books of the Issuer or any other person who has obtained a properly completed bond power from the registered holder. The undersigned has completed, executed and
delivered this Letter of Transmittal to indicate the action the undersigned desires to take with respect to the Exchange Offer. Holders who wish to tender their 2022 Original Euro Notes must complete this Letter of Transmittal in its entirety. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>14
<FILENAME>d558803dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LETTER OF TRANSMITTAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>With respect to the Exchange Offer Regarding the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#128;900,000,000 4.500% Senior Notes due 2025 issued by Teva Pharmaceutical Finance Netherlands II B.V. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE EXCHANGE OFFER WILL EXPIRE AT 11:59 PM, NEW YORK CITY TIME, ON &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, UNLESS
EXTENDED </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deliver to: The Bank of New York Mellon, London Branch (the &#147;<U>Exchange Agent</U>&#148;) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>By Facsimile (Eligible Institutions</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Only)</I>: +44 (0) 207 964 2728</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(provide call back telephone number on</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">fax cover sheet for confirmation)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>By Mail, Overnight Courier or Hand:</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The Bank of New York Mellon, London Branch</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">One Canada Square London E14 5AL</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tel: +44 (0) 1202 689 644</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fax: +44
(0) 20 7694 2728</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">email: <U>debtrestructuring@bnymellon.com</U></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DELIVERY OF THIS INSTRUMENT TO AN ADDRESS OTHER THAN AS SET FORTH ABOVE OR TRANSMISSION OF INSTRUCTIONS VIA A FACSIMILE
NUMBER OTHER THAN THE ONE LISTED ABOVE WILL NOT CONSTITUTE A VALID DELIVERY. THE INSTRUCTIONS ACCOMPANYING THIS LETTER OF TRANSMITTAL SHOULD BE READ CAREFULLY BEFORE THIS LETTER OF TRANSMITTAL IS COMPLETED. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To My Broker or Account Representative: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, the
undersigned, hereby acknowledge receipt of the Prospectus, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 (the &#147;<U>Prospectus</U>&#148;) of Teva Pharmaceutical Finance Netherlands II B.V., a private company
with limited liability incorporated under Dutch law (the &#147;<U>Issuer</U>&#148;), and this Letter of Transmittal and the instructions hereto with respect to the Issuer&#146;s exchange offer of an aggregate principal amount of up to
&#128;900,000,000 of the Issuer&#146;s 4.500% Senior Notes due 2025 (the &#147;<U>2025 Exchange Euro Notes</U>) for an equal principal amount of its outstanding 4.500% Senior Notes due 2025 (the &#147;<U>2025 Original Euro Notes</U>&#148;), which
have been registered under the United States Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), set forth therein (the &#147;<U>Exchange Offer</U>&#148;). I understand that the Exchange Offer must be accepted on or prior to
11:59 PM, New York City Time, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter instructs
you as to action to be taken by you relating to the Exchange Offer with respect to the 2025 Original Euro Notes held by you for the account of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate face amount of the 2025 Original Euro Notes held by you for the account of the undersigned is (FILL IN AMOUNT):
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of the 2025 Original Euro Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the Exchange Offer,
the undersigned hereby instructs you (CHECK APPROPRIATE BOX): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; TO TENDER the following 2025 Original Euro Notes held by you for the account of the
undersigned (INSERT PRINCIPAL AMOUNT AT MATURITY OF 2025 ORIGINAL EURO NOTES TO BE TENDERED, IF ANY): &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (must be in minimum denominations of &#128;100,000 and
integral multiples of &#128;1,000 in excess thereof). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; NOT TO TENDER any 2025 Original Euro Notes held by you for the account of the undersigned.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned instructs you to tender the 2025 Original Euro Notes held by you for the account of the undersigned, the undersigned
hereby represents for the benefit of the Issuer and you that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The undersigned is acquiring the 2025 Exchange Euro Notes, for which the 2025 Original Euro Notes will be exchanged, in the ordinary course of its business; </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Neither the undersigned nor any other person acquiring 2025 Exchange Euro Notes in exchange for the undersigned&#146;s 2025 Original Euro Notes in the Exchange Offer is engaging in or intends to engage in a distribution
of the 2025 Exchange Euro Notes within the meaning of the federal securities laws of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The undersigned is not engaged in, and does not intend to engage in, and does not have an arrangement or understanding with any person to participate in, the &#147;distribution&#148; (as defined in the Securities Act)
of 2025 Exchange Euro Notes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The undersigned is not an &#147;affiliate,&#148; as defined under Rule 405 of the Securities Act, of the Issuer; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The undersigned is not a broker-dealer and does not engage in, and does not intend to engage in, a distribution of the 2025 Original Euro Notes or the 2025 Exchange Euro Notes. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the Issuer accepts the tender of the 2025 Original Euro Notes, this Letter of Transmittal is a binding agreement between the undersigned and the Issuer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Issuer reserves the absolute right to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">reject any and all tenders of any particular 2025 Original Euro Notes not properly tendered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">refuse to accept any 2025 Original Euro Notes if, in its reasonable judgment or the judgment of its counsel, the acceptance would be unlawful; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">waive any defects or irregularities or conditions of the Exchange Offer as to any particular 2025 Original Euro Notes before the expiration of the offer. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the undersigned is a broker-dealer, and acquired the 2025 Original Euro Notes for its own account as a result of market making activities or other trading
activities, the undersigned represents that it will deliver a prospectus meeting the requirements of the Securities Act in connection with any resale of 2025 Exchange Euro Notes received in respect of such 2025 Original Euro Notes pursuant to the
Exchange Offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned also authorizes you to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">confirm that the undersigned has made such representations; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">take such other action as necessary under the Prospectus to effect the valid tender of such 2025 Original Euro Notes. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges that any person participating in the Exchange Offer for the purpose of distributing the 2025 Exchange Euro Notes must comply with
the registration and prospectus delivery requirements of the Securities Act in connection with a secondary resale transaction of the 2025 Exchange Euro Notes acquired by such person and cannot rely on the position of the Staff of the Securities and
Exchange Commission set forth in <FONT STYLE="white-space:nowrap">no-action</FONT> letters that are discussed in the section of the Prospectus entitled &#147;Exchange Offer.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Exchange Offer is subject to certain conditions, described in the Prospectus in the section entitled &#147;The Exchange Offer&#151;Conditions of the
Exchange Offer.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of beneficial owner(s): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signatures:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name&nbsp;(please&nbsp;print):&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone&nbsp;Number):&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Taxpayer&nbsp;Identification&nbsp;or&nbsp;Social&nbsp;Security&nbsp;Number:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signatures:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Because all of the 2025 Original Euro Notes are held in book-entry accounts maintained by the Exchange
Agent through Euroclear Bank S.A./N.V. as operator of the Euroclear System (&#147;<U>Euroclear</U>&#148;) or Clearstream Banking, </B><B><I>soci</I></B><B></B><B><I>&eacute;</I></B><B></B><B><I>t</I></B><B></B><B><I>&eacute;</I></B><B></B><B><I>
</I></B><B></B><B><I>anonyme</I></B><B> (&#147;<U>Clearstream</U>&#148;), a holder need not manually execute this Letter of Transmittal, provided, however, that tenders of 2025 Original Euro Notes must be effected in accordance with the procedures
mandated by Euroclear or Clearstream, as the case may be. However, all holders who exchange their 2025 Original Euro Notes for 2025 Exchange Euro Notes in accordance with the procedures outlined in the Prospectus will be deemed to have acknowledged
receipt of, and agreed to be bound by, and to have made all of the representations and warranties contained in the Letter of Transmittal. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>YOUR BANK OR BROKER CAN ASSIST YOU IN COMPLETING THIS FORM. THE INSTRUCTIONS INCLUDED WITH THIS LETTER OF TRANSMITTAL MUST BE FOLLOWED.
QUESTIONS AND REQUESTS FOR ASSISTANCE OR FOR ADDITIONAL COPIES OF THE PROSPECTUS AND THIS LETTER OF TRANSMITTAL MAY BE DIRECTED TO THE EXCHANGE AGENT. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter of Transmittal is to be used if certificates of 2025 Original Euro Notes are to be forwarded herewith. Delivery of documents to a
book-entry transfer facility does not constitute delivery to the Exchange Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Holder&#148; with respect to the Exchange
Offer means any person in whose name 2025 Original Euro Notes are registered on the books of the Issuer or any other person who has obtained a properly completed bond power from the registered holder. The undersigned has completed, executed and
delivered this Letter of Transmittal to indicate the action the undersigned desires to take with respect to the Exchange Offer. Holders who wish to tender their 2025 Original Euro Notes must complete this Letter of Transmittal in its entirety. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>15
<FILENAME>d558803dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LETTER OF TRANSMITTAL </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>With respect to the Exchange Offer Regarding the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6.000% Senior Notes due 2024 issued by Teva Pharmaceutical Finance Netherlands III B.V. </B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE EXCHANGE OFFER WILL EXPIRE AT
11:59 PM, NEW YORK CITY TIME, ON &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2018, unless extended </B></P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To My Broker or Account Representative: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, the
undersigned, hereby acknowledge receipt of the Prospectus, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 (the &#147;<U>Prospectus</U>&#148;) of Teva Pharmaceutical Finance Netherlands III B.V., a private
company with limited liability incorporated under Dutch law (the &#147;<U>Issuer</U>&#148;), with respect to the Issuer&#146;s exchange offer set forth therein (the &#147;<U>Exchange Offer</U>&#148;). I understand that the Exchange Offer must be
accepted on or prior to 11:59 PM, New York City Time, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter instructs you as to action to be taken by you relating to the Exchange Offer with respect to the Issuer&#146;s 6.000% Senior Notes
due 2024 (the &#147;<U>2024 Original Dollar Notes</U>&#148;) held by you for the account of the undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate face amount of
the 2024 Original Dollar Notes held by you for the account of the undersigned is (FILL IN AMOUNT): $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of the 2024 Original Dollar Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the Exchange Offer, the undersigned hereby instructs you (CHECK APPROPRIATE BOX): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">TO TENDER the following 2024 Original Dollar Notes held by you for the account of the undersigned (INSERT PRINCIPAL AMOUNT AT MATURITY OF 2024 ORIGINAL DOLLAR NOTES TO BE TENDERED, IF ANY):
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (must be in minimum denominations of $200,000 and any integral multiples of $1,000 in excess thereof). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">NOT TO TENDER any 2024 Original Dollar Notes held by you for the account of the undersigned. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned instructs you to tender the 2024 Original Dollar Notes held by you for the account of the undersigned, the undersigned
hereby represents for the benefit of the Issuer and you that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The undersigned is acquiring the 2024 Exchange Dollar Notes (as defined in the Prospectus), for which the 2024 Original Dollar Notes will be exchanged, in the ordinary course of its business; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Neither the undersigned nor any other person acquiring 2024 Exchange Dollar Notes in exchange for the undersigned&#146;s 2024 Original Dollar Notes in the exchange offer is engaging in or intends to engage in a
distribution of the 2024 Exchange Dollar Notes within the meaning of the federal securities laws; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The undersigned is not engaged in, and does not intend to engage in, and does not have an arrangement or understanding with any person to participate in, the distribution (as defined in the Securities Act of 1933, as
amended (the &#147;<U>Securities Act</U>&#148;)) of 2024 Exchange Dollar Notes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The undersigned is not an &#147;affiliate,&#148; as defined under Rule 405 of the Securities Act, of the Issuer; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The undersigned is not a broker-dealer and does not engage in, and does not intend to engage in, a distribution of the 2024 Original Dollar Notes or the 2024 Exchange Dollar Notes. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the Issuer accepts the tender of the 2024 Original Dollar Notes, this letter of transmittal is a binding agreement between the undersigned and the
Issuer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Issuer reserves the absolute right to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">reject any and all tenders of any particular 2024 Original Dollar Notes not properly tendered; </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">refuse to accept any 2024 Original Dollar Notes if, in its reasonable judgment or the judgment of its counsel, the acceptance would be unlawful; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">waive any defects or irregularities or conditions of the Exchange Offer as to any particular 2024 Original Dollar Notes before the expiration of the offer. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the undersigned is a broker-dealer, and acquired the 2024 Original Dollar Notes for its own account as a result of market making activities or other
trading activities, the undersigned represents that it will deliver a prospectus meeting the requirements of the Securities Act in connection with any resale of 2024 Exchange Dollar Notes received in respect of such 2024 Original Dollar Notes
pursuant to the Exchange Offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned also authorizes you to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">confirm that the undersigned has made such representations; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">take such other action as necessary under the Prospectus to effect the valid tender of such 2024 Original Dollar Notes. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges that any person participating in the Exchange Offer for the purpose of distributing the 2024 Exchange Dollar Notes must comply
with the registration and prospectus delivery requirements of the Securities Act in connection with a secondary resale transaction of the 2024 Exchange Dollar Notes acquired by such person and cannot rely on the position of the Staff of the
Securities and Exchange Commission set forth in <FONT STYLE="white-space:nowrap">no-action</FONT> letters that are discussed in the section of the Prospectus entitled &#147;The Exchange Offer.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Exchange Offer is subject to certain conditions, described in the Prospectus in the section entitled &#147;The Exchange Offer&#151;Conditions of the
Exchange Offer.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="78%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Name&nbsp;of&nbsp;beneficial&nbsp;owner(s):</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signatures:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name&nbsp;(please&nbsp;print):</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone&nbsp;Number:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Taxpayer&nbsp;Identification&nbsp;or&nbsp;Social&nbsp;Security&nbsp;Number:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>16
<FILENAME>d558803dex994.htm
<DESCRIPTION>EX-99.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LETTER OF TRANSMITTAL </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>With respect to the Exchange Offer Regarding the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6.750% Senior Notes due 2028 issued by Teva Pharmaceutical Finance Netherlands III B.V. </B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE EXCHANGE OFFER WILL EXPIRE AT
11:59 PM, NEW YORK CITY TIME, ON &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018, unless extended </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To My Broker or Account Representative: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, the
undersigned, hereby acknowledge receipt of the Prospectus, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 (the &#147;<U>Prospectus</U>&#148;) of Teva Pharmaceutical Finance Netherlands III B.V., a private
company with limited liability incorporated under Dutch law (the &#147;<U>Issuer</U>&#148;), with respect to the Issuer&#146;s exchange offer set forth therein (the &#147;<U>Exchange Offer</U>&#148;). I understand that the Exchange Offer must be
accepted on or prior to 11:59 PM, New York City Time, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter instructs you as to action to be taken by you relating to the Exchange Offer with respect to the Issuer&#146;s 6.750% Senior Notes
due 2028 (the &#147;<U>2028 Original Dollar Notes</U>&#148;) held by you for the account of the undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate face amount of
the 2028 Original Dollar Notes held by you for the account of the undersigned is (FILL IN AMOUNT): $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of the 2028 Original Dollar Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the Exchange Offer, the undersigned hereby instructs you (CHECK APPROPRIATE BOX): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">TO TENDER the following 2028 Original Dollar Notes held by you for the account of the undersigned (INSERT PRINCIPAL AMOUNT AT MATURITY OF 2028 ORIGINAL DOLLAR NOTES TO BE TENDERED, IF ANY):
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (must be in minimum denominations of $200,000 and any integral multiples of $1,000 in excess thereof). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">NOT TO TENDER any 2028 Original Dollar Notes held by you for the account of the undersigned. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned instructs you to tender the 2028 Original Dollar Notes held by you for the account of the undersigned, the undersigned
hereby represents for the benefit of the Issuer and you that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The undersigned is acquiring the 2028 Exchange Dollar Notes (as defined in the Prospectus), for which the 2028 Original Dollar Notes will be exchanged, in the ordinary course of its business; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Neither the undersigned nor any other person acquiring 2028 Exchange Dollar Notes in exchange for the undersigned&#146;s 2028 Original Dollar Notes in the exchange offer is engaging in or intends to engage in a
distribution of the 2028 Exchange Dollar Notes within the meaning of the federal securities laws; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The undersigned is not engaged in, and does not intend to engage in, and does not have an arrangement or understanding with any person to participate in, the distribution (as defined in the Securities Act of 1933, as
amended (the &#147;<U>Securities Act</U>&#148;)) of 2028 Exchange Dollar Notes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The undersigned is not an &#147;affiliate,&#148; as defined under Rule 405 of the Securities Act, of the Issuer; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The undersigned is not a broker-dealer and does not engage in, and does not intend to engage in, a distribution of the 2028 Original Dollar Notes or the 2028 Exchange Dollar Notes. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the Issuer accepts the tender of the 2028 Original Dollar Notes, this letter of transmittal is a binding agreement between the undersigned and the
Issuer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Issuer reserves the absolute right to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">reject any and all tenders of any particular 2028 Original Dollar Notes not properly tendered; </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">refuse to accept any 2028 Original Dollar Notes if, in its reasonable judgment or the judgment of its counsel, the acceptance would be unlawful; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">waive any defects or irregularities or conditions of the Exchange Offer as to any particular 2028 Original Dollar Notes before the expiration of the offer. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the undersigned is a broker-dealer, and acquired the 2028 Original Dollar Notes for its own account as a result of market making activities or other
trading activities, the undersigned represents that it will deliver a prospectus meeting the requirements of the Securities Act in connection with any resale of 2028 Exchange Dollar Notes received in respect of such 2028 Original Dollar Notes
pursuant to the Exchange Offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned also authorizes you to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">confirm that the undersigned has made such representations; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">take such other action as necessary under the Prospectus to effect the valid tender of such 2028 Original Dollar Notes. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges that any person participating in the Exchange Offer for the purpose of distributing the 2028 Exchange Dollar Notes must comply
with the registration and prospectus delivery requirements of the Securities Act in connection with a secondary resale transaction of the 2028 Exchange Dollar Notes acquired by such person and cannot rely on the position of the Staff of the
Securities and Exchange Commission set forth in <FONT STYLE="white-space:nowrap">no-action</FONT> letters that are discussed in the section of the Prospectus entitled &#147;The Exchange Offer.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Exchange Offer is subject to certain conditions, described in the Prospectus in the section entitled &#147;The Exchange Offer&#151;Conditions of the
Exchange Offer.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="78%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Name&nbsp;of&nbsp;beneficial&nbsp;owner(s):</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signatures:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name&nbsp;(please&nbsp;print):</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone&nbsp;Number:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Taxpayer&nbsp;Identification&nbsp;or&nbsp;Social&nbsp;Security&nbsp;Number:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g558803dsp049.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g558803dsp049.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M')_<8YX;V/- &!H7Q!TS5;O7;>\DMM-_LN_DL@9[I09=G5\$# X/'/2@#KZ
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M7]G%=K:27<*7+1F40M( Y0=6QUP/6@"A#XJ\.W#Q)#KVFR-,P2,)=QDNQ(
MP>221CZT 69=9TNWU*+39M2M([^89CMGG42O]%)R>AH 4:SI;:JVE+J5H=15
M=QM1,OF@8SG9G.,$'I0!F:CXLL[4Z0;%H=0BU#41IYDAG!$3;'8G(SDC9C''
M6@"^NOZ,]E!>KJUD;2XD$4,PN$V2.>BJV<$\=!0!SWA;XC:1K^EBZO;BSTJ=
MKF2!+>:\4L^PXR,[2<^F* -]_$>AQ1S/)K-@B0S_ &:1FN4 27_GF>>&X^[U
MH LP:E87-[<65O>V\MW;8\Z%)59XL]-R@Y&?>@"U0 4 % !0 4 % !0 4 %
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M>^&T4&GR+XA@.G2,Z6K[X[<*<@R!< !\?+G(ZXH B\36NNWVM^,/$&E69CM
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MY;#;&"<GDKT)[YZT 9PT=/\ A#_$6DZWH$]QX^N+YY(9ELWD>5F*D/'*%PJ
M;CU X- '7:W#;_\ "SO ^+5W\06K;-4NH;5T5\PJ 2^TAAUQ\QQR#[ '>^$O
M"<?AC2'L9+A;TF\ENUD:';L+DG@9/(R1F@#R98M*D^+=I9VDEY_8-UJ<>IM&
M+*5/L]\@90I)7[K,0<C([<#F@#>\:>!]'N?%WA71='T*"S:>[-[=WT$&"D<0
M)VEL=6)[]P* .>N-"U6]\.^.UM=.N)Y$\4M=")8R7DC63)*CJW'I0!U&A6^G
M:K\8(==\-:?)%IR6,WVZY-I);B6=Y"V#O4%VYS],>@H ]7H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#'U;Q
M1I&AWMO9W]Q(EQ<1O+''';R2EE3&X_(IP!GO0!!I/C30-<NH;;3KYI9)D,D6
MZ"1%E4=2C,H# >H)Z'TH WZ "@ H * "@ H * "@ H BN;F"RM9KJYE6*WA0
MR22.<*B@9))] * .1\$WOAC1M)TWPUHUS>&+#M:B[MI8VE4EI"RLR*&7D\CC
MI0!V= !0 4 % ',O!H7@:35M<NKF:"+4[E9+B1U9XXWVX!^5?D4XZMQD@9Y
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MZ!YX)87C>($X&0P'7!QZCD<$&@#6H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * ,?7K*V_L[4K_ ,E?M0L)81)W"8)Q^8H
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M4D'!Y/2@#'O/$OB.R;54N+>3_A)O#^BW,4]R@)CF4R0^3< =,[/-;IP0<^@
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M 36B/#/B[P='HC,D%\\L5X Q99H50'>_.,KG=O\ <\X)! .WTC6=.UW3TO\
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M2J$C!*J> 2.I R<G/4T ,_X1+PY]D-I_86GFV,HF:$VR;&D (WE<8+8)Y/-
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M#_\ T'=._P# I/\ &@ _X2?P_P#]!W3O_ I/\: #_A)_#_\ T'=._P# I/\
M&@ _X2?P_P#]!W3O_ I/\: #_A)_#_\ T'=._P# I/\ &@ _X2?P_P#]!W3O
M_ I/\: #_A)_#_\ T'=._P# I/\ &@ _X2?P_P#]!W3O_ I/\: #_A)_#_\
MT'=._P# I/\ &@ _X2?P_P#]!W3O_ I/\: #_A)_#_\ T'=._P# I/\ &@ _
MX2?P_P#]!W3O_ I/\: #_A)_#_\ T'=._P# I/\ &@ _X2?P_P#]!W3O_ I/
M\: #_A)_#_\ T'=._P# I/\ &@ _X2?P_P#]!W3O_ I/\: #_A)_#_\ T'=.
M_P# I/\ &@ _X2?P_P#]!W3O_ I/\: +EGJ-CJ*,]C>072H<,89 X!]\&@"S
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 1/:V\CEY((W;IED!-
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#D?&EB+G4_"MP-/>Y^QZF)I)$@
M,ABC$3@G@$CYBG3N >U %/QJ^K:]X<2'2+*Z@N5#7R&5&4AH'#1*0%.69@K!
M>#\O/I0 S7-*N_$)T#58](VSWT#V&HQ3QJ'@@E0LQ.[/W&7@=RV.] &GX$T2
M;2M'\^^@$6H2I';R<#/EPKY<?0#@@%^G!D([4 <FWAS6%N5'V*1M</B3[2-0
M$8P+3.=V_.-NSY=F<YXQWH NZ!X5>3X@^(-3O+!$TY;QYH5DMMK22E(U$B-C
M)'$X(S@[LX.0: ,;1/!4D'PUUYYM'5;^6QO;:T@6U*2@22.RJ5Q\V<0E2<[<
M8&.<@&^-)DCU/PS)?:8\^@0:0T!M1;,X@N,)AFB SR@=1\O'/3- &-KGAA&\
M2:&+;1KB#2(-)$,D;V)N<(9D+0G&[#%!(,C.W/;J #0;1;F;QY:ZA#I4WE+<
M6XEANH,B,+!D2Q3#&-N2C*<Y(Z<T >F4 % ',?#W_D2;/I_K9^G_ %V>@#IZ
M "@#AO D-YK?@KP[J-SJUXP?3)89PTK;Y7=DQ)OSG<NQ@#U^<\CN 6?".BW^
MD>)/$:W%UJ<]@)(5LC>W<DX*>4"Y7<3_ !EA0!?U?3VBAU:ZN;K4[BUN1#LM
MK!I%EBVGG848'YB1G&. >M ',/HWB.3X9K>3W.K)XFM+>5K=([MMS$.QB$B*
MVR1MNT'.>] #]<7Q,^G>*95;4(9Y-*LS9"VWMBY_>;P@7."6V!CTQ@DX&: .
MF\(KJ3:;=W6II<127=Y+/'!</N>&,G"KU( P,X'KV.10!F6WANXM?&TQ6]UF
M339K!]QEU&5XUE9\?*"WRD+G&.G:@##U'2?%>G2Z[#HD^IW,%E-8WEC'<73N
M9\,QGB$C-DJ0!E23Z=Z $@M/%)\*:Y)'/K'VOR[6*Q:5BLID0AGD$9)PI9R"
M"22J8.1B@#HO!5OJ-E<:Y:W)U-K".Z3[$^HRF21E\I0_S,22-X;\^* .MH *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@!OF)YGE[UWXW;<\X]<4 .H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M .8\5ZYJ>ASVC6HMC;W:2P1B2)F?[5L+1+PP!5MK+C@Y*@'F@"GI?B+Q!KNA
M7][I\%FES;6B(L,L3D&]"[I$)#?<&57C)SNYXQ0!5TKQS>ZUJGV:TC@2*]^S
MRZ<TD1R\6,W.[Y^63!7C&&('.#0 W5O'.HZ)K-U97D5OLM;Z*29UB8!-.D7
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M$X]: )/ L:1>#-/2-%1%W@*HP!^\:@#HJ "@ H * "@ H * "@ H * "@ H
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M&: -'0-';0['[&)H7@7_ %<<-JD"Q^N%3CD\T :M !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MY^\,#!)XST_, J^/;?5Y[^U-E+?I%';2/"EJDQ62X#(45S$PV@@'E\J.3VY
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MK.VDN)F*Q1J68A2QP/0#DGV')H I:=K^F:K*8K6Y)F!D!BDC:*0;"H?Y7 .
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M0O%O>,[D9"K*Q5E*L 0001@CM0!;H * "@ H * "@ H * "@ H * "@ H *
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M/&KBX;RF0;\@X7+9XR1@=QF@!/%?A;6=;N-#$,UK/'90W"7,L\C1/*TD#19
M12!]XD\CVH R[GP'KWV26**[MYIU@@2"?[5);C*)"KH8U0@+F)G7!X+GCO0
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MOY;D?*H(RI/<T :'A3P#>^&=6MI1J(DMH4VNP=@\V+>&%49?N[5,3,#R1D
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M/&./3K0!UGAO1I-$TV>&:59)[B[GNY"GW5:61GVC/.!N SWQGVH V* "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H AGNK>V_X^+B*+@M\[A>!C)Y],C\Z
M(O[4T_?L^WVV_.-OFKGO[^Q_(T ,_MK2LL/[3M/E^]^_7CMSS0 )K6E2;MFI
MVC;1N.)U.!Z]: ''5]-4,3J-J GWB9EXYQSSZT 1_P!O:/\ ]!6R_P# A/\
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M5S_,>HH TJ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M<1L65  "6*Y4D+@E"N030!T$UM)-*6%Y/$AB:/RTVXR<8?)7.X8XYQR<@\8
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M93U7)!X.3GZT 0P:(8M9&J2:E=SRB)H0DGEA I(.,*@[@<YS0!JT % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <?XFU;4[/7FM;/4!;1#1[F]&Z
M)7421/& 3D9P0Y!&1T&,=P"E:?$D3);PMI4CWDNGM=>7'(,[TABE>/')4XEP
M ><KR,$$@$L/CMI[L3Q6S/:3V\#6J;P!+YMP(5?<1D EAQZ#.,G% $&F^(=7
MO?AQ8:K)=NM])J:6KNL<>60WWD$8(VYV'J.X% #M%\=7,DUOI=U:-=7RK=27
M$BLJ>6D-P8CD?Q.!@D+P2#CB@"HWQ*EU2VMUTVT^S22D[VE<$HK637,148P3
MC;G(P"".<@T 3V/Q+#VT-LVG37>I*JAUB9<2'[,LY(]"0V #@9!Y&* +#_$4
MKI_VX:0XM3=26ZRF;( CD,;NP5691N"XR,?,,D4 0^-/$6LZ-J\XT^["0PVL
M$Q21$,8W7 1V;C<1LSPISG&* ,>Z^(NHQ6VIZ9$X.I6T]PYNI%55B@2[\A?E
MQAV['I@<YZ @'8^+?&5OX9\'WGB&U@&J1VSA"D$HQNW[&RP!Q@Y!XX(Q0 S^
MW;O7O EOK&D;[*[OH/,M89/+WNY4E%&_Y>2 ?]W.,=0 8/A/QKJFM^)X8)Y(
MS93HVTK%M7<(()"F#\RN#(Q.3C! '(. "/2?&5W)XDU&SU/5)X+:#5KBWMW$
M$0241(C"#.,ACN8Y.,A0 <YH T;#XB37\^CP1Z%()=6B:XM\W"[6B6..3(..
M3B0J1C@HPR>M %"Z^+<=MH%EJYT.4PWBS20@S 95(O-Y..I (QS@CJ0<T :_
MB37+^S\;^%M+LKAQ::I'=>8D0C+,8T5E*E^/XB?PH S/"OQ N[[3-%M[BW%_
MJ%[:J[O'*B$RM'-*J;1PHQ PR2.2.",D %ZP^($M^-,:/0Y0+Y&F"F7#K$K1
MHYP5 +*\AW*2,*A;)X! *D/Q/S%%)<:1Y2F.X>4+,S,AB1W,>#&/WA\MN#@<
M$J6Q0!4U7XDWDFG7J65E]CN[3#32-)N 'F1J-@*?O,^8,_=QSSF@#?U_6]2T
M_P 2P6T6_P#L]A:JSP"-C%)),4 E5OFV/PH9>5()(/8 P]-^*4\F@)?76C[Y
M$TO^U9_)EPJQ%I%"@$9)R@'T.<\8(!L2^-[O[1<VD6BL+FWM'N6\R7:F,RB,
M@[<E6\DG. 0&7@\X *.I_$*[T'X9:#XGGTEM2N;]+<2Q6SE0K2)G=T..>,>K
M 9H T_%^MW=C9Z(;*[-G<WFHVL,D>U"_E2.$;A@<8W=?7'TH SK?XBW-[=6<
M-GH]N_VV[GM8"]^$.8_-^^NPE2?*'&"/G&">: *R?%.26S:>'1%D*QM(T8N\
ML MQ)$W 3)PL>_ !)R1CC- "7WQ'>XOY=+MO)M&46\JWD<XD 0W,,<BLKH-N
M1+P?0_PD< $D_P 3IUTQ[^WT.,Q">XB43WRQL1"DSMD!6*G$!X( ^=<$\X +
M:^+=8U_P1KM]H5C!!JMFWEP++<*R',<<F[<0 /EDZ'C(ZXYH S[7QA>RWGAP
M'7+6,7][*!#<^6C7%IYDBQR#N6;,(4*.?F/3. "&Y\=ZG:^!A?B2:6\:\N(W
MGBLVF2%(KG8%8(N%8IC!;'<\\ @"OXI\2VNE>*Y+NZ@2?2[*67S$\MXX9A))
MY:#![QA,JV6&1TW#(!O_ -N7G_"P5TXW7F6#,8ECMY(7V.(BY$JX\Q.A(.<?
M='&>0!='\8WNI^/]6\-S>'[FTMK&+?'?2$[9L%1P-N!G=D<GA3^ !@MXIU/1
M-=\7F]U:;4;7P_;6UQ]F6&)#(7BD++D+D#.QL\X []P#4L?&6?&SV.IWMM:6
MTUK"+:#SXW5YFGF0;' RV]8T(!Z9Z YH I>)?%&LV5SJL\%VEM8Z?>"UD1%C
M,N#:B1&4/G<6ED1=H&<+P,DT 3+JFLV<E]/K7B-+6WM-/2XNU6WB7[-([?*B
MDYRP"..<Y+*<=B 6?"7B34-0&GQ7M[;7;7&F-/)<VP#0)+')L?##@Y+=N/D;
M!Q0!%X?\91SKJTL>IOKUM%,!;M;1*[(NSG?Y8 4%U<+D9P <D$$@'/)\0]2O
M/#<%ZM[Y$ZLEQ>*AA#>48$E*6ZO_ *S:)5R"2V<>H% &GKWC#5=.L/B"\%[$
M)-%:#[(2B_)OC1L'U^8D<T 7DUCQ,WQ'DTAO*_LR16>)HRC^7%Y2XE;'(;S.
M-IP"&.,A2: ,L>*O$LB>#Y;:1;A=7@LW956/,C,2UQE?O*%0#!' Y!).,@&]
MJ7C'4['XD:;X9B\/3W%C=P>8]\I.V,Y;T!&!MYR0>?ID S[WQ)J=OXO\0PB_
M?[!I8AN)$!B"PQ"!I&S\A8ABH&<G&>,=P")/B=(VCQ73V=E%))="T,CWA\N,
MO'$Z2'Y<[,S(K=-IZ]> #J;_ %@7-IICZ5>1>5>WH@-P",*!N+ 9!&24*<CJ
M: .#M=>\7R:=KDU]JS1-:O%;VS6L4$@EO'RODHQ4@H&:($D9&2"1@X -*Y\4
MS6NMZM96_B=;N>PTV5YH62$A+B,*P("C=MP&#[N,L I!R  :GC'7SI6M:/:0
M>(8K"YGE1FMI?+"R0AP)"=REBQ# *JD$G)Y . "KJ?C:\C\4Z=9+97-E8-%'
M-.TR!)7+W*0@ ,"-JE@7YSAUQCN 9T'C*_7PO?WUWJ@6YM[BUS-!+!<6I224
M*5C=4&3MSD')'RG.#R 3>(?%6I:9JVN_8M66>TAT>ZN(-GE2""YA895L#*]0
MN&W9.<;2.0"67Q:R7_A^1?$,<EK<P@:@D30M]FW6QD25AC*#Y6?>3M 'W<'(
M -KP+JE_JFEW_P#:-R;J6VOY84G'EE7CX:,AH\*WRL 2 .001D4 =30 4 %
M!0 4 % !0 4 % !0 4 % !0 4 4+S0])U"Z2ZO=+L[FXC7:DLT"NZC.< D9
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ML94GJ1Z=!0 UM,L',Q:QMV,W^MS$IW\YYXYY]: 'K8VB+,J6L*K, )0(P X
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MG7B1A=/48P1N<\^O3Z\?KQR 7+/[;L?[;Y&[=\ODYQC'?/?.: +% !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 (2%&20.W- "T % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MA 7)R' YS0!H>'4UNVT;5X8+:2ZTG[3<;3NEAG:,PJ5%LC@\%RP&YNH)SS@
M$-OI<-_HNI6<-I+);SZBB6,X6:-8U>.,.X5VW#8 QYX+>Y( !3UZSE@UBZL=
M&CO(;ZP@V6,\CS.\T@M"$B3 VA.A+NW+EAUP: #[-;RZ?=Q0V^JV^C2S1_9#
M<03NL<OV<[BZ!A)C)Q\N!Y@[G@@%NST<2VUM>7EEJUI<Z?HD=S<2Q%C<23M$
MR[5S\K.@1CC;]YDR.,4 ;'PZB@CMM1:%)[8R2(TEE)%.%MFVXP'E WDXRQ4
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MIU(!'?MK0US3-.%SJ)$LET+FZMX%$,4$GF&'DJ?WB%8P" 0!DM]X9 *%O?\
MB.SU?3[*234[B*#5I;:266S#+<6GV<.)'9(P 1(552,9P?O8. "K;7?B^^DM
M+#49-3M?.-M&9[*!%VJ8I7>5V>)@#N"(R +@J",!]M '0Q6EUK?@ZQEU6.==
M2M2MP!LV.9HR=I*XQR0#@#'/% &-8VWBFYT*0S:WJ\5T-.@OHW-M"'^T.LN^
M'!B *@A/EQN&>O(% &KXDN_%LO@.*Z\-6D7]OS1Q,89 %V9 +X$A !'HW\Z
M&ZT=<G\):)',UU;:Q/<V:70T\$A<LOGY(!VH%WG.<9 Y/< R-2N/%L,-I;65
MS?R2A)XO.-H#EEOH8XG?Y0.8BY., KN8#T %C_X22_\ #:SP:QK<$D6HK:Q[
MK*..6:V:X13*Z/%D%8V8[@%^[DCK0!3N;OQ%>0:Q+:ZGK)@#3000Q01N?/%Y
M)&NQTB!55$)+!B<"09/&2 +>W'BJWFEL'O=:%E9S7*"[@L1)+-"$@,71#N;S
M)"NY5Y59,\@L #>UU=6U&+PO;P3ZE:SW,@-ZUHI01Q^42Q=BI"D-M !()R<
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M227<RADC"L"<ACCD8!Q&YP>?E/% &Y0 4 % !0 4 % !0 4 % !0 4 % !0
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MZE^B@8X!H A'A?5=.\'75FUO"TLNH6DL=I92N\<:)+#O.7P3D(SL, <GODD
MDB^'C6MG<?89UM+E[H>0L<C&*WMA-"<*&!^?RX%(XP&)[<T =5X<T^YTGP[8
MV%Y(DMS!'MDD0G:Y[D9Z9ZX[=* -2@ H * "@ H * "@ H * .?\3^%+'Q&M
MG)+:6C7=K=03)/-"'=4257= >HW!2/3F@#(\3>"[O49X1HQLK* ;5;<I41KL
MN$<JBC#%A<-W&#SSTH U/$UC>:G<:?:"PBN=/^T(UQOPP*_,K*5/5=I.?K0!
MCM\/OL^JQRZ>UE#8"<.+8P8$""2.0&+'W6#+)[?/GC&" 6/"7@R[\/WT4MU?
M17$5I;-:VP2,ABA\I<N<XR$@B7 '8G)S0!E^&_ ,T&@VMQ=6UO!K"W=I<QR.
M 9;>.-8$DCWC)^987!P<'?@]Z -_0_!=CH]WI-\MI9K?6M@;6>XCA >9R(QO
M+8R?N-UY^;ZT =10 4 8R^*-)^WZG:27(A.FJCSR3#9'AL\JQX;!!!QT/'6@
M!O\ PENAO#YEOJ,%QB6*(B.5<J7E\L9R1_%G(Z\'@G H E7Q)IL]O97-E.M]
M;W=PMNDMLZNJL5+9)STP.V3STH DN/$.CVFH&PN-1MXKI0I,3. 1N95'ZLO_
M 'T/44 1/XGTF*YE@ENTC:)V1BQ&,JCNWN,"-LDXZ4 5Y?&.D0RWL3S,C6@8
MG?A ^U&=@"Q&,!&SNP.* -AKR".Q-[)(([=8_-9V/"KC))_"@#'D\8Z3%X?@
MUAG<)-"9DMSM6;"D!QM)'*D@'G@\=2,@&E8:OI^I_P#'C=)<#;NS'R -S+U_
MWD8?\!/I0!=H * "@ H * "@ H * "@ H * ,/5_%>GZ)>R6EXDZR+:M<QD(
M-LNT,3&K$@;\(3M.,CGL< #Y_%>@VWVGSM4@C^ROLFW'[A^;K[?NWYZ#8WH:
M !?%F@M<S6W]J0"6%]DBDXV'<R<YZ#<C+GID8[B@!+GQ3IL&@1:W$[7-A+-'
M"LD>!R\HB!.XC #-R?2@".#QAHTJNS70B1;AX%=B&5RI52P*D@+EU&3CD@'%
M #[;Q=H%Y>I9V^J0O<.5"KR,E@2O)&.=K8^A% %C6M>LM!BMWO"_[^9(5" $
MC<0"Q']U<Y)["@"";Q1IL&O1Z0TA\UD8M(!E$8/$@0G^\3.G';/.,B@#3L[R
MWO[5;FUD$D+DA6 (!P2#^H- $] !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M96VH@X('R@XSS0 X^"+#]X$N[J-714* 1%1B&2'."AR2)23G()4<8R" 11>
M=/M9[B6UU#4(#<6QM75959?+VLH #*>FX$>FU1TR" 7G\,I<:(^D7FHW5Q:/
M-O8,$RT08'R3\O*8&T]"1QF@"B_@.R,]U)%J>HP+<?:%:)&CV*DQ5I$4%#@%
MEW>H+-SS0!JVN@6]C>37%K<7$/G71N7C5EV'*D%,$<*69I"!SO8G/.* -:@
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MRMH[:U@C@MXE"QQ1J%5 .@ ' % $M !0 4 % !0 4 % !0 4 -$:"1I BAV
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M;UIQ;7*2&"=K9\'I(!DK[D>WOZ4 /N;ZVM+62XED_=QQM*=@+L549.%7);Z
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M+"3!.W@' YP<'H0!FB>&1H-C'':S0O>#>KW,L)8LA9F"@;OE 9@< X.#QDY
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M?0_*?RH <\=O')).ZQJ[1A79L#*+D\^PW'\Z #S;7>#OBW'+CD9.!@G\N,T
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M@AD?RYU;:\L F5<''&-P))&,#@YX -)O&C13"WFTJ038E!"R@KNB+>9AB!D
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M&3:&^8Y(8YH ZOP_ILFCZ!9:?-(DDL$>UY$! =N[8/3)R<=LT :5 !0 4 %
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MQ:F&>V;#QNF"O' (^F* *5]/X<T41B_ETRPWHVP3M'%N5=I;&<9 ^7/IQ[4
M7TM[.69+Z.&!Y64;9U4%BI'&&],4 (-/LE1$%G %0;5 C&%'H/2@!C0:=;&*
M%HK:(SS;HT*JOF2@%L@=VPI/KA2>U "&+3'OC;&.V-T!]H*%5W\_+OQU[8S[
M4 6O)C\P2>6N\'(;'(XQ_(4 /H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@#'\4:M>:#X>O-5L[*&\^QQ//+'+<&']VBECM(1LMP, @#GJ* ,>]\4
MWOAW48+;6TM66]DDECDCE*);0(T*DNS#!P9&8G@8 % &S9ZQ+J'A^UU"V@A6
MYO$W6\%Q,8U<D$@;MI/W03PIX[4 <MK'Q'FT:VDDFL+#SHK6>:2!M0*D/%(Z
M%0?+Y#[&V' )(Q@<D %G_A/YH[J"RFT<+>-<_990MSF*-_.2,?/M&0P9F' )
M*[2 2,@%S6?%E[H.J-;7NFV[0S*'M9([LY9?.AB(<% %.9U(P6S@CB@"E8>,
MM4\1Z8[Z5ID=K*MM'.\UQ<#RXRR>8O&W<R,N,-C(R<J"I% '4:'J$VK:'9:A
M/:_99+F(2^3O+;0>1R0#TP>0#Z@4 :% !0 4 % !0 4 % ',ZQ=^(AK":98O
M8V\=XKFWN6#.\6Q 263H<L<=1QSUXH SCXSO[76[/17LX;JZGN/LX*/M)"%/
M-DQCH%?<!['TH G\7^-8O#[F*VO=*\^**626.\NA&=RJC+$.>'8/D9[<T 2O
MK^LQFZ!M]/,<<<=S]H><QQPP.)?GDW?W3&,X/1CTQF@#+TSXC/J5Q:006UI<
MYF-O<SVETLD4;^='&K \95ED)'&0<#G.: +^L>*[S3O$)L4?3([0+)YDUU(\
M?D;(T8NY(V[=TL2]<_./0X ,S2?B4VHWMC:B*QDDN)EA46]SO$Q$TT4K1GC(
M4)%+CKLD[\&@"QK7C'4+?5]4LK;[-;Q:8L]Q)-*K.&CABM9&! YY%RW3^Z/6
M@"_HGBJ_U'7O[,NM.2W55<F8/D,R+%O0#J&5Y".>"%R.^ #K* "@#AG\,:N$
MU6;,<\^L6%Q'=ASMQ*<^2O4@A5=DSZ!2>: (WT'Q7(2C7\JD3-YDBW;@3*7<
MJP /R?*5!48YZ< &@#5U'0;K4=/T-I8(6OX)[9[N1B"2J9+#=C+#).![T <]
M>^%/$D]Q*(PL=G;W32V<,5ZZ&,>5=1KL(YC&)+?Y1@#:^!V(!)<>&_%KNK+<
MI))&L3!IKJ1T,JBX5F R"F]9(LE=N""0!@4 ;VM^'KCQ)I-GIETTEI:^0S3;
M9S(Z3!0(^3]\*27R?XD4T 9]_HGBF[LKN:.^:*[N=+V^4EVZK%>[-NY2. G.
M<#NH.,DT 17&@>)]T)AN9=PNIY&<ZA*#Y;3/L7;NVX$13MP5X([@"V.C^*]+
MUB.Z65[VW3=F*747(8&&!<88$9$B2L#[X_BX -'Q'HVK:IJ!NK8IC3XXYM/B
M:3:LEQORQ?C(&Q0@([22>M &;<>'?$SZG=7]M<)'=Q1L+:66Y<B0BY,B(Z@8
M"&,[#Z=AP#0!TD>D_;=#GT;58VFM@HA$CS%WG4*OSL<#:V[/'/0'O@ %_3M/
MMM*TZWL+-#';6Z!(U+$X ]S0!9H * "@ H * "@ H Q;B+5+;7[B\L[*"XAG
MMH8AON#&5=7D)R-I^7#CGK['L <C<>%_&+Z#+:1:E(+YHG\NX_M*8&,^4ZA/
M]H[BC;C@\G^Z 0#?U_0;ZZU+2)K!2\5I'<([->-'*N]0 5?#$GJ>3V'7L <Y
M+9>);36]*MDMKB&*07$LD=K<2M )'FW*"P50%4,<[L$@?*,T ;&G:1XFT](K
MF3R[F>!)REN=1FV,SNA4-N!W;1YF"<GD#W !;\4Z#JFN2L;.:"WDLH5FT^5^
M0+H/NRPP<+M0+D<XE<8Z4 9L7ACQ*[7TSZA'!>D;K>Y6YD<LRSO*BNN !&58
M(5!('. >#0!U^G12VT!M7BV0VY6*!C,9&DC"KAF)&0<Y'?IG/- %R@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * &R1I+&T<B*Z,"K*PR"#U!% &=>
M7>C7.I1Z)>M;37DL?G+:RJ&)0-D-@]LID>Z^U %Z6V@GD@DEB5W@?S(F89*-
MM*Y'H=K,/H30 V2SM95VR6T3C=NPR \Y)S]<DG\: ([I;&SMI[NXCB2*)3-*
MY0<!?FW'Z8S^% $J""Y6*X"*X*Y1RO.#@]^G0'\!0 JK!N=$6/(4(P ' [ ^
MW)_.@"15"*%4 *!@ =!0 M !0 4 % !0 4 % !0 P11B8RB-1*5"E\<D#H,^
MG)_.@!L=O##+-+'$B23,&D8#!<@  GUX 'X4 9S^)]$34;'3_P"TH'N;XR"W
M2,[P_EKN?D9 PO/)% &HLB.Q574L.H!Z<D?S!_*@"G)=:=IMQAY$BEO)@#U.
MY_+XSZ?)'U.!\M #[G4[*R, N+F./SYO(0EN"^TMMSV.%- #8SIME-=2I)#%
M)<.9IB9 -S*@0L<GLL8'_ : )(M1L9Y_(AO8))L9\M)06Q],T 6: "@#D[7Q
MH[QV4UUIA2*]CF>$6\IF?,9Y!7:.OJ"?? YH 8WQ$T>6P^T69F?S+=IH6:([
M&(B>4*2/]F)^G'RGGID LMXRMI=6CT^T@E9_M7D.\B$(0&D1BK#@D/&RD'![
M]* %N/$-^;76;RSLK8V^FM)&?M$Y0N47+-PI '8#OC/% %1OB!81I8SS121Q
M3HXDC"%G1Q)#&N,<$$SKS_M#W% %RP\;:7?ZO'I:1W45TS^41)%@))MD;82"
M1G$,G3CY>O(R 3^)O$T/AJW@FE@\U'?,I\Q4\J(%0\G/7;N7@<\T 5+CQG;P
M:Z]FMO*]I!#<//,%Y#1/ &P.Z@3$D_[/&: -W3=0CU2Q2\ACD2-V8*)!@G:Q
M7/T.,@]P10!;H * "@ H * "@ H * "@ H * .?\1^*(O#UQ8QM 9EFD7SR&
MP88BZQ^9COAY$X]-Q[8H JW/C2.WU2*W:PND@,\MMN*(QDD4J $P^0"6QR!^
M% #[?Q-?WEEK$]MHTXGLX%E@M)AY<SL5)V,.0#N4@8R#V)!S0!5TSQO]IU"Q
MMIX=R72']XD9C:-_-*!'1SN4\8(YP?;F@">'QW8RPV$IT^^C%W*(B&$>827B
M12^'/!:>/[N[J<]* *TWQ(TVWMY97TW4?W=L+S:%BRUN59Q*/GP1M1SC.[Y#
MQDC(!T6N:H-'TJ2Z""28LL4$1;;YLKL$C3/;+,!GMU[4 8S^-H);33;BQM);
M@7<<,I7*@A9 ^$&3]_,;#'3(P2* -C1-:MM>T];ZT218'",A?;\P:-7!&">S
MX/N#]2 :5 !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!%<VMO>VLEM=0
M1SV\J[7BE0,KCT(/!% '-:?X(L-,LWAM;>SAD^W_ &F-XK=4,<?G+)Y8QT&%
M ]* &>&?#&H>&=#OQ#/:S:G-&! I#+!'LC"1(2/F*C')QG!X P!0!GOX&N;Z
MYGGN9+=!+>1N5="[+''=W,ORD'@NDX3V!8=\4 :'A?P?+HKROJ%S#=DPF !8
MV&\,VZ1GW,02QV\   *!R,8 ,VW^&<%NUKMN(1!#*LC6R1%(G_?22,-JD 8W
MH4Q]TQ]PQ% %W5/ -K<78DTUH-/ADCBCN$BA >;9/%(KE^I8+&Z@GD%\YXH
MZ#P_IC:-H-GISR+*]O'L,B@C>?[W))R>IYZYH TJ "@ H * "@ H * "@ H
M1E#J58 J1@@]#0!S)\%6":=XBL[=+>!=7,FS9;*!;AX$B( '7)3<>F<X]Z '
MZ%X>O=%_M:X^UPS7%V\CPQ^65CBS++* 3DEOGF;)XXP .,D K6/A+?;:O+J%
MK9-J-\98_,9&EC,;\X9-PR,D\9!P>M ")X(\WP3_ ,([J5\EZSS^9/<O!DR
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MH.0F!" 3C)D(YQ0!>T;Q3-?ZO;Z;<VRQ3&*?S=JN0)(IVB&&(QM?8[ $YPM
M'44 % 'F$>@3C29%/ALKJ_\ 9EU%?W;(#+<S&,!2'#$2!R6(!W;< ?+@4 7K
MFZ\:NDJQ?;8YQ/,K%;>'RU41SE/+)R64LL'+#/S'GG"@&E87/B=M;U**:.?[
M,\$S6OG1QA(W60A!E>3E6'4GA>QSD Y2?19[W0IFN?#LNM37&DQ160O!O\NY
MPXF60;@8G+MEI 1WY&T4 =/)<>)I+Z=0VHPP_;&7*6\#*L:K.R["<DAML .X
M=6P#R=H!BVB>-8->M;\6\TL\]O;P7#RI&J2JOVU@6 P5P6A. 01NP=W< L/<
M^.!8B:-KXA7#1AK>#S7YM@5D&, 9:Y^Z =J Y/&0!]W8:A?^$TM);&XEB35Y
M6MQY:R[($DD:(O&Y >/(50H(.TJ01C- %+2=.\6Z5JK+;:?-9V5V8A/'"\+K
M!MM[2/*,^6)4K*O.00N>O- #5A\<BW>]MK2>UU.YM(OM)58#ON1;D D$D;/,
MP#MP0,=!DT ;L3>,!KT3.TYLO/;?&5A">7]HD"\XW?ZG8W7/"]R00"GKGAK6
MK;Q5/JGA^UA<3-%?$R, /M* PE>H(#Q2,<CH4/\ >H 2[TSQ-ID]Q8Z)Y\5N
MMND<%Q!#;;F*6[! =XY&]%'/3<.0.@ 0MXW6UDC*7J7!>YDC*"W>/)FEVHQ=
MMP78T)7&<;3G(XH Z&RN-9A\/W4#V]W=:K;1@))<>4OVB1D#<%=J[59MIX'W
M>_4@'+WFA>)].\.7WA[3X)+VP)N )2T1DG26)SM_>,1@2L<YP<%<9&: -_0[
M?Q#I\J17@>:RBBBCBB4Q9^94#ECQQ&5;&"2P<]<"@#1\-Z GAS39+*.ZFN4:
M9Y0TIR5W'.WZ#M0!L4 % '!^+]!U34/$0NK+3A<+]F@2.4F/$<BW&XGYF!7Y
M"?F )P3@$\4 4[]OB%]B=X#=131FX9M_V01G;%(8MISG87\O[V",'/!) !7F
ME\8SF_G\,%Y;7S;A[>2$6HBF9OM YR 20WDX;Y@?XL_,: -&2S\9R3VQE$MS
M;B5#)%<"V;A+JW=7P !N\O[1@C^XIX;!(!-#9>*+WPOXDL-9BFNY+FP*6R2F
M!=SM&RM'F,KCG')(^]P?0 H:-I'B72FGBAT^>TLKF]$@6T:W$D7[N%=S*6V[
M/DD!P2Q+;MN>* (8M%\5P#1&&G,9],0Q!HYH0%A,4:E(R>0WRG.[(++]X*5V
M@%F[B\?R K%)>QNK3ES$UIM<JCF+RRP)",?+7# $'.>,F@"V;7QG'/AKB\E@
MDBQ)Y;VRNC%K8Y0E<9 :Z'/90,YVF@"/0IO'%M)87.N6]S.7*Q7$*&W\M-RP
M O\ )\W#F8]3PK>JY -#7;77;G78=0L[1S'I4T1MXO,0?:@_RSMRW 5&XS@Y
M4XZC(!D0:;XS&I7.I0QO#?/!:PR-.\&R8J]PKGY,_*HF21<@$A0IR<T =Y8/
M.]MBX@DBDC=HQYC*Q=5) ?Y3_$ &QU&<&@"S0 4 % !0 4 % !0 4 % !0 4
M % !0 4 9NI:UI.B6US=7][!;1Q#?,2>1P.2!R>,4 +9VNE6%U.UH((99]JN
MJ-C.,A0%S@=&' ['TH EO&T^2XMK:[EA\XN)8(W<!F9>X&><4 -.M:4N_.IV
M@V %LSK\N<8SSWR/S% $8N=(T.%;(3P6PCC:18-_S;>22%ZGOTH 6/7](DLQ
M>+J=J+<@-YC2JH&<=<].HZ^M &@K*Z*Z,&5AD$'((H 6@ H * "@ H * "@
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M1XB<$?,C%&'/HRD4 34 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MD!<$D80[E R2N9%7/KD=J -*36=,ACA>34+=4FA:>-C(,/&NW+@]P-R\CU%
M&?#KWA>XN%\J^L3):1I,IW ;$E VLI]&#KR./F&>U  ?&OAE7D4ZY9@Q3>1)
MF4?(^6&&].4;D\<4 7;77=*OK^YL+._@N+RVSYL$<@+I@X(([$'\LCU% &;I
MOBKPOJ/V;4H+RTCN+V((&DVK)A5W^6Q[%0Q.TGCYO>@#1LO$&D:C>M966I6T
M]TBEVA20%U .TDCJ,$@?B/6@#2H * ,5?%NB-9:==K>EH=1NOLEL5A<EY<L"
MN,9&"C9)P!CDT 6)M=LK72H=1NO-@BE$1\N2(B1/,954,G48+ 'TYS0!+J&K
M66EV$U[<S 0PQ^:VWYCM]0!U% #'US38]<_L5[I4U#[-]J$3*1F+=M+;L8Z]
MLYH =I6L6&MZ?;WVGW EM[B/S8B5*%ESC.U@#C\* %MM6LKI+ATF4);NR.SG
M:/E )//;D<^] "WFIVEC:3W$DH80QERB$%F 4M@#N< G'M0 ^.\L[I1Y<\4@
M,K1C# Y=&(8?4%&_[Y/I0!ES^,-%M;ZYLIKB1;FW9U9# _S,D0E8*<88[&!P
M#0!I0ZI936?VH7,:Q!%=B[ ; P!&[TX(ZT -BU>QEMY9S<)%'"[(YE8)M*R-
M'DY[%E8 ]\4 6%N8'G:!)HVE099 P+ >XH @75+)]8DTE;A#?1PB=HL\A"2
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M;\6]P]N^]=OS(<$CU'<'N* &V.M6&HS7T5M.&:QN/LTV> 'PIP/7EL?4$=J
M&:-KVGZYI=E?VLP6.\0/$DA ?E=V",]=I!QZ4 := !0 4 % !0 4 % !0 4
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M$A,XG,.S4+@;)&7$;9P2 &"-C)QMP.IH Z.ST748/">HZ9,\4UR[W9M2\[.
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MC#%@"21M'.#TH MS>++*RU Z;>QRQWR0I(T<2&16RR(0AP"V&E09P,YXY!
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M$<\4R\>QB Z]&- &AH>EC1=&MM/$[3^2"#(R@%B223@=.M &A0 4 % !0 4
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MLQ$2D$Y,8"J3@ ]1UX ->@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M9V*LYCB.<'(Q\_1B ,@#I@$ &Y0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MT0*9SN/=".2<4 =_:7<%]9PW=K*LMO,@DCD7HZD9!'L10!-0 4 % !0 4 %
M!0 4 % !0 4 </XOO]:M[K6DT[S/+CT-YHV61DV2@OAEPIW-P./;WH J7>MZ
M[9ZK/]D23;&+M(TDBEE21A-:K'QG).'D P0.2>QH GU_4-;OCX2?2PX?4(IF
MEC$CPQDFV+H&(Y4;P/?M0!7U#7?$$?F?9&;=87+)"SVDK"ZC$4WRNJD%F+1
M KQEA\IX! +<?B+Q/>:W:VL$%E:P2W302"6UFEDA""9FW$,J<A(L$-CYR><J
M" :OB.[U.^TJWM_#CLMS>Q/-'<8P(T5-RGYO[SF-<=<,QXQ0!A3>(/$>HZW#
M+86DMM%'#(T=M-;2 3;K>.1"Y) ^_P"8@'&"I/J* .MT*_N[ZS,E]$89I"98
MXC T92%F;RPVXGY]H&X<8)Y H U* "@ H * "@ H * "@ H * "@ H * "@
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M6JW-I,LT#$A74Y!P2#^H(H GH * "@ H * "@ H * "@!DLJ00O-(2$C4LQ
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MDIE@-Q^Z<9X H @/@6]E0/<75M-=/9RHTS*^8IY5E\TI@@>6SRYVL#T']U<
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M"V'&W(+9!XP0"UX7\/ZOI6JZE<-#:6J7%XSN0FXR0[Y655(?UD!R0,<KMQC
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M<?JHH PO$O@Z#Q)-YCZA<VC&,1,T&W=M!)XW X.2.<?X@ T+O0H;R.ULW?\
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MRU:-I+&8RHH4L=C+C<H8 Y YP02.HSSB@"[0 4 % !0 4 % !0 4 % !0 4
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MPQ-R>V/8T ;FGW\.IV,=Y;A_)D)V%U*[@"0&&>QQD'N"#WH M4 % !0 4 %
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MXH N6FBV%A('LX6@_>RS%8Y&5&>0Y=F4'#'/J#CMB@"_0 4 % !0 4 % !0
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M12&R<$L,#G&0 O=>\6I>7,4%M(@:[,0)TZ2188_.9492,;]R ,3DA=W.,8H
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MG!R0" #7T/1X=!TJ/3X)I9D5Y)#)-MWNSNSL3M 'WF/0 4 :- !0 4 % !0
M4 4GTN"2'48BS@7Y)E(/(S&L?'IPH_&@#/T3PEIV@WMQ>6[SRW$PV;YG!\M.
M/D4   <#W.!DF@")_"<=W:HFI:E>7%Q]F6VEFCD\HR*"2WW>1N)&<'G8H]<@
M#G\&:/)<VTIA(2!0IA4*J2X8OEP!\WSL6(/!;G&: $TOP5HFE1)&EJ+A(GC>
M$7($@A*%BA0$84@NYW#G+'F@"7_A%=..I1WK&9S'<27(B9@8_,==I)&.>.E
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MN?NOC H ZKP]=WM]HR75_"\$LLLK)')'L=8C(WE!E/(;R]F0>^: -2@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0!3U#5M.TF(2ZC?V]HAS@S2A,XZXSUH
MIVGB33;R8VDSFTN3+)"+>Z 1WV-M+ 9Y4G&#WS0!8.IZ9::0FI+/&MA*%D22
M,95_,.01CKN+9]\T 59/$GAY+SY]1M3<1P&0,"&/E%0Y*D=00%/'^SZB@"Q_
M;^D?8H;W^T(/LLSND<N_Y69 [.,^PC<G_=- $(\5:$7NT_M. -:$B4,<$$,%
M.,_>^8@<9Y8#N,@&C97MMJ-I'=6<Z3029VNAR.#@CV(((([$8H GH * "@ H
M * "@ H * ,Z^US3].O8+*YG*7-P0L,>PG>3G !QC/!ZGM0!G6?C/2I=.-S>
MM)ITT<!N)K6Z0K- @4M\Z]CM4G'L: -/4M4L-"LDFO&:*WW",>7"[A>#U"@X
M  /)X&.: *D_BS0[>XF@DOAYL,;2,J1NV0K*A"X!W-N=!M&22PXY% #8_&/A
M^1$=-3C(<@#Y6!SN*XQC@A@01U!ZXH =<>*]&M;&WO9+B5K6XD>*.2.VED&4
MW;L[5.T#:QR<# )SB@"*3QGH42SDW4I:%@I1+65G?)P"BA<R+P?F4$>] %JW
M\2:1=7Z6-O?)+<OM*HH)R&3>K9QC:5&<].V<\4 :M !0!Y<WCK5[74(H7E@E
MF$Q=HF9$@F@:"YDC9)0"5!\E<AEW KU(- &A+\0YK?4[V&WLEN8E;SOW]R(C
M##Y5H> $.<FY)^8_PGYL8  'V7CR\U>X,,-C;6T<,L EE2^#M\UZ]N0H\O#
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MX%X5;_4QR2AMW88_<X]0YP.": .QH * "@ H * "@ H * "@ H * "@ H *
M"@ H * *FIV":IIL]E([(DHP67J.<T 9&O\ A--<OXKU-2NK&>-%CWP;20%D
M#@KN! ;(QD@C!/% &G::;_9\.GVEE+Y-C9P^2(-@.Y0H"?-U&,?C0!EWWA<R
M:+;V5G>R1S6MK]EAE?\ N[HSDXQS^Z X]30!./"U@MII=K@M#83O.5<!A.SQ
MRHY?/7=YSL?>@#/?P):S2&:;4+IKC?-*LH" I(\T,JL!C'R-;QX!!!YSG- &
M[HVE1Z+IJV4<\T_[R25I9MN]WDD:1B=H Y9CT % %^@ H * "@ H * "@ H
MI7^F0:A<:?-*\BO87'VB+8V,ML=,'U&V1J ,36/ FEZWJ[ZA=37($N!-#&X5
M90(WCVDXW;2LC @$9X]* -R:Q>>XG9[J06\T'DF  8!R?G!QG.#CTXH P8_
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M)(0L4\R-U((DC(4')&<J,8H RK?PQXJM+F^%M=K%;W,LDP5;QP$9KFY<E1C
MRDT1.,9*>HH 5/#'B\K"[ZFIG6!</+</(8;CR)(RZ] 5W.&P5!/(R1@  NV&
MB>(+&2"]VR32V]LVRUDU>9XS,S\EC@!QM)(W X.,8Z@ N>)=#UC5M06[L9H8
M)M.5)=.9I"%:8DB3S,*2%V +QV=O; !0A\,^)&&H2/J(@O697MKE;N1]S)/+
M(JNF /+*RA2H) QP.!0!UFEP3VELUG)'M@MBL5NYF,CR1A%PSDC.[.X=^F<\
MT 7J "@ H * "@ H * "@ H * "@#F==T35;W7K._P!.E@M_),(:4RL&9!(3
M(K1X*R K@+G!5B2#0!SNF^ =7M+:PM3<6EO%!IS6<KV\LA9F\N((P!&!B2(O
M_P #/J2P!N:KX3N=2\-V&DM=*7%SY]Y-N9=Q;>9"@YX+OPIXV\4 9ESX4\47
MAD>?4;0S-:B-9(I98A%(@D4;4'&UUD^89^4CC=M7 !%>>"]>FANA;2V5LUQ:
MW40"7$N(GE-RP(^7& TL7("GY2>=JB@#IWLM870+S3K3[-;2 B&TD65SLA(4
M%LD$AUR^!R/E7D9. #G)? ^K6_G65C=0OI.+I(()IG4Q"=$.[Y5P2KB0 ?W9
M2,C&" ;^E:%>:-J,[P31SVLUP=JS,V^" AW(4\Y/FN>#CY,#/RB@#H: "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H 0@$8(![\T +0 4 % !0 4 %
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MJ3G&/O1L/<C ZC(!/:>(])O;N*UMKL232YV@(V#B-),9Q@'9*C8[@^QP :M
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M::>5]-AD:<!9 XW!@'\P#!X WDMCU)- &G#;Q0>9Y2!?,<NV.['J: )* "@
MH * "@ H * "@"M-I]G<R&2>TAE?Y.70-]UMR]?1N1Z$9H KV^@:1:N'@TRU
MC8$$%8E&"'9P1QQ\TCGZL: &IX<T., )H]BH4$*!;IA0=N0..!\B_P#?(]*
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M9I[VXMVL;=H!&(A&8E*A!T7&,8&!Q0!:H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M6.,4 =KI!O%LQ#?F5[F+ DF=5 =B QV[>PSMZ#IWZT :% !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
K 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g558803dsp050.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g558803dsp050.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MH TDOK20PA+J%O/R8ML@/F8Z[?7'M0 ^&>&X0O!*DJ@E248$ CJ.* )* "@
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MI-021T!4.'PV/4<-B@"R?!GAC2OC+X<T;P[I1LIK.%]2NYO->3<OW40;F/\
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M7"$-\K/RQX//3)YZYH I7AC\0:5KMG;@S^(O$TFGQ2Z?;6LB_P!G)$%)#DJ
M,!?8<9&0* /HR@#RGQIHD'A'0_'?B6[MK75+35);23[#(A0 JZK\S \\MN_#
MWH P5\+SQ^._&$O@S3!I9TG2#9P! 5,T\@+;E/KC('/4+TS0!GZ3IMG&O@M/
M".GW=MXM@N(_[8<PR*8X\8F\[< ,%CT].G:@#;T_2-'U3XC>)=*\-0O9:?J?
MAZ:">7[-(D:W!EV$@,!G <'C@T >A6/AW2]$\&V]MJUM;W'V'2OL5S.EN2SP
MJGSJ, L0<9VCJ>V: /+/AYHVF:CXRNM'U&2[U'3=.M'@TEIK5XXY()"6=7+
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M5>#DD@# !)S@4 :&DZ[IFL^='87@N)+?:)E*E70G. P(&"<9QB@#3H * "@
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M3C .: *NB:KXDLM*\.Z+K-_>WJ:TUC>Z=J"3NLG+QM/;R,""<1F0C)Y'J<
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MTI=+NK1)K%55/)DRRD 8 .>OXT 5+?PCX?M;B":#2;=&MVWP@+\L)]47HOX
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
< !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g558803dsp051.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g558803dsp051.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M=/89Z' YH V[33K#Q+\4Q?>&],N+*R_L^Y34;M[-X \TI/!# %V!;)^G7C@
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M[86>HP""^M(+J$,&"31AUR.AP>] $=EI6G:;$T5C8V]LC@!Q%&%W8]<=?QH
MBM-!TFQNA<VNFVT,P!"LD8!0'J%_N@]P,9H B/A?P^;6>U.A:=]GN)!+-%]D
M39(X_B88P3[F@ ;POX?:9IFT+3C*R!"YM4W%1C SCH,#CVH MVNEZ?8R;[.P
MMK=_+6+=%$J'8HPJ\#H!T'04 .73K%+)[);.!;1]VZ 1@(VXDME>AR22?4DT
M 9P\'^&%C,8\.:4(R=Q7[%'@GKG&* )KCPUH-W=RW=SHFGS7,PQ)+):HSN.G
M)(R: +@L;006\ M81#;E3"GEC;'M&%VCM@=,=* ([C2M.N[V"]N;"VFN[?\
MU,TD*L\?^ZQ&1^% #8]&TN'4WU*+3;1+^08>Y6!1*P]"V,F@"&T\-Z)8.&M-
M(LX"JE5$<*J$!&"% &!GOCKWH 9_PBOAW[ EA_8.F_8XY/-2#[)'Y:OC&X+C
M ..] %JWTC3+34)[^VTZUAO;CB:XCA59)/\ >8#)_&@"&Z\.Z'?7XO[O1K"X
MO0 !/+;(T@ Z?,1F@":TTC3+"[N+NSTZUM[FX_UTL4*H\G^\0,G\: '7VE:=
MJBQKJ%A;78C.Y!/$K[3ZC(XH (-*TZUM9;6WL+:&WESYD4<2JCY&#D 8/'%
M#+?1=+M3(8-/MXS(GEMB,<I_<_W?;I0!/96-IIMI':6-K#:VT>0D,,81%R<\
M <#DF@">@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g558803g0327082700035.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g558803g0327082700035.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "% )0# 2(  A$! Q$!_\0
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MO^J;_<7^5>1'%5,,^>&_F=N/H1G3LSTNUU.VO)3'"S%@,\BKE<KX;_Y"+?\
M7(_S%=57TV68F>)H>TJ;W/EL13C3GRQ"BBBO0, HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
3!1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g558803g21e62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g558803g21e62.jpg
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M<71U@9&7L[37)"<S-38XDJ&UPCE24U=F=WB6LK;$T?_$ !T!  (" P$! 0
M           '!@@#! 4! @G_Q !;$0 " 00  P0$ P\/"0<%   ! @, ! 41
M!A(A!Q,Q010B46$C,G$(%1<S-#5"4E5R<X&1H=06)%1B='6"DY2QLK.TPM$E
M1%.2E:+!TM4F-D-D96;P18.UX?'_V@ , P$  A$#$0 _ '^.%%+)_% 9)D=7
MTM=/]%5W=G7T.2;ML&Y'5!&3C!WOT5A-J151VL,,C&'#@SSDD0#$I) TIT1/
MI^O!#(QL]DD43Y?)2/&K218]>Z=E!:/GN$#\A(VI8  D:.MC>B:@':"\BX^R
M1794DNV[Q02 _+$Q7F \0I)(!Z;T=; TD'Q_TIJZRZ#+V^QWK;Z1['&[>QI+
M1W4EI*O:;6&3A$.#M=D8W6V(,LD$D:R@V0!1(%B'*KA3@22 RXI1YI8W<;B.
M..7 9I)461/G5?MRNH8<R6LKJP!!TR,H9&'56 92" :Z6'=X\MC6C9D;T^T
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M#<?!R/%]L7M^+4-*E:!#<7%9N3'*^QL6#)&AA85%5#33H]\((\:MC:R8>R3
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MAA4KIR2RR9W/F()(F>^:>>9[Y9I7NDD<Y[E57VJJJA5 55 554 *J@:  '0
M#H .@'04J2222222222=DD]223U))\37C<]KRCA11PHKY:YS7(YJJUS51S7-
M54<UR+W145/=%1?=%3W1?=.%%?"KW]U]U7W55^_A11PHHX44^QE7PT_A\Y)D
M5U>@Y;U+X:+;V1EC!C.+; U[^#U'&7.^=*RF;DFI,CNF5HB/]$1EE=613(&,
M9(7*Y%>M<X>U;B6**.-H,3.414,TUM<][)R@#GD[J]BCYFUMN2-%WX**<4G
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M"6ZQL.<A0>D8YEANB!ZTEE,_*A.MD^CW#J5\@D\S$Z45/N!,JT%[)BY6^!O
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M<H[LQG1 +>L5&@6WP.(^*;7.645LEE+#)'<+,LLDB-R@)(C*H5=GGYQO9 Z
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M'<?(33\/*XTY*.%%'"BCA159/XM%#5XYXDG6/75#(HQ)]TY#>RMA1$9])Y1
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MXBAU7B;G,D3U(TM[0W)[Z%[?+$;4'TA34<WTWK!\W<"6Y$*G:VZE3^$?1?\
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M7.;])VPJBYR/'^G[&ZJZUUL^1LY U/B=M:?1@>JLA.D16J56RJ0?@*+*^?\
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MHT&2TC^U-EU5'Y%!MX%*&C?2V=,:;:OA?B*VXEQ<5]#RQW":BOK8'9M[D#;
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5-VP^I(?O:W-S1K<HX44<**.%%?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g558803g83b10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g558803g83b10.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!)@)> P$1  (1 0,1 ?_$ )0  0 " P$! 0$!
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MA*7N3TD0'&J+)FY"C3A:[M8:L]Y7 'QR8Z\HZ#0\I[5ZO*,8Y'((V1P(>>?
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MA"X7E3%U(2T&T^55 T=E77^@NJ 08$=R^=S[ %:_)R7Y:#IKYV<5_P 2\?\
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MB0XM2E5I5)83DZE,H)$,D].>2.PP#!>X1!O:]KWM>@]% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MH.>2#B),0.*_*LA]CWB&B(4</* 0RT0!I[D8602C4>R62GR\D41"W_Y$F&J
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MO?E,4*"P6Y1"M:@W+VHL=[C/$_\ 09RE0/:BQWN,\3_T&<I4#VHL=[C/$_\
M09RE0/:BQWN,\3_T&<I4#VHL=[C/$_\ 09RE0/:BQWN,\3_T&<I4#VHL=[C/
M$_\ 09RE0::S\8C$<@F4SQXQZB\2%UG..DL66SN)H=*\E*'Z)))NE<EL04O[
M<6,2EM)DB1G5&(Q&!#8\"<RX>6P;T&Y>U%CO<9XG_H,Y2H'M18[W&>)_Z#.4
MJ![46.]QGB?^@SE*@>U%CO<9XG_H,Y2H'M18[W&>)_Z#.4J![46.]QGB?^@S
ME*@UN9<7C%N.8A*LA9#U"XD<&@$$C;Y,IS-9/I-E%MC</A\7;%3W)I3(7$01
MA0,<?94)ZM6=>U[%)R1BY+\E!U3:75 ^-38]M1_6FQX;T3JW*>B.(ZP@<$Q:
MM&?T*@LE03TR<X(N:8 (P\O(*UK\MJ#(4"@4"@4"@KWM/DV7X@P;+9W 0QN\
MQ2.D!C\?-E[2YOT91.$ZR+$X(!T>6-ED$3='E&TER42FZ4AS0#47*L7TY7.N
M.P1\HB>^2-.>K5[.Z=)4J4DU0I4J-(\R$)TZ<@ C3CSSC>(6$LDDDL-Q"$*]
M@A#:][WY*#SML>WG>4*=S9]I],G5M5A$-*X-NE.8%R%2 !@RAB3JTO$--(."
M$T @WN$5[6%:]ORVH/B!FW?,<CV4O:[2PQX2]7ZTT@TNRZ-R3=;3G*TO3H \
M0ZZHGK*5.887S@6YY98A6Y;!O>P93Q*WZ[RVH'H/9G_$)H'B5OUWEM0/0>S/
M^(30>?Q5WOZ/INT_IQT/6.J=+V)<Q]'UKK74>K<_VA?-ZQU[]#S.7G=+^9R<
M[W*"*-A)%OU@? 6<,X^?C4"5>9G#^2\K^*_8SS.Q^,GF[A;U+_ /AOM\/'@?
MPQX'ZOUKJBKJ_2=)T)O-Y@@Z/4"@4"@4"@Y@<%+^4?PY?J@8/_R2UT'3^@4"
M@4"@4"@4',#A=?X=WF_N?[S?*E0=/Z!0*!0*!0*#F W?SH9C_; QK]JW*]!T
M_H% H% H% H%!27;I]=D:R&,\7V%9<(2QU97Y%&_#)[X%N!*G";8M#$IP^I&
MDE0UNC*RK$*IBNWOG1,R\<FOTHC!D!3G!7-9C'95%FK(V2X]N5KZ-Z>6T+3#
M@2V+8_>Y)'H(VJH\&0M'A,B/('V/QE2").;B>UH50FXM^*"K4W47*/"(+9:]
M2[(9DXRU!,K9?A^19"T/!#A&6J.Q\EA,9&%:E0RM0C(5)FMO22-&RQS(<9(&
M:$Q0K3V.(-5<WKJ<P\+:4"@4"@4"@4"@4"@Y@<9+^7AF+_K_ %;^UI@R@Z?T
M"@4"@4"@4',#6;^9_P 4C_H#A]_)_G*@Z?T"@4"@4"@H!Q8OY67$L^H!N1]G
M7(U!;_$W[J\:?Z?PW_+C;02!0*!0*!0*"G^]_P!&:4?Z@8 ^T+BR@N!04V;=
M*84S)DR-JRWL,@2)8KCN#E-Y&4!69"XACF"-\#2L"6,C91Q=M2R=.UD.3N8D
M1)U*AV#<\HP@ AE""GVPT'UBQCD2&,>2)UL^T9!8Y/B:<M.>6"2&NLB:W638
M-GF'""W!]%&G5I(,FK%JD V0F#0EKW%U6E*.GLA*/+2A65KROI<T2=@)==D-
MZ6-.\L*YN1+W"7*WE.N$RYEF$>?8TOCC7 W%[3"N.!JH\<<>E3W71DU*!((\
M)I"VP7!Q+@3!&R<1D[="-K-RY.6R8\>L.2!U>\HFHW8;9D2&R=A=94:6X0H$
M=D4S<4DD6C+D(DRM0!Q0$GD&6L22,83HS:"PQG<X6L\^NR[HU0;)Z7*S9$73
M($8,B;B\HIP'("1A?VM' 41KO$$+ZE162(##K60DMR?JHR3 C,,#<.(3] 7>
M'ZH&RWR,36@M_0*"NN8]CF?$$W@&."\:Y:RE-<C17(TV9&'%4>8'I0BBV+7?
M&C%+'=Z42.5Q1"B))=LMLA)  &FFG"/'>P;!+%>@TGM82/N>;@? K%?SR4#M
M82/N>;@? K%?SR4#M82/N>;@? K%?SR4%).&Q.LPZP:!:>Z[Y4TTVL29(POK
MYC+'$X3,D<Q.\M!$FBT90M;L4VNI.82RG!&!60*P#@AM88?=M:@NWVL)'W/-
MP/@5BOYY*!VL)'W/-P/@5BOYY*#,0;:IMEN3HSB:086SQBB2S*/RZ1197DZ+
M1-M8WI+!Q,'C$D3.$9G4K,*<$A<E2F! <44$P A<T5[AO:@M104M;]T$DA4R
MB\)UKVBGK'%LA9-QF=+(O"H *..TEQ'D23XLFMV0U[R@RN:IM13.'+TQ1QJ4
MGIP$V,"'F"#>X9+M82/N>;@? K%?SR4#M82/N>;@? K%?SR4#M82/N>;@? K
M%?SR4%)-()UF' [1L\BR!IIM8G/RKNWL]G:)6:XYB=S"= ,JSGP]$E"\1>80
M61.AS?[IZ:_*(@?YM[WH+M]K"1]SS<#X%8K^>2@=K"1]SS<#X%8K^>2@=K"1
M]SS<#X%8K^>2@S#+MSCQ=B783+\BC&2,?-6KWC;YY(M-HXWI9M'?$[$<5SDX
M]6:F-]?VYVZYC::-JY+U=8/I1*.B%S# C"$,/VL)'W/-P/@5BOYY*!VL)'W/
M-P/@5BOYY*!VL)'W/-P/@5BOYY*"DB.=9A)XCTBV:'IIM9YK7+22&8)2JK1S
M$]WJ\_9,[SS("].-G\\/3 :PQV0)A!4\[FB-N(')RAY:"[?:PD?<\W ^!6*_
MGDH':PD?<\W ^!6*_GDH':PD?<\W ^!6*_GDH+"8LR/&<Q8QQSER%FK#X=E.
M!Q#(\3.<4@T#@=&9O'V^3,)JY"8(8T2PQK<RKFDBO>Y8[W#>]^2@WR@U>;R]
MFQ["Y?/I&-05'H/%W^7OQB0@2I46S1II5O3H-,E#<(E*@"%$.X"[7M<8N2W^
MV@JRV;A.KRVM[PV:B;?*VUU0I')O5 A&+P 4H5R<M4D4! ;F(!H0G$&A%:P@
MV%:U_=M:]![NUA(^YYN!\"L5_/)017D'(D1RH]P619 T0VXDKOC22-4P@ZA7
M&H(G*8).QN[:_,[X0A09U2(%3@VNK0082-04=S+6&"WZ,TT(PI)',=QV%;!M
MC-$^&)G1MU:#K L@R]S$U,2O)9.1VQXC4-B\42*U^R:E0&!@PX0L*.'8'3B6
MD)Q7.YX WH+KPB?0S&\A<95"-#-M(\^NK.SL"Y:DB\"- :SL$<B,1:$($2O.
MBA F+11R!M"0-RB@#$6A!<5[BN,0@ECM82/N>;@? K%?SR4#M82/N>;@? K%
M?SR4%A,69'C.8L8XYRY"S5A\.RG XAD>)G.*0:!P.C,WC[?)F$U<A,$,:)88
MUN95S217O<L=[AO>_)0;Y0*!0*"I<AVU;VW(&1\>1/!6PF5E^*)(SPZ;/N.(
MG#5T9;)4]X^A.4$S$4ODN08NL6+"(9D1G5'"+3"(!=78NQ@A@'8(>/M82/N>
M;@? K%?SR4#M82/N>;@? K%?SR4%).(I.LP[*ZBY#PWC#33:Q5-9)*\'.[80
M\QS$[0W"1P+/F,,AR 1S@;F$PLDPN-Q56(H-[7Z4ZP06Y+BM>@NWVL)'W/-P
M/@5BOYY*!VL)'W/-P/@5BOYY*!VL)'W/-P/@5BOYY*#Q@W;@26*9@D<GQIFR
M$.F%/-UXTP.4Q%@*F[GYV'83# ?%A$SS!Y973Q@>BQ)@=(O3]$8&]S>8#D%<
M/9VL)'W/-P/@5BOYY*!VL)'W/-P/@5BOYY*!VL)'W/-P/@5BOYY*"DF%IUF&
M#;M[PYV?M--K"X!GF*:F-&/U"6.8G4NBA9A^)Y/9YF%U;0YA"8V%D+94DLG$
M(0NL!$*]N3FWH+M]K"1]SS<#X%8K^>2@=K"1]SS<#X%8K^>2@UN9;P$8\B$J
MR!.M6=M(M"(-&WR8S&3.,%QP<WQV*QEL5/4A?5Q+;EI>XFHVAH1'*#0IR#CQ
M +O8!8Q<@;A(61=I&R"96=<.,N',Y98F$?Q[!LF2(6+8Q%75G88UD>29*BT0
MLX.,FF\3Y7)S=,2O?Z$@!W1%)P"&(/2 M<,#VL)'W/-P/@5BOYY*!VL)'W/-
MP/@5BOYY*"J&^>4LJ[!Z-;G8$QSIKM@IR%F_5#8K$,$3NT8Q0UM2B99*Q!,(
M9&"7-S-S$84W-YKV]$!./$&X22[W'>U[6H+!P+9B7QZ#0M@<=.MO N#'$XZS
MKPDPW%9I05K8SHT2JQ1MLQVL878\@7-%_MM[M!MG:PD?<\W ^!6*_GDH':PD
M?<\W ^!6*_GDH#'M^A>W*=1J^OVR#3/(-#XG/!8\=X?"")9*HO+I8X0Y(XQ$
M*;(ZQA7^#')I5&K2U*Y(84F($,%C+W"$07 H% H*?[W_ $9I1_J!@#[0N+*"
MP63&R</$04H,=NR%FDXWJ(*.LN*LUN3*XZAE[$OFS'9U3LT@5LRJ2PI,X-R=
M<0D-4(3U0#RK@,+"8$*INS=Q#D1"%.R/VN3I>\B:D-ESB3*3W F+W1R(#B\R
M2Q#+%VYR=BUQ+&,86Q.A+&7=U"40"ZM )I#6)/%>)VYPU*W,V1M3FN8*9"H&
M]/*%MR,W-A42"DCZU"@CZ5;'),L1/1CP0Y(5IYYA_2M2@HU+=$M!8P 2H@B^
MY3H<Q-<]DFLKU$'!V0^<MJ(A<X5W>H<[==33&',:)S=+MX24[>46! I7]9ZW
M9P, K*L%%:[B&#A.,=LXK$89$RIWBEL+B.0L8*U!S:E5'-K[B*%8^Q[#YA D
M,>002+(88NR!(6E]?RCTPU93&>J(1E@5)[B$2&IMN/-]$^6;RIYRQ"7;$8YM
ME%R7X\;EB=CE143>L=,D7A;7%G$W'#NUW"QSAJ5/S>E<UHCB+KA 6.*DL84J
M(-FW=+DY/#<V[)FREG63(K2#/I<M5QXE4G8%4G!@:6!?E+&0NO=:0SGNMC1)
M@'?I0DW#8?YUKT%WZ!05 FOT^M:?J@;P_+/P]J"W] H*,1_B#8(=$CZI>"YI
M'3&&/PN4*4OBNOE)HFO(406SJ+M@APH,A))FA4=8GD;JRW%=:T78%YI]NI!2
MK%08^8<0W#\4A\6FX(ODAW:)JHDY,6;DD< 3+7\$+R.]8XE!C-##UEI,Y*&@
M]D$YG(BDPG(AM/)N>G)/'<@(7+@<N0S^$Q&=-A!B9MF,;99.WICCT:E0F0OK
M>G<TB=6<WGJT UA!"D(3N@..)L;85@&&!M8=PVR@J!E7Z9.H7_0&T_\ R&&J
M"W]!332)Q;RL3RMI,7(RW1;MGQ%W%&VC4D@<%;>U\0#89,Y+DR,0[*#T;<H=
MTA9YH W 2-42$=[7,!806'RXBFSEB[(*#&LF+AN154/?R8')SP,AJ5FF0VU1
M:,JUI<B9)(RC;_#70A46/0J0W($+D!<7-O8(%*<MY4R^)=+&]<7%G.E440S4
MJSS.DSVVPPA^))G3^P.%B0-C_(ED<).,9T9J)K3V4&DB4F%VZ5.6$)R=RWPQ
M4G021/E_7'(Q$S<CFMJCN836O&+"QKWLYVO$D$6D\/;T2Z:KAG$-Q0BC0EFJ
MDZX\10!')B@J@V]0[\31(I9^JQ/3A^2JD<:$]V.<\L10QF7&.Q5Y:6C."XS'
MPVG3L81@07N2DN)4((S/S W+$'JF"WB.K$28J',^KS2:;+F\M4K6GSE6Y$0D
MG(<8<5:LM*<X'-('Y=B*SJ@-3\]04GE BKE'&MX.M&!]L43G;689!@#',GG6
MB\;B*APOFXO%,R5R24*W)# GN+JX]X)=$:@QE1H<V%GF7%:R)6) W).E$G/-
M<6D@+GE2>-'DHU!,A8SD[BH3I&\\IV0&$KE2L]6F2ID9H%%P*E"E2@/++ "X
MA#&28&UKW *U@Y.YS^C;QZ?_ 'A_[3VJ=!U^H*N9VW"PGKJL>FS(SH^%N['"
MVR=*&IE853FK5,[\XR9CCI2$=Q)T1RQ\D<5/;@7$:!.C4'IQ+34I!X#J"%5/
M$YU=(BALJ)>)4X$MY.-%3XD11!_Z1F19+DID=1+U!BU"BL8A9@MKFL5FV#8%
MD[=S;7N<M;BE@;0P\1?563R+',;8ID_."K+$J40J#+BH1*@M3M)DLL+A9S<<
MM,; 6; V>CRN8>I"4F-(- :68( K7H/+)>(EKY#);XCRL^4,\H<9 ]1R,-'@
M(YP6/2]F>11RQ+F4V"6"A2AS>BQ!3E//4AV($"Y_0J J4R8-ZP5N-C;8.5G1
M2$,TR3FIT,M6&.CZQG-;2,R&,V#71Y2H5YU^JO @'YT1I@&HAJ$X[H#C@F73
MG(SE(6UH*@</;Z NCWU0-:?D8A5!;^@HOL-L7@J=8VWJP!$LKP=[S?A+ >0@
MY5Q.D?D89]"B)=@X4WC+D[1@\9+K=C>HS*T"@AP)*-0C$?<GI>G+-+ %J,3?
MNKQI_I_#?\N-M!HN7]C<<X+?(PV9&/=FEKDT9FTF\9TK2N=F9E30EU@+,<G?
M/!9*M:@$\N.0T1",X175Q*>0D8P&&DA&$+'<0O7$45:IHU/$D>X^LRG'\.NI
MR",.EE\?G$IB$@E[&VK6Q440K6EJBF0I(8>CLH2IEBRQ1QH!I5P4H8=)Q+=5
M%+:L=C9%,&Y ULCY)WI6XP*2$(&>-1JS8-_>U+P!(:R+$[.0\)S%)*-2J6$@
M'>XR;7".P0\L8XFFK,M630AH?)<8FA;C&F@]4;"9 48\.,E=TD9():$(D?7!
MA22]S3M)@3PDJ.GZ=7T/@I*<XA"9M?=O,+[/R#(K)AMZ<)(EQDWP-5(7Q0SN
M3*@&LGQ4G5-[6B3O*9"YGJ&]%&ND4F=!8@(U 2;#N<4H 4%GZ"H'#V^@+H]]
M4#6GY&(501QLXLQO#,JQY;D3)V4D1V9 XHQ_%88G9DC_ (S1O45S3#Y)'45F
M).2TN,A73^2J0MCPV)#E[PZLBA2#D+2IR1)@J&3%-<G%YQZ..\23(5O,FRRH
M2@,:F#\,LZ*RB1II#X, O8'8EE9X2DC+,@:T!*0F]KHBT@R3N8<F (+-:\MK
MB#.3 UVVPS!F,,9@[I=>3)@I"X3D<I)&8%-;R)O(9G ]I&H3-&S<:5&*[IT=
MC @2)TH3RDQ]TH>)=LIQ-2%JPE#PPH$N1$JE!2-:/?R I!K$I9HP)U0D@\(&
MC2B4%6L.Y=Q"N"]^2][\G+09SA]RO+4UD>^<AS=B-MP=D17N2P%.V.6G)+;E
MI$T)4NB^DZ=J5%SAIC\70N0G9N++4B+"C+NF$9<J]QW#<5PNKE"=FXZC*20$
M-!;X:NFF.82G0FN0FDNSADN?QK'+.K.6 ;G00$:%ZE28U3S21CLE 8( 1F!"
M6,(*CN\>NDH58_1MLGD12C)ZIO)AQ+I 9NT'KD;S,;8[C[RL2N3"F5M#+(YW
M>[6A/5%DV/.+--Y+)B3CRPC&/\1["QCHR->0V.<8L%,6/%<A@"^1QYR4MLX;
MLN,S[(6/P$:B1=<-,9&B,.@W0ZY'@\LQJ5V2JE90$YRD-BQOQ%]5<J.$<:HO
M,GX+C+),EB;$C=H1*FT]:ZJW6-1\H5RS6P0B$()%-F5"8>9S0%'.J<8^:1TI
MQ09C'FZD(R)'X?(FZ*R)(BFDN8(6V7.4M-[@>I)%X)D%(0:2<J2K^:U8ZE#P
MZN1]B.I)K0YY 6H4  A/6A<V@X_[-?XQWE__ %L?+LYT'7I04,].>24H.1F'
M$FE%JTX4XE"49@!  H("K(5)1'$"OS@V-*,+N*UN<$5N6UPI S>T(8(<@0*"
M]=IS)FN.PYL&ZREQD[6Y220WBK>IF\I>UL08H_&T))4L(5)4;:@94Q9Q"DHV
MYY-B!V4!K.0E6ZC).R'2%Y@P8<Y/4WCCC']<9^!C8T#EC8&%6%EF2=OF38A-
MR :X)\Z77+D@P%+.8G&4$PX9'_!4'M(>.)N F(*E$2TY4G*(>XCG;*6XY6;[
M-L["^2XAM)C$CN[.MG.+^+Q3(H%=2V)U)RDQ45<2<-P&%!E75UXC2@I6%GB^
MJ3=TJ%26D,6.F1URQ*XK6YW)0FF  I(1&)61[$A-47_.$L0A.N666>(!(0\,
M=,XC!Q6/VJ5HM=TI0LQN:G),I87-_L\$X3;LN*W6/-T::5[2O9U,KD&' H6Y
MT$:639.YFN 4IH>@0N*L-XXA/T!=X?J@;+?(Q-:!"OI];+?5 T>^6?B$T$RY
MA:\M.;$R"PW(FU@DS=)D+BO)>[-H6*0,:9&X741]Y4K(M*W!"VN+A=-8\YN*
M)<"R;#N2:$7YH@KZ_3C;J+":G&>'ZOPJ N/C4DD4K62E_CCW$5"J#.9F/2FC
MQG4.42?G0W(:E"0X74&DDEH4BH1)"D1A%!'Q2?B1P2.O"5EFVN6=G-9(E;@"
M69.1*\?$P5@\1L5*$K0-HQJG;T,@0AD1\J47-/-3++%@0CN;=.MZ-L"5D[MM
M^-LRBP2QWP PS<QO8I!K^HBUGA 3(QL#BUCF,=R&TRQZE*TAG>G5S;F7PDU$
MC,2$.HC;6*5W26&$9O!7$440-L:L;377.2R-OR88F>YW)1*U"ESA$<E1Y#RQ
MA%%V)!&6^6'*F=4T.EK,=KMR6]NAYSB8:)L"ZN-#\EJ(FG'EM%$4,U"Y/A*H
MJ$&.8X^<UIWE<0P+2 .QZM:E5.#(60<>2(XZQ)I@@V'?DY+!7YN^GU,?J@8U
M^6?*]!;^@4"@C?+F*HGFS'L@QE. O'BU)/!(UAL??'*-OB16Q/C;)&9P:7YG
M/2N36X-KVT)U!1I)@1!&7;\MN6UP@CL;QW^/FW_I/92_;- [&\=_CYM_Z3V4
MOVS0.QO'?X^;?^D]E+]LT%&L48ED4JXA&Z& 'K9+;51C##>NVC>0H"S%[$Y!
M3K&N4YND^Y#9D1:I>"' #HYDNR/#["$HE0:84DNE'<D(+G&\X+R]C>._Q\V_
M])[*7[9H'8WCO\?-O_2>RE^V:#6YEH1C?(40E4!FF8]LY%#IQ&WR(2R/N&SF
M51M[[&9*V*F5^9EP"WLLP2-S:UII!M@B#>X!WY+V_+07CH%!4":_3ZUI^J!O
M#\L_#VH+?T'.P^"<1L*1Y&T9/P8-P4-:Y.F!*C9,)O4O;TM1F.:Q"DCL++71
M1CC0;K@, >ONBQ2ENC$NZ T"@D0>Q' N(VO@Z9HDV8< )YBE:YJE*DD19Y,U
MA4+EN%L@Q>&.$A)<(JO1O2Q%E]PCK\I$WI&%,2G2K0 2J C3)BPUF2LW%#B:
M]<7"9!KED!F<3V=K:U;Z5)+/J)Y$U)DCI/9(W*+P]I9H,K?D@UZE@:%3JXMZ
M%3U!&<K.MX2"&\,\9XC+:-Z+/G>LSJC+=LF.L9N]$SI<Y*4[G-79SQC'Y0K:
MHC'$O@EFARQ,B<C$"<A3UA-<9(A@'R!"X>.D\P28^@B7(2I*NGR:&QA/.%R&
MQ042R8$LB$N2JD=B %DV2J'H)XR[ "$/,O;DM:WN4%<LJ_3)U"_Z VG_ .0P
MU06_H.9F ]=\<YVPX_'3PI\&<Q[/\3:-MIK*\GM!B=#,^(+FM>ZG!&0 0K."
M=="F\Y(?:]AICB>>#\[DO8);OH#KX)P4.!A$\.ZPX-;GU%3/'Q6VD*69G6L[
M:4E1*C#BD[6FLMZUU /_   UQ=E R1&#.N:$52+0+63#N*YX_)6[++JQQ"(R
M^8&QY'D)[6K#[LL6<E B8VD,"80V/0R"1=6&E++&8L"G,-Z4:5)<@*FH!:L!
MA*S5*8X*V'B<0;Y(UJD3LQ.J:4(&(4S9H_A8MM%D=2%H38Y,ZDO1)',3(=8#
M G/5!<U[?<M^2)@BB/L6D^;Y ZEP\[<-@8E..&-_0M3:P!1&,BF3XQQFQ-<D
M$ZW?'5>:C?(UKXB.);PI2FISE[H[%EC5/TC&D5!<O!N,-9,R3>!N4<A.Q<:7
M-K7DK(C"9D%P=(H2UN"B=Q&2S!F=8P0:8U%EK7O)H!,R;D$C0-!!:9G E:&N
M/V3!;I?I7@E?/X;E 33(DTX@\VETZ;'U)*'4I2X+IIDM1EMS87ZPC# /$)0S
MA:I6M[*;;P<@4*CE!)050[J*#Y(=+\0M\^B&2BE,N,E,'"UIH^>>Y,XTI#4R
MRF4R]L:#TH6  5)*5VF*\(50K^$K)3Q$=:Z,0PC"F^<_HV\>G_WA_P"T]JG0
M=?J!04RR#!]N%62)1*\62G$S2SJ)5#F]A3RM,L1K!XX0PU&EDY,B4L\5D+G+
M%R"7O[PNCB,:MI2M:RQIBBZTI?S$H:FM9N)@G2O9K5+]/G)U5REVLSDNS9E-
MK8&N&%-BLY@- E0-CB\CD*I\(2D+DYRY4G*0J%!I*@9Q9(!!OD 1[H R"Q),
MHN>(E&.VI=$G1V=X00YEN\E+>L.RY).XV8E=PIKMK;"<V(FY0TJ2R;J'9D<B
MK'] >@4V5A;V@4%0.'M] 71[ZH&M/R,0J@HCF#"1FTO%@RQBB;YYV]@&-\;<
M/+5'(49A&O&WNQ>M\8M-Y_LENS&Y9*GADPID:$MK\_.S# 6=(-4L*./LG;R2
M["YH VL''?8'_P",R@MMYNQQ!IEM]L&@QW'<3J9#@>+LF;\L3G8V3K(9J^P1
MF1FYTV7RB]/L_-C9TLCK@A(9$:IQ,51DQ.E\(H4Y5D-@_KUQ-^ZO&G^G\-_R
MXVT$@4%>9_#<X/F9\;OT0G#2Q8;;&62MV28YX1<$<H=U;LR2%O:EK 6"/.K0
M(YK=%S>N":H/)- 8WV++N$LT\)P:#)81MXMQKCUA8<IP]HR65DAO>,AS@",M
M>U*(>FDX'E2V-S.KC"0@;6HC))K6-N+3$JCSC"!A<4UNG46#-Z[1G:2,,..V
MG8&60V6O+7$<CILB/T8=#W9/(Y4OG4?=,9K6P:R#P12A)8H8<[H%P+(P .&%
M*/E&*U^8%J:!0?P\IO\ Y NT.N<VX2FB,"T.S-$(-+,:Z61V69)GD01/^0-B
MX(? ($WO[;J7&6Z3(\>.J60 M9,D>EK^K4BN>-.<@:EA?/ ']$+WOPWR9P97
M:1\*;B,R!UCBHI='G-[UDPPZN#"M(6HG(E8RK5^<3U+6J)<6U,H"80(L83DY
M8[7YP WL&HMVW&,VA*I0M/!PWK:T2U.2D6(V[4#7]$E5I4R(;:G3*4Z;,I11
MZ<AN-$G  =KA"0*X+6L&][4&W<*;*3IG5NW5R9)X)*H$\-6\N5\:Q6*Y+AT7
MB>3\>XUBV,L& C.-Y"DC2AT)1I8^#W"$MEZP!)-B@!'S2P! '66@J!K3^^?B
M$_6_A7V!='J"W] H*,;/8\W;FTI7&ZTY@A&,HPGQQ'T*%)*".<:ZY"/R<A52
M58H6%PR8JFQO08R2'63&EDBN:X#+3"+Z%0<J1A:F#%S\"B;&SN[26G52XI3"
M4#4M$YV:XJ*'1$M8B6.1C6SGKCKSHIZ.(&80 84)Q +VMS.:$-^H%!Q_V:_Q
MCO+_ /K8^79SH.LTD=QQ^.O[\6B.<ALC*Z.X&Y/>X5#@-M0GK HB!!+.N$Y5
M<GHPWL 5["%;W+_DH*!,'$((?@1IM!KAG-+,7K+\1Q&[1M2QDH$D<520A$>M
MDATB?/ J!ZCC28<>E+<6\*AG6+2+EA7 +"H.3A7O,FR&J6Q!#<OGF$-DUD/G
M6"&B1 FEL=N<9?V9BOD.(2R/1A-'UU@RR*R]4XH#3WA.N+;5C<6@ZF>2(\T1
M9 :"T,6J\BRXS-S5B_;DA]9&'(RN+*GQR.+865YCP7=]=8<M80C?T/BJJ)0C
M3HS5A*]A7IT1;;T2E"FLG"%N=;<UI(3B)*A;,*3R-1MH@<WR58#S/3<BN &]
MBG"R"(4*R5C:0B<7![5-!K@-6I.,N!H!=P5J#CQGT&VX3W@\["Q2WOF%YGC9
MQ2^8$D+'(%G3R1U4YM:0C=3(ZR"9VXY]9\72)026\+21]&!FN:YCL2$KJPPW
M3B$_0%WA^J!LM\C$UH$*^GULM]4#1[Y9^(306_H*"[ YOQJJ6R>"97QCD9^8
MH Y.$O2MT')>'"1R(R$M\+4%65-2-.S-P&F7CR"80UI/#!I[TB:W90(@"%K=
MS4(<\9.+A^NT*\&*\5;<H&5ZC,.3+XI&V8Q(Y ;HBP,>(6MGDD>:GL9:9=+V
M2%HBSAKR^:ZD%*#2#NA\)V"%@Y6AUZDN/8%&6G'&QLE;TF86+75UBK@YEM<F
M;7S+$BQMF50ID4G=A/"IQ.B(<3Q9^LZ)W0DHX2HD*MR,-4+[E!/6G^?VEY9(
M%CMOPW-\<ER9&[S-:V/ZI&X/,2E>3)EG?(;@W25L:(W'6ED9S6V'6=+*$Q9*
M1':5L:,E/T2L@ZX="Z"H#=]/J8_5 QK\L^5Z"W] H% H% H%!S P-_-PXD/U
M0.&%_G;B+4'3^@4"@4"@J!G&!Y]\_N%LXX.B6'YYXAX?V%Q1*(OE?+DTP_\
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MK5#:ZSV%MC@C,N2K0.$I8T:U*;:UKW*4)5*XL\@RUKVOS1!M?W:#Q^=G%?\
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MAE[\L?\ 'BY,N5F$M6/G8XQ^CS(8D.;D11BYL/?%::ZRXAJ%"!.C =>XB>0
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MWENQF=$3XVKT4HN8'HBF\TDTFW*,P(N0(0BW?SH9C_; QK]JW*]!T_H% H%
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ME[:MAK)CZ2M+BHG5T"!+D[)K>KBRY4E4QL"AMDP)1"T#.E6)C0W:D!A5S.A
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MM6N$&)5KL4,RM6Z,//LW)9 >A V+.E)4 5VL'[B$9W':(:P-,KED'?96W1^
MH)&\-[QSRY$\H)P_*I2\,SJMQ^V CICC%%",I<%4R.A70E!"C*L?8P1@3UB5
MIR:R1Y<VY2DZ68.R=V*+:'\"!N;7-Q:RH^PDN:UZ1LJ1"R)CG":E.ZI 2E*!
M9,R'H2#N546>*X2E0<@6;Z.V./[OV:O^Z9GZ@Z_4%9,\PO9"42_$SA@[(T;A
M,38?'OSI-3X,T"N4>%&MG(A'@NQ<0DH1>!').K,/Y3T7($T/)TW^Z$-19\;;
M8DH)\F=\LQD2A[SK,9##U+:N7C-8,'RM^DK&V1P1KK"EO0S*#P21IWIO*" ]
ML-D;$D0&""B4*EUPU?,>/]Z9+/G!ZQ%EC'L.AI#[&+-\3?#32RET6(9X8OD1
M8GA+CZ2.2=]O*FUY3$GB+Z(YL<_TA72DIA$!FY]&=TG91%A0B<PV+M:.=2MX
MER4(6M:^NN/+RX2YOAK8[.\4=&H3\OCUP)&I=9"V]13!'=:8-3<)E!;:)ER<
MF*QHF;*6=9,BH^S%RU7'B52=@52<#<F"_*6,A=>ZTAG/=;&B3 ._2A)N&P_S
MK7H*P;P_N8A7UO\ A[?;ZUIH$*^GULM]4#1[Y9^(306_H*+23%&Y:^*YJ;V;
M-L532.0Y%1/6%URA4XI$$,@"[-R.12&-2(;5"B'96N08>9B4#8(LY1;K[BL3
M&F!3A)67"5QQC8M(3EI<FFL=6N+E!;IL/(3SRS6^-SP^&"0KU\C(%#D%G5MO
M-V-"X).4VX"B79P)N2$HE, 80Q <>[VQN7/"J997@,UA"]VQS9C2A5&)9*P,
M:;*S$_Y!3KD(<>M[4[JCL;GN3,F46<0&W+(3FB":KN:<,-QQ3%=RVO+,D=\K
M9&@<BQ0YR18?'(PUM*1(OCL7"#(UEB/K*5D0N![@X/"N)',_6%KA9(T(W8I8
M:)4<EO8+D4%/W+Z?<-^I_DOY:,34$ -W\Z&8_P!L#&OVK<KT'3^@4"@4"@4"
M@4'+?6/4'4S+\'R3D++.KVNV4)\^;<[Y)WJ<9$PGC6;2]W3L&[^PL;82'22R
M6,N;TX$LD=:$B!($T\84R)*2078)18 A#5'7''"]BD\R1CV;Z*ZN,[UCN2-S
M(<)AU+@<S3.")YBL1F+0\&G,N(^A:BU33+RP#*,&/HE2)05<=[#1#6!I;DV<
M+A0TQ:4X]X>VO&4X9)6N1.UY!%-3\1)[MR2-SUUQJM4*TK[ FQ,C1VE;.:4$
MY:I1!4EF$C265=*&U@UBTIX&;\VK']/JCJI((_%%$<<W"0D:20-P;&$R36 "
M*/)!@\8"5*"W=*X!,3JD!2BP2#N<(0+7%R!MS>LX*[NT!?6?5C5IW;+DS11<
MUKTNAC@H+2X^5EH)4M.;4N+C70EM0JUJ()2L9(4JP"VQJ<PTI,X&(PUV,RW@
MIR5/(EY>J&JC:WQUX?6DP]=J3BDU0Y%QR59(BSD\-#>V05P6.S/?S1R%R+&E
M">:%J0@..+),5H25(64U[UVX9&RN-T&2\>:1:J!:CU%FQT;7O5C$#8[,3\4V
MMKFN9EQ!\(L6>8D3NI(@J"!&I5)0PFD&&%# .X2+IA!81C&<;UX]QK#HKCV
MQ;;F-)XQ!X/'FB)Q".)W;2#3*2.I##&F!&WLK02YR)[6KU 4Y!83EJLX\=KF
MFC$(+TT"@4"@4"@4$39>PCCS.33&VC(*657##94";1)Y@^2,DXEE\9E(8W)8
M<8[L,ZQ/+83-&HY5$YBZMJ@!"\!2E$O.)-", [AH(9[#V&/?KM_]X3OUZRU
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M@2KAL.X W%R\VW(&1R_C36#$3C$1K--\+2.+O@7X3^\L.&X>O=HW9J*;^I&
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M3R$)@S[B4(CQ7<#;&F*0%)R"@N10*!0<P&[^=#,?[8&-?M6Y7H.G] H% H%
MH% H% H%!S XEO\ B+AI_P!S_ 7R6Y\H.G] H% H% H% H% H% H% H% H%
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M ;T);L>.\?9 \+S&3GW<M=403TK&V_I3"B;FJ3+>X66._N4%^>W#ACWE;?\
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MC);Y J96M2^($]KV3H7@]"0:YHR+74*[V)3+1# ']*;^:&WYXORW#DWPS_\
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M'E]&H+0K91"(@0),0)29=YR#-&"!1P BPW#<*<R0R5*$XS\A15Q#ORV#R4$
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M:VS%?)%3%XH1!+.GX4-?D6/XVRQJ'("E;G!?&M@:$[\1('(H"YK<;J@D%F$
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M5TJ;%SA'@.:PIL33MC3-R8T:9.I)9CAJ$I"@U6G#VX=Q3E1'*D:#(VM6!8[
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M,I)CS'#Q#'!OEDYAZ5*ME,5;5 R2[/C D7Q6<H%#H@4W+&4 ]G<B+BM^D3F
MYP;AH?9IS/\ U"=O_@5H+ZCU [-.9_ZA.W_P*T%]1Z@=FG,_]0G;_P"!6@OJ
M/4#LTYG_ *A.W_P*T%]1Z@=FG,_]0G;_ .!6@OJ/4#LTYG_J$[?_  *T%]1Z
M@AK8W61R/UZSN3G;B([BH\('89R@5F16GA.D0E"7%1D(? 9#4$!B^BZJ2B.(
;B-U@@V;BC%UQ6MU<(C>9:X=)*!0*!0*!0?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g558803g94y08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g558803g94y08.jpg
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M)E96 #9)4@DC;@ E@=.]6V.D::ME<VUV\B2RN'@$+(RR-N&>\FC*L#D8 (P
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MZMGZ?LO??DQ7&>W?81=?T[]>XB=[,TOQ/-H<+)XFQFD(:J*YLC%]T-Q:1JK
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MO/T;K_=,ND7;_:Y&/L4C'B.1B2;<D_-D.3%[I"4Y[Q0N%WQ_XW,V_P"LA_\
M=@/+OV,?\E_1W_TQ_P"VW595[4_^4#J?^'1_V.VIR?T8]\SZX[*F:ELS71XO
MO"CGK(8))%:/!G&*C&WF-F>7*K(WF5B9%1HQC6O,-LZMCGN4>)BM)#@X]_\
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M646D9(Y6.)4EDVGW2/(@;GSA'NJ5+Q/4Q:.%%'"BCA15:9ZPG72GZQ^H3O\
MP/%J^&KPK([JNVEA@ T38 P*;956-E!U4 ,Q$C%K:+)S,AH*P:/]7#7U8S&(
MUJ(QNK.A]4?5NF=-N)F+W$4;6<[$DLTEHYA5V)Y+R0K%*Y]6<TANI[%=/UN]
MAC7;$[K<1*. $G42%5'HJ2%T4>@4"FRN6RH"LI6_RW]G_><ZY/3Z_P E%6ZG
M,5UIBF:_7YC<_P!+#L,YJ>4BNM*R/7_S6KN_7L2+_P!N1B?U\O79N?\ '#3/
MC'?C_N^Z/Y*J_68_Q=OO@UH?_NX!^6JZOFGJ1]'"BK!KX=A57TS\*15\^-J;
M:1/Z$_2-B^$_K55_TJO,U=I_[*Y_X%9?U9IT]#_K#%_";G_;%/G<7E6^CA14
M6GXI,8IVA>K!C$=]B@V]F0Q"I_$0HK#(90T=^SW+$&<K?Z&O\?MXWNR$C[):
MP/G&Q@(^@3G=_.5I>=H0/L>G'T%S*#])B&/Y@:A6\?5*JCA17W)5V:HBI7'*
MBHBHJ"$*BHOU145(_"HJ?DO..]?NE_"/[Z^X/N/X*\_=5I_-I_\ L9'_  ^&
M]/NE_&']]&#[C^ T?=5I_-I_^QD?\/AO3[I?QA_?1@^X_@-'W5:?S:?_ +&1
M_P /AO3[I?QA_?1@^X_@-'W5:?S:?_L9'_#X;T^Z7\8?WT8/N/X#1]U6G\VG
M_P"QD?\ #X;T^Z7\8?WT8/N/X#4D?X9?6&>3=S-H;,?BU^+@>/=>,JQP[*2*
MLZ"B7)<CSW6T]/C[+*2%@DMH97TEY91B,E=*@M03,]K4:SW*OM8N[<:%:6G?
M1FYEU.&580ZF3NHK:Z#RE,[@BM)&N['RG ]]7OH&"8ZK<3]VXA2QD1I"IV=Y
M)- 43=C&Y@CL![D:EZ_$.ZG)%SKK]O(89SPKS%;_ %7<EL8J1BFXS;2Y9CD,
M[_"(LMD/E63.&3W*Y8Z<CRB-8WRH] ERD\!/*LLJCX,-K?@VK^&J_P!LNG,M
MUH^JJN5EMYM/E8>2M!(;B 'XN+B?;ZXC;W"HWS'OC>V2-SF2,<U['L<K7L>U
M4<US7-5'-<UR(K7(J*BHBHOGE@95=61U5T=2K*P#*RL,,K*<AE8$@@@@@X-)
M,$@@@X(Y!'!!'D0:Z_1[;_A#R7(*V[.G)S&IBJI+&<Q86SW(KZFN1EI$D38T
M>L3GL%,56K*K_D%3/<\Q?;4=1Z#MNCM)T@Z+9QVG3MS"?9+> R-%87$CR3S6
MOVQG9$DD:6>W0,(T0O!"J1P*H5O:KH%[:ZM%U$V^>SURUT^22=LDQ:@NGVZS
MQ2G&!W_=M<0DGQ@RJ!]J.>^Z@S@G66U]:;%$E?"1@V>8EEC'L5456T%Z#9RQ
M.\?QHYHAGPS1KY;+%(^-[7,>Y%@!P1_Z50NG-5?0^H-$UF-BKZ5JVGZ@",^5
MG=Q3LIQYJRH59?)E)4@@D4^;Z\&>RRV?7K6@Q'^*P5V:9[90M?[F$2G$4]!0
M$*B+X_Q:,#(V1O\ "^Y#'HU41%\\W/D/KK5/YJ_5F:?H_1$?P)#J>K3*#X7:
M5[:TM'QY> 0W@4^Z4X]:CNVEH!2UQMM:%1!5U>/(485,OB.&&)JN<Y?"*YSE
M_BQQL1TDLCFQQM=(YK5[+2TN+ZY@L[2)Y[FYD6*&)!EG=S@#W #S9F(5%!9B
M%!(R-9VES?W5O96<+SW5U*D,$*#+/(YPH'H!ZLS$*B@LQ"@D)XCV&=LBO!N)
M7$150K[,&@KIY5>VOK([8UZ>(T<L<<YL[Y33$C\I\^=T:/?'%&O&(>EK3I6[
MO+6*.$WUW['=:K=QH%:\O/8+:$%GP'>.WACCMK??C$48;:K.^=*Z?H\O3VG6
M.BS7!N'LH<NP_4UENG>[G2$<?:UFG=58@,X4.P!.T=/TCK&TW3N'6&I:5LJV
M.QL[Q?#X9(F^YPD5[;B %V+_ *.1@]8',18%2N160C#2RO\ P,=SY/*(8993
MY1QL_P!) ) ^DG 'O)J9TJPDU34K#3HL[[V[@M@1\T2R*C.?WL:DNQ]%4GTJ
M8]ZV^/L@])WM#040R#!T^-ZB8$) B^P6HQW=>K27PL3ZJD0]77R-^JKXB8OE
M?'GG@[/W ZQT=W/RI+P9_?2:?=J/PLPK675<03IF_BC&U8X[154< )%=VW ^
MA%Q5<1S4E(ZCA14_;X;RVKK'TXXPPGQN)H=\;0JK=K%171V$P>)WD394_9(M
M3<UCT1?Y)\:_DJ<S=VIHR=4EFSB33K-TSZJ&FC./AOC<?2#3EZ$96T/ QE+R
MX5_OBL3C/\5E\_2G\N+BKG1PHHX44<**@)?$DVE;8>HP.("^-Q5)U^UC5W*,
M5/='92V^;W43)?'U21:BWJGHCO"_*?$O\54YI#LK1UZ7+-Y2:E=O']X([>,X
M_CH_UYI,]=,K:Y@>:6=NK_?%I7&?XKK3 G&15-K*5O\ +?V?]YSKD]/K_)15
MNIS%=:8IIWUR*22^]+'M<)$SWRB4^LKM/'YLCQ_=FM;PEZ?^R)7D>[_U/=RY
M]GT@CZPT9B<!GNX_KET^[C4?C,*K?5R;^G=1'N6W?\2[MV/\P-5O/-2TBZ.%
M%6!7PYEM7V7IL4 84\<Q-!N3:U3;QL<BN%L)CJJ]B@E1%56R.J;JL)1KO"_*
M(C=X]KFJN;.U%&7JJ1F! DL+-T/O4*\9(^&^-Q](-.?H9E;0E .2EW<*P]S'
M8^#_ !74_013[W%U5QHX44PO\1IJ,O8_IUGYA7"OG)TAM[7VQS'0L5\[:*T;
M<ZRLVHUJ*]1HR<_K+$Q6IXBAK?M,BMA'D<C&[+KT6O4ZP,<#4+&YM5R<#O$[
MN[0_?$6SHOO+X')%4WKFV,^AF51S:74$[8\]C;[<_5NG5C[@N?(&J_\ YI*D
MS1PHJSA]+'L;3=H.AW7;88%A";?4N TFL]@P-E:\JOV!K:N$Q3(FGQ(JN%EN
M5 $RH*"15>M-D-60BN9.QRY-ZPTN32.HM3M64K')<R7=L<$!K:Z9IHMI^<(]
MS0L1QWD3CTI^].WR:AH]C,K ND*6\XSRLT"B-]P]-^T2*/N'4TX/RLU-T<**
M.%%'"BCA11PHI#/J-=87]LNIVQM:50D96<U,,.>ZS]WM1ZYUB<1)(%="]_AD
M4F2U9%QB7SI'-C';?N)>J)#Y3VZ?<^RW4<I.$/@D^\?@G^*</_%JJ]::%^>'
MIZ]L8U#72*+NQSY^UVX9D0$^1G0R6^3P!,2?*H!9 Y A$XA<$PI0LTHY(Q$3
MX2!R(7NCF@GAD:V2*:*1KHY8I&M?&]KFN:CD5.7L'/(Y!Y!'K60F4J2K JRD
MJRL""I!P00>00>"#R#24<QR.UQ/;1N0TTZCV%;-431.7RL<K/N.N9,,0QJM6
M08F%SX"(_*>^*1R(K7>'(YK#3+35^E+73KV/O+:ZL51Q\Y&R626-B#MEB<"2
M-L':Z@X(R#=[[2K/6]#33+^/O+:ZTVR1_+?&PM86CFB8@[)87"R1M@X91D$9
M!<.P/-JK/\:!R*J=[$F;\DX)ST?-6V,36J4%,J>/*QJYKX9%:SYXTD)",:DJ
M-3,G4.A7?3NJ3Z;=C.P[[><*0EU;,3W4\?G\H JZY/=RJ\9)*YK'G4G3]YTU
MJUQI=X,F,[[><*5CNK5R>YN(\YX8 JZ@MW<JR1$DH27F_6'N2;;?>EVSO<Y!
M^KFLY5:JJJ*38Y#G9Q,R^?K[Y/G0L<J^%5(F>4\\AW\P/A_3_P"E.?\ -'W+
MW'5O3(<D[.@]#)SZO->:M*[<^K;E!^]%1DNPFW/TJL7X=CY7NQNI(_Y0*@?Y
MCNK2!RHOM>U?$M< ]%:/X_5$E(\K];'&%(W1/9QT=]B+9=:U&+&IWD7Z7B<>
M*QM) #RI^3<W"X,F?%%$1#X6:93+=F'1'V&M5UW4X<:K>Q_I6&1?%86<B@Y*
MD92ZN5.9/G10E8?"SSJ=EU-_T%J/_>V7^\R^176'[(+S[RU_LL-636_UQF^]
MB_JDJ27Z"75TG-MRY5V@R*N<N*Z@!+Q7"")XE^38;(RJM<-9D"O<UT<WZ+8:
M:6TV-4:^$O+:,F!_O'D1JZURY"0K;*?%*0S_  C0Y&?OG Q]Z:979'H+76IW
M&O3)^E]-5[>U)'#WMQ'MD*GR/<6SL&'HUQ$P.5J1UW;U 3OWJ#V5T[7C*7=9
M_I;8-'C0[6^]9,M7'#B\1_!^;_9DPM2]6-\.<C5:QS7*CDC.G[T:;K>E7S';
M';7]M)*?=!WJK/\ 1]I+BGOJ]L;S2[^U49>:TG6,>^3NR8O]8%JJZ<U6JK7(
MK7-56N:Y%16JB^%147ZHJ+]%1?JB\V#6>*\<**E*_#.=OJ3 MH;4Z@9G;05P
MNY?L>P]5.,F; ,1L+%JV4'+,<@5SO$EIE&'P5MH"UWRVN9@I0K7R%FAP/4/:
MOHDES9V>MP(6:PW6UYM&2+:9PT,I]R0SED;^$ _)5B&%T%J:07-QIDK;1=XF
MMLG ,\2D21C]])%AE_Z$CS8"IJ?$+36HX44<**UG,\RQ;7>(Y-GN;WE?C.'8
M;0VN391D-K.@U;2T-(%-86ED;,OGV#AACRS2>U'/<C/;&Q[W-:O;!!-=3Q6U
MO&TT\\B10Q(,O))(P5$4>]F( ]/?Q77++'!%)-,ZQQ1(TDDC'"HB LS$^X $
M_P!%5=_>CLL9V_[:;Q[$$1$BU^PLS(FQ6O,\(55X+0!B8O@E:6QKGQ,.$Q"E
MIH[)(%^2^R^V3,3]:JKKGI[2ET31=/TP$,UM !,R^3W$C--<,/7:9Y)-F>=F
MT'RK/NKWYU/4KN^(($\I,:GS6% (X5/[X1(@;'FV3ZTDWDU4;64K?Y;^S_O.
M=<GI]?Y**MU.8KK3%)*[Z:K-W;TK[2ZMJAG&WF7Z,V.'C8;&+(\O*0\:/M<6
M&1J(KE^?D(%;%^%%>GN\L17HB+-=.7BV&O:/=N=L<.HVK2MY;86F5)C]4;.>
M>/>:C=9MS=Z3J-NHR\EG.(Q[Y%C9HQ]<BK569S7U9YHX44^_Z(GJE8YT/V#E
MNJ]W36$?7;<=C6VEA?@"%6<^L,]!'2LAS%U2%',;8X]=U*#5.7P5PQ=O#%44
M%E6C$)6&5]BNNO\ I"7J*VAO-/"G5+%618V8(+NV8ES '8A5EC?+P%BJ$O(C
MD;U9;ATGU"FC3RV]WN]ANBK,Z@L;>9?")=HY9'7"RA07PL;*#M*M._UGN74F
MY\<%R_4FS,%V5C)L#"(+O",II<EK_ER-1_MGFJC"D$GC\^V<4I(21I6OA(AB
ME8]C<[7=C>V$I@O;2XM)E)!CN(9(FR/<'5=P]Q&01R"0:<%O=VMU&);:XAGC
M89#Q2(X^@[2<'W@X(/! -)_WKZAG27K45#6[I[*ZOQ"ZFE2']&Q[M^698/Y=
M[4F.Q/"QLBR2N#5WEJ''U0P7N:]OS_,;T;)Z=TSK^J@O8:5>3Q@9[TQ]S"?@
MLTYBB9OWJN6\N.17BO-<TBP.VZO[>-_\F&,L@^^CA$CJ/BR@?&NG9E0:C[D=
M;\IQ<+(*?.-.]@M8W="+E.-&"VM=8XYF-,37PWE(;$YT/VZN>0TX&3RPBNM@
MH_F) 6*YL?D@DO=#U6&9HGM[[3+N.1H904998) QCD'GM;&UAR&1CC*GGT2I
M;:I821AUEM;VW=!)&0P9)5*AT;D;ESE3\UASR*J\=^Z3SCKAN?96B]D .K\T
MUAEEIBMRSY<C!S?L4ONKKNM65K7STV0U4H-]1E^$:;3V01;/+)FKS7.FW]OJ
MEA::A:MN@NX4F3D$KN'BC?'E)$^Z.1?FNK ^59]O+2:QNI[.==LMO(T;^XX/
MA=?>KKAT/JK ^M<AY[:\U.V>D[ZHN6^G3M.R&O0+3-.N^RB@&;0P8"6-;6I.
M$3[,%L'"(RYH F915"/<+85A$X8.64[8ZRP*$+ HK:GI?6?2,/5%FAC9(-3M
M%;V.X8'8ZMRUM<%06[EV *N S0OEU5E:1'LG3G4,NAW#;@TME.5]HA4C<I'
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MS&8))/HZ.O6_LCVU\/C\+8 FP0L8B,9&UB(U)JSTZPT]#'865K9H<96UMXH
MV/5N[5=Q^+9/QJ-N+NZNV#W5S/<L/)IY9)2/HWLV/H&*Y3SV5YZ4+U7[,[2Z
MA;SP7?>G[1 <NPVQ]\E>3\Z2ERJA-1![W#\D#@DB>=0Y" Z0(R%CXR1I5'LZ
MV<.V  -&C-8TFSUO3KC3;Y-T$Z_*7 DAD7F.>)B"%DB;#*2"",JP9&93[=.O
M[C3+N&]M6VRQ-G!SLD0\/%(!C*2+E6'!'#*5=586D6I<W,V9JO6>R+'%KC!K
M#8&O\-S8["LA:K+[#S,JQVNO2<7NV.B@<RWH)CWU5BUT$#FF"3(Z&)45C<AW
MMNMI>7=JLR7"VUS/;K/$<QSK#*\8FC.3E) N]#D^%AR:T);3&XMK>=HVA:>"
M*8Q.,/$9(U<QN,##(6VL,#D'BN@\\U=]:]EF)XUG>,WV&9C25V28KE%4;1Y!
M0VXS"ZVVJ;&!XQH)@\B*V2&>&1S5\>'L7Q)&YDC6O3DCM&RNC%74AE8<$$>1
M%=-Q;P7<$MM<Q)/;SQM%-#(H9)(W!5D93Y@@_E'-5ROJ\= <TZ+]E[(?Y!5M
MI3:"S7^F\S6*98IJP"$,6SPNZG>LC&99A[WBP')\UWWK4EU&01-'6SGKZ_3W
M06O6NLZ'!#&0EYIRK!>6^>5R6,4R>IAF4':3RLBR1G.T,R-ZAT)M"O!#&A%@
MZ*+%^2!%$BIW#,Q)[R$!5;))=2DF<L0K47+Q5?J0)\1@5]K[9=9I47RDG1'3
M4Z_1?/N(V1NR1?/G][58O]?Y^>+7LO7;HVK#W=17P_!:V _OJY];G.HZ>1^X
M]I_//=G\M,)8_C]YEE]2XOC-387^29);5U%0450),?:W-U;EP@5=56@C,D(,
M/L#2(!!!8(WS3D2QQ1M<]R(K'EDCACDFE=8XHD>261R%2.-%+.[L<!55068G
M@ $FJ<B/(ZQQJSN[*B(H+,[L0JJH')9B0 !R2<"K&3TC_3;I^A.AJ:?-!:^V
M[&YW3Q&;,OXEA+BQ4<\I;>'6F-F1K)&E71320MO[ 25[,FR$1QZS2U0- .!E
M7K'7TU_6KNZMMRV6]$MPV095AC2$3NIP09=F]$891&"G#;J='2W2]MH4<MW(
MBOJM\D?M4QPQAC55"VD)^;&I4-*0?MTOB)*)$$=MY5*MU'"BFU?5)]/?&?4,
MZY'8$V6OHMP8-,;E>DLT.8J05.4N%;$=C=T1#'(4S$<V%''J[U(&3*"6/2Y&
MP.P)Q\8$BU](=33=,ZHMQXI+&XVPZA;KYO#D[98P2!WUN27CSC<IDBRHD+"!
MZAT2/6[%H?"EU#F2TF;R63',;D GNI@ KXS@A),,8PIK?-G:QS[3.?Y7JW:.
M*VV%9_A%P319/C-V/]GL*RQ%5/+5\*^$H0F%\1E=8ARD5UI7$"V5:44 4.1+
MJ6TN[:_MH;RSF2XMKA!)#-&<JZG^<,#E65@&1@58!@0$7/!-:S26]Q&T4T3%
M)(W&&5A_,01@JP)5E(925()T3GHKIHX44<**.%%'"BCA11PHK*5O\M_9_P!Y
MSKD]/K_)15NIS%=:8HX44EOM_P!/=)]W=-7.E=X4#[&D,D^\L=R*L="+EF"9
M1!!-#7Y7B-I- 0T"V#;/+#-#/ 36VH$Q55< G5I9 TDQHFN7_3]]'?Z?)MD7
MP2Q/DPW$)(+0S("-R-@$$$.C .C*P!J.U32[35[5K2[3*GQ1R+@20R $+)$Q
M!PPR00059258%214#WO+Z*7<7IM:W-[4XC9[ZTF-+.17;4UC2FVI-=5L<YS'
MY_A :V&08:2/"C7GG^RVQ&-7L:/E$\SGCPZ)Z>Z]T/74CC>9--U X#6=W(J!
MW/[6N&VQSJ3\E?!/[X0,$I[5^E-4TMG=8FO+09*W-NA8A??/"-SPD>I\47NE
M)R S\J*U5:Y%14545%3PJ*GT5%1?JBHOT5%_+EWJLUXX44<**5%U.ZT]HNQV
MTL;JNK. YQDF<4.04UJ)EV,Q%U=1KZT!.@.J\EOLY<HU-AK:LN"$X2QL+(.?
M[1#$VN:0<X>"2(UG5=(TNSE?5[FWBMY(I$:"4J[W*,I5X8[?EY]ZDJR*K#!.
M["Y(D-.L-0OKB-=/AFDF1U82QY586!#+(\W"Q;2 P9F!R!MR<"K2'#!<F!P_
M% LUL0;C,@\:HA<MMJN!PM9:9,/5BQ7UC7#.CB<.";:L+)$@=%$Z(>6.-8V*
MWVID.<Q-/,UNK) TLAA1SETB+DQJQR<LJ8#')R03DUH2(2"*(3,KRB-!*RC"
MM(% =E'&%+9(&. :8F]3CT)]4=Q[*]W3H2QI-)=B[)9["^80'-'K#:MG)Y?(
M9EH-6/.;B^4F2^)"LSH 3_O*19YL@QZXL2_O@5B=)=HEYH:QV&I+)J&EIA8\
M,/:[-/186<A9H5'"P2,NW@12QHNPT_7^C[;5&>[LV6TOFRSY!]GN6/K(%!,<
MA/G*@.[DO&S'<(9'9KHQVNZ?W1-3O_2N984!&4HP.9MKW7>N[M5D5L+Z3/:1
M3\6.DG8L<OW?]YQVXK)HF6%<&0Y84>ND]0Z-KD8?3+^"X;;EH-W=W4?'/>6T
MFV90#D;]AC8@['8<TK=0TC4=,<K>VDL(S@2[=\#^[9,FZ-B?/;NWCYR@\4DS
MDU4;1PHHX44KKK'T/[:=PK@:MT#I/,<QK)24&,S><!U!KBF]K_;.ZWSZ]4#%
MQI1V))*M;%8D7)3898Z^M,(:D+H75NHM%T-"^I7\$#@96W#=Y=2>[9;1[IB#
MY;RH09&YU'-26GZ1J6IN%LK2649P9<;($YYWS/MC!'GMW;S@[5)&*F0>FMZ"
MFG^I5E0;C[$V%)O??U7(-9T5=$%*_4VLK:!6RP'8[6VH\!N8Y*!.WYP.59("
M -6SH.52XQ66P$%U(C.JNT:^UI)+'2UDT[37!21BP]MNT/!65T)6")APT,+,
MSC*R3/&QCIHZ#T=;::R75\R7EZN&10#[-;N,$,BL 99%/*R2*H7@I&KJ'J0=
MQ:5=:.%%'"BDE]V>GNLN\G7S,="[-';!#<0_>F&Y; +$3;Z_SNN@(3'<QID>
MZ)SI@)9Y1;,%I S+N@.MJ(B>(>RED;-:!KEWT_J<&HVAR4.R>$L52YMF([V"
M3&>& !1L'NY%20 E *C=6TNWU>REL[@8W>**4 %H)E!V2IY?)R0RY&]"R$@-
MFJSOL?UZV;U6W1GFB-O4KJ7-\!N)*TU(_F/K;FOD:TFFR:@+EBA4_'LCJY1;
M>F-^5%)*$5&PF 8R,@6'5VEZG::Q86VHV4G>6]S&'7RW(PXDBD )VRQ."DBY
M.&4X)7!*$OK*XTZZFL[I-DT+;3C.UU\UD0D#='(N&0X!(/(!R [G\07+)/V>
MZNR2L>QSN@NA5]KVN:J*_,-N2O1$<G^2^1S7(WRB/1S5_$CD2E=FN/L3J^.?
M\9-2_J++\E67K0YU#3^,?X&LN#Y\RW/_ *?53H?P^7I<IBU53]]M\X[_ ,Y+
M\&5W6[$K@7P^AQT^!XY6WCA)V^]MID8DLP.!)*QC1,=F+RB)"G7^/F5E1[2^
MKN^=^G-.E^U1MC59D/ZI*I!6R5A\R)@&N<?*E"PG'=RJ]@Z*Z>V*NLWB>-Q^
MD(V'R4((-T0?G.#B#W)F09WQE987$U3(HX44<**.%%-:>I#Z4>A/40QF.RO5
M_@VWOCU:X'"]T4-; 58()&LDH^-YS4?-#;F6)-(D?*,+,:%<4<\LT]#;@PEV
MH-I;^ENLM2Z8E*1_IK3I6W3V$CD)N. 9;=\-W$V!@D*R2  2(Q5&2NZ[TY9:
MVFY_TO>(NV*[106QZ1S+D=['GD D.ASL90S!H-O</TNNY72:TLW[6U7:W6O@
MYI?L6X]>CG9=K$\-KU;$6;>!AL*Q*6?PY&5F;5V.6<BQR/'%(&:PF30>A]7:
M%KZ)[%>)'<D#=8W)6&[5CYJL;-MG ]7MVE09&6!.*4>J=/ZII+-[3;,T()Q=
M0@RV[#T)<#,9/HLPC8^@(YIO3EFJ%HX45E*6DN<DM :/'JBTOKNSG8+6T]*
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M<TM%5>^ VKCO",8&,9\L5+L](3K!UJRX&>ZROKSHW)[FMKXC*ZVR'4N W5F
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8 "(8(80V-PBB2,-C.,[%&<9.,^637__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g558803logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g558803logo.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M5? &L:7J_P -/#=IXKU7Q?<:UI,^BWVDZI#X?GT4V%C!F\-U=1^(;;='(J"
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M/;X*_%>\_9A^)U_F"R\8>$G\%>(?L?@BXN97*6^IVJI)%:6KR,8)X+C2XW:
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M6OV2/^36?V<_^R(_##_U#='H ^0OA%_RE6_:O_[(=\-__39\-Z .K_X*M?\
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MKZ?JUEJT=C;WMI)/<VT]@CQH+F$,V%D)C9T< \7\,_LQ?$VR^(/[+?CWQ?\
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M>%? 6C_"_P !:MJ=AN-G/XO33=3O[[Q/ K.[?9Y9H%7)1&5))5F-OD&WR/T
MAAAMH8K>WBC@MX(XX8((8UBAAAB4)%%%$@"QQHBJJJH    &!0!\5?M#_LI>
M)OB%\5O ?[0WP6^)4?PH^.'@+2+CPNNJ:IH*>)O"OBSPE<R7TK:#XATAIXF0
M1OJFI;+F/S6VW9&P2P6L]H;?(-OD>8^+_P!@GQ+\=?-\8?M'?'37=;^+FCP6
MT7PL\1?"O25^'WA[X.2VM]#J9O/#>E)>3W?B'4;N_MK=[F]U2[6;RT2.U-M)
M!#<QFWR#;Y'V/\%O"_Q=\&^%(_#OQ>^(^A?%;5=,\JWTSQEIWA&;P;K&HV$:
M% ?$U@NN:C9W>JKMCS=V8M%D&3)"90TLIL&Q\F_$G]D+XY:Q^TYXD_:5^$G[
M0WA[X6:UKG@K3/A_'I=W\*+3QL4\-V4>F3W,-Y/K/B)+>:YGU?38KD2PV=NT
M:1Q1!F D:8V\@V\C=UW]ESX]>._@E\:OAK\4OVE(?'GBOXM0:)HFG>))?AW9
MZ!X7\#^%],N8+F_M-(\$:'K4$-SJ^HL;Q9K^2[1R/L>=PM-LAL&QR?@K]E7]
ML/PGX8\$_#H?MJV=K\./"-IX:\.MI?AOX(>&]"\3R>#/#XL[,Z)IOB_^VI[W
M3;Z31[7[*FI#S)XV*RDNP;>;?(-OD.\6?L>_M ?\-)_$K]HSX2_M(>&_AEJG
MQ#T;1/"\^BW/PALO&BV_AOP_IFAZ?96L]WKOB/9->R2Z#;74EQ#;6[;Y6C&8
MQAC8-B_\1?V/OC5\7OV>_B)\(/BG^T?%XT\7_$/QAX9UB3QK=?#^+2=!\,>&
M/"MSINIV'A[PYX&T37[:UMKN75;":2XU W.Z=+W;*CM;1.#8-CIM:^"/[77A
MB[\/7GP8_:)\&V&F6G@?P5X8USP!\0? -WK7@\ZYX4T.UT&[\2>%KVWU275/
M#UMJ-O9V\\FDQRF(3^;+)-+),74V^0;?(Z#X$_LM:]X(^*7B?]H3XT?$?_A;
M7QT\5>'K?P@NKV'A^U\*>$?!_A*VGAN%T#PMH-O-,Q,DMM;M+?W,@E<*^(T>
MXN9+LV#8^K?%&FWVL>&?$.CZ9<VMEJ.J:'JVFV%Y?6TMY96=[?6$]K;7-W:0
M7$$EU;132H[PQSPLZH561"P8 'YD_"3]BG]KWX&_#NV^%OPR_;0\.^'?"%C-
MJUQI]JW[/WAS5+VPGUJZFO;^6WU+5_$5S<%VO+B:5?->01L^$ 4*H-@V.Y^*
MG[&?QD\5_%#X(_%GP!^T7;^#_&GP5^&J>!;/Q-XE^'T?CW7/$^J7]IJEEXI\
M3:V=4\0PV)EU2#5;D?9A9N(&FD:*0?NA";?(-OD=SIG[/7[2NJ^&/B_H_P 6
M/VH;;XAWGC[X8ZW\.?"-O:?#'3/!GA7P;+XFMKFQUKQ3?Z!H.L*WB?64M)($
MM#/<PB "Y0-LNF"&P;'L?[+WP:U+]GOX&^!O@[JGB.Q\63>"(-6LH/$%AI,^
MAQW]IJ&O:GK4!ETVXU*_,%Q"-2,#%;EU?R X";RBFP;'OU !0 4 % !0 4 %
M '!?%#QW8?##X>^+_'NHB-X/#&B7>H0V\LCQ)?ZCM%OI&EB2..1HY+[5IK*S
M0JCD/=+A3TH ^2=#_;9M+JS^%VOZYX3L]+\&>+/#'B#_ (6)XNM-<-[I7PJ\
M<Z%XVC^'*P:T7LXI+OP#=>,DEL/^$@$</V6/4=)OKN&*QNY9[4 BTS]KGQS)
M9:QXRU/X?^%E^'W@]?@%%XR^P>)M7?QE;R_''PMX$UH7OA[3)M ^PZQ!HNH^
M.;6W:RDO+:ZO8;*5[?%R\-K. >N?%+]I'2OAG\:/A'\*+C3[.[@\?7=O:>)=
M5DOYK>]\+MXHO9_#OPXDLM/2RECU9-9\86ESIMP)+FT^R1B.<>=O$9 /(?!W
M[5WQ*\8:=\*[JW\!^&[*?XI?$OQEX%LHI8?B1<QZ/:>#X-1EEU.5K;P<6U>R
MN7L8@VLV"R:-8B>?[7>H=.N0H!Z%\)/VD-=^)5YJD%QX3TG2(;#X=^*_&D+P
M:O>7KO>>'OBY\2?AM;:?*&T^)1;3V7@2WOWF5BZRZC+"J,D"RR@'%>%_VQY_
M%?BCX/\ @BR\/^&;'Q#\6_@QX;\8V\M_X@U#^S?#WQ0\9>!YOB'X<\#ZAY6D
M>=<:&_AG3M2FFU*(?:%ENM(A6T+:DIC (/ '[47Q4\6W/P$@O_ W@JQ'QLN_
MB/=(^C7OCSQ%_P (_H/PV\1>%O#E^UXNG>$F:WNKVYUR^D2_O%M=,LUMK47=
MRAN"4 .P^%/[2/B_Q=K'PWB\7^"_#FE>'?C'K_Q5\-^!=1\-^)+[4M7TS5?A
M7>^*!=0>+='U+1[15L]4T?PGJUU%?Z=<W$=K/%!9W"$WT,U ')WW[6_C/2-3
M^+EU?_#C27\$_#[5/BCX9T_Q+:ZSKBK;^*O!6L>'O#O@S3/%LLWAW[#9CQEK
M_B."SM8M.N[R[M?L%S/+;26ZM+  8-G^V]J^LZE\%++0/ NA:A)\3O#V@3:E
MI;^(]2M[VW\9S_$R?X8^+_"N@:H^A?V<\>@WFF>(=52]U>33%U"VT%K>!%N[
MZWCH Z+4/VF?C%X9L?$>J:S\+?"WBJ'PQ\;+?X1W>@_#O7]?OO%.IVMCX5;Q
MKXK\0:#8:UH5I%J5]8^'29;/1ED6;4)[*:VCE22>#< :WA[]JG4_&_Q&^'_A
M?P/H_AK7?"/CK6_B,UCXRTZ7Q7KMO/X0\!W'PI,.JPKX>\/W<6FSZC9?$J7-
MSJTMEI]G<Z1':W-PLMX!$ >>^$OVS?B3XT\#^*_%&A?"?3M1'AJ_\$QZMJ&A
M77BOQ';^#=,\3ZQXIM=;N_$/A+3_  ZGB/Q,^@Z#H.C:S,WABUU"&Z@\6Q)!
M)YFD7P !>U_]N1= TKQU+;>&;3QC<^'/"WP7U_PQXA\%6/CC6_AWXF?XF6EJ
M^JSZEXOL_"\]EX-TJTNI)Q9/K$]M-<(@65(Y%=5 .FU?]J'XE1>(K?1/"_PN
MTGQ7-%X@^+%C=Z-8:QKK>(-4TOX:_&W3_A) -!CMO#]Q:PZI=V-^VMSR:I+9
MZ=9K8S137B0DW48!ZE\#?C/XD^)'B'QWX<\:Z/H7@?Q1X5GCD?X<2CQ';^.=
M!TR;6-<TZQU35Y-7TVVTSQ1H&HVNFV=Q9>(/#,]YILSS7%OYGFVYR ?25 !0
M 4 % !0 4 % !0 4 % !0 4 % &'KOAO1/$T6FP:Y8)J$.D:YI'B33XI);B.
M.#6] O(]1T:_9()D$[VE_##<1I,)(Q+!%(4+1J5 .-3X,_"Z/5/&.L?\(7I$
MU[\0++6=-\9K="YO+#Q%8>(H--M=?M=0TB[N)+!H=1@TC3DNE2V3S_LP,FXN
MY<V#8P=)_9R^"FAZQIFNZ9X!TV"_T>+PG%IRRWNL7FFV[^!-$L?#O@N\.B7N
MI3:=-JNB:-IFGV]AJ$MH]U;?8XI(IEE4/1L&QU^M_"_P%XCA\6P:WX<M-0C\
M=2:#+XI\Z>^635)?"_V5O#L@FBNEDL7TV:SMY[9K-K<Q3H9UQ,[2,;!L5M%^
M$OPZ\.IX*CT;PO:6"_#JX\1W7@L1W.H/_85SXN6]3Q'- 9KQS<27RZE?>8;D
MS8-RY3:<$&P;',V_[.GP9L[S3+ZR\&1V%SH]M>V-D=/UWQ-80FRU#Q-K'C*\
MLKVUL]:C@U2SD\4:_K&H^3>QW$:S7\A50H55-O(-O(U=(^!WPHT'PWIGA'2/
M!FGV7AW1?$OAOQAI.G)<:D_V#Q+X/BT>W\,:M;74UZ]S'/IMIX?T:V@43>6M
MOIT5OL,(*$V^0;?(H2?L^?!][/P;81^#UL[;X?Q^(8?!Z:9KGB729-$M_%FI
M6NK^);2&XTO6;>6XL]2U&RM)KFWN7FBD-M&K)L4+1MY!MY&CX+^"'PK^'NK/
MKOA#P=8:3JQ76([>]:ZU/4I-,A\0ZG_;/B"WT)-6OKI/#]KJ>K;;N\@TQ;2.
MYFCCDG5VB0J;!L:MO\*_A_9^:+;PU9PK/\0)_BI.BSWWES?$"X):7Q+-$;HI
M+>&4B41LI@66..58EEC1U-O(-O(YF\_9Y^#%_?\ BC4[WP#I-Q?>,OM#>(IY
M9]3/VV>Y\0:9XLDO((OMWEZ9J*^*-&TO6([RQ2VN(;ZRCNX9$G!D)L&QU,'P
MP\!VUTU[#X=MDNG\=O\ $UY_M-^SMX[DT3_A&Y/$;;KL@W;:)_HAC(\G;SY6
M_P":@#DO^&=O@RFH6.J6G@BVTN^T[6?%6OV<VAZMX@T!8=3\<:GI&M>+Y#!H
MNK6L4MIK&JZ!H]U>64B/:S2V$;/"3G<;>0;>0P?LZ?!V&+2X].\)3>'Y-$TT
M:-IE_P"%/$_B_P (ZQ;:2FLZIX@ATW^W/#&OV&H36,&KZYK=Q##+<R) =9OD
MA"1W<R2&WD&WD7(/@!\&[30/$'A:T\ :):>'?%6F^%-'U_2+3[9:V6HZ9X'1
M$\+6CQ6]TGDQV&P,I@,;2.SO,9'D=F-O*P;>5CHM#^%W@'PUK[^)]#\.6MAK
MSIXPC?48[B_DD*>/_%$'C3QBIBGNWBQJGBBV@U&;]WQ+&!'L0E";!L1^#OA5
MX$\!:A?ZOX:T>XAU?4;&UTJXU;5]=\0^)]5BT6QN;J]LM T_4?%&K:A<:3X=
EM[R^O)XM)L9;>RCEN9)$@5W)HV#8]#H * "@ H * "@ H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g558803logo2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g558803logo2.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M6@_&6Y\1>-/".@:KH\^IZ1J.M:1-X%T_2]6FDF^P6T]KI>JS26[WCD[OL\@
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MJNP/+!%(X0-N"!G4D+NYQTSS0 YK>!XE@>&)H5"!86C1HE$>/+"QE=H"[1C
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M TWC21&CD1'C8%61U#(RGJ&5@01[$4 01V-E"XDBL[6*1<[7CMXD=<@J<,J
MC*DCCL30 U=.T]"I2PLU*D%2MK I4K]TJ0G!&!C% $R6UO%(\L4$,<K[M\J1
5(DC[F#-O=5!;+ $Y/)&: )J /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
